| SemMedDB Concept | ERG | PC | Shared | Score | Mean CP | Mean Odds | Hierarchy |
|---|
| SemMedDB Concept | Observed | Expected | Odds Ratio | P-value | Corrected P-value |
|---|---|---|---|---|---|
| Androgen Antagonists:0 | 4/190 | 5,655/16,348,907 | 62.15 | 7.16e-07 | 5.89e-06 |
| Androgen therapy:0 | 6/190 | 5,391/16,348,907 | 98.86 | 7.39e-11 | 1.10e-09 |
| Gland structure:0 | 12/190 | 17,877/16,348,907 | 61.59 | 7.95e-18 | 1.83e-16 |
| TRANSCRIPTION FACTOR:0 | 58/190 | 73,851/16,348,907 | 96.83 | 2.01e-87 | 2.99e-85 |
| Elements:0 | 7/190 | 31,020/16,348,907 | 20.12 | 1.04e-07 | 9.60e-07 |
| Fusion Gene:0 | 50/190 | 3,748/16,348,907 | 1557.51 | 3.33e-136 | 1.09e-133 |
| African American:0 | 6/190 | 24,443/16,348,907 | 21.78 | 5.33e-07 | 4.50e-06 |
| Genomic Instability:0 | 5/190 | 3,926/16,348,907 | 112.52 | 1.51e-09 | 1.87e-08 |
| CAP - NOS:0 | 13/190 | 2,768/16,348,907 | 433.73 | 4.19e-30 | 1.59e-28 |
| Nuclear Proteins:0 | 6/190 | 10,873/16,348,907 | 49.00 | 4.71e-09 | 5.35e-08 |
| DNA Binding:0 | 7/190 | 8,694/16,348,907 | 71.89 | 1.76e-11 | 2.71e-10 |
| Glutaminase:0 | 7/190 | 754/16,348,907 | 829.36 | 7.25e-19 | 1.80e-17 |
| Reporter:0 | 7/190 | 11,671/16,348,907 | 53.54 | 1.34e-10 | 1.94e-09 |
| Polymerase Chain Reaction:0 | 15/190 | 113,051/16,348,907 | 12.31 | 8.37e-12 | 1.34e-10 |
| Tissue-Specific Gene Expression:0 | 3/190 | 1,291/16,348,907 | 203.15 | 5.50e-07 | 4.62e-06 |
| Fluorescent in Situ Hybridization:0 | 49/190 | 14,341/16,348,907 | 395.83 | 1.32e-104 | 2.69e-102 |
| epitheliasin|TMPRSS2:0 | 36/190 | 246/16,348,907 | 15535.63 | 2.72e-134 | 7.41e-132 |
| epitheliasin:0 | 3/190 | 20/16,348,907 | 13114.08 | 2.74e-12 | 4.57e-11 |
| Specimen from prostate:0 | 38/190 | 1,141/16,348,907 | 3581.89 | 3.08e-118 | 7.20e-116 |
| FLI1|FLII:0 | 2/190 | 114/16,348,907 | 1525.64 | 8.95e-07 | 7.26e-06 |
| ERG:0 | 4/190 | 33/16,348,907 | 10654.20 | 1.17e-15 | 2.33e-14 |
| Candidate Disease Gene:0 | 17/190 | 53,728/16,348,907 | 29.80 | 2.63e-19 | 6.82e-18 |
| Proto-Oncogenes:0 | 7/190 | 8,723/16,348,907 | 71.65 | 1.80e-11 | 2.75e-10 |
| Chromosomal Rearrangement:0 | 18/190 | 1,838/16,348,907 | 930.76 | 6.28e-47 | 3.81e-45 |
| Gene Family:0 | 6/190 | 10,474/16,348,907 | 50.87 | 3.78e-09 | 4.39e-08 |
| 5' Untranslated Regions:0 | 4/190 | 4,742/16,348,907 | 74.12 | 3.57e-07 | 3.11e-06 |
| Oncogene Proteins:0 | 17/190 | 8,427/16,348,907 | 190.54 | 8.83e-33 | 3.61e-31 |
| ERG-associated protein with SET domain|SETDB1:0 | 2/190 | 112/16,348,907 | 1552.89 | 8.65e-07 | 7.04e-06 |
| Urine:0 | 31/190 | 29,355/16,348,907 | 108.39 | 2.34e-50 | 1.47e-48 |
| DELETION:0 | 13/190 | 20,760/16,348,907 | 57.77 | 8.07e-19 | 1.97e-17 |
| Enhancer:0 | 7/190 | 7,241/16,348,907 | 86.33 | 4.96e-12 | 8.04e-11 |
| Transcription factor genes:0 | 10/190 | 1,385/16,348,907 | 655.74 | 2.59e-25 | 8.16e-24 |
| Prostate-Specific Antigen:0 | 22/190 | 14,799/16,348,907 | 144.54 | 3.35e-39 | 1.66e-37 |
| Prostate cancer metastatic:0 | 22/190 | 7,354/16,348,907 | 290.99 | 7.64e-46 | 4.31e-44 |
| Consensus Sequence:0 | 4/190 | 3,834/16,348,907 | 91.68 | 1.54e-07 | 1.37e-06 |
| Patient observation:0 | 3/190 | 1,373/16,348,907 | 191.01 | 6.62e-07 | 5.50e-06 |
| elk-1 protein:0 | 5/190 | 100/16,348,907 | 4418.60 | 1.94e-17 | 4.41e-16 |
| ALK gene|ALK:0 | 3/190 | 745/16,348,907 | 352.04 | 1.07e-07 | 9.81e-07 |
| Cancer Model:0 | 7/190 | 4,416/16,348,907 | 141.58 | 1.60e-13 | 2.85e-12 |
| Infantile fibrosarcoma:0 | 3/190 | 349/16,348,907 | 751.51 | 1.11e-08 | 1.20e-07 |
| Epithelial Cells:0 | 18/190 | 126,298/16,348,907 | 13.44 | 1.93e-14 | 3.59e-13 |
| PCA3:0 | 23/190 | 189/16,348,907 | 11913.33 | 2.84e-84 | 3.87e-82 |
| Cell Proliferation:0 | 12/190 | 80,896/16,348,907 | 13.56 | 3.10e-10 | 4.23e-09 |
| PRL increased:0 | 2/190 | 92/16,348,907 | 1890.47 | 5.87e-07 | 4.90e-06 |
| Molecular Fingerprint of Tumor:0 | 3/190 | 629/16,348,907 | 416.97 | 6.43e-08 | 6.23e-07 |
| Gleason pattern:0 | 2/190 | 39/16,348,907 | 4459.59 | 1.10e-07 | 1.01e-06 |
| Sarcosine:0 | 3/190 | 812/16,348,907 | 322.99 | 1.38e-07 | 1.24e-06 |
| Gel Shift Analysis:0 | 3/190 | 188/16,348,907 | 1395.10 | 1.76e-09 | 2.15e-08 |
| Transcription, Genetic:0 | 47/190 | 90,323/16,348,907 | 59.16 | 3.50e-62 | 3.02e-60 |
| Gene Fusion:0 | 13/190 | 311/16,348,907 | 3860.91 | 2.52e-42 | 1.29e-40 |
| Immunohistochemistry:0 | 26/190 | 40,249/16,348,907 | 64.24 | 7.43e-37 | 3.38e-35 |
| Prostatic Intraepithelial Neoplasias:0 | 7/190 | 1,354/16,348,907 | 461.83 | 4.27e-17 | 9.57e-16 |
| Tumor stage:0 | 6/190 | 3,763/16,348,907 | 141.64 | 8.70e-12 | 1.38e-10 |
| Common Carcinoma:0 | 3/190 | 205/16,348,907 | 1279.41 | 2.28e-09 | 2.72e-08 |
| Prostatic epithelium:0 | 7/190 | 924/16,348,907 | 676.77 | 2.98e-18 | 7.08e-17 |
| Transcript:0 | 11/190 | 20,496/16,348,907 | 48.96 | 2.13e-15 | 4.16e-14 |
| BCR gene|BCR:0 | 4/190 | 6,028/16,348,907 | 58.30 | 9.22e-07 | 7.40e-06 |
| ETV5:0 | 9/190 | 1,240/16,348,907 | 655.54 | 6.24e-23 | 1.76e-21 |
| Raised prostate specific antigen:0 | 7/190 | 829/16,348,907 | 754.33 | 1.40e-18 | 3.38e-17 |
| Chromosomal translocation:0 | 21/190 | 6,997/16,348,907 | 290.22 | 7.79e-44 | 4.11e-42 |
| ETS Variant Gene 6 Protein|ETV6:0 | 5/190 | 220/16,348,907 | 2008.44 | 9.22e-16 | 1.89e-14 |
| ETS Family Gene:0 | 6/190 | 37/16,348,907 | 14408.52 | 1.39e-23 | 4.11e-22 |
| IGH@ gene cluster:0 | 3/190 | 1,273/16,348,907 | 206.02 | 5.28e-07 | 4.48e-06 |
| Clone:0 | 7/190 | 30,775/16,348,907 | 20.28 | 9.84e-08 | 9.31e-07 |
| Signal Transduction:0 | 10/190 | 76,577/16,348,907 | 11.81 | 3.14e-08 | 3.25e-07 |
| Human tissue:0 | 8/190 | 33,444/16,348,907 | 21.44 | 8.00e-09 | 8.79e-08 |
| PCA3 gene|PCA3:0 | 10/190 | 100/16,348,907 | 9082.67 | 1.65e-36 | 7.32e-35 |
| ELK1 gene|ELK1:0 | 10/190 | 1,051/16,348,907 | 864.14 | 1.67e-26 | 5.57e-25 |
| Gene Rearrangement:0 | 8/190 | 1,607/16,348,907 | 447.15 | 3.18e-19 | 8.14e-18 |
| Neoplasm progression:0 | 41/190 | 37,131/16,348,907 | 120.88 | 2.25e-67 | 2.84e-65 |
| MicroRNAs:0 | 11/190 | 76,708/16,348,907 | 13.04 | 2.44e-09 | 2.90e-08 |
| Transcriptional Regulation:0 | 8/190 | 9,809/16,348,907 | 73.22 | 5.55e-13 | 9.66e-12 |
| SPOP:0 | 3/190 | 117/16,348,907 | 2241.71 | 4.33e-10 | 5.68e-09 |
| integral to membrane:0 | 27/190 | 13,201/16,348,907 | 204.98 | 1.25e-51 | 8.51e-50 |
| Transfection:0 | 10/190 | 17,763/16,348,907 | 51.08 | 2.56e-14 | 4.70e-13 |
| Carcinogens:0 | 15/190 | 29,931/16,348,907 | 46.73 | 4.26e-20 | 1.14e-18 |
| Prostatectomy:0 | 9/190 | 3,080/16,348,907 | 263.89 | 2.16e-19 | 5.70e-18 |
| Prostatic secretions:0 | 3/190 | 461/16,348,907 | 568.93 | 2.55e-08 | 2.66e-07 |
| Ets Variant Protein 1|ETV1:0 | 4/190 | 107/16,348,907 | 3285.86 | 1.06e-13 | 1.90e-12 |
| Prostatic Neoplasms:0 | 26/190 | 3,143/16,348,907 | 824.50 | 1.90e-65 | 2.07e-63 |
| Neoplasm Metastasis:0 | 18/190 | 100,066/16,348,907 | 16.99 | 3.80e-16 | 8.07e-15 |
| Chromosome abnormality:0 | 7/190 | 19,185/16,348,907 | 32.56 | 4.03e-09 | 4.65e-08 |
| ETV1 gene|ETV1:0 | 19/190 | 379/16,348,907 | 4792.88 | 9.06e-63 | 8.24e-61 |
| Aggressive behavior:0 | 10/190 | 27,698/16,348,907 | 32.74 | 1.96e-12 | 3.35e-11 |
| NKX3-1 gene|NKX3-1:0 | 4/190 | 278/16,348,907 | 1264.69 | 4.55e-12 | 7.52e-11 |
| Acute Erythroblastic Leukemia:0 | 9/190 | 7,204/16,348,907 | 112.79 | 4.30e-16 | 9.03e-15 |
| Tissue specimen:0 | 15/190 | 20,806/16,348,907 | 67.27 | 2.00e-22 | 5.45e-21 |
| ETS1 gene|ETS1:0 | 61/190 | 3,178/16,348,907 | 2432.15 | 2.74e-176 | 1.12e-173 |
| Benign prostatic hypertrophy:0 | 7/190 | 23,882/16,348,907 | 26.15 | 1.78e-08 | 1.91e-07 |
| Family member:0 | 11/190 | 19,277/16,348,907 | 52.06 | 1.10e-15 | 2.22e-14 |
| transcription factor PEA3:0 | 2/190 | 77/16,348,907 | 2258.75 | 4.14e-07 | 3.56e-06 |
| Breast Cancer Cell:0 | 7/190 | 19,866/16,348,907 | 31.44 | 5.11e-09 | 5.77e-08 |
| Biological function, NOS:0 | 6/190 | 15,496/16,348,907 | 34.37 | 3.77e-08 | 3.84e-07 |
| Digital Rectal Examination:0 | 4/190 | 1,378/16,348,907 | 255.12 | 2.64e-09 | 3.11e-08 |
| Sequence Analysis:0 | 4/190 | 6,206/16,348,907 | 56.63 | 1.03e-06 | 8.22e-06 |
| Tissue specimen from prostate:0 | 4/190 | 282/16,348,907 | 1246.75 | 4.81e-12 | 7.88e-11 |
| 5q21:0 | 3/190 | 107/16,348,907 | 2451.22 | 3.33e-10 | 4.47e-09 |
| ETV6 gene|ETV6:0 | 10/190 | 843/16,348,907 | 1077.37 | 1.87e-27 | 6.37e-26 |
| ELF1:0 | 2/190 | 78/16,348,907 | 2229.79 | 4.24e-07 | 3.64e-06 |
| SPINK1 gene|SPINK1:0 | 6/190 | 642/16,348,907 | 830.37 | 2.27e-16 | 4.89e-15 |
| Somatic mutation:0 | 4/190 | 4,263/16,348,907 | 82.45 | 2.34e-07 | 2.07e-06 |
| Solid tumor:0 | 9/190 | 33,165/16,348,907 | 24.46 | 3.07e-10 | 4.23e-09 |
| Biopsy:0 | 47/190 | 137,987/16,348,907 | 38.61 | 1.03e-53 | 8.05e-52 |
| Prostate carcinoma:0 | 20/190 | 10,986/16,348,907 | 174.96 | 1.77e-37 | 8.26e-36 |
| CRISP-3 protein:0 | 2/190 | 60/16,348,907 | 2898.73 | 2.54e-07 | 2.23e-06 |
| ETV4:0 | 15/190 | 556/16,348,907 | 2520.30 | 7.63e-46 | 4.31e-44 |
| DNA-Binding Proteins:0 | 5/190 | 5,453/16,348,907 | 81.00 | 7.69e-09 | 8.51e-08 |
| ETS1 protein, human|ETS1:0 | 3/190 | 104/16,348,907 | 2521.93 | 3.06e-10 | 4.23e-09 |
| Chicken Cells:0 | 4/190 | 1,872/16,348,907 | 187.79 | 8.94e-09 | 9.75e-08 |
| TMPRSS2 gene|TMPRSS2:0 | 148/190 | 267/16,348,907 | 215765.89 | 0.00e+00 | 0.00e+00 |
| AR gene|AR:0 | 23/190 | 4,311/16,348,907 | 522.16 | 1.23e-53 | 9.17e-52 |
| TNM category pT:0 | 3/190 | 107/16,348,907 | 2451.22 | 3.33e-10 | 4.47e-09 |
| Normal hematopoiesis:0 | 3/190 | 734/16,348,907 | 357.32 | 1.02e-07 | 9.49e-07 |
| Castration:0 | 4/190 | 4,619/16,348,907 | 76.10 | 3.22e-07 | 2.82e-06 |
| Angiogenesis:0 | 7/190 | 41,445/16,348,907 | 15.05 | 7.12e-07 | 5.89e-06 |
| Promoter (Genetics):0 | 5/190 | 9,176/16,348,907 | 48.13 | 1.00e-07 | 9.37e-07 |
| FLVCR1:0 | 10/190 | 2,066/16,348,907 | 439.57 | 1.39e-23 | 4.11e-22 |
| RNA, Small Interfering:0 | 9/190 | 33,696/16,348,907 | 24.08 | 3.52e-10 | 4.69e-09 |
| Carcinoma:0 | 13/190 | 144,987/16,348,907 | 8.21 | 2.17e-08 | 2.29e-07 |
| DNA Sequence:0 | 25/190 | 102,730/16,348,907 | 23.96 | 3.83e-25 | 1.18e-23 |
| Heregulin:0 | 3/190 | 795/16,348,907 | 329.90 | 1.29e-07 | 1.17e-06 |
| Glutamate Carboxypeptidase II:0 | 3/190 | 1,550/16,348,907 | 169.20 | 9.50e-07 | 7.58e-06 |
| Ewings sarcoma:0 | 6/190 | 8,391/16,348,907 | 63.50 | 1.02e-09 | 1.29e-08 |
| PROSTATE SPECIFIC:0 | 4/190 | 196/16,348,907 | 1793.80 | 1.14e-12 | 1.97e-11 |
| Response Elements:0 | 5/190 | 8,833/16,348,907 | 50.00 | 8.30e-08 | 7.95e-07 |
| RNA, Messenger:0 | 10/190 | 80,755/16,348,907 | 11.19 | 5.12e-08 | 5.02e-07 |
| Specimen:0 | 7/190 | 6,593/16,348,907 | 94.82 | 2.59e-12 | 4.37e-11 |
| RNA:0 | 11/190 | 126,350/16,348,907 | 7.89 | 3.60e-07 | 3.12e-06 |
| GA-Binding Protein Transcription Factor:0 | 3/190 | 53/16,348,907 | 4948.70 | 4.28e-11 | 6.43e-10 |
| hydrogen sulfite:0 | 3/190 | 531/16,348,907 | 493.92 | 3.88e-08 | 3.92e-07 |
| ETV4 gene|ETV4:0 | 15/190 | 120/16,348,907 | 11677.70 | 1.66e-55 | 1.36e-53 |
| Regulatory Element:0 | 5/190 | 6,689/16,348,907 | 66.03 | 2.11e-08 | 2.24e-07 |
| Tumor Suppressor Genes:0 | 12/190 | 33,756/16,348,907 | 32.58 | 1.39e-14 | 2.61e-13 |
| Pathologic stage:0 | 4/190 | 1,244/16,348,907 | 282.61 | 1.76e-09 | 2.15e-08 |
| Androgens:0 | 40/190 | 38,318/16,348,907 | 113.51 | 9.42e-65 | 9.63e-63 |
| Transcriptional Activation:0 | 11/190 | 17,807/16,348,907 | 56.36 | 4.67e-16 | 9.67e-15 |
| High-Risk Cancer:0 | 6/190 | 7,468/16,348,907 | 71.35 | 5.11e-10 | 6.64e-09 |
| Serum Response Factor:0 | 6/190 | 2,279/16,348,907 | 233.89 | 4.37e-13 | 7.69e-12 |
| Adenocarcinoma of prostate:0 | 11/190 | 2,164/16,348,907 | 464.21 | 4.79e-26 | 1.57e-24 |
| fluorouracil/methotrexate protocol:0 | 5/190 | 321/16,348,907 | 1376.49 | 5.96e-15 | 1.14e-13 |
| Utrophin|UTRN:0 | 4/190 | 711/16,348,907 | 494.48 | 1.90e-10 | 2.70e-09 |
| Gene Expression:0 | 10/190 | 59,582/16,348,907 | 15.19 | 3.03e-09 | 3.54e-08 |
| Matrix Metalloproteinases:0 | 6/190 | 26,797/16,348,907 | 19.86 | 9.05e-07 | 7.29e-06 |
| Tumorigenesis:0 | 34/190 | 42,358/16,348,907 | 83.90 | 3.43e-51 | 2.24e-49 |
| [M]Unspecified tumor cell NOS:0 | 25/190 | 75,073/16,348,907 | 32.84 | 1.98e-28 | 7.03e-27 |
| Erythroblastosis:0 | 3/190 | 507/16,348,907 | 517.31 | 3.38e-08 | 3.46e-07 |
| KLK3 gene|KLK3:0 | 17/190 | 9,016/16,348,907 | 178.09 | 2.76e-32 | 1.08e-30 |
| cohort:0 | 45/190 | 121,378/16,348,907 | 41.49 | 5.32e-53 | 3.79e-51 |
| Cell Growth:0 | 9/190 | 44,816/16,348,907 | 18.09 | 4.11e-09 | 4.70e-08 |
| SP1 gene|SP1:0 | 7/190 | 8,423/16,348,907 | 74.21 | 1.41e-11 | 2.20e-10 |
| epitheliasin|ERG:0 | 16/190 | 36/16,348,907 | 41759.57 | 5.99e-67 | 7.00e-65 |
| Trans-Activation (Genetics):0 | 6/190 | 7,069/16,348,907 | 75.38 | 3.69e-10 | 4.88e-09 |
| leukemia:0 | 21/190 | 53,501/16,348,907 | 37.85 | 1.71e-25 | 5.47e-24 |
| Retroviridae:0 | 8/190 | 14,532/16,348,907 | 49.41 | 1.23e-11 | 1.93e-10 |
| Primary Neoplasm:0 | 9/190 | 35,552/16,348,907 | 22.82 | 5.61e-10 | 7.23e-09 |
| Serum Response Element:0 | 3/190 | 766/16,348,907 | 342.39 | 1.16e-07 | 1.05e-06 |
| High-Grade Prostatic Intraepithelial Neoplasia:0 | 17/190 | 1,431/16,348,907 | 1122.57 | 8.39e-46 | 4.58e-44 |
| Tumor focality:0 | 9/190 | 228/16,348,907 | 3565.43 | 1.77e-29 | 6.60e-28 |
| Homologous Gene:0 | 12/190 | 79,266/16,348,907 | 13.84 | 2.47e-10 | 3.48e-09 |
| Proto-Oncogene Proteins c-ets:0 | 51/190 | 672/16,348,907 | 8926.00 | 8.98e-177 | 4.90e-174 |
| Needle biopsy procedure:0 | 10/190 | 5,778/16,348,907 | 157.14 | 3.85e-19 | 9.69e-18 |
| Adenocarcinoma:0 | 19/190 | 90,559/16,348,907 | 19.95 | 3.48e-18 | 8.14e-17 |
| Binding Sites:0 | 20/190 | 59,087/16,348,907 | 32.43 | 4.43e-23 | 1.27e-21 |
| AKR1C3|AKR1A1|PCA3:0 | 2/190 | 87/16,348,907 | 1999.12 | 5.26e-07 | 4.48e-06 |
| ERG gene|ERG:0 | 178/190 | 1,893/16,348,907 | 128093.35 | 0.00e+00 | 0.00e+00 |
| Probes:0 | 10/190 | 56,887/16,348,907 | 15.91 | 1.96e-09 | 2.36e-08 |
| Prostatic Tissue:0 | 16/190 | 5,110/16,348,907 | 294.11 | 5.83e-34 | 2.51e-32 |
| ETS Family Protein:0 | 29/190 | 391/16,348,907 | 7531.37 | 4.08e-100 | 7.42e-98 |
| Carcinogenesis:0 | 23/190 | 60,832/16,348,907 | 36.88 | 1.84e-27 | 6.37e-26 |
| Androgen Receptor|AR:0 | 17/190 | 13,713/16,348,907 | 117.06 | 3.27e-29 | 1.19e-27 |
| overdiagnosis:0 | 3/190 | 278/16,348,907 | 943.44 | 5.64e-09 | 6.32e-08 |
| Cancer Promoting Genes:0 | 4/190 | 3,424/16,348,907 | 102.66 | 9.84e-08 | 9.31e-07 |
| SLC45A3:0 | 4/190 | 15/16,348,907 | 23439.27 | 6.85e-17 | 1.51e-15 |
| White American:0 | 3/190 | 500/16,348,907 | 524.55 | 3.24e-08 | 3.34e-07 |
| ETV2:0 | 3/190 | 166/16,348,907 | 1580.00 | 1.22e-09 | 1.54e-08 |
| Cell Line, Tumor:0 | 6/190 | 15,602/16,348,907 | 34.14 | 3.93e-08 | 3.94e-07 |
| Leukemia, Myelocytic, Acute:0 | 14/190 | 65,224/16,348,907 | 19.86 | 7.55e-14 | 1.37e-12 |
| Tumor cells, malignant:0 | 9/190 | 49,808/16,348,907 | 16.27 | 1.01e-08 | 1.10e-07 |
| Gleason grading system for prostatic cancer:0 | 6/190 | 887/16,348,907 | 601.00 | 1.56e-15 | 3.08e-14 |
| TDRD1:0 | 2/190 | 45/16,348,907 | 3864.98 | 1.45e-07 | 1.30e-06 |
| Urine specimen:0 | 4/190 | 2,827/16,348,907 | 124.35 | 4.60e-08 | 4.56e-07 |
| Endothelial Cells:0 | 13/190 | 114,443/16,348,907 | 10.42 | 1.36e-09 | 1.70e-08 |
| Stratification:0 | 4/190 | 3,430/16,348,907 | 102.48 | 9.91e-08 | 9.32e-07 |
| Normal cell:0 | 6/190 | 15,779/16,348,907 | 33.75 | 4.19e-08 | 4.19e-07 |
| Prognostic Factor:0 | 7/190 | 20,896/16,348,907 | 29.89 | 7.21e-09 | 8.03e-08 |
| PTEN gene|PTEN:0 | 45/190 | 16,075/16,348,907 | 315.32 | 4.36e-92 | 7.13e-90 |
| Oncogenes:0 | 9/190 | 9,037/16,348,907 | 89.91 | 3.25e-15 | 6.25e-14 |
| Radical prostatectomy:0 | 33/190 | 15,642/16,348,907 | 219.48 | 1.98e-63 | 1.91e-61 |
| ELF3 gene|ELF3:0 | 4/190 | 600/16,348,907 | 585.96 | 9.65e-11 | 1.41e-09 |
| Cancer Diagnosis:0 | 17/190 | 3,927/16,348,907 | 409.00 | 2.17e-38 | 1.05e-36 |
| Amino Acids|ASAH1:0 | 2/190 | 29/16,348,907 | 5997.39 | 6.25e-08 | 6.09e-07 |
| TP53 gene|TP53:0 | 10/190 | 108,855/16,348,907 | 8.29 | 7.67e-07 | 6.27e-06 |
| cDNA Library:0 | 8/190 | 16,096/16,348,907 | 44.60 | 2.74e-11 | 4.15e-10 |
| advanced disease:0 | 7/190 | 17,023/16,348,907 | 36.70 | 1.78e-09 | 2.16e-08 |
| Chromosomes, Human, Pair 11:0 | 5/190 | 3,274/16,348,907 | 134.93 | 6.14e-10 | 7.85e-09 |
| Biopsy sample:0 | 7/190 | 27,682/16,348,907 | 22.55 | 4.83e-08 | 4.76e-07 |
| cell motility:0 | 9/190 | 30,404/16,348,907 | 26.69 | 1.44e-10 | 2.07e-09 |
| Tissue Microarray:0 | 10/190 | 2,648/16,348,907 | 342.95 | 1.64e-22 | 4.55e-21 |
| Endopeptidases:0 | 24/190 | 40,740/16,348,907 | 57.87 | 3.85e-33 | 1.62e-31 |
| Fusion Protein:0 | 16/190 | 23,054/16,348,907 | 65.12 | 1.40e-23 | 4.11e-22 |
| MYC gene|MYC:0 | 5/190 | 8,634/16,348,907 | 51.15 | 7.42e-08 | 7.15e-07 |
| Disease Progression:0 | 9/190 | 28,836/16,348,907 | 28.14 | 9.11e-11 | 1.34e-09 |
| Promoter Regions (Genetics):0 | 6/190 | 6,625/16,348,907 | 80.44 | 2.51e-10 | 3.52e-09 |
| ETS2 Protein:0 | 2/190 | 18/16,348,907 | 9662.46 | 2.55e-08 | 2.66e-07 |
| Chromosomes, Human, Pair 21:0 | 14/190 | 2,920/16,348,907 | 445.29 | 1.90e-32 | 7.58e-31 |
| Aggressive cancer:0 | 7/190 | 1,584/16,348,907 | 394.76 | 1.27e-16 | 2.78e-15 |
| SemMedDB Concept | Observed | Expected | Odds Ratio | P-value | Corrected P-value |
|---|---|---|---|---|---|
| Antithymoglobulin:0 | 7/61,988 | 8,973/16,348,907 | 0.21 | 3.99e-08 | 3.32e-07 |
| Entire genitourinary tract:0 | 64/61,988 | 709/16,348,907 | 23.83 | 2.26e-62 | 1.25e-60 |
| PIM-1 Serine/Threonine Kinase|PIM1:0 | 17/61,988 | 314/16,348,907 | 14.28 | 2.69e-14 | 3.68e-13 |
| Nephritis:0 | 2/61,988 | 7,208/16,348,907 | 0.07 | 1.09e-09 | 1.06e-08 |
| Prior Chemotherapy:0 | 35/61,988 | 1,195/16,348,907 | 7.73 | 1.63e-19 | 2.98e-18 |
| Deformity:0 | 8/61,988 | 18,641/16,348,907 | 0.11 | 6.37e-21 | 1.25e-19 |
| Mammary Neoplasms:0 | 237/61,988 | 21,389/16,348,907 | 2.93 | 1.21e-44 | 4.92e-43 |
| Increased frequency of micturition:0 | 7/61,988 | 131/16,348,907 | 14.09 | 1.15e-06 | 8.12e-06 |
| Multiparity:0 | 1/61,988 | 5,025/16,348,907 | 0.05 | 2.12e-07 | 1.63e-06 |
| Cerebral Ischemia:0 | 3/61,988 | 16,214/16,348,907 | 0.05 | 1.90e-22 | 3.97e-21 |
| Etoposide:0 | 224/61,988 | 20,728/16,348,907 | 2.86 | 1.05e-40 | 3.89e-39 |
| HIF1alpha protein:0 | 101/61,988 | 5,793/16,348,907 | 4.60 | 2.09e-34 | 6.47e-33 |
| Disseminated carcinoma:0 | 19/61,988 | 269/16,348,907 | 18.63 | 8.43e-18 | 1.41e-16 |
| Platelet-Derived Growth Factor Receptor:0 | 40/61,988 | 3,257/16,348,907 | 3.24 | 3.94e-10 | 4.02e-09 |
| procalcitonin:0 | 1/61,988 | 6,565/16,348,907 | 0.04 | 9.89e-10 | 9.65e-09 |
| Prunus africana:0 | 4/61,988 | 14/16,348,907 | 75.36 | 5.97e-07 | 4.37e-06 |
| Cyclin-Dependent Kinase 4:0 | 18/61,988 | 937/16,348,907 | 5.07 | 5.02e-08 | 4.14e-07 |
| Levamisole:0 | 2/61,988 | 6,229/16,348,907 | 0.08 | 3.80e-08 | 3.18e-07 |
| Puncture biopsy:0 | 94/61,988 | 1,334/16,348,907 | 18.61 | 1.61e-81 | 1.11e-79 |
| Technetium Tc 99m Medronate:0 | 28/61,988 | 718/16,348,907 | 10.29 | 5.64e-19 | 1.01e-17 |
| Cancer Registry:0 | 33/61,988 | 382/16,348,907 | 22.80 | 2.11e-32 | 6.23e-31 |
| CDCP1 gene|CDCP1:0 | 7/61,988 | 124/16,348,907 | 14.89 | 8.13e-07 | 5.86e-06 |
| Clients:0 | 13/61,988 | 13,213/16,348,907 | 0.26 | 1.05e-09 | 1.02e-08 |
| Masculinity:0 | 11/61,988 | 325/16,348,907 | 8.93 | 9.50e-08 | 7.60e-07 |
| Cancer Promoting Genes:0 | 178/61,988 | 3,424/16,348,907 | 13.75 | 2.43e-131 | 2.75e-129 |
| Energy, Physics:0 | 90/61,988 | 46,134/16,348,907 | 0.51 | 2.27e-12 | 2.73e-11 |
| histone deacetylase activity:0 | 13/61,988 | 366/16,348,907 | 9.37 | 3.84e-09 | 3.56e-08 |
| Posterior lobe of prostate:0 | 5/61,988 | 8/16,348,907 | 164.85 | 9.65e-10 | 9.43e-09 |
| Caseins:0 | 8/61,988 | 8,560/16,348,907 | 0.25 | 6.06e-07 | 4.43e-06 |
| small molecule:0 | 266/61,988 | 16,058/16,348,907 | 4.38 | 4.61e-83 | 3.24e-81 |
| NDRG1 gene|NDRG1:0 | 24/61,988 | 493/16,348,907 | 12.84 | 1.48e-18 | 2.58e-17 |
| Drug Interactions:0 | 224/61,988 | 39,797/16,348,907 | 1.49 | 2.61e-08 | 2.22e-07 |
| Octreotide|BGLAP:0 | 9/61,988 | 40/16,348,907 | 59.35 | 2.80e-13 | 3.59e-12 |
| Upper Extremity:0 | 377/61,988 | 55,955/16,348,907 | 1.78 | 2.15e-24 | 4.86e-23 |
| Bladder outflow obstruction:0 | 11/61,988 | 245/16,348,907 | 11.84 | 5.96e-09 | 5.42e-08 |
| Persistent infection:0 | 7/61,988 | 8,704/16,348,907 | 0.21 | 1.05e-07 | 8.34e-07 |
| Radiotherapy planning:0 | 26/61,988 | 393/16,348,907 | 17.46 | 4.09e-23 | 8.83e-22 |
| Prostatic mass:0 | 14/61,988 | 21/16,348,907 | 175.87 | 2.59e-25 | 6.09e-24 |
| Flow Cytometry:0 | 259/61,988 | 23,238/16,348,907 | 2.95 | 4.76e-49 | 2.12e-47 |
| ^103^Palladium:0 | 21/61,988 | 31/16,348,907 | 178.72 | 2.26e-37 | 7.68e-36 |
| Critical Illness:0 | 4/61,988 | 48,155/16,348,907 | 0.02 | 4.73e-72 | 2.96e-70 |
| Supportive care:0 | 64/61,988 | 8,358/16,348,907 | 2.02 | 4.40e-07 | 3.27e-06 |
| Prostate cancer metastatic:0 | 4,113/61,988 | 7,354/16,348,907 | 157.92 | 0.00e+00 | 0.00e+00 |
| Non-alcoholic fatty liver:0 | 4/61,988 | 43,876/16,348,907 | 0.02 | 4.97e-65 | 2.87e-63 |
| Rats, Inbred WKY:0 | 1/61,988 | 6,516/16,348,907 | 0.04 | 9.31e-10 | 9.14e-09 |
| Cancer Model:0 | 568/61,988 | 4,416/16,348,907 | 34.23 | 0.00e+00 | 0.00e+00 |
| Immunologic Deficiency Syndromes:0 | 142/61,988 | 16,838/16,348,907 | 2.23 | 3.77e-17 | 6.10e-16 |
| Soy bean product:0 | 13/61,988 | 132/16,348,907 | 25.98 | 2.31e-14 | 3.18e-13 |
| Urine cytology:0 | 28/61,988 | 747/16,348,907 | 9.89 | 1.50e-18 | 2.62e-17 |
| Gleason grading system for prostatic cancer:0 | 677/61,988 | 887/16,348,907 | 203.51 | 0.00e+00 | 0.00e+00 |
| Forecast of outcome:0 | 14/61,988 | 515/16,348,907 | 7.17 | 2.55e-08 | 2.17e-07 |
| Interleukin-17:0 | 17/61,988 | 13,901/16,348,907 | 0.32 | 2.32e-08 | 1.98e-07 |
| Bacillus subtilis:0 | 1/61,988 | 12,731/16,348,907 | 0.02 | 9.76e-20 | 1.81e-18 |
| Peripheral Nerves:0 | 12/61,988 | 12,001/16,348,907 | 0.26 | 7.06e-09 | 6.38e-08 |
| Not significant:0 | 46/61,988 | 3,312/16,348,907 | 3.67 | 3.64e-13 | 4.61e-12 |
| KLF6:0 | 20/61,988 | 479/16,348,907 | 11.02 | 1.59e-14 | 2.21e-13 |
| Transgenic Model:0 | 213/61,988 | 4,452/16,348,907 | 12.66 | 7.09e-150 | 9.04e-148 |
| Pancreatitis:0 | 23/61,988 | 48,636/16,348,907 | 0.12 | 8.64e-51 | 3.98e-49 |
| Hypothalamic structure:0 | 30/61,988 | 53,237/16,348,907 | 0.15 | 2.84e-51 | 1.32e-49 |
| Brain-Derived Neurotrophic Factor:0 | 7/61,988 | 25,919/16,348,907 | 0.07 | 7.16e-33 | 2.15e-31 |
| Difluoromethylornithine:0 | 40/61,988 | 4,353/16,348,907 | 2.42 | 8.04e-07 | 5.80e-06 |
| ORALIT:0 | 39/61,988 | 2,406/16,348,907 | 4.28 | 2.32e-13 | 2.99e-12 |
| biochanin A:0 | 17/61,988 | 855/16,348,907 | 5.25 | 7.26e-08 | 5.87e-07 |
| Stromal Cells:0 | 477/61,988 | 26,512/16,348,907 | 4.77 | 8.94e-161 | 1.23e-158 |
| VTN gene|VTN:0 | 11/61,988 | 62/16,348,907 | 46.80 | 6.40e-15 | 9.10e-14 |
| Oncolytic Virotherapy:0 | 12/61,988 | 261/16,348,907 | 12.13 | 9.51e-10 | 9.31e-09 |
| Preservation, Biological:0 | 379/61,988 | 25,524/16,348,907 | 3.93 | 5.09e-104 | 4.31e-102 |
| Tumor stage:0 | 245/61,988 | 3,763/16,348,907 | 17.24 | 8.65e-202 | 1.44e-199 |
| integral to membrane:0 | 187/61,988 | 13,201/16,348,907 | 3.74 | 1.89e-49 | 8.49e-48 |
| Transcript:0 | 183/61,988 | 20,496/16,348,907 | 2.36 | 3.17e-24 | 7.13e-23 |
| Histone Deacetylase Inhibitor:0 | 73/61,988 | 2,304/16,348,907 | 8.37 | 5.04e-41 | 1.90e-39 |
| Diethylstilbestrol:0 | 361/61,988 | 10,507/16,348,907 | 9.11 | 1.12e-206 | 1.90e-204 |
| Hemophilia A:0 | 12/61,988 | 16,702/16,348,907 | 0.19 | 8.62e-15 | 1.22e-13 |
| Radioisotopes:0 | 111/61,988 | 8,895/16,348,907 | 3.30 | 9.83e-26 | 2.36e-24 |
| Alkaline Phosphatase:0 | 308/61,988 | 41,924/16,348,907 | 1.94 | 1.13e-25 | 2.69e-24 |
| Cancer of Urethra:0 | 15/61,988 | 246/16,348,907 | 16.09 | 1.71e-13 | 2.23e-12 |
| Focal Adhesion Protein-Tyrosine Kinases:0 | 92/61,988 | 9,239/16,348,907 | 2.63 | 1.58e-15 | 2.34e-14 |
| tissue polypeptide specific antigen:0 | 12/61,988 | 371/16,348,907 | 8.53 | 4.05e-08 | 3.38e-07 |
| Entire thumb:0 | 3/61,988 | 6,485/16,348,907 | 0.12 | 1.36e-07 | 1.06e-06 |
| circulating cancer cell:0 | 34/61,988 | 233/16,348,907 | 38.51 | 2.12e-40 | 7.80e-39 |
| Fatty Acids, Omega-6:0 | 44/61,988 | 2,127/16,348,907 | 5.46 | 1.51e-18 | 2.63e-17 |
| Introduction procedure:0 | 95/61,988 | 13,580/16,348,907 | 1.85 | 5.82e-08 | 4.75e-07 |
| estromustine:0 | 9/61,988 | 23/16,348,907 | 103.22 | 4.06e-15 | 5.86e-14 |
| Cholesterol:0 | 183/61,988 | 78,273/16,348,907 | 0.62 | 1.48e-12 | 1.80e-11 |
| RAC-Alpha Serine/Threonine Kinase|AKT1:0 | 73/61,988 | 7,395/16,348,907 | 2.61 | 1.84e-12 | 2.22e-11 |
| LZTS1:0 | 6/61,988 | 68/16,348,907 | 23.27 | 4.32e-07 | 3.21e-06 |
| Spontaneous abortion:0 | 5/61,988 | 12,463/16,348,907 | 0.11 | 1.49e-14 | 2.08e-13 |
| Free Calcium:0 | 9/61,988 | 11,738/16,348,907 | 0.20 | 2.32e-10 | 2.42e-09 |
| trichostatin A:0 | 84/61,988 | 7,897/16,348,907 | 2.81 | 5.53e-16 | 8.37e-15 |
| General body state finding:0 | 26/61,988 | 2,264/16,348,907 | 3.03 | 1.37e-06 | 9.52e-06 |
| MBD2:0 | 10/61,988 | 333/16,348,907 | 7.92 | 1.03e-06 | 7.30e-06 |
| Androgen Metabolism:0 | 39/61,988 | 158/16,348,907 | 65.14 | 4.73e-54 | 2.31e-52 |
| Endometriosis, site unspecified:0 | 58/61,988 | 34,669/16,348,907 | 0.44 | 9.68e-13 | 1.19e-11 |
| MAP2K4:0 | 24/61,988 | 945/16,348,907 | 6.70 | 1.31e-12 | 1.60e-11 |
| Vaginal Neoplasms:0 | 8/61,988 | 145/16,348,907 | 14.55 | 1.58e-07 | 1.22e-06 |
| Cell Death:0 | 980/61,988 | 74,554/16,348,907 | 3.51 | 4.56e-229 | 8.38e-227 |
| Cytostatic Agents:0 | 115/61,988 | 14,227/16,348,907 | 2.13 | 5.92e-13 | 7.39e-12 |
| EPHB2|MAPK1:0 | 259/61,988 | 30,102/16,348,907 | 2.27 | 3.75e-31 | 1.06e-29 |
| Normal blood pressure:0 | 5/61,988 | 16,210/16,348,907 | 0.08 | 4.01e-20 | 7.63e-19 |
| tripterine:0 | 22/61,988 | 1,439/16,348,907 | 4.03 | 8.92e-08 | 7.15e-07 |
| Penicillamine:0 | 2/61,988 | 9,391/16,348,907 | 0.06 | 4.28e-13 | 5.38e-12 |
| Hyperthermia, Local:0 | 25/61,988 | 569/16,348,907 | 11.59 | 2.89e-18 | 4.97e-17 |
| Acute Disease:0 | 1/61,988 | 6,031/16,348,907 | 0.04 | 5.76e-09 | 5.25e-08 |
| beta Thalassemia:0 | 2/61,988 | 8,328/16,348,907 | 0.06 | 2.23e-11 | 2.50e-10 |
| Linear accelerator electrons procedure:0 | 17/61,988 | 283/16,348,907 | 15.85 | 5.40e-15 | 7.73e-14 |
| GRPR gene|GRPR:0 | 31/61,988 | 99/16,348,907 | 82.63 | 4.54e-46 | 1.90e-44 |
| Risk:0 | 95/61,988 | 13,709/16,348,907 | 1.83 | 1.00e-07 | 8.00e-07 |
| Fracture Fixation, Internal:0 | 9/61,988 | 18,502/16,348,907 | 0.13 | 8.59e-20 | 1.60e-18 |
| Reperfusion Injury:0 | 2/61,988 | 30,360/16,348,907 | 0.02 | 1.43e-46 | 6.04e-45 |
| Proto-Oncogene Protein pp60 (c-src)|SRC:0 | 168/61,988 | 14,960/16,348,907 | 2.97 | 8.10e-33 | 2.42e-31 |
| Potassium:0 | 5/61,988 | 31,281/16,348,907 | 0.04 | 1.80e-43 | 7.08e-42 |
| Streptokinase:0 | 3/61,988 | 10,656/16,348,907 | 0.07 | 9.10e-14 | 1.21e-12 |
| MAP1LC3A:0 | 23/61,988 | 1,514/16,348,907 | 4.01 | 5.15e-08 | 4.24e-07 |
| Cholecystokinin:0 | 2/61,988 | 10,734/16,348,907 | 0.05 | 4.22e-15 | 6.08e-14 |
| branched chain fatty acid:0 | 23/61,988 | 513/16,348,907 | 11.83 | 4.14e-17 | 6.70e-16 |
| Castration Cell:0 | 150/61,988 | 314/16,348,907 | 126.30 | 2.51e-239 | 4.80e-237 |
| Buffers:0 | 46/61,988 | 32,719/16,348,907 | 0.37 | 1.82e-15 | 2.69e-14 |
| PA2024:0 | 6/61,988 | 9/16,348,907 | 175.85 | 1.41e-11 | 1.61e-10 |
| Positioning - therapy:0 | 22/61,988 | 420/16,348,907 | 13.82 | 9.02e-18 | 1.50e-16 |
| clopidogrel:0 | 4/61,988 | 14,299/16,348,907 | 0.07 | 2.40e-18 | 4.14e-17 |
| Methadone:0 | 4/61,988 | 8,566/16,348,907 | 0.12 | 9.69e-10 | 9.47e-09 |
| Neurotoxins:0 | 1/61,988 | 4,919/16,348,907 | 0.05 | 3.02e-07 | 2.29e-06 |
| EIF4EBP1:0 | 12/61,988 | 415/16,348,907 | 7.63 | 1.31e-07 | 1.03e-06 |
| Acetaldehyde:0 | 2/61,988 | 6,592/16,348,907 | 0.08 | 8.99e-09 | 8.03e-08 |
| Transforming Growth Factor beta Receptors:0 | 32/61,988 | 2,244/16,348,907 | 3.76 | 6.64e-10 | 6.60e-09 |
| Reader:0 | 53/61,988 | 6,127/16,348,907 | 2.28 | 1.10e-07 | 8.74e-07 |
| Entire periprostatic tissue:0 | 26/61,988 | 56/16,348,907 | 122.50 | 1.37e-42 | 5.28e-41 |
| Local Anesthetics:0 | 9/61,988 | 9,049/16,348,907 | 0.26 | 7.51e-07 | 5.43e-06 |
| Vasodilator Agents:0 | 1/61,988 | 6,551/16,348,907 | 0.04 | 9.67e-10 | 9.45e-09 |
| Dental Pulp:0 | 1/61,988 | 9,713/16,348,907 | 0.03 | 8.40e-15 | 1.19e-13 |
| CDK4 gene|CDK4:0 | 28/61,988 | 1,719/16,348,907 | 4.30 | 4.46e-10 | 4.53e-09 |
| CK2:0 | 20/61,988 | 341/16,348,907 | 15.47 | 3.47e-17 | 5.64e-16 |
| Factor VIII-Related Antigen:0 | 10/61,988 | 14,034/16,348,907 | 0.19 | 1.01e-12 | 1.23e-11 |
| Carcinoma, Neuroendocrine:0 | 45/61,988 | 2,981/16,348,907 | 3.98 | 4.07e-14 | 5.52e-13 |
| VIM gene|VIM:0 | 78/61,988 | 3,030/16,348,907 | 6.80 | 1.07e-37 | 3.68e-36 |
| Repression:0 | 43/61,988 | 3,460/16,348,907 | 3.28 | 6.28e-11 | 6.85e-10 |
| Treats:0 | 65/61,988 | 7,156/16,348,907 | 2.40 | 5.93e-10 | 5.94e-09 |
| Gastric Emptying:0 | 1/61,988 | 9,920/16,348,907 | 0.03 | 4.10e-15 | 5.92e-14 |
| Tartrates:0 | 12/61,988 | 337/16,348,907 | 9.39 | 1.47e-08 | 1.28e-07 |
| Chromatography:0 | 29/61,988 | 20,808/16,348,907 | 0.37 | 1.85e-10 | 1.94e-09 |
| Dexmedetomidine:0 | 2/61,988 | 6,931/16,348,907 | 0.08 | 3.22e-09 | 3.01e-08 |
| Right ventricular structure:0 | 4/61,988 | 19,424/16,348,907 | 0.05 | 3.44e-26 | 8.39e-25 |
| Signal Transduction Pathways:0 | 409/61,988 | 35,895/16,348,907 | 3.02 | 5.37e-79 | 3.63e-77 |
| SLC25A4 protein, human|SLC25A4:0 | 56/61,988 | 1,744/16,348,907 | 8.48 | 3.70e-32 | 1.09e-30 |
| Testicular ablation:0 | 11/61,988 | 23/16,348,907 | 126.16 | 5.89e-19 | 1.05e-17 |
| basolateral membrane:0 | 4/61,988 | 7,022/16,348,907 | 0.15 | 1.50e-07 | 1.17e-06 |
| Dyslipidemias:0 | 26/61,988 | 19,927/16,348,907 | 0.34 | 9.83e-11 | 1.06e-09 |
| AIFM1:0 | 14/61,988 | 590/16,348,907 | 6.26 | 1.28e-07 | 1.01e-06 |
| anti-apoptosis:0 | 101/61,988 | 5,946/16,348,907 | 4.49 | 1.61e-33 | 4.91e-32 |
| ABNORMAL GROWTH:0 | 30/61,988 | 790/16,348,907 | 10.02 | 6.55e-20 | 1.23e-18 |
| Endocarditis:0 | 4/61,988 | 15,316/16,348,907 | 0.07 | 7.17e-20 | 1.34e-18 |
| Kidney Neoplasms:0 | 79/61,988 | 8,622/16,348,907 | 2.42 | 8.69e-12 | 1.01e-10 |
| Clinic Activities:0 | 57/61,988 | 1,429/16,348,907 | 10.53 | 2.04e-37 | 6.95e-36 |
| Gonadal Steroid Hormones:0 | 154/61,988 | 9,516/16,348,907 | 4.28 | 1.11e-47 | 4.82e-46 |
| Radium therapy:0 | 8/61,988 | 129/16,348,907 | 16.36 | 6.72e-08 | 5.46e-07 |
| Retinitis Pigmentosa:0 | 1/61,988 | 7,459/16,348,907 | 0.04 | 3.78e-11 | 4.18e-10 |
| Fertilization:0 | 5/61,988 | 8,941/16,348,907 | 0.15 | 1.48e-09 | 1.43e-08 |
| Electroconvulsive Therapy:0 | 8/61,988 | 11,171/16,348,907 | 0.19 | 2.34e-10 | 2.43e-09 |
| Eligard:0 | 9/61,988 | 16/16,348,907 | 148.38 | 3.03e-16 | 4.66e-15 |
| PTH protein, human|PTH:0 | 37/61,988 | 22,807/16,348,907 | 0.43 | 3.25e-09 | 3.03e-08 |
| Kidney Tubules, Proximal:0 | 18/61,988 | 21,142/16,348,907 | 0.22 | 1.09e-16 | 1.73e-15 |
| Neoplastic Processes:0 | 23/61,988 | 1,074/16,348,907 | 5.65 | 1.00e-10 | 1.07e-09 |
| Gammaretrovirus:0 | 36/61,988 | 219/16,348,907 | 43.38 | 2.30e-44 | 9.24e-43 |
| Support Groups:0 | 18/61,988 | 516/16,348,907 | 9.20 | 5.63e-12 | 6.62e-11 |
| Heart Transplantation:0 | 8/61,988 | 10,854/16,348,907 | 0.19 | 6.12e-10 | 6.11e-09 |
| RUNX2:0 | 50/61,988 | 5,071/16,348,907 | 2.60 | 4.02e-09 | 3.71e-08 |
| Secondary Lesion:0 | 15/61,988 | 687/16,348,907 | 5.76 | 1.31e-07 | 1.03e-06 |
| FLVCR1:0 | 369/61,988 | 2,066/16,348,907 | 47.38 | 0.00e+00 | 0.00e+00 |
| Reporting:0 | 61/61,988 | 8,101/16,348,907 | 1.99 | 1.26e-06 | 8.83e-06 |
| Carcinoma:0 | 4,988/61,988 | 144,987/16,348,907 | 9.78 | 0.00e+00 | 0.00e+00 |
| Cystic Fibrosis:0 | 8/61,988 | 67,785/16,348,907 | 0.03 | 2.14e-97 | 1.72e-95 |
| Neuraminidase:0 | 17/61,988 | 12,347/16,348,907 | 0.36 | 1.06e-06 | 7.49e-06 |
| Cyproterone Acetate:0 | 236/61,988 | 3,875/16,348,907 | 16.12 | 3.21e-188 | 5.10e-186 |
| Chromosomal Rearrangement:0 | 28/61,988 | 1,838/16,348,907 | 4.02 | 1.86e-09 | 1.78e-08 |
| Xenograft Model:0 | 604/61,988 | 9,453/16,348,907 | 17.01 | 0.00e+00 | 0.00e+00 |
| enterodiol:0 | 11/61,988 | 249/16,348,907 | 11.65 | 7.00e-09 | 6.33e-08 |
| Finasteride 5 MG:0 | 5/61,988 | 30/16,348,907 | 43.96 | 2.27e-07 | 1.74e-06 |
| Dimethyl Sulfoxide:0 | 25/61,988 | 15,807/16,348,907 | 0.42 | 5.22e-07 | 3.84e-06 |
| Urease:0 | 1/61,988 | 4,611/16,348,907 | 0.06 | 8.86e-07 | 6.35e-06 |
| Peptic Ulcer:0 | 6/61,988 | 21,161/16,348,907 | 0.07 | 1.17e-26 | 2.92e-25 |
| Argipressin|AVP:0 | 2/61,988 | 16,931/16,348,907 | 0.03 | 5.22e-25 | 1.21e-23 |
| Stem cells:0 | 596/61,988 | 66,239/16,348,907 | 2.39 | 3.99e-76 | 2.60e-74 |
| Telomerase|EREG|ESR1:0 | 4/61,988 | 12/16,348,907 | 87.92 | 3.57e-07 | 2.68e-06 |
| Pathologic stage:0 | 294/61,988 | 1,244/16,348,907 | 62.62 | 0.00e+00 | 0.00e+00 |
| Physicist:0 | 8/61,988 | 185/16,348,907 | 11.41 | 9.19e-07 | 6.57e-06 |
| Androgen replacement therapy:0 | 15/61,988 | 237/16,348,907 | 16.70 | 1.03e-13 | 1.36e-12 |
| California:0 | 59/61,988 | 2,000/16,348,907 | 7.79 | 6.53e-32 | 1.91e-30 |
| Thrombolytic Therapy:0 | 10/61,988 | 14,313/16,348,907 | 0.18 | 3.78e-13 | 4.79e-12 |
| Pads:0 | 117/61,988 | 7,003/16,348,907 | 4.41 | 6.71e-38 | 2.32e-36 |
| Bariatric Surgery:0 | 3/61,988 | 6,842/16,348,907 | 0.12 | 3.32e-08 | 2.80e-07 |
| Electric Countershock:0 | 1/61,988 | 6,410/16,348,907 | 0.04 | 1.33e-09 | 1.29e-08 |
| Cancer Cell Growth Regulation:0 | 5/61,988 | 12/16,348,907 | 109.90 | 4.58e-09 | 4.20e-08 |
| Cancer Fatigue:0 | 19/61,988 | 1,027/16,348,907 | 4.88 | 3.85e-08 | 3.21e-07 |
| Graft acceptance:0 | 3/61,988 | 6,321/16,348,907 | 0.13 | 1.83e-07 | 1.42e-06 |
| Stem cell transplant:0 | 7/61,988 | 11,078/16,348,907 | 0.17 | 6.32e-11 | 6.89e-10 |
| Ulcer of rectum:0 | 16/61,988 | 236/16,348,907 | 17.89 | 5.76e-15 | 8.22e-14 |
| Radionuclide therapy:0 | 36/61,988 | 955/16,348,907 | 9.95 | 1.81e-23 | 3.97e-22 |
| Caucasoid Race:0 | 519/61,988 | 48,558/16,348,907 | 2.83 | 2.43e-90 | 1.81e-88 |
| PCGEM1:0 | 13/61,988 | 44/16,348,907 | 77.94 | 6.68e-20 | 1.25e-18 |
| Bone neoplasms:0 | 71/61,988 | 3,563/16,348,907 | 5.26 | 5.76e-28 | 1.48e-26 |
| Gangliosides:0 | 11/61,988 | 10,781/16,348,907 | 0.27 | 6.66e-08 | 5.42e-07 |
| Protein Isoprenylation:0 | 10/61,988 | 317/16,348,907 | 8.32 | 6.69e-07 | 4.86e-06 |
| Binding protein 3:0 | 11/61,988 | 278/16,348,907 | 10.44 | 2.07e-08 | 1.78e-07 |
| epitheliasin|ERG:0 | 16/61,988 | 36/16,348,907 | 117.25 | 1.56e-26 | 3.86e-25 |
| Cardiomyopathy, Dilated:0 | 2/61,988 | 19,531/16,348,907 | 0.03 | 4.17e-29 | 1.12e-27 |
| Dermatitis:0 | 5/61,988 | 11,495/16,348,907 | 0.11 | 3.16e-13 | 4.03e-12 |
| Gastrointestinal Diseases:0 | 7/61,988 | 8,324/16,348,907 | 0.22 | 3.81e-07 | 2.85e-06 |
| Major Depressive Disorder:0 | 15/61,988 | 43,686/16,348,907 | 0.09 | 4.63e-51 | 2.14e-49 |
| invasive treatment:0 | 93/61,988 | 2,708/16,348,907 | 9.07 | 1.32e-54 | 6.53e-53 |
| CEP 701:0 | 9/61,988 | 72/16,348,907 | 32.97 | 3.19e-11 | 3.56e-10 |
| Seminal Vesicles:0 | 529/61,988 | 7,044/16,348,907 | 19.97 | 0.00e+00 | 0.00e+00 |
| Urethral sphincter:0 | 15/61,988 | 580/16,348,907 | 6.82 | 1.55e-08 | 1.35e-07 |
| Gonadorelin|ELANE:0 | 5/61,988 | 35/16,348,907 | 37.68 | 4.53e-07 | 3.36e-06 |
| Bone remodeling:0 | 43/61,988 | 4,106/16,348,907 | 2.76 | 8.91e-09 | 7.96e-08 |
| Sulfhydryl Compounds:0 | 24/61,988 | 18,089/16,348,907 | 0.35 | 9.83e-10 | 9.60e-09 |
| Xenopus oocyte:0 | 2/61,988 | 8,132/16,348,907 | 0.06 | 4.56e-11 | 5.03e-10 |
| Quinidine:0 | 2/61,988 | 6,111/16,348,907 | 0.09 | 5.31e-08 | 4.36e-07 |
| CDKN1A gene|CDKN1A:0 | 89/61,988 | 4,171/16,348,907 | 5.63 | 9.47e-37 | 3.19e-35 |
| Gingiva:0 | 13/61,988 | 24,837/16,348,907 | 0.14 | 2.64e-25 | 6.20e-24 |
| DNA Methylation:0 | 149/61,988 | 11,446/16,348,907 | 3.44 | 7.53e-36 | 2.43e-34 |
| Diazepam:0 | 2/61,988 | 18,569/16,348,907 | 0.03 | 1.64e-27 | 4.17e-26 |
| Macrophages, Alveolar:0 | 2/61,988 | 22,007/16,348,907 | 0.02 | 4.65e-33 | 1.40e-31 |
| DAB2IP gene|DAB2IP:0 | 9/61,988 | 30/16,348,907 | 79.13 | 2.99e-14 | 4.09e-13 |
| Alveolar:0 | 14/61,988 | 25,114/16,348,907 | 0.15 | 5.67e-25 | 1.32e-23 |
| Simple atrophy:0 | 6/61,988 | 28/16,348,907 | 56.52 | 3.57e-09 | 3.32e-08 |
| Naloxone:0 | 4/61,988 | 23,701/16,348,907 | 0.04 | 6.98e-33 | 2.10e-31 |
| investigation:0 | 189/61,988 | 27,571/16,348,907 | 1.81 | 1.28e-13 | 1.68e-12 |
| Eczema:0 | 1/61,988 | 7,811/16,348,907 | 0.03 | 8.33e-12 | 9.66e-11 |
| GALACTOSYLGALACTOSYLGLUCOSYLCERAMIDASE:0 | 21/61,988 | 371/16,348,907 | 14.93 | 1.13e-17 | 1.87e-16 |
| PARP1|COL11A2:0 | 88/61,988 | 5,132/16,348,907 | 4.53 | 1.03e-29 | 2.82e-28 |
| Chemoembolisation:0 | 9/61,988 | 9,779/16,348,907 | 0.24 | 8.92e-08 | 7.15e-07 |
| Diagnostic Neoplasm Staging:0 | 50/61,988 | 1,285/16,348,907 | 10.27 | 1.48e-32 | 4.41e-31 |
| Neuroendocrine Cell:0 | 175/61,988 | 3,362/16,348,907 | 13.76 | 3.02e-129 | 3.33e-127 |
| Retina:0 | 16/61,988 | 125,111/16,348,907 | 0.03 | 3.30e-177 | 4.91e-175 |
| Light, Visible:0 | 4/61,988 | 11,660/16,348,907 | 0.09 | 2.13e-14 | 2.94e-13 |
| Locally Advanced Malignant Neoplasm:0 | 898/61,988 | 13,570/16,348,907 | 17.70 | 0.00e+00 | 0.00e+00 |
| Germ-Line Mutation:0 | 130/61,988 | 8,355/16,348,907 | 4.11 | 7.41e-39 | 2.64e-37 |
| Purkinje Cells:0 | 5/61,988 | 9,374/16,348,907 | 0.14 | 3.91e-10 | 4.00e-09 |
| Bone structure of humerus:0 | 4/61,988 | 6,431/16,348,907 | 0.16 | 1.13e-06 | 8.00e-06 |
| Taxol:0 | 123/61,988 | 10,303/16,348,907 | 3.15 | 1.07e-26 | 2.66e-25 |
| Cell Cycle:0 | 604/61,988 | 32,670/16,348,907 | 4.91 | 8.91e-209 | 1.53e-206 |
| Conn Syndrome:0 | 1/61,988 | 5,936/16,348,907 | 0.04 | 8.30e-09 | 7.45e-08 |
| Phospholipids:0 | 87/61,988 | 62,101/16,348,907 | 0.37 | 1.98e-28 | 5.19e-27 |
| CD29 Antigen:0 | 52/61,988 | 5,332/16,348,907 | 2.57 | 4.27e-09 | 3.92e-08 |
| Oxidopamine:0 | 1/61,988 | 10,311/16,348,907 | 0.03 | 9.47e-16 | 1.42e-14 |
| Percutaneous insertion of nephrostomy tube:0 | 26/61,988 | 879/16,348,907 | 7.80 | 5.33e-15 | 7.64e-14 |
| E-Cadherin:0 | 336/61,988 | 16,321/16,348,907 | 5.45 | 2.10e-129 | 2.32e-127 |
| Somatostatin analog|GRHL3:0 | 10/61,988 | 8/16,348,907 | 329.73 | 2.52e-20 | 4.84e-19 |
| Muscular Dystrophies:0 | 2/61,988 | 7,295/16,348,907 | 0.07 | 7.57e-10 | 7.49e-09 |
| Maintenance therapy:0 | 13/61,988 | 11,064/16,348,907 | 0.31 | 3.63e-07 | 2.72e-06 |
| Cyanides:0 | 2/61,988 | 5,643/16,348,907 | 0.09 | 3.20e-07 | 2.41e-06 |
| Estrogen Metabolism:0 | 9/61,988 | 234/16,348,907 | 10.15 | 4.96e-07 | 3.66e-06 |
| MULTISECTION:FINDING:POINT IN TIME:PROSTATE:NARRATIVE:MRI:0 | 13/61,988 | 17/16,348,907 | 201.73 | 3.59e-24 | 8.04e-23 |
| DNA ploidy analysis:0 | 12/61,988 | 169/16,348,907 | 18.73 | 8.31e-12 | 9.64e-11 |
| Thyroid Hormones:0 | 17/61,988 | 20,514/16,348,907 | 0.22 | 1.58e-16 | 2.47e-15 |
| Immune Sera|HSD3B1:0 | 11/61,988 | 8/16,348,907 | 362.71 | 1.64e-22 | 3.44e-21 |
| Imipramine:0 | 1/61,988 | 12,831/16,348,907 | 0.02 | 6.77e-20 | 1.27e-18 |
| Mercury:0 | 6/61,988 | 16,451/16,348,907 | 0.10 | 1.60e-19 | 2.93e-18 |
| Microbubbles:0 | 32/61,988 | 2,641/16,348,907 | 3.20 | 2.79e-08 | 2.36e-07 |
| Cancer Risk:0 | 12/61,988 | 185/16,348,907 | 17.11 | 2.24e-11 | 2.52e-10 |
| POTED:0 | 8/61,988 | 52/16,348,907 | 40.58 | 8.90e-11 | 9.61e-10 |
| Hematopoietic Stem Cell Transplantation:0 | 7/61,988 | 13,726/16,348,907 | 0.13 | 1.11e-14 | 1.56e-13 |
| Blood - brain barrier function:0 | 3/61,988 | 12,822/16,348,907 | 0.06 | 3.56e-17 | 5.77e-16 |
| Carcinoembryonic Antigen:0 | 118/61,988 | 12,639/16,348,907 | 2.47 | 1.42e-17 | 2.34e-16 |
| Prostatic radiotherapies:0 | 82/61,988 | 113/16,348,907 | 191.64 | 3.24e-143 | 3.96e-141 |
| histone methylation:0 | 13/61,988 | 346/16,348,907 | 9.91 | 2.01e-09 | 1.92e-08 |
| Suicidal:0 | 2/61,988 | 5,922/16,348,907 | 0.09 | 1.08e-07 | 8.62e-07 |
| Gene Silencing:0 | 58/61,988 | 3,941/16,348,907 | 3.88 | 3.02e-17 | 4.92e-16 |
| Motor Cortex:0 | 2/61,988 | 9,858/16,348,907 | 0.05 | 1.10e-13 | 1.45e-12 |
| Biopsy site:0 | 7/61,988 | 127/16,348,907 | 14.54 | 9.47e-07 | 6.75e-06 |
| Disks:0 | 6/61,988 | 8,515/16,348,907 | 0.19 | 4.29e-08 | 3.56e-07 |
| Tissue Recombination:0 | 12/61,988 | 83/16,348,907 | 38.14 | 3.45e-15 | 5.00e-14 |
| Peptide Hydrolases|OMA1:0 | 31/61,988 | 1,818/16,348,907 | 4.50 | 1.81e-11 | 2.04e-10 |
| Asymptomatic:0 | 386/61,988 | 38,353/16,348,907 | 2.66 | 3.21e-61 | 1.75e-59 |
| galiellalactone:0 | 6/61,988 | 43/16,348,907 | 36.80 | 3.53e-08 | 2.97e-07 |
| Chronic Obstructive Airway Disease:0 | 29/61,988 | 92,185/16,348,907 | 0.08 | 1.64e-109 | 1.47e-107 |
| Prophylactic treatment:0 | 584/61,988 | 123,509/16,348,907 | 1.25 | 2.45e-07 | 1.87e-06 |
| Entire limb:0 | 10/61,988 | 35,911/16,348,907 | 0.07 | 9.36e-45 | 3.80e-43 |
| Proctitis:0 | 54/61,988 | 1,184/16,348,907 | 12.04 | 2.42e-38 | 8.47e-37 |
| Atopic:0 | 1/61,988 | 9,030/16,348,907 | 0.03 | 1.09e-13 | 1.44e-12 |
| Mammary Gland Parenchyma:0 | 106/61,988 | 10,997/16,348,907 | 2.54 | 9.38e-17 | 1.49e-15 |
| MG 132|ATF6B|GNA13:0 | 8/61,988 | 11/16,348,907 | 191.84 | 3.02e-15 | 4.39e-14 |
| Gonadorelin|BRD2:0 | 108/61,988 | 47/16,348,907 | 607.10 | 2.31e-222 | 4.15e-220 |
| Nomograms:0 | 22/61,988 | 172/16,348,907 | 33.75 | 1.48e-25 | 3.51e-24 |
| Prostate manipulation:0 | 24/61,988 | 94/16,348,907 | 67.36 | 3.50e-34 | 1.08e-32 |
| Prostate-Specific Antigen|PGR|PR@|PRH2|TMEM37|ERVK-10:0 | 7/61,988 | 20/16,348,907 | 92.32 | 9.12e-12 | 1.05e-10 |
| Japanese Americans:0 | 12/61,988 | 395/16,348,907 | 8.01 | 7.81e-08 | 6.29e-07 |
| Endobronchial metastases:0 | 10/61,988 | 139/16,348,907 | 18.98 | 4.00e-10 | 4.08e-09 |
| Secretory Cell:0 | 104/61,988 | 2,987/16,348,907 | 9.20 | 2.15e-61 | 1.18e-59 |
| Phenylalanine:0 | 24/61,988 | 16,821/16,348,907 | 0.38 | 2.46e-08 | 2.10e-07 |
| Carp, fish:0 | 1/61,988 | 4,511/16,348,907 | 0.06 | 1.27e-06 | 8.90e-06 |
| Surgeon:0 | 290/61,988 | 26,085/16,348,907 | 2.94 | 1.72e-54 | 8.48e-53 |
| Tissue Kallikrein:0 | 88/61,988 | 2,553/16,348,907 | 9.10 | 6.84e-52 | 3.22e-50 |
| Urinary Sphincter, Artificial:0 | 60/61,988 | 1,836/16,348,907 | 8.63 | 9.91e-35 | 3.10e-33 |
| Entire lip:0 | 54/61,988 | 6,640/16,348,907 | 2.15 | 6.41e-07 | 4.67e-06 |
| Testosterone Propionate:0 | 61/61,988 | 3,786/16,348,907 | 4.25 | 7.43e-20 | 1.39e-18 |
| Mammals:0 | 56/61,988 | 42,175/16,348,907 | 0.35 | 4.71e-21 | 9.35e-20 |
| Integrins:0 | 263/61,988 | 28,396/16,348,907 | 2.45 | 1.75e-36 | 5.81e-35 |
| Glandular proliferation:0 | 13/61,988 | 111/16,348,907 | 30.90 | 2.96e-15 | 4.30e-14 |
| PRAC1:0 | 5/61,988 | 37/16,348,907 | 35.64 | 5.82e-07 | 4.27e-06 |
| Blind Vision:0 | 5/61,988 | 17,053/16,348,907 | 0.08 | 1.61e-21 | 3.25e-20 |
| Mitotic arrest:0 | 42/61,988 | 1,110/16,348,907 | 9.99 | 3.64e-27 | 9.16e-26 |
| Graft-vs-Host Disease:0 | 3/61,988 | 7,697/16,348,907 | 0.10 | 2.18e-09 | 2.07e-08 |
| Tumor cells, malignant:0 | 2,361/61,988 | 49,808/16,348,907 | 12.96 | 0.00e+00 | 0.00e+00 |
| CREBBP protein, human|CREBBP:0 | 30/61,988 | 2,391/16,348,907 | 3.31 | 3.55e-08 | 2.98e-07 |
| Vesicle:0 | 99/61,988 | 63,707/16,348,907 | 0.41 | 4.08e-25 | 9.56e-24 |
| TERT protein, human|TERT:0 | 43/61,988 | 4,042/16,348,907 | 2.81 | 5.75e-09 | 5.24e-08 |
| Male urethral structure:0 | 18/61,988 | 650/16,348,907 | 7.31 | 2.09e-10 | 2.18e-09 |
| Orchiectomy:0 | 534/61,988 | 3,377/16,348,907 | 42.06 | 0.00e+00 | 0.00e+00 |
| Necrotizing fasciitis:0 | 1/61,988 | 5,285/16,348,907 | 0.05 | 7.06e-08 | 5.73e-07 |
| Leuprolide Acetate|HSD3B1:0 | 11/61,988 | 1/16,348,907 | 2901.69 | 2.67e-26 | 6.55e-25 |
| tomography:0 | 646/61,988 | 97,084/16,348,907 | 1.76 | 3.71e-39 | 1.33e-37 |
| Dapsone:0 | 2/61,988 | 5,433/16,348,907 | 0.10 | 6.36e-07 | 4.64e-06 |
| AZIN2|GADL1:0 | 23/61,988 | 1,068/16,348,907 | 5.68 | 9.00e-11 | 9.70e-10 |
| Phantoms, Imaging:0 | 363/61,988 | 20,059/16,348,907 | 4.80 | 1.76e-123 | 1.87e-121 |
| liarozole:0 | 19/61,988 | 253/16,348,907 | 19.81 | 2.90e-18 | 4.98e-17 |
| Nicotinic Receptors:0 | 2/61,988 | 16,069/16,348,907 | 0.03 | 1.39e-23 | 3.06e-22 |
| Phytoestrogens:0 | 159/61,988 | 5,058/16,348,907 | 8.31 | 9.76e-87 | 7.07e-85 |
| Aptosyn:0 | 5/61,988 | 19/16,348,907 | 69.41 | 3.08e-08 | 2.60e-07 |
| Ubiquitination:0 | 48/61,988 | 3,620/16,348,907 | 3.50 | 5.71e-13 | 7.14e-12 |
| atrasentan:0 | 41/61,988 | 366/16,348,907 | 29.56 | 4.32e-44 | 1.72e-42 |
| RNA, Untranslated:0 | 47/61,988 | 3,168/16,348,907 | 3.92 | 2.08e-14 | 2.87e-13 |
| Cell Transplantation:0 | 3/61,988 | 6,329/16,348,907 | 0.12 | 1.83e-07 | 1.42e-06 |
| Nickel:0 | 9/61,988 | 8,923/16,348,907 | 0.27 | 9.95e-07 | 7.08e-06 |
| PROSTATE ABNORMAL:0 | 19/61,988 | 29/16,348,907 | 172.85 | 9.60e-34 | 2.95e-32 |
| Pravastatin:0 | 4/61,988 | 7,570/16,348,907 | 0.14 | 2.95e-08 | 2.50e-07 |
| Malignant neoplasm of prostate:0 | 56,120/61,988 | 129,049/16,348,907 | 1202.04 | 0.00e+00 | 0.00e+00 |
| Anti-Bacterial Agents:0 | 16/61,988 | 16,489/16,348,907 | 0.26 | 5.99e-12 | 7.02e-11 |
| ONO AE3-208:0 | 4/61,988 | 16/16,348,907 | 65.94 | 9.40e-07 | 6.70e-06 |
| Influenza:0 | 11/61,988 | 31,849/16,348,907 | 0.09 | 2.21e-37 | 7.51e-36 |
| Superoxides:0 | 42/61,988 | 33,584/16,348,907 | 0.33 | 2.95e-18 | 5.05e-17 |
| Electronic:0 | 30/61,988 | 17,937/16,348,907 | 0.44 | 3.77e-07 | 2.82e-06 |
| Cyclin-Dependent Kinase Inhibitor 2A|CDKN2A:0 | 11/61,988 | 315/16,348,907 | 9.21 | 7.02e-08 | 5.70e-07 |
| Purpose:0 | 165/61,988 | 12,262/16,348,907 | 3.56 | 3.43e-41 | 1.30e-39 |
| zoledronic acid:0 | 460/61,988 | 6,754/16,348,907 | 18.09 | 0.00e+00 | 0.00e+00 |
| Immunocompetent:0 | 7/61,988 | 9,469/16,348,907 | 0.19 | 1.17e-08 | 1.03e-07 |
| Down Syndrome:0 | 8/61,988 | 29,640/16,348,907 | 0.07 | 2.16e-37 | 7.36e-36 |
| Ferritin:0 | 17/61,988 | 27,965/16,348,907 | 0.16 | 1.49e-26 | 3.69e-25 |
| BRF1 protein, human|ZFP36L1|BRF1|MST1L:0 | 7/61,988 | 83/16,348,907 | 22.25 | 6.23e-08 | 5.08e-07 |
| Candidate Disease Gene|AR:0 | 14/61,988 | 41/16,348,907 | 90.08 | 4.53e-22 | 9.36e-21 |
| receptor function:0 | 103/61,988 | 2,217/16,348,907 | 12.27 | 2.90e-72 | 1.82e-70 |
| Localized Carcinoma:0 | 194/61,988 | 875/16,348,907 | 58.66 | 6.34e-254 | 1.29e-251 |
| anemia; profound:0 | 6/61,988 | 8,260/16,348,907 | 0.19 | 7.89e-08 | 6.35e-07 |
| stage, prostate cancer:0 | 88/61,988 | 104/16,348,907 | 223.48 | 7.33e-158 | 9.93e-156 |
| Adrenergic alpha-Antagonists:0 | 97/61,988 | 6,118/16,348,907 | 4.19 | 4.81e-30 | 1.32e-28 |
| Intestinal Mucosa:0 | 6/61,988 | 8,614/16,348,907 | 0.18 | 3.09e-08 | 2.61e-07 |
| Tuberculosis, Pulmonary:0 | 7/61,988 | 24,017/16,348,907 | 0.08 | 5.74e-30 | 1.58e-28 |
| General Population:0 | 326/61,988 | 43,258/16,348,907 | 1.99 | 7.09e-29 | 1.89e-27 |
| Secondary malignant neoplasm of skin NOS:0 | 38/61,988 | 1,431/16,348,907 | 7.01 | 1.15e-19 | 2.12e-18 |
| clinical aspects:0 | 73/61,988 | 5,781/16,348,907 | 3.33 | 8.97e-18 | 1.50e-16 |
| VEGFC gene|VEGFC:0 | 11/61,988 | 360/16,348,907 | 8.06 | 2.55e-07 | 1.94e-06 |
| Cystadenoma:0 | 23/61,988 | 1,512/16,348,907 | 4.01 | 5.03e-08 | 4.15e-07 |
| Bone Marrow Transplantation:0 | 2/61,988 | 15,796/16,348,907 | 0.03 | 4.26e-23 | 9.19e-22 |
| Common Terminology Criteria for Adverse Events:0 | 18/61,988 | 161/16,348,907 | 29.50 | 3.15e-20 | 6.04e-19 |
| Steroid biosynthesis:0 | 61/61,988 | 5,337/16,348,907 | 3.02 | 2.59e-13 | 3.33e-12 |
| 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene:0 | 4/61,988 | 9/16,348,907 | 117.23 | 1.42e-07 | 1.11e-06 |
| Prostatomegaly:0 | 9/61,988 | 26/16,348,907 | 91.31 | 1.01e-14 | 1.42e-13 |
| ROS1:0 | 76/61,988 | 9,971/16,348,907 | 2.01 | 5.12e-08 | 4.22e-07 |
| Alternative Therapies:0 | 66/61,988 | 4,334/16,348,907 | 4.02 | 4.01e-20 | 7.63e-19 |
| Prostate biopsy sample:0 | 26/61,988 | 28/16,348,907 | 245.01 | 1.71e-48 | 7.59e-47 |
| Cerebrovascular Disorders:0 | 10/61,988 | 10,771/16,348,907 | 0.24 | 1.67e-08 | 1.45e-07 |
| Osteomyelitis:0 | 20/61,988 | 20,402/16,348,907 | 0.26 | 1.60e-14 | 2.22e-13 |
| Colchicine:0 | 14/61,988 | 13,619/16,348,907 | 0.27 | 1.22e-09 | 1.18e-08 |
| MAPT:0 | 5/61,988 | 15,601/16,348,907 | 0.08 | 3.24e-19 | 5.86e-18 |
| Rectum excision:0 | 28/61,988 | 2,180/16,348,907 | 3.39 | 6.21e-08 | 5.07e-07 |
| saturated fat:0 | 26/61,988 | 1,843/16,348,907 | 3.72 | 3.05e-08 | 2.58e-07 |
| Aortic Aneurysm, Abdominal:0 | 14/61,988 | 13,741/16,348,907 | 0.27 | 9.17e-10 | 9.02e-09 |
| Amino Acids:0 | 225/61,988 | 113,658/16,348,907 | 0.52 | 1.11e-27 | 2.83e-26 |
| Anaphylaxis:0 | 7/61,988 | 12,567/16,348,907 | 0.15 | 6.51e-13 | 8.09e-12 |
| Seminal fluid:0 | 107/61,988 | 4,522/16,348,907 | 6.25 | 9.01e-48 | 3.94e-46 |
| Cerebellum:0 | 21/61,988 | 59,113/16,348,907 | 0.09 | 5.17e-68 | 3.07e-66 |
| Mucin-1 Staining Method:0 | 36/61,988 | 1,600/16,348,907 | 5.94 | 1.51e-16 | 2.37e-15 |
| treatment complications:0 | 14/61,988 | 530/16,348,907 | 6.97 | 3.59e-08 | 3.01e-07 |
| Brachytherapy:0 | 1,667/61,988 | 11,085/16,348,907 | 40.73 | 0.00e+00 | 0.00e+00 |
| Spinal Cord Injuries:0 | 22/61,988 | 31,318/16,348,907 | 0.18 | 2.82e-27 | 7.13e-26 |
| Corpus Callosum:0 | 5/61,988 | 7,711/16,348,907 | 0.17 | 7.86e-08 | 6.33e-07 |
| Pregnancy, Ectopic:0 | 2/61,988 | 7,017/16,348,907 | 0.08 | 2.23e-09 | 2.12e-08 |
| ICI-118630:0 | 12/61,988 | 36/16,348,907 | 87.93 | 5.18e-19 | 9.27e-18 |
| Genitourinary symptoms NOS:0 | 8/61,988 | 138/16,348,907 | 15.29 | 1.10e-07 | 8.72e-07 |
| IL2 gene|IL2:0 | 46/61,988 | 28,760/16,348,907 | 0.42 | 1.73e-11 | 1.96e-10 |
| Noninfiltrating Intraductal Carcinoma:0 | 75/61,988 | 10,437/16,348,907 | 1.90 | 6.10e-07 | 4.46e-06 |
| Pruritus:0 | 12/61,988 | 12,313/16,348,907 | 0.26 | 2.87e-09 | 2.70e-08 |
| Thapsigargin:0 | 67/61,988 | 5,803/16,348,907 | 3.05 | 1.17e-14 | 1.64e-13 |
| Fluconazole:0 | 4/61,988 | 11,389/16,348,907 | 0.09 | 6.21e-14 | 8.31e-13 |
| Human tissue:0 | 893/61,988 | 33,444/16,348,907 | 7.13 | 0.00e+00 | 0.00e+00 |
| CTRL gene|CTRL:0 | 32/61,988 | 563/16,348,907 | 15.00 | 3.68e-26 | 8.98e-25 |
| cancer genetics:0 | 15/61,988 | 115/16,348,907 | 34.41 | 5.10e-18 | 8.66e-17 |
| Immunotherapy:0 | 560/61,988 | 27,020/16,348,907 | 5.51 | 7.29e-216 | 1.29e-213 |
| Testosterone:0 | 1,914/61,988 | 77,922/16,348,907 | 6.65 | 0.00e+00 | 0.00e+00 |
| Cytonal:0 | 6/61,988 | 13/16,348,907 | 121.74 | 7.55e-11 | 8.19e-10 |
| Diagnosis, Computer-Assisted:0 | 21/61,988 | 666/16,348,907 | 8.32 | 6.47e-13 | 8.05e-12 |
| Bombesin Receptor:0 | 128/61,988 | 1,264/16,348,907 | 26.76 | 8.86e-129 | 9.74e-127 |
| Adsorption:0 | 12/61,988 | 19,118/16,348,907 | 0.17 | 3.46e-18 | 5.92e-17 |
| Microbicides:0 | 56/61,988 | 48,730/16,348,907 | 0.30 | 2.11e-28 | 5.52e-27 |
| Simvastatin:0 | 31/61,988 | 21,163/16,348,907 | 0.39 | 7.46e-10 | 7.39e-09 |
| bicalutamide 50 MG:0 | 4/61,988 | 5/16,348,907 | 211.01 | 2.53e-08 | 2.15e-07 |
| immortalized cell:0 | 61/61,988 | 2,248/16,348,907 | 7.16 | 4.83e-31 | 1.36e-29 |
| MSR1 gene|MSR1:0 | 11/61,988 | 55/16,348,907 | 52.76 | 1.98e-15 | 2.91e-14 |
| Thrombus:0 | 26/61,988 | 39,927/16,348,907 | 0.17 | 4.80e-36 | 1.57e-34 |
| San Francisco:0 | 27/61,988 | 1,143/16,348,907 | 6.23 | 2.81e-13 | 3.60e-12 |
| European Organization for Research and Treatment of Cancer:0 | 7/61,988 | 77/16,348,907 | 23.98 | 3.85e-08 | 3.21e-07 |
| dehydroepiandrosterone:0 | 140/61,988 | 14,695/16,348,907 | 2.52 | 3.24e-21 | 6.46e-20 |
| Hypertrophic Cardiomyopathy:0 | 1/61,988 | 22,620/16,348,907 | 0.01 | 1.17e-35 | 3.76e-34 |
| Structure of capsule of prostate:0 | 38/61,988 | 86/16,348,907 | 116.61 | 7.33e-61 | 3.96e-59 |
| Ets Variant Protein 1|ETV1:0 | 14/61,988 | 107/16,348,907 | 34.52 | 6.24e-17 | 9.97e-16 |
| deoxypyridinoline:0 | 18/61,988 | 1,165/16,348,907 | 4.08 | 1.09e-06 | 7.69e-06 |
| Recombinant Vaccinia-Prostate Specific Antigen:0 | 4/61,988 | 10/16,348,907 | 105.50 | 1.98e-07 | 1.53e-06 |
| Bone structure of ischium:0 | 104/61,988 | 44,575/16,348,907 | 0.61 | 1.12e-07 | 8.91e-07 |
| Recombinant Growth Hormone:0 | 2/61,988 | 15,277/16,348,907 | 0.03 | 2.53e-22 | 5.28e-21 |
| Gentian Violet:0 | 20/61,988 | 1,321/16,348,907 | 3.99 | 3.88e-07 | 2.90e-06 |
| jejunum:0 | 14/61,988 | 24,480/16,348,907 | 0.15 | 6.17e-24 | 1.37e-22 |
| Muscle Fibers:0 | 5/61,988 | 23,782/16,348,907 | 0.06 | 8.08e-32 | 2.35e-30 |
| methaneselenol:0 | 13/61,988 | 79/16,348,907 | 43.41 | 5.38e-17 | 8.62e-16 |
| Implantation procedure:0 | 517/61,988 | 99,676/16,348,907 | 1.37 | 1.20e-11 | 1.37e-10 |
| Entire renal artery:0 | 2/61,988 | 5,475/16,348,907 | 0.10 | 4.25e-07 | 3.17e-06 |
| Lupron:0 | 11/61,988 | 149/16,348,907 | 19.47 | 4.13e-11 | 4.56e-10 |
| Bystander Effect:0 | 24/61,988 | 1,167/16,348,907 | 5.43 | 8.80e-11 | 9.51e-10 |
| Xenotropic murine leukemia virus:0 | 7/61,988 | 65/16,348,907 | 28.41 | 1.30e-08 | 1.14e-07 |
| BIRC5 gene|BIRC5:0 | 122/61,988 | 7,616/16,348,907 | 4.23 | 9.68e-38 | 3.34e-36 |
| adult stem cell:0 | 21/61,988 | 1,239/16,348,907 | 4.47 | 3.26e-08 | 2.75e-07 |
| Radical prostatectomy:0 | 7,258/61,988 | 15,642/16,348,907 | 138.48 | 0.00e+00 | 0.00e+00 |
| Radiation Therapy Oncology Group:0 | 34/61,988 | 252/16,348,907 | 35.60 | 2.38e-39 | 8.61e-38 |
| Sleep Disorders:0 | 5/61,988 | 8,328/16,348,907 | 0.16 | 1.09e-08 | 9.66e-08 |
| Tumor necrosis:0 | 28/61,988 | 1,905/16,348,907 | 3.88 | 3.95e-09 | 3.65e-08 |
| Grains:0 | 245/61,988 | 4,992/16,348,907 | 12.99 | 1.51e-174 | 2.22e-172 |
| Prostatic pain:0 | 13/61,988 | 163/16,348,907 | 21.04 | 2.85e-13 | 3.65e-12 |
| monocyte:0 | 59/61,988 | 71,037/16,348,907 | 0.22 | 5.02e-54 | 2.45e-52 |
| LPXN gene|LPXN:0 | 6/61,988 | 25/16,348,907 | 63.30 | 1.97e-09 | 1.88e-08 |
| Basal Ganglia:0 | 4/61,988 | 14,679/16,348,907 | 0.07 | 5.76e-19 | 1.03e-17 |
| Oral mucous membrane structure:0 | 9/61,988 | 12,071/16,348,907 | 0.20 | 9.10e-11 | 9.81e-10 |
| Tetrahydrocannabinol:0 | 8/61,988 | 10,189/16,348,907 | 0.21 | 5.85e-09 | 5.33e-08 |
| Subtotal prostatectomy:0 | 5/61,988 | 19/16,348,907 | 69.41 | 3.08e-08 | 2.60e-07 |
| student:0 | 9/61,988 | 50,357/16,348,907 | 0.05 | 2.14e-68 | 1.28e-66 |
| Bladder:0 | 2,775/61,988 | 91,053/16,348,907 | 8.37 | 0.00e+00 | 0.00e+00 |
| Spastic syndrome:0 | 7/61,988 | 12,084/16,348,907 | 0.15 | 2.32e-12 | 2.79e-11 |
| CD79A:0 | 10/61,988 | 22,595/16,348,907 | 0.12 | 7.49e-25 | 1.73e-23 |
| Extracellular Signal Regulated Kinases:0 | 81/61,988 | 9,112/16,348,907 | 2.35 | 1.93e-11 | 2.17e-10 |
| Dislocations:0 | 3/61,988 | 18,600/16,348,907 | 0.04 | 3.41e-26 | 8.32e-25 |
| Leuprolide 7.5 MG:0 | 5/61,988 | 7/16,348,907 | 188.40 | 5.96e-10 | 5.96e-09 |
| Benign neoplasm of prostate:0 | 5/61,988 | 10/16,348,907 | 131.88 | 2.24e-09 | 2.12e-08 |
| Estrone:0 | 50/61,988 | 4,730/16,348,907 | 2.79 | 4.40e-10 | 4.48e-09 |
| Casodex:0 | 212/61,988 | 709/16,348,907 | 79.13 | 2.16e-301 | 5.21e-299 |
| Prostate carcinoma:0 | 5,869/61,988 | 10,986/16,348,907 | 155.53 | 0.00e+00 | 0.00e+00 |
| Macaca:0 | 7/61,988 | 15,477/16,348,907 | 0.12 | 3.58e-17 | 5.81e-16 |
| Positive Finding:0 | 76/61,988 | 2,419/16,348,907 | 8.30 | 2.14e-42 | 8.22e-41 |
| Lymph Node Involvement:0 | 164/61,988 | 2,761/16,348,907 | 15.70 | 9.35e-130 | 1.04e-127 |
| Protein p53:0 | 31/61,988 | 2,056/16,348,907 | 3.98 | 3.34e-10 | 3.44e-09 |
| Urokinase Plasminogen Activator Receptor|PLAU|PRAP1:0 | 27/61,988 | 1,167/16,348,907 | 6.10 | 4.48e-13 | 5.64e-12 |
| 16s:0 | 13/61,988 | 25,719/16,348,907 | 0.13 | 1.25e-26 | 3.10e-25 |
| SCID Mice:0 | 283/61,988 | 9,013/16,348,907 | 8.31 | 8.64e-153 | 1.15e-150 |
| Epidermal Growth Factor|EREG|ESR1:0 | 16/61,988 | 44/16,348,907 | 95.93 | 2.19e-25 | 5.18e-24 |
| Autistic Disorder:0 | 5/61,988 | 29,901/16,348,907 | 0.04 | 1.75e-41 | 6.67e-40 |
| Diffusion weighted imaging:0 | 41/61,988 | 654/16,348,907 | 16.54 | 1.22e-34 | 3.79e-33 |
| JUN gene|JUN:0 | 83/61,988 | 9,922/16,348,907 | 2.21 | 1.59e-10 | 1.67e-09 |
| Proto-Oncogene Proteins c-akt|AKT1:0 | 1,139/61,988 | 60,321/16,348,907 | 5.05 | 0.00e+00 | 0.00e+00 |
| Hypoprothrombinemias:0 | 20/61,988 | 464/16,348,907 | 11.37 | 9.03e-15 | 1.27e-13 |
| Rectal Fistula:0 | 16/61,988 | 142/16,348,907 | 29.72 | 3.40e-18 | 5.81e-17 |
| Plates:0 | 9/61,988 | 14,879/16,348,907 | 0.16 | 1.47e-14 | 2.05e-13 |
| hemolysis:0 | 2/61,988 | 9,371/16,348,907 | 0.06 | 4.26e-13 | 5.37e-12 |
| Entire ejaculatory duct:0 | 21/61,988 | 575/16,348,907 | 9.64 | 4.33e-14 | 5.86e-13 |
| MIR gene|MLXIP|MYLIP|MARCH8:0 | 14/61,988 | 341/16,348,907 | 10.83 | 1.62e-10 | 1.70e-09 |
| Ceftriaxone:0 | 3/61,988 | 7,789/16,348,907 | 0.10 | 1.52e-09 | 1.47e-08 |
| DNMT3B gene|DNMT3B:0 | 21/61,988 | 1,114/16,348,907 | 4.97 | 5.57e-09 | 5.09e-08 |
| Chromogranin A|CHGA:0 | 50/61,988 | 32/16,348,907 | 412.43 | 3.74e-99 | 3.02e-97 |
| Toxicology screen, general:0 | 78/61,988 | 8,589/16,348,907 | 2.40 | 1.51e-11 | 1.71e-10 |
| pertuzumab:0 | 15/61,988 | 735/16,348,907 | 5.38 | 3.02e-07 | 2.28e-06 |
| Buthionine Sulfoximine|TH:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| Evisceration - action:0 | 17/61,988 | 857/16,348,907 | 5.23 | 7.50e-08 | 6.05e-07 |
| Breeding:0 | 4/61,988 | 6,843/16,348,907 | 0.15 | 3.02e-07 | 2.29e-06 |
| Androgenetic Alopecia:0 | 37/61,988 | 2,458/16,348,907 | 3.97 | 7.42e-12 | 8.65e-11 |
| Colon and rectum:0 | 52/61,988 | 527/16,348,907 | 26.04 | 7.63e-53 | 3.66e-51 |
| Sample weight:0 | 8/61,988 | 87/16,348,907 | 24.26 | 3.76e-09 | 3.49e-08 |
| prostate cancer screening:0 | 313/61,988 | 378/16,348,907 | 219.49 | 0.00e+00 | 0.00e+00 |
| Muramidase:0 | 4/61,988 | 8,247/16,348,907 | 0.13 | 2.65e-09 | 2.50e-08 |
| Plasma testosterone:0 | 9/61,988 | 251/16,348,907 | 9.46 | 8.69e-07 | 6.25e-06 |
| Nerve Degeneration:0 | 11/61,988 | 17,269/16,348,907 | 0.17 | 2.31e-16 | 3.58e-15 |
| Vagina:0 | 46/61,988 | 25,993/16,348,907 | 0.47 | 5.17e-09 | 4.73e-08 |
| Ventricular Fibrillation:0 | 5/61,988 | 13,499/16,348,907 | 0.10 | 4.91e-16 | 7.45e-15 |
| Integrin alpha6:0 | 10/61,988 | 291/16,348,907 | 9.06 | 3.15e-07 | 2.38e-06 |
| Amitriptyline:0 | 1/61,988 | 7,630/16,348,907 | 0.03 | 1.75e-11 | 1.98e-10 |
| Strontium-89 chloride:0 | 17/61,988 | 58/16,348,907 | 77.32 | 1.56e-25 | 3.71e-24 |
| Tongue:0 | 45/61,988 | 28,083/16,348,907 | 0.42 | 2.79e-11 | 3.12e-10 |
| Stromal Neoplasm:0 | 31/61,988 | 2,283/16,348,907 | 3.58 | 3.68e-09 | 3.42e-08 |
| Angiogenesis Factor:0 | 69/61,988 | 4,825/16,348,907 | 3.77 | 1.45e-19 | 2.66e-18 |
| SRD5A3:0 | 5/61,988 | 38/16,348,907 | 34.71 | 6.57e-07 | 4.78e-06 |
| Sprain:0 | 1/61,988 | 6,307/16,348,907 | 0.04 | 1.91e-09 | 1.83e-08 |
| Mammalian Oviducts:0 | 24/61,988 | 17,249/16,348,907 | 0.37 | 8.52e-09 | 7.63e-08 |
| Toremifene:0 | 42/61,988 | 1,873/16,348,907 | 5.92 | 5.54e-19 | 9.90e-18 |
| Entire diaphragm:0 | 18/61,988 | 18,450/16,348,907 | 0.26 | 3.07e-13 | 3.92e-12 |
| Mesentery:0 | 14/61,988 | 11,713/16,348,907 | 0.32 | 2.28e-07 | 1.75e-06 |
| Papillary adenocarcinoma:0 | 23/61,988 | 1,030/16,348,907 | 5.89 | 4.53e-11 | 4.99e-10 |
| TMEFF2:0 | 13/61,988 | 118/16,348,907 | 29.06 | 6.11e-15 | 8.69e-14 |
| Trachea:0 | 21/61,988 | 33,555/16,348,907 | 0.16 | 4.27e-31 | 1.21e-29 |
| Pancreatic Trypsin Secretory Inhibitor, Kazal|SPINK1:0 | 7/61,988 | 74/16,348,907 | 24.95 | 2.99e-08 | 2.53e-07 |
| IL2-inducible T-cell kinase|ITK|SLC22A3:0 | 38/61,988 | 2,053/16,348,907 | 4.88 | 9.11e-15 | 1.28e-13 |
| Aminoglycosides:0 | 2/61,988 | 5,426/16,348,907 | 0.10 | 6.30e-07 | 4.59e-06 |
| Defibrillators, Implantable:0 | 1/61,988 | 21,781/16,348,907 | 0.01 | 2.11e-34 | 6.53e-33 |
| Triticum aestivum:0 | 1/61,988 | 8,960/16,348,907 | 0.03 | 1.66e-13 | 2.16e-12 |
| Pathological Dilatation:0 | 38/61,988 | 36,205/16,348,907 | 0.28 | 2.10e-23 | 4.60e-22 |
| remifentanil:0 | 1/61,988 | 5,908/16,348,907 | 0.04 | 8.13e-09 | 7.30e-08 |
| Antitumor Response:0 | 59/61,988 | 1,852/16,348,907 | 8.41 | 1.30e-33 | 3.98e-32 |
| Prostate-Specific Antigen|KLK3:0 | 27/61,988 | 54/16,348,907 | 131.93 | 7.22e-45 | 2.94e-43 |
| SHC4:0 | 8/61,988 | 64/16,348,907 | 32.97 | 4.00e-10 | 4.08e-09 |
| Blotting, Northern:0 | 56/61,988 | 4,450/16,348,907 | 3.32 | 5.83e-14 | 7.82e-13 |
| Steroid Metabolism:0 | 14/61,988 | 292/16,348,907 | 12.65 | 2.30e-11 | 2.58e-10 |
| Insecta:0 | 2/61,988 | 13,155/16,348,907 | 0.04 | 4.96e-19 | 8.89e-18 |
| Furosemide:0 | 6/61,988 | 12,124/16,348,907 | 0.13 | 4.08e-13 | 5.14e-12 |
| Somatotropin|TH:0 | 7/61,988 | 46/16,348,907 | 40.14 | 1.45e-09 | 1.40e-08 |
| Breast cancer metastatic:0 | 138/61,988 | 21,573/16,348,907 | 1.69 | 1.35e-08 | 1.18e-07 |
| thymocyte:0 | 3/61,988 | 18,181/16,348,907 | 0.04 | 1.40e-25 | 3.34e-24 |
| Paraurethral gland:0 | 11/61,988 | 90/16,348,907 | 32.24 | 2.60e-13 | 3.34e-12 |
| Carbon Dioxide:0 | 12/61,988 | 27,196/16,348,907 | 0.12 | 1.17e-29 | 3.18e-28 |
| 13q:0 | 26/61,988 | 631/16,348,907 | 10.87 | 2.76e-18 | 4.75e-17 |
| UGT2B15:0 | 10/61,988 | 129/16,348,907 | 20.45 | 2.02e-10 | 2.11e-09 |
| CYP24A1 gene|CYP24A1:0 | 5/61,988 | 45/16,348,907 | 29.31 | 1.41e-06 | 9.82e-06 |
| Haloperidol:0 | 5/61,988 | 20,279/16,348,907 | 0.06 | 2.04e-26 | 5.02e-25 |
| Malignant neoplasm of skin:0 | 168/61,988 | 9,025/16,348,907 | 4.92 | 9.12e-60 | 4.90e-58 |
| Archaea:0 | 2/61,988 | 13,635/16,348,907 | 0.04 | 1.26e-19 | 2.33e-18 |
| Gill structure:0 | 1/61,988 | 6,885/16,348,907 | 0.04 | 2.16e-10 | 2.25e-09 |
| trastuzumab|EGFR:0 | 9/61,988 | 17/16,348,907 | 139.65 | 4.61e-16 | 7.01e-15 |
| Small RNA:0 | 113/61,988 | 9,008/16,348,907 | 3.31 | 2.41e-26 | 5.92e-25 |
| Urokinase Plasminogen Activator Receptor|PLAUR:0 | 23/61,988 | 1,796/16,348,907 | 3.38 | 9.28e-07 | 6.63e-06 |
| Renal glomerular disease:0 | 2/61,988 | 10,672/16,348,907 | 0.05 | 4.04e-15 | 5.83e-14 |
| Digital palpation:0 | 42/61,988 | 526/16,348,907 | 21.07 | 1.79e-39 | 6.46e-38 |
| Digital Rectal Examination:0 | 656/61,988 | 1,378/16,348,907 | 126.89 | 0.00e+00 | 0.00e+00 |
| Salvage procedure:0 | 137/61,988 | 6,137/16,348,907 | 5.90 | 8.62e-58 | 4.50e-56 |
| Hot flushes:0 | 46/61,988 | 1,253/16,348,907 | 9.69 | 4.64e-29 | 1.24e-27 |
| hydroxyurea:0 | 18/61,988 | 15,276/16,348,907 | 0.31 | 2.00e-09 | 1.91e-08 |
| GCK|KCNA2:0 | 9/61,988 | 56/16,348,907 | 42.39 | 4.13e-12 | 4.89e-11 |
| Microtubule-Associated Proteins:0 | 78/61,988 | 9,323/16,348,907 | 2.21 | 6.51e-10 | 6.48e-09 |
| PRCA1 gene|RNASEL:0 | 44/61,988 | 112/16,348,907 | 103.69 | 2.30e-68 | 1.38e-66 |
| Prostatic Secretory Proteins:0 | 7/61,988 | 35/16,348,907 | 52.75 | 2.64e-10 | 2.73e-09 |
| soy protein isolate:0 | 77/61,988 | 2,319/16,348,907 | 8.77 | 1.55e-44 | 6.24e-43 |
| alpha 1-Antichymotrypsin:0 | 33/61,988 | 1,270/16,348,907 | 6.86 | 5.01e-17 | 8.05e-16 |
| Maps:0 | 83/61,988 | 9,288/16,348,907 | 2.36 | 9.09e-12 | 1.05e-10 |
| Aortic Valve Insufficiency:0 | 1/61,988 | 9,982/16,348,907 | 0.03 | 2.74e-15 | 3.99e-14 |
| New South Wales:0 | 16/61,988 | 694/16,348,907 | 6.08 | 2.46e-08 | 2.10e-07 |
| Palliative Care:0 | 154/61,988 | 7,014/16,348,907 | 5.80 | 8.03e-64 | 4.58e-62 |
| Acinar Cell Carcinoma:0 | 60/61,988 | 1,453/16,348,907 | 10.90 | 4.25e-40 | 1.55e-38 |
| Respiratory physiology:0 | 4/61,988 | 13,048/16,348,907 | 0.08 | 1.59e-16 | 2.48e-15 |
| Mammaplasty:0 | 1/61,988 | 5,167/16,348,907 | 0.05 | 1.55e-07 | 1.21e-06 |
| 2-aminodiphenyl:0 | 17/61,988 | 72/16,348,907 | 62.29 | 3.79e-24 | 8.49e-23 |
| Inactivation:0 | 236/61,988 | 30,483/16,348,907 | 2.05 | 9.91e-23 | 2.10e-21 |
| PROSTVAC:0 | 18/61,988 | 45/16,348,907 | 105.53 | 5.38e-29 | 1.44e-27 |
| Rheumatism:0 | 18/61,988 | 21,671/16,348,907 | 0.22 | 2.31e-17 | 3.78e-16 |
| Cancer Family:0 | 13/61,988 | 465/16,348,907 | 7.37 | 5.80e-08 | 4.74e-07 |
| Alcoholic Intoxication, Chronic:0 | 2/61,988 | 20,179/16,348,907 | 0.03 | 3.18e-30 | 8.79e-29 |
| Measles:0 | 6/61,988 | 8,796/16,348,907 | 0.18 | 1.58e-08 | 1.37e-07 |
| High Density Lipoprotein Cholesterol:0 | 28/61,988 | 19,129/16,348,907 | 0.39 | 4.20e-09 | 3.86e-08 |
| Capra hircus:0 | 3/61,988 | 13,290/16,348,907 | 0.06 | 5.83e-18 | 9.86e-17 |
| WWP1:0 | 9/61,988 | 246/16,348,907 | 9.65 | 7.40e-07 | 5.36e-06 |
| Tuberculosis, Meningeal:0 | 1/61,988 | 4,555/16,348,907 | 0.06 | 1.32e-06 | 9.23e-06 |
| saliva:0 | 7/61,988 | 11,347/16,348,907 | 0.16 | 3.49e-11 | 3.88e-10 |
| Receptor Signaling:0 | 139/61,988 | 2,188/16,348,907 | 16.79 | 5.94e-114 | 5.62e-112 |
| Chlorophyll:0 | 1/61,988 | 8,722/16,348,907 | 0.03 | 3.21e-13 | 4.09e-12 |
| Helminths:0 | 3/61,988 | 7,955/16,348,907 | 0.10 | 7.45e-10 | 7.38e-09 |
| Urinary Retention:0 | 127/61,988 | 2,575/16,348,907 | 13.03 | 1.24e-91 | 9.51e-90 |
| alpha-Synuclein:0 | 2/61,988 | 10,033/16,348,907 | 0.05 | 5.18e-14 | 6.96e-13 |
| Diet, Fat-Restricted:0 | 25/61,988 | 1,639/16,348,907 | 4.02 | 1.29e-08 | 1.13e-07 |
| Metabolic Rates:0 | 5/61,988 | 8,636/16,348,907 | 0.15 | 4.03e-09 | 3.72e-08 |
| EIF3H:0 | 6/61,988 | 60/16,348,907 | 26.38 | 2.17e-07 | 1.67e-06 |
| Felis catus:0 | 31/61,988 | 97,992/16,348,907 | 0.08 | 3.95e-116 | 3.83e-114 |
| Elbow:0 | 3/61,988 | 11,081/16,348,907 | 0.07 | 1.43e-14 | 1.99e-13 |
| Stiffness:0 | 27/61,988 | 22,892/16,348,907 | 0.31 | 1.33e-13 | 1.75e-12 |
| Transurethral cystoscopy:0 | 15/61,988 | 211/16,348,907 | 18.75 | 2.10e-14 | 2.89e-13 |
| Sleeves:0 | 4/61,988 | 10,494/16,348,907 | 0.10 | 1.43e-12 | 1.74e-11 |
| Myocytes, Cardiac:0 | 9/61,988 | 46,918/16,348,907 | 0.05 | 6.30e-63 | 3.52e-61 |
| Cystadenocarcinoma, Papillary:0 | 11/61,988 | 168/16,348,907 | 17.27 | 1.38e-10 | 1.46e-09 |
| Transitional cell carcinoma of bladder:0 | 53/61,988 | 1,282/16,348,907 | 10.91 | 1.21e-35 | 3.88e-34 |
| Intima:0 | 1/61,988 | 7,517/16,348,907 | 0.04 | 2.49e-11 | 2.78e-10 |
| PATHOLOGIC FINDINGS:0 | 130/61,988 | 4,874/16,348,907 | 7.05 | 2.58e-63 | 1.45e-61 |
| liarozole fumarate:0 | 5/61,988 | 19/16,348,907 | 69.41 | 3.08e-08 | 2.60e-07 |
| IGF1R gene|IGF1R:0 | 14/61,988 | 639/16,348,907 | 5.78 | 3.26e-07 | 2.45e-06 |
| Bone pain:0 | 230/61,988 | 2,005/16,348,907 | 30.36 | 2.75e-241 | 5.30e-239 |
| Neoplasms, Hormone-Dependent:0 | 5/61,988 | 29/16,348,907 | 45.48 | 1.95e-07 | 1.51e-06 |
| Malignant disease:0 | 312/61,988 | 12,923/16,348,907 | 6.39 | 5.28e-138 | 6.22e-136 |
| Metoclopramide:0 | 4/61,988 | 7,673/16,348,907 | 0.14 | 1.39e-08 | 1.22e-07 |
| Clusterin|CLU:0 | 100/61,988 | 3,932/16,348,907 | 6.72 | 2.21e-47 | 9.53e-46 |
| Convulsions:0 | 2/61,988 | 7,222/16,348,907 | 0.07 | 1.10e-09 | 1.07e-08 |
| Telencephalon:0 | 1/61,988 | 4,858/16,348,907 | 0.05 | 4.51e-07 | 3.35e-06 |
| Occult carcinoma:0 | 16/61,988 | 641/16,348,907 | 6.58 | 8.46e-09 | 7.58e-08 |
| Ovum:0 | 13/61,988 | 20,102/16,348,907 | 0.17 | 1.02e-18 | 1.79e-17 |
| Thalidomide:0 | 88/61,988 | 13,001/16,348,907 | 1.79 | 6.94e-07 | 5.04e-06 |
| Abdominal Pain:0 | 16/61,988 | 15,477/16,348,907 | 0.27 | 8.43e-11 | 9.11e-10 |
| N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid:0 | 6/61,988 | 12/16,348,907 | 131.88 | 5.18e-11 | 5.68e-10 |
| TNFSF11 gene|TNFSF11:0 | 33/61,988 | 861/16,348,907 | 10.11 | 7.38e-22 | 1.51e-20 |
| Decapeptyl:0 | 15/61,988 | 270/16,348,907 | 14.66 | 6.10e-13 | 7.61e-12 |
| Destructive procedure on pituitary gland:0 | 6/61,988 | 53/16,348,907 | 29.86 | 1.10e-07 | 8.74e-07 |
| Adenosine Diphosphate Ribose:0 | 30/61,988 | 2,101/16,348,907 | 3.77 | 2.15e-09 | 2.05e-08 |
| Soybeans:0 | 15/61,988 | 804/16,348,907 | 4.92 | 8.97e-07 | 6.42e-06 |
| TRANCE protein|TNFSF11:0 | 62/61,988 | 6,219/16,348,907 | 2.63 | 4.06e-11 | 4.49e-10 |
| diindolylmethane:0 | 52/61,988 | 1,070/16,348,907 | 12.83 | 2.84e-38 | 9.91e-37 |
| MicroRNAs:0 | 697/61,988 | 76,708/16,348,907 | 2.41 | 1.46e-90 | 1.10e-88 |
| GSTT1 gene|GSTT1:0 | 37/61,988 | 2,016/16,348,907 | 4.84 | 2.59e-14 | 3.55e-13 |
| Hepatitis C virus:0 | 16/61,988 | 71,167/16,348,907 | 0.06 | 4.37e-92 | 3.37e-90 |
| Luciferases:0 | 282/61,988 | 15,682/16,348,907 | 4.76 | 9.94e-96 | 7.85e-94 |
| Aggressive cancer:0 | 320/61,988 | 1,584/16,348,907 | 53.55 | 0.00e+00 | 0.00e+00 |
| Degenerative abnormality:0 | 39/61,988 | 42,150/16,348,907 | 0.24 | 4.68e-30 | 1.29e-28 |
| Respiratory syncytial virus:0 | 2/61,988 | 7,501/16,348,907 | 0.07 | 3.74e-10 | 3.83e-09 |
| integrin-linked kinase:0 | 36/61,988 | 2,538/16,348,907 | 3.74 | 6.90e-11 | 7.48e-10 |
| Methylnitrosourea:0 | 46/61,988 | 2,813/16,348,907 | 4.32 | 1.32e-15 | 1.96e-14 |
| Annexins:0 | 55/61,988 | 4,684/16,348,907 | 3.10 | 1.34e-12 | 1.63e-11 |
| RIEG2|SLURP1:0 | 24/61,988 | 1,873/16,348,907 | 3.38 | 5.41e-07 | 3.97e-06 |
| Urticaria:0 | 2/61,988 | 5,923/16,348,907 | 0.09 | 1.09e-07 | 8.62e-07 |
| methylene diphosphonate:0 | 15/61,988 | 307/16,348,907 | 12.89 | 3.49e-12 | 4.15e-11 |
| Male mammary gland:0 | 27/61,988 | 1,028/16,348,907 | 6.93 | 2.52e-14 | 3.46e-13 |
| Adenoma of large intestine:0 | 50/61,988 | 3,755/16,348,907 | 3.51 | 1.65e-13 | 2.15e-12 |
| Visual impairment:0 | 13/61,988 | 14,161/16,348,907 | 0.24 | 6.86e-11 | 7.45e-10 |
| Membrane Proteins:0 | 75/61,988 | 35,892/16,348,907 | 0.55 | 1.54e-08 | 1.34e-07 |
| Arthropathies NOS:0 | 8/61,988 | 17,947/16,348,907 | 0.12 | 6.95e-20 | 1.30e-18 |
| Granulocyte-Macrophage Colony-Stimulating Factor|CSF2:0 | 12/61,988 | 284/16,348,907 | 11.15 | 2.36e-09 | 2.24e-08 |
| Urosepsis:0 | 14/61,988 | 700/16,348,907 | 5.28 | 9.30e-07 | 6.65e-06 |
| Acid phosphatase measurement:0 | 5/61,988 | 7/16,348,907 | 188.40 | 5.96e-10 | 5.96e-09 |
| Periodontal Ligament:0 | 2/61,988 | 13,783/16,348,907 | 0.04 | 5.74e-20 | 1.08e-18 |
| FRAP1 protein, human|MTOR:0 | 150/61,988 | 9,038/16,348,907 | 4.39 | 9.60e-48 | 4.18e-46 |
| rhenium-186 HEDP:0 | 27/61,988 | 97/16,348,907 | 73.44 | 3.85e-39 | 1.38e-37 |
| Low-Density Lipoproteins:0 | 27/61,988 | 30,185/16,348,907 | 0.24 | 1.86e-22 | 3.91e-21 |
| Prostate cancer stage C:0 | 70/61,988 | 130/16,348,907 | 142.17 | 1.52e-115 | 1.46e-113 |
| Malnutrition:0 | 21/61,988 | 36,361/16,348,907 | 0.15 | 6.17e-35 | 1.94e-33 |
| cell transformation:0 | 56/61,988 | 5,706/16,348,907 | 2.59 | 9.24e-10 | 9.08e-09 |
| Receptor, EphA2:0 | 14/61,988 | 140/16,348,907 | 26.38 | 1.93e-15 | 2.84e-14 |
| Submandibular gland:0 | 7/61,988 | 13,984/16,348,907 | 0.13 | 5.90e-15 | 8.41e-14 |
| Receptors, Opioid, mu:0 | 2/61,988 | 9,301/16,348,907 | 0.06 | 6.14e-13 | 7.66e-12 |
| valylvaline:0 | 15/61,988 | 576/16,348,907 | 6.87 | 1.42e-08 | 1.24e-07 |
| infliximab:0 | 3/61,988 | 27,160/16,348,907 | 0.03 | 6.76e-40 | 2.46e-38 |
| Application procedure:0 | 436/61,988 | 79,249/16,348,907 | 1.45 | 2.10e-13 | 2.71e-12 |
| procaspase-3:0 | 19/61,988 | 848/16,348,907 | 5.91 | 1.99e-09 | 1.90e-08 |
| Metronidazole:0 | 8/61,988 | 12,361/16,348,907 | 0.17 | 6.82e-12 | 7.96e-11 |
| Intracranial Hypertension:0 | 6/61,988 | 7,371/16,348,907 | 0.21 | 1.44e-06 | 9.97e-06 |
| Primary carcinoma of the liver cells:0 | 250/61,988 | 149,029/16,348,907 | 0.44 | 3.13e-50 | 1.43e-48 |
| Respiratory Distress Syndrome, Adult:0 | 10/61,988 | 22,126/16,348,907 | 0.12 | 4.15e-24 | 9.28e-23 |
| Eulexin:0 | 20/61,988 | 41/16,348,907 | 128.70 | 1.87e-33 | 5.72e-32 |
| Emcyt:0 | 14/61,988 | 37/16,348,907 | 99.82 | 1.36e-22 | 2.87e-21 |
| lymph nodes:0 | 684/61,988 | 62,543/16,348,907 | 2.91 | 5.61e-123 | 5.93e-121 |
| Gastrointestinal toxicity:0 | 97/61,988 | 910/16,348,907 | 28.16 | 5.14e-100 | 4.17e-98 |
| Abscess:0 | 30/61,988 | 19,975/16,348,907 | 0.40 | 4.39e-09 | 4.03e-08 |
| Insulin-Like-Growth Factor I Receptor|IGF1R:0 | 17/61,988 | 812/16,348,907 | 5.52 | 3.55e-08 | 2.98e-07 |
| CCND2 gene|CCND2:0 | 16/61,988 | 665/16,348,907 | 6.35 | 1.39e-08 | 1.22e-07 |
| cytotoxicity:0 | 415/61,988 | 37,559/16,348,907 | 2.93 | 1.80e-76 | 1.18e-74 |
| Defecation:0 | 47/61,988 | 3,786/16,348,907 | 3.28 | 8.80e-12 | 1.02e-10 |
| Septicemia:0 | 60/61,988 | 75,485/16,348,907 | 0.21 | 3.26e-59 | 1.73e-57 |
| Equus caballus:0 | 10/61,988 | 55,761/16,348,907 | 0.05 | 1.49e-75 | 9.62e-74 |
| Apolipoprotein E|APOE:0 | 8/61,988 | 19,180/16,348,907 | 0.11 | 1.16e-21 | 2.36e-20 |
| somatostatin receptor 5|SSTR5:0 | 9/61,988 | 259/16,348,907 | 9.17 | 1.12e-06 | 7.87e-06 |
| Herbicides:0 | 9/61,988 | 9,611/16,348,907 | 0.25 | 1.17e-07 | 9.23e-07 |
| MCF7:0 | 221/61,988 | 18,383/16,348,907 | 3.18 | 5.45e-47 | 2.33e-45 |
| Ischemia:0 | 26/61,988 | 80,050/16,348,907 | 0.09 | 2.08e-94 | 1.63e-92 |
| Ligation:0 | 24/61,988 | 24,792/16,348,907 | 0.26 | 1.36e-17 | 2.24e-16 |
| Cell-Cell Adhesion:0 | 53/61,988 | 2,887/16,348,907 | 4.85 | 8.39e-20 | 1.56e-18 |
| Electromyography:0 | 8/61,988 | 17,349/16,348,907 | 0.12 | 5.37e-19 | 9.60e-18 |
| CYTOCHROME C OXIDASE:0 | 8/61,988 | 9,686/16,348,907 | 0.22 | 2.88e-08 | 2.44e-07 |
| Candida albicans:0 | 3/61,988 | 10,227/16,348,907 | 0.08 | 3.56e-13 | 4.51e-12 |
| Selenium Compounds:0 | 20/61,988 | 644/16,348,907 | 8.19 | 2.95e-12 | 3.51e-11 |
| Antineoplastic Agents:0 | 631/61,988 | 26,836/16,348,907 | 6.25 | 2.15e-271 | 4.69e-269 |
| Urokinase:0 | 188/61,988 | 17,708/16,348,907 | 2.81 | 1.60e-33 | 4.89e-32 |
| anticoagulation:0 | 17/61,988 | 18,146/16,348,907 | 0.25 | 1.90e-13 | 2.46e-12 |
| Molar tooth:0 | 2/61,988 | 12,708/16,348,907 | 0.04 | 3.10e-18 | 5.31e-17 |
| Plastids:0 | 1/61,988 | 5,505/16,348,907 | 0.05 | 3.44e-08 | 2.90e-07 |
| CDKN1A|TCEAL1|NSG1|H3F3AP6:0 | 433/61,988 | 21,430/16,348,907 | 5.36 | 2.04e-163 | 2.84e-161 |
| Cell Communication:0 | 116/61,988 | 11,487/16,348,907 | 2.67 | 9.22e-20 | 1.71e-18 |
| Calmodulin:0 | 12/61,988 | 24,382/16,348,907 | 0.13 | 1.57e-25 | 3.73e-24 |
| Prostatic Intraepithelial Neoplasias:0 | 684/61,988 | 1,354/16,348,907 | 134.71 | 0.00e+00 | 0.00e+00 |
| Swelling:0 | 19/61,988 | 14,367/16,348,907 | 0.35 | 5.95e-08 | 4.86e-07 |
| Prostatectomy:0 | 1,251/61,988 | 3,080/16,348,907 | 109.31 | 0.00e+00 | 0.00e+00 |
| Epoprostenol:0 | 7/61,988 | 26,042/16,348,907 | 0.07 | 5.06e-33 | 1.52e-31 |
| Lipolysis:0 | 6/61,988 | 11,288/16,348,907 | 0.14 | 5.86e-12 | 6.87e-11 |
| Cyclin D1:0 | 31/61,988 | 1,424/16,348,907 | 5.74 | 4.20e-14 | 5.69e-13 |
| Infarction:0 | 20/61,988 | 39,333/16,348,907 | 0.13 | 4.46e-40 | 1.63e-38 |
| ID-1:0 | 27/61,988 | 404/16,348,907 | 17.63 | 4.73e-24 | 1.05e-22 |
| Pilum:0 | 1/61,988 | 6,516/16,348,907 | 0.04 | 9.31e-10 | 9.14e-09 |
| Magnetic resonance imaging guided biopsy:0 | 40/61,988 | 159/16,348,907 | 66.39 | 1.10e-55 | 5.54e-54 |
| 8p21:0 | 16/61,988 | 79/16,348,907 | 53.43 | 7.14e-22 | 1.46e-20 |
| Subgroup:0 | 24/61,988 | 1,592/16,348,907 | 3.98 | 3.08e-08 | 2.60e-07 |
| Carcinoma, Signet Ring Cell:0 | 49/61,988 | 2,180/16,348,907 | 5.93 | 6.51e-22 | 1.33e-20 |
| Stage:0 | 25/61,988 | 1,211/16,348,907 | 5.45 | 3.35e-11 | 3.73e-10 |
| Vascular Diseases:0 | 22/61,988 | 25,855/16,348,907 | 0.22 | 3.67e-20 | 7.00e-19 |
| Primordium:0 | 4/61,988 | 6,444/16,348,907 | 0.16 | 7.65e-07 | 5.53e-06 |
| hypothermia, natural:0 | 7/61,988 | 10,262/16,348,907 | 0.18 | 8.62e-10 | 8.51e-09 |
| DNA Damage:0 | 181/61,988 | 25,153/16,348,907 | 1.90 | 5.59e-15 | 7.99e-14 |
| CHEK2 gene|CHEK2:0 | 44/61,988 | 1,719/16,348,907 | 6.75 | 6.44e-22 | 1.32e-20 |
| Receptors, Steroid:0 | 109/61,988 | 2,993/16,348,907 | 9.62 | 4.01e-66 | 2.33e-64 |
| Somatropin:0 | 7/61,988 | 8,734/16,348,907 | 0.21 | 1.08e-07 | 8.55e-07 |
| Anoikis:0 | 44/61,988 | 1,668/16,348,907 | 6.96 | 2.10e-22 | 4.40e-21 |
| Mycoses:0 | 8/61,988 | 20,101/16,348,907 | 0.10 | 5.35e-23 | 1.15e-21 |
| Gastrin releasing peptide|GRP:0 | 39/61,988 | 730/16,348,907 | 14.10 | 1.42e-30 | 3.95e-29 |
| hepsin|HPN:0 | 45/61,988 | 410/16,348,907 | 28.97 | 7.29e-48 | 3.20e-46 |
| Placenta:0 | 46/61,988 | 41,745/16,348,907 | 0.29 | 1.44e-25 | 3.43e-24 |
| Malignant Bone Neoplasm:0 | 46/61,988 | 2,646/16,348,907 | 4.59 | 1.50e-16 | 2.35e-15 |
| Increased Cellular Migration:0 | 8/61,988 | 151/16,348,907 | 13.97 | 2.12e-07 | 1.63e-06 |
| Cancer-related morbidities:0 | 15/61,988 | 113/16,348,907 | 35.02 | 4.02e-18 | 6.85e-17 |
| CDC2 Protein Kinase:0 | 15/61,988 | 763/16,348,907 | 5.19 | 4.76e-07 | 3.52e-06 |
| patient characteristics:0 | 24/61,988 | 1,786/16,348,907 | 3.55 | 2.38e-07 | 1.82e-06 |
| Bulbar urethra:0 | 14/61,988 | 428/16,348,907 | 8.63 | 2.70e-09 | 2.55e-08 |
| CD4 Positive T Lymphocytes:0 | 6/61,988 | 7,855/16,348,907 | 0.20 | 2.86e-07 | 2.17e-06 |
| Secondary malignant neoplasm of bone marrow:0 | 25/61,988 | 457/16,348,907 | 14.43 | 2.07e-20 | 4.00e-19 |
| 17beta-hydroxysteroid dehydrogenase type 3:0 | 8/61,988 | 48/16,348,907 | 43.96 | 5.01e-11 | 5.50e-10 |
| DNA Repair:0 | 124/61,988 | 12,898/16,348,907 | 2.54 | 2.45e-19 | 4.45e-18 |
| Chemoprevention:0 | 303/61,988 | 4,192/16,348,907 | 19.15 | 1.14e-261 | 2.39e-259 |
| Percent (qualifier value):0 | 16/61,988 | 926/16,348,907 | 4.56 | 1.05e-06 | 7.42e-06 |
| Ivermectin:0 | 2/61,988 | 6,509/16,348,907 | 0.08 | 1.29e-08 | 1.14e-07 |
| Excretory function:0 | 72/61,988 | 56,259/16,348,907 | 0.34 | 5.32e-29 | 1.42e-27 |
| PERINEURAL INVASION:0 | 134/61,988 | 1,360/16,348,907 | 26.04 | 2.87e-133 | 3.29e-131 |
| Non-Aspirin:0 | 14/61,988 | 599/16,348,907 | 6.17 | 1.53e-07 | 1.19e-06 |
| Ellagitannins:0 | 11/61,988 | 320/16,348,907 | 9.07 | 8.18e-08 | 6.57e-07 |
| Tissue specimen:0 | 510/61,988 | 20,806/16,348,907 | 6.51 | 2.74e-227 | 5.01e-225 |
| BRCA1 Mutation:0 | 29/61,988 | 1,461/16,348,907 | 5.24 | 2.40e-12 | 2.87e-11 |
| Octreotide|CALCA|PCYT1A:0 | 5/61,988 | 15/16,348,907 | 87.92 | 1.14e-08 | 1.01e-07 |
| Cornea:0 | 4/61,988 | 39,321/16,348,907 | 0.03 | 9.35e-58 | 4.86e-56 |
| Androgen Receptor:0 | 282/61,988 | 2,781/16,348,907 | 26.86 | 1.33e-281 | 3.07e-279 |
| NRP1 gene|NRP1:0 | 12/61,988 | 417/16,348,907 | 7.59 | 1.37e-07 | 1.08e-06 |
| Hyperplasia:0 | 452/61,988 | 28,023/16,348,907 | 4.28 | 6.78e-136 | 7.84e-134 |
| Depressive disorder:0 | 108/61,988 | 109,945/16,348,907 | 0.26 | 1.34e-72 | 8.44e-71 |
| DLC1 protein, human|DLC1:0 | 7/61,988 | 127/16,348,907 | 14.54 | 9.47e-07 | 6.75e-06 |
| validation study:0 | 18/61,988 | 910/16,348,907 | 5.22 | 3.28e-08 | 2.77e-07 |
| Family member:0 | 124/61,988 | 19,277/16,348,907 | 1.70 | 5.83e-08 | 4.77e-07 |
| Myotonic Dystrophy:0 | 1/61,988 | 4,985/16,348,907 | 0.05 | 2.08e-07 | 1.61e-06 |
| Statistical Analysis:0 | 95/61,988 | 9,890/16,348,907 | 2.54 | 4.71e-15 | 6.77e-14 |
| Vitamin E:0 | 218/61,988 | 29,797/16,348,907 | 1.93 | 1.97e-18 | 3.41e-17 |
| Medication Management:0 | 82/61,988 | 6,852/16,348,907 | 3.16 | 1.96e-18 | 3.40e-17 |
| VN 85-1:0 | 4/61,988 | 6/16,348,907 | 175.84 | 4.20e-08 | 3.49e-07 |
| Triptorelin:0 | 59/61,988 | 924/16,348,907 | 16.86 | 1.58e-49 | 7.11e-48 |
| Cyclic GMP:0 | 27/61,988 | 28,710/16,348,907 | 0.25 | 1.31e-20 | 2.56e-19 |
| Ofloxacin:0 | 2/61,988 | 5,582/16,348,907 | 0.09 | 3.01e-07 | 2.28e-06 |
| Breast Cancer Cell:0 | 341/61,988 | 19,866/16,348,907 | 4.55 | 5.14e-110 | 4.65e-108 |
| Tumour flare:0 | 13/61,988 | 28/16,348,907 | 122.48 | 5.08e-22 | 1.05e-20 |
| Thiamine:0 | 2/61,988 | 6,241/16,348,907 | 0.08 | 3.87e-08 | 3.22e-07 |
| Sucrose:0 | 12/61,988 | 16,416/16,348,907 | 0.19 | 1.54e-14 | 2.14e-13 |
| mRNA Expression:0 | 78/61,988 | 9,473/16,348,907 | 2.17 | 1.02e-09 | 9.99e-09 |
| RC 3940-II:0 | 8/61,988 | 87/16,348,907 | 24.26 | 3.76e-09 | 3.49e-08 |
| Neural Development:0 | 10/61,988 | 18,006/16,348,907 | 0.15 | 2.85e-18 | 4.90e-17 |
| Chromosome 8 Short Arm:0 | 38/61,988 | 253/16,348,907 | 39.64 | 2.16e-45 | 8.95e-44 |
| Lipopolysaccharides:0 | 41/61,988 | 111,592/16,348,907 | 0.10 | 3.10e-126 | 3.37e-124 |
| Hydroxyindoleacetic Acid:0 | 2/61,988 | 5,532/16,348,907 | 0.10 | 4.47e-07 | 3.32e-06 |
| Proto-Oncogene Proteins c-akt:0 | 48/61,988 | 4,092/16,348,907 | 3.10 | 3.49e-11 | 3.87e-10 |
| CDC2 Protein Kinase|CDK1:0 | 37/61,988 | 3,600/16,348,907 | 2.71 | 1.43e-07 | 1.12e-06 |
| Tetradecapeptide:0 | 10/61,988 | 247/16,348,907 | 10.68 | 7.35e-08 | 5.94e-07 |
| Regional Cancer:0 | 33/61,988 | 234/16,348,907 | 37.21 | 8.14e-39 | 2.89e-37 |
| Nephrons:0 | 3/61,988 | 6,141/16,348,907 | 0.13 | 3.65e-07 | 2.74e-06 |
| Chromaffin Cells:0 | 3/61,988 | 8,002/16,348,907 | 0.10 | 7.71e-10 | 7.62e-09 |
| Nose:0 | 27/61,988 | 52,329/16,348,907 | 0.14 | 1.77e-52 | 8.44e-51 |
| Vaccines, DNA:0 | 48/61,988 | 5,179/16,348,907 | 2.45 | 5.23e-08 | 4.30e-07 |
| Umbilical Cord Blood:0 | 5/61,988 | 7,296/16,348,907 | 0.18 | 2.90e-07 | 2.20e-06 |
| AIDS patient:0 | 3/61,988 | 9,823/16,348,907 | 0.08 | 1.45e-12 | 1.76e-11 |
| Lymphangiography:0 | 45/61,988 | 3,130/16,348,907 | 3.79 | 2.08e-13 | 2.69e-12 |
| Apoptosis Regulator:0 | 21/61,988 | 422/16,348,907 | 13.13 | 1.30e-16 | 2.05e-15 |
| Apigenin:0 | 60/61,988 | 3,918/16,348,907 | 4.04 | 1.48e-18 | 2.58e-17 |
| fatty-acid synthase activity:0 | 8/61,988 | 118/16,348,907 | 17.88 | 3.50e-08 | 2.94e-07 |
| Hemibody Irradiation:0 | 22/61,988 | 259/16,348,907 | 22.41 | 5.55e-22 | 1.14e-20 |
| Heart Atrium:0 | 4/61,988 | 23,374/16,348,907 | 0.05 | 1.97e-32 | 5.82e-31 |
| differentiation therapy:0 | 14/61,988 | 482/16,348,907 | 7.66 | 1.15e-08 | 1.01e-07 |
| Ectopic Expression:0 | 56/61,988 | 2,216/16,348,907 | 6.67 | 3.56e-27 | 8.95e-26 |
| Protoplasm:0 | 680/61,988 | 145,573/16,348,907 | 1.23 | 1.36e-07 | 1.06e-06 |
| SP1 gene|SP1:0 | 89/61,988 | 8,423/16,348,907 | 2.79 | 1.14e-16 | 1.80e-15 |
| Gentamicins:0 | 6/61,988 | 19,522/16,348,907 | 0.08 | 3.19e-24 | 7.17e-23 |
| Lung Neoplasms:0 | 67/61,988 | 8,005/16,348,907 | 2.21 | 9.31e-09 | 8.30e-08 |
| Peptidoglycan:0 | 1/61,988 | 8,463/16,348,907 | 0.03 | 1.02e-12 | 1.25e-11 |
| Organoids:0 | 17/61,988 | 859/16,348,907 | 5.22 | 7.74e-08 | 6.24e-07 |
| Prions:0 | 3/61,988 | 13,931/16,348,907 | 0.06 | 7.18e-19 | 1.27e-17 |
| Iressa:0 | 25/61,988 | 1,006/16,348,907 | 6.56 | 7.18e-13 | 8.89e-12 |
| GPI gene|GPI:0 | 23/61,988 | 14,881/16,348,907 | 0.41 | 8.96e-07 | 6.41e-06 |
| Macaca mulatta:0 | 13/61,988 | 23,673/16,348,907 | 0.14 | 9.97e-24 | 2.19e-22 |
| Coronary artery:0 | 6/61,988 | 42,726/16,348,907 | 0.04 | 2.14e-60 | 1.16e-58 |
| Lipase:0 | 5/61,988 | 18,932/16,348,907 | 0.07 | 3.09e-24 | 6.97e-23 |
| Toluene:0 | 1/61,988 | 6,029/16,348,907 | 0.04 | 5.75e-09 | 5.24e-08 |
| 25-hydroxyvitamin D:0 | 35/61,988 | 2,997/16,348,907 | 3.08 | 1.57e-08 | 1.37e-07 |
| cetrorelix:0 | 24/61,988 | 891/16,348,907 | 7.11 | 3.97e-13 | 5.01e-12 |
| APC8015:0 | 8/61,988 | 13/16,348,907 | 162.32 | 8.07e-15 | 1.14e-13 |
| HK3:0 | 12/61,988 | 53/16,348,907 | 59.73 | 2.82e-17 | 4.60e-16 |
| Glutathione:0 | 93/61,988 | 43,134/16,348,907 | 0.57 | 2.74e-09 | 2.58e-08 |
| Limited:0 | 28/61,988 | 2,431/16,348,907 | 3.04 | 5.22e-07 | 3.84e-06 |
| Entire utricle:0 | 39/61,988 | 1,279/16,348,907 | 8.05 | 3.80e-22 | 7.88e-21 |
| Opioids:0 | 53/61,988 | 37,199/16,348,907 | 0.38 | 3.33e-17 | 5.42e-16 |
| Entire cerebellar cortex:0 | 1/61,988 | 5,475/16,348,907 | 0.05 | 5.34e-08 | 4.39e-07 |
| Immune System Diseases:0 | 10/61,988 | 10,364/16,348,907 | 0.25 | 5.66e-08 | 4.63e-07 |
| Goserelin:0 | 129/61,988 | 1,311/16,348,907 | 26.00 | 2.69e-128 | 2.94e-126 |
| Gastroesophageal reflux disease:0 | 8/61,988 | 31,922/16,348,907 | 0.07 | 6.32e-41 | 2.36e-39 |
| Receptors, Antigen, B-Cell:0 | 2/61,988 | 5,243/16,348,907 | 0.10 | 1.30e-06 | 9.10e-06 |
| human leukocyte interferon|IFNA1:0 | 42/61,988 | 24,848/16,348,907 | 0.45 | 3.00e-09 | 2.81e-08 |
| Prostate Rhabdomyosarcoma:0 | 33/61,988 | 63/16,348,907 | 138.22 | 5.05e-55 | 2.53e-53 |
| 13q14:0 | 17/61,988 | 523/16,348,907 | 8.57 | 6.18e-11 | 6.75e-10 |
| Rats, Inbred F344:0 | 77/61,988 | 9,674/16,348,907 | 2.10 | 6.85e-09 | 6.20e-08 |
| Coitus:0 | 58/61,988 | 3,907/16,348,907 | 3.92 | 2.08e-17 | 3.40e-16 |
| Cerebrovascular accident:0 | 62/61,988 | 145,345/16,348,907 | 0.11 | 1.22e-155 | 1.64e-153 |
| National Cancer Institute:0 | 33/61,988 | 627/16,348,907 | 13.89 | 6.27e-26 | 1.52e-24 |
| Tumor tissue sample:0 | 20/61,988 | 627/16,348,907 | 8.42 | 1.85e-12 | 2.23e-11 |
| Echinococcosis:0 | 1/61,988 | 17,952/16,348,907 | 0.01 | 3.55e-28 | 9.19e-27 |
| Bronchial:0 | 32/61,988 | 19,354/16,348,907 | 0.44 | 8.39e-08 | 6.73e-07 |
| Radiotherapy Research:0 | 76/61,988 | 3,335/16,348,907 | 6.02 | 2.02e-33 | 6.16e-32 |
| Residual Tissues:0 | 26/61,988 | 843/16,348,907 | 8.14 | 2.08e-15 | 3.06e-14 |
| alpha 1-Antichymotrypsin|ADRA1D:0 | 20/61,988 | 319/16,348,907 | 16.54 | 1.03e-17 | 1.71e-16 |
| Radioisotope scan of bone:0 | 63/61,988 | 1,077/16,348,907 | 15.44 | 1.38e-50 | 6.29e-49 |
| Purpura, Thrombocytopenic, Idiopathic:0 | 2/61,988 | 8,743/16,348,907 | 0.06 | 5.46e-12 | 6.43e-11 |
| Chemotherapy-Oncologic Procedure:0 | 271/61,988 | 21,257/16,348,907 | 3.37 | 5.62e-62 | 3.09e-60 |
| Carnitine:0 | 3/61,988 | 11,536/16,348,907 | 0.07 | 3.65e-15 | 5.29e-14 |
| cyclin-dependent kinase inhibitor 1B|IFI27|PSMD9|SSSCA1|DCTN6|TMED7:0 | 19/61,988 | 454/16,348,907 | 11.04 | 6.86e-14 | 9.15e-13 |
| HPCX:0 | 5/61,988 | 11/16,348,907 | 119.89 | 3.24e-09 | 3.03e-08 |
| Genus Mycobacterium:0 | 1/61,988 | 7,574/16,348,907 | 0.03 | 2.71e-11 | 3.02e-10 |
| Dissection of aorta:0 | 3/61,988 | 8,332/16,348,907 | 0.09 | 2.82e-10 | 2.92e-09 |
| Urology department:0 | 18/61,988 | 115/16,348,907 | 41.29 | 1.29e-22 | 2.71e-21 |
| Atom:0 | 19/61,988 | 22,616/16,348,907 | 0.22 | 6.30e-18 | 1.06e-16 |
| Databases:0 | 174/61,988 | 9,383/16,348,907 | 4.90 | 1.32e-61 | 7.22e-60 |
| Ketamine:0 | 3/61,988 | 17,803/16,348,907 | 0.04 | 6.04e-25 | 1.40e-23 |
| ARCH:0 | 2/61,988 | 6,284/16,348,907 | 0.08 | 2.58e-08 | 2.19e-07 |
| Transitional cell carcinoma in situ:0 | 10/61,988 | 97/16,348,907 | 27.19 | 1.49e-11 | 1.69e-10 |
| COGNITIVE DEFICIT:0 | 1/61,988 | 10,422/16,348,907 | 0.03 | 6.70e-16 | 1.01e-14 |
| Acute Lung Injury:0 | 1/61,988 | 9,708/16,348,907 | 0.03 | 8.35e-15 | 1.18e-13 |
| Red blood cells, blood product:0 | 1/61,988 | 4,803/16,348,907 | 0.05 | 4.30e-07 | 3.20e-06 |
| SDC1 gene|SDC1:0 | 25/61,988 | 1,855/16,348,907 | 3.56 | 1.28e-07 | 1.01e-06 |
| Hospitalization:0 | 60/61,988 | 32,690/16,348,907 | 0.48 | 2.99e-10 | 3.08e-09 |
| CYP24|CYP24A1:0 | 17/61,988 | 466/16,348,907 | 9.62 | 1.10e-11 | 1.27e-10 |
| Leishmaniasis:0 | 2/61,988 | 7,441/16,348,907 | 0.07 | 5.55e-10 | 5.56e-09 |
| High-Grade Prostatic Intraepithelial Neoplasia:0 | 623/61,988 | 1,431/16,348,907 | 115.98 | 0.00e+00 | 0.00e+00 |
| autologous dendritic cells:0 | 34/61,988 | 414/16,348,907 | 21.67 | 1.19e-32 | 3.55e-31 |
| Bilateral Disease:0 | 19/61,988 | 1,245/16,348,907 | 4.03 | 6.66e-07 | 4.84e-06 |
| MATCHING:0 | 50/61,988 | 4,216/16,348,907 | 3.13 | 9.55e-12 | 1.10e-10 |
| estramustine-binding protein:0 | 36/61,988 | 229/16,348,907 | 41.49 | 9.83e-44 | 3.89e-42 |
| Reflux:0 | 11/61,988 | 19,243/16,348,907 | 0.15 | 4.59e-19 | 8.24e-18 |
| Adenocarcinoma:0 | 4,556/61,988 | 90,559/16,348,907 | 14.24 | 0.00e+00 | 0.00e+00 |
| Bacteremia:0 | 19/61,988 | 29,307/16,348,907 | 0.17 | 9.23e-27 | 2.30e-25 |
| Adrenergic beta-Antagonists:0 | 24/61,988 | 33,465/16,348,907 | 0.19 | 1.24e-28 | 3.28e-27 |
| Malignant neoplasm of urinary bladder:0 | 1,133/61,988 | 29,148/16,348,907 | 10.42 | 0.00e+00 | 0.00e+00 |
| HSV-Tk Gene:0 | 39/61,988 | 1,439/16,348,907 | 7.15 | 1.96e-20 | 3.79e-19 |
| Chronic Fatigue Syndrome:0 | 77/61,988 | 10,913/16,348,907 | 1.86 | 7.29e-07 | 5.28e-06 |
| GGN:0 | 12/61,988 | 81/16,348,907 | 39.08 | 2.65e-15 | 3.86e-14 |
| TNS gene|TNS1:0 | 6/61,988 | 83/16,348,907 | 19.07 | 1.29e-06 | 9.03e-06 |
| granulocyte:0 | 8/61,988 | 13,297/16,348,907 | 0.16 | 3.60e-13 | 4.57e-12 |
| Inflammatory Response:0 | 83/61,988 | 44,093/16,348,907 | 0.50 | 9.26e-13 | 1.14e-11 |
| Antibiotics:0 | 163/61,988 | 125,747/16,348,907 | 0.34 | 3.73e-62 | 2.06e-60 |
| Local anesthesia:0 | 59/61,988 | 6,988/16,348,907 | 2.23 | 4.89e-08 | 4.04e-07 |
| Adriamycin:0 | 132/61,988 | 18,769/16,348,907 | 1.86 | 1.02e-10 | 1.10e-09 |
| Multimodal Imaging:0 | 16/61,988 | 939/16,348,907 | 4.49 | 1.25e-06 | 8.76e-06 |
| prostate cancer prevention:0 | 92/61,988 | 114/16,348,907 | 213.16 | 1.36e-163 | 1.90e-161 |
| Pelvic Exenteration:0 | 57/61,988 | 1,324/16,348,907 | 11.36 | 4.24e-39 | 1.52e-37 |
| Testis:0 | 454/61,988 | 54,670/16,348,907 | 2.20 | 1.71e-49 | 7.71e-48 |
| Large T-Antigen:0 | 56/61,988 | 4,723/16,348,907 | 3.13 | 5.85e-13 | 7.31e-12 |
| Evaluable Disease:0 | 350/61,988 | 11,731/16,348,907 | 7.91 | 7.78e-182 | 1.19e-179 |
| Transcriptional Activation:0 | 232/61,988 | 17,807/16,348,907 | 3.45 | 7.36e-55 | 3.66e-53 |
| Nodule:0 | 249/61,988 | 26,639/16,348,907 | 2.47 | 3.68e-35 | 1.17e-33 |
| Permeability:0 | 30/61,988 | 29,709/16,348,907 | 0.27 | 4.09e-20 | 7.76e-19 |
| Autoimmune Diseases:0 | 45/61,988 | 47,146/16,348,907 | 0.25 | 1.10e-32 | 3.29e-31 |
| Anorexia Nervosa:0 | 1/61,988 | 16,728/16,348,907 | 0.02 | 4.44e-26 | 1.08e-24 |
| R-1881:0 | 198/61,988 | 855/16,348,907 | 61.27 | 1.97e-262 | 4.14e-260 |
| Hyperparathyroidism, Primary:0 | 8/61,988 | 12,986/16,348,907 | 0.16 | 9.64e-13 | 1.18e-11 |
| Chitosan:0 | 11/61,988 | 10,488/16,348,907 | 0.28 | 1.65e-07 | 1.28e-06 |
| Vision:0 | 68/61,988 | 31,625/16,348,907 | 0.57 | 3.36e-07 | 2.53e-06 |
| irofulven:0 | 13/61,988 | 247/16,348,907 | 13.88 | 3.93e-11 | 4.35e-10 |
| Protein p53|TP53:0 | 122/61,988 | 10,111/16,348,907 | 3.19 | 7.02e-27 | 1.76e-25 |
| SLC5A5 protein, human|SLC5A5:0 | 36/61,988 | 2,684/16,348,907 | 3.54 | 2.99e-10 | 3.09e-09 |
| Carcinoma, urological:0 | 7/61,988 | 22/16,348,907 | 83.93 | 1.59e-11 | 1.80e-10 |
| Combined radiotherapy NOS:0 | 30/61,988 | 596/16,348,907 | 13.28 | 3.41e-23 | 7.39e-22 |
| Pathologic Neovascularization:0 | 139/61,988 | 20,563/16,348,907 | 1.78 | 4.66e-10 | 4.72e-09 |
| Focal segmental glomerulosclerosis:0 | 1/61,988 | 4,997/16,348,907 | 0.05 | 2.09e-07 | 1.61e-06 |
| Animal Model:0 | 408/61,988 | 42,389/16,348,907 | 2.55 | 9.53e-60 | 5.10e-58 |
| Camptothecin:0 | 64/61,988 | 5,875/16,348,907 | 2.88 | 5.30e-13 | 6.63e-12 |
| MTSS1 gene|MTSS1:0 | 9/61,988 | 154/16,348,907 | 15.42 | 1.66e-08 | 1.44e-07 |
| Oils:0 | 34/61,988 | 29,698/16,348,907 | 0.30 | 7.57e-18 | 1.27e-16 |
| Farm Animals:0 | 1/61,988 | 4,651/16,348,907 | 0.06 | 9.19e-07 | 6.57e-06 |
| dietary intervention:0 | 40/61,988 | 3,942/16,348,907 | 2.68 | 6.41e-08 | 5.23e-07 |
| Transrectal Ultrasound:0 | 640/61,988 | 1,339/16,348,907 | 127.37 | 0.00e+00 | 0.00e+00 |
| Duodenum:0 | 28/61,988 | 33,644/16,348,907 | 0.22 | 3.11e-26 | 7.63e-25 |
| Singleton:0 | 2/61,988 | 6,282/16,348,907 | 0.08 | 2.58e-08 | 2.19e-07 |
| Entire iris:0 | 11/61,988 | 12,161/16,348,907 | 0.24 | 1.31e-09 | 1.27e-08 |
| Tyrosine 3-Monooxygenase|TH:0 | 1/61,988 | 16,191/16,348,907 | 0.02 | 2.64e-25 | 6.20e-24 |
| Amylin:0 | 1/61,988 | 6,743/16,348,907 | 0.04 | 4.64e-10 | 4.70e-09 |
| matrix metalloproteinase 26:0 | 9/61,988 | 230/16,348,907 | 10.32 | 4.32e-07 | 3.21e-06 |
| response to hormone stimulus:0 | 24/61,988 | 779/16,348,907 | 8.13 | 2.48e-14 | 3.40e-13 |
| BONE INVOLVEMENT:0 | 36/61,988 | 899/16,348,907 | 10.57 | 2.64e-24 | 5.95e-23 |
| High dose brachytherapy:0 | 9/61,988 | 60/16,348,907 | 39.57 | 7.23e-12 | 8.43e-11 |
| Brain natriuretic peptide:0 | 1/61,988 | 13,578/16,348,907 | 0.02 | 5.53e-21 | 1.09e-19 |
| Tumor Oxygenation:0 | 17/61,988 | 394/16,348,907 | 11.38 | 8.70e-13 | 1.07e-11 |
| Osteoclastic resorption:0 | 18/61,988 | 1,152/16,348,907 | 4.12 | 9.35e-07 | 6.67e-06 |
| Amikacin:0 | 1/61,988 | 6,523/16,348,907 | 0.04 | 9.36e-10 | 9.19e-09 |
| radiotracer:0 | 27/61,988 | 1,692/16,348,907 | 4.21 | 1.38e-09 | 1.33e-08 |
| Ductal Carcinoma:0 | 44/61,988 | 1,969/16,348,907 | 5.90 | 9.38e-20 | 1.74e-18 |
| Violence:0 | 2/61,988 | 17,886/16,348,907 | 0.03 | 2.13e-26 | 5.24e-25 |
| Systolic blood pressure:0 | 7/61,988 | 19,939/16,348,907 | 0.09 | 9.70e-24 | 2.13e-22 |
| Pancreas:0 | 682/61,988 | 122,255/16,348,907 | 1.48 | 2.06e-21 | 4.13e-20 |
| Gleason pattern:0 | 29/61,988 | 39/16,348,907 | 196.21 | 6.48e-52 | 3.06e-50 |
| XRCC1 gene|XRCC1:0 | 48/61,988 | 3,893/16,348,907 | 3.25 | 6.71e-12 | 7.84e-11 |
| Carcinoma in Situ:0 | 160/61,988 | 7,386/16,348,907 | 5.73 | 1.80e-65 | 1.04e-63 |
| Cell Line, Tumor:0 | 567/61,988 | 15,602/16,348,907 | 9.66 | 0.00e+00 | 0.00e+00 |
| Monoclonal Antibodies:0 | 662/61,988 | 103,477/16,348,907 | 1.69 | 2.21e-35 | 7.04e-34 |
| quetiapine:0 | 1/61,988 | 5,701/16,348,907 | 0.05 | 1.67e-08 | 1.45e-07 |
| Renal function:0 | 56/61,988 | 34,090/16,348,907 | 0.43 | 6.21e-13 | 7.74e-12 |
| MSMB gene|MSMB:0 | 83/61,988 | 1,733/16,348,907 | 12.65 | 1.43e-59 | 7.65e-58 |
| Phosphatidylinositols:0 | 17/61,988 | 14,277/16,348,907 | 0.31 | 7.30e-09 | 6.58e-08 |
| Thyroxine:0 | 16/61,988 | 24,296/16,348,907 | 0.17 | 3.55e-22 | 7.35e-21 |
| PDPN:0 | 22/61,988 | 1,069/16,348,907 | 5.43 | 5.15e-10 | 5.19e-09 |
| Curettage procedure:0 | 1/61,988 | 4,591/16,348,907 | 0.06 | 8.80e-07 | 6.32e-06 |
| Low Grade Prostatic Intraepithelial Neoplasia:0 | 53/61,988 | 87/16,348,907 | 160.81 | 4.12e-90 | 3.06e-88 |
| Deficiency of testosterone biosynthesis:0 | 35/61,988 | 903/16,348,907 | 10.23 | 3.10e-23 | 6.72e-22 |
| Prostate Stromal Sarcoma:0 | 9/61,988 | 23/16,348,907 | 103.22 | 4.06e-15 | 5.86e-14 |
| Crohn's disease:0 | 19/61,988 | 46,666/16,348,907 | 0.11 | 1.63e-51 | 7.62e-50 |
| Clamp:0 | 3/61,988 | 5,807/16,348,907 | 0.14 | 1.00e-06 | 7.11e-06 |
| Norepinephrine:0 | 25/61,988 | 89,081/16,348,907 | 0.07 | 4.19e-109 | 3.74e-107 |
| Mucocutaneous Lymph Node Syndrome:0 | 2/61,988 | 12,340/16,348,907 | 0.04 | 1.37e-17 | 2.26e-16 |
| nuclear receptor coactivator 1|SRC:0 | 17/61,988 | 404/16,348,907 | 11.10 | 1.27e-12 | 1.55e-11 |
| Hyperuricemia:0 | 3/61,988 | 6,892/16,348,907 | 0.11 | 3.45e-08 | 2.91e-07 |
| Rumen:0 | 2/61,988 | 8,987/16,348,907 | 0.06 | 1.78e-12 | 2.16e-11 |
| Ovarian Carcinoma:0 | 562/61,988 | 62,529/16,348,907 | 2.38 | 1.12e-71 | 6.96e-70 |
| Cerebral Vasospasm:0 | 1/61,988 | 4,664/16,348,907 | 0.06 | 9.36e-07 | 6.68e-06 |
| Acetic Acid:0 | 10/61,988 | 11,333/16,348,907 | 0.23 | 3.66e-09 | 3.40e-08 |
| Age:0 | 558/61,988 | 54,184/16,348,907 | 2.73 | 2.89e-91 | 2.21e-89 |
| Creatine Kinase, BB Form:0 | 19/61,988 | 729/16,348,907 | 6.88 | 1.78e-10 | 1.87e-09 |
| Rectal hemorrhage:0 | 135/61,988 | 1,907/16,348,907 | 18.71 | 1.63e-116 | 1.61e-114 |
| Knee joint:0 | 1/61,988 | 4,966/16,348,907 | 0.05 | 3.19e-07 | 2.40e-06 |
| Monkeys:0 | 22/61,988 | 50,426/16,348,907 | 0.11 | 2.75e-54 | 1.35e-52 |
| Polymerase Chain Reaction:0 | 618/61,988 | 113,051/16,348,907 | 1.45 | 8.94e-18 | 1.49e-16 |
| Antiepileptic Agents:0 | 2/61,988 | 14,150/16,348,907 | 0.04 | 1.33e-20 | 2.60e-19 |
| Transforming Growth Factor beta:0 | 365/61,988 | 54,605/16,348,907 | 1.77 | 4.44e-23 | 9.56e-22 |
| Biopsy:0 | 5,998/61,988 | 137,987/16,348,907 | 12.59 | 0.00e+00 | 0.00e+00 |
| Lymph Node Dissection:0 | 491/61,988 | 7,473/16,348,907 | 17.46 | 0.00e+00 | 0.00e+00 |
| Choroid:0 | 20/61,988 | 15,645/16,348,907 | 0.34 | 7.09e-09 | 6.40e-08 |
| Cholecystectomy, Laparoscopic:0 | 3/61,988 | 10,635/16,348,907 | 0.07 | 8.79e-14 | 1.17e-12 |
| Radionuclide Imaging:0 | 372/61,988 | 38,798/16,348,907 | 2.54 | 3.22e-54 | 1.58e-52 |
| IODINE,I-125:0 | 142/61,988 | 678/16,348,907 | 55.36 | 3.02e-183 | 4.70e-181 |
| Cellulose:0 | 2/61,988 | 8,456/16,348,907 | 0.06 | 1.62e-11 | 1.84e-10 |
| Intussusception:0 | 7/61,988 | 9,055/16,348,907 | 0.20 | 4.20e-08 | 3.49e-07 |
| procaspase-9:0 | 14/61,988 | 314/16,348,907 | 11.76 | 5.74e-11 | 6.28e-10 |
| Propranolol:0 | 7/61,988 | 34,463/16,348,907 | 0.05 | 5.72e-46 | 2.39e-44 |
| Adipocytes:0 | 38/61,988 | 40,883/16,348,907 | 0.24 | 4.28e-29 | 1.15e-27 |
| Nuclear Translocation:0 | 92/61,988 | 3,640/16,348,907 | 6.67 | 1.58e-43 | 6.23e-42 |
| Mass Screening:0 | 56/61,988 | 1,361/16,348,907 | 10.86 | 1.84e-37 | 6.27e-36 |
| bone morphogenetic protein 6:0 | 13/61,988 | 388/16,348,907 | 8.84 | 7.49e-09 | 6.74e-08 |
| Osteolytic lesion:0 | 32/61,988 | 1,495/16,348,907 | 5.65 | 2.58e-14 | 3.54e-13 |
| Antihistamines:0 | 2/61,988 | 6,664/16,348,907 | 0.08 | 9.78e-09 | 8.70e-08 |
| Tumor destruction:0 | 15/61,988 | 297/16,348,907 | 13.32 | 2.23e-12 | 2.68e-11 |
| Core needle biopsy:0 | 470/61,988 | 4,763/16,348,907 | 26.22 | 0.00e+00 | 0.00e+00 |
| Bone finding:0 | 16/61,988 | 135/16,348,907 | 31.27 | 1.62e-18 | 2.82e-17 |
| Transurethral Resection:0 | 479/61,988 | 4,657/16,348,907 | 27.33 | 0.00e+00 | 0.00e+00 |
| Oocytes:0 | 20/61,988 | 58,518/16,348,907 | 0.09 | 3.42e-68 | 2.04e-66 |
| bevacizumab|COX5A:0 | 12/61,988 | 1/16,348,907 | 3165.53 | 1.09e-28 | 2.89e-27 |
| Palpation:0 | 42/61,988 | 4,380/16,348,907 | 2.53 | 1.89e-07 | 1.47e-06 |
| Phosphoenolpyruvate Carboxylase:0 | 1/61,988 | 5,565/16,348,907 | 0.05 | 3.66e-08 | 3.07e-07 |
| Ureterostomy procedure:0 | 13/61,988 | 306/16,348,907 | 11.21 | 4.84e-10 | 4.88e-09 |
| Propidium Iodide:0 | 27/61,988 | 1,950/16,348,907 | 3.65 | 2.44e-08 | 2.08e-07 |
| Progressive Disease:0 | 193/61,988 | 8,361/16,348,907 | 6.10 | 5.82e-83 | 4.08e-81 |
| ileum:0 | 34/61,988 | 37,627/16,348,907 | 0.24 | 1.74e-27 | 4.41e-26 |
| Aorta:0 | 41/61,988 | 114,377/16,348,907 | 0.09 | 2.73e-130 | 3.06e-128 |
| PCA3:0 | 90/61,988 | 189/16,348,907 | 125.77 | 3.23e-144 | 3.97e-142 |
| Kidney Failure, Chronic:0 | 22/61,988 | 84,790/16,348,907 | 0.07 | 5.77e-106 | 5.02e-104 |
| Hypothyroidism:0 | 8/61,988 | 27,015/16,348,907 | 0.08 | 2.01e-33 | 6.13e-32 |
| Screening for cancer:0 | 24/61,988 | 134/16,348,907 | 47.26 | 6.53e-31 | 1.83e-29 |
| Adrenal Cortex Hormones:0 | 88/61,988 | 97,827/16,348,907 | 0.24 | 1.32e-69 | 7.96e-68 |
| alpha-methylacyl-CoA racemase:0 | 104/61,988 | 403/16,348,907 | 68.18 | 5.08e-143 | 6.16e-141 |
| Risk Assessment:0 | 49/61,988 | 4,687/16,348,907 | 2.76 | 9.25e-10 | 9.09e-09 |
| Indomethacin:0 | 36/61,988 | 45,215/16,348,907 | 0.21 | 7.46e-36 | 2.42e-34 |
| Chromosomes, Human, Pair 8:0 | 41/61,988 | 2,017/16,348,907 | 5.36 | 3.84e-17 | 6.22e-16 |
| Interleukin 6 Receptor:0 | 29/61,988 | 2,668/16,348,907 | 2.87 | 1.02e-06 | 7.27e-06 |
| Prostatic acid phosphatase measurement:0 | 16/61,988 | 20/16,348,907 | 211.05 | 1.17e-29 | 3.18e-28 |
| Vasectomy:0 | 44/61,988 | 1,623/16,348,907 | 7.15 | 7.57e-23 | 1.61e-21 |
| Synovitis:0 | 3/61,988 | 7,336/16,348,907 | 0.11 | 5.92e-09 | 5.39e-08 |
| Autologous Stem Cell Transplantation:0 | 3/61,988 | 5,699/16,348,907 | 0.14 | 1.40e-06 | 9.75e-06 |
| keratinocyte:0 | 30/61,988 | 40,966/16,348,907 | 0.19 | 1.89e-34 | 5.86e-33 |
| Prion Diseases:0 | 3/61,988 | 7,933/16,348,907 | 0.10 | 1.14e-09 | 1.11e-08 |
| CCNB1 gene|CCNB1:0 | 21/61,988 | 1,159/16,348,907 | 4.78 | 1.08e-08 | 9.60e-08 |
| Diagnostic tests:0 | 41/61,988 | 3,761/16,348,907 | 2.88 | 6.61e-09 | 5.98e-08 |
| Entire substantia nigra:0 | 2/61,988 | 24,998/16,348,907 | 0.02 | 8.57e-38 | 2.96e-36 |
| Asian Americans:0 | 18/61,988 | 1,148/16,348,907 | 4.14 | 8.91e-07 | 6.39e-06 |
| MSR1:0 | 16/61,988 | 190/16,348,907 | 22.22 | 2.41e-16 | 3.72e-15 |
| Colorectal cancer metastatic:0 | 19/61,988 | 13,860/16,348,907 | 0.36 | 1.72e-07 | 1.33e-06 |
| Diet:0 | 194/61,988 | 18,955/16,348,907 | 2.70 | 1.42e-32 | 4.23e-31 |
| PHLPP1:0 | 10/61,988 | 317/16,348,907 | 8.32 | 6.69e-07 | 4.86e-06 |
| Body mass index procedure:0 | 103/61,988 | 4,418/16,348,907 | 6.16 | 1.67e-45 | 6.94e-44 |
| Radical cystoprostatectomy:0 | 133/61,988 | 414/16,348,907 | 84.91 | 2.49e-193 | 4.02e-191 |
| Liver and Intrahepatic Biliary Tract Carcinoma:0 | 106/61,988 | 9,459/16,348,907 | 2.96 | 2.71e-21 | 5.43e-20 |
| Parkinson Disease:0 | 36/61,988 | 82,730/16,348,907 | 0.11 | 2.09e-88 | 1.53e-86 |
| Bulla:0 | 7/61,988 | 9,356/16,348,907 | 0.20 | 1.60e-08 | 1.39e-07 |
| Action Potentials:0 | 1/61,988 | 13,041/16,348,907 | 0.02 | 3.28e-20 | 6.27e-19 |
| Heparin Binding Growth Factor:0 | 21/61,988 | 1,279/16,348,907 | 4.33 | 5.47e-08 | 4.49e-07 |
| Nerve Block:0 | 43/61,988 | 4,184/16,348,907 | 2.71 | 1.50e-08 | 1.31e-07 |
| Accessory Sex Organs:0 | 18/61,988 | 238/16,348,907 | 19.95 | 1.97e-17 | 3.23e-16 |
| TWIST1 gene|TWIST1:0 | 53/61,988 | 3,172/16,348,907 | 4.41 | 4.12e-18 | 7.01e-17 |
| chromosome 8p22:0 | 11/61,988 | 52/16,348,907 | 55.80 | 1.15e-15 | 1.71e-14 |
| brush border membrane:0 | 6/61,988 | 11,582/16,348,907 | 0.14 | 2.12e-12 | 2.55e-11 |
| Nuclear Receptor Coactivator 4|NCOA4:0 | 29/61,988 | 141/16,348,907 | 54.27 | 1.40e-38 | 4.95e-37 |
| Forearm:0 | 11/61,988 | 12,495/16,348,907 | 0.23 | 5.29e-10 | 5.32e-09 |
| Immunosuppressive Agents:0 | 18/61,988 | 15,821/16,348,907 | 0.30 | 4.84e-10 | 4.89e-09 |
| Injection site granuloma:0 | 6/61,988 | 17/16,348,907 | 93.09 | 2.77e-10 | 2.87e-09 |
| Signal Transduction:0 | 664/61,988 | 76,577/16,348,907 | 2.30 | 1.29e-78 | 8.67e-77 |
| Ductal Mouse MIN:0 | 35/61,988 | 380/16,348,907 | 24.31 | 3.69e-35 | 1.17e-33 |
| atrial natriuretic factor prohormone (31-67):0 | 11/61,988 | 138/16,348,907 | 21.03 | 1.91e-11 | 2.15e-10 |
| ESR1 gene|ESR1:0 | 45/61,988 | 3,762/16,348,907 | 3.16 | 7.60e-11 | 8.24e-10 |
| Loss of Heterozygosity:0 | 151/61,988 | 5,442/16,348,907 | 7.33 | 1.93e-75 | 1.24e-73 |
| Rectal ultrasound:0 | 15/61,988 | 39/16,348,907 | 101.46 | 3.42e-24 | 7.68e-23 |
| Stenosis:0 | 3/61,988 | 7,935/16,348,907 | 0.10 | 1.15e-09 | 1.11e-08 |
| Kidney Failure, Acute:0 | 36/61,988 | 23,981/16,348,907 | 0.40 | 9.92e-11 | 1.07e-09 |
| 17 alpha-ethinyl-3-isopropylsulfonyloxyestradiol:0 | 10/61,988 | 28/16,348,907 | 94.21 | 2.54e-16 | 3.91e-15 |
| Proto-Oncogene Proteins c-ets:0 | 71/61,988 | 672/16,348,907 | 27.90 | 1.92e-73 | 1.23e-71 |
| Black race:0 | 156/61,988 | 11,185/16,348,907 | 3.69 | 8.61e-41 | 3.20e-39 |
| Isoflavones:0 | 182/61,988 | 6,568/16,348,907 | 7.33 | 1.87e-90 | 1.40e-88 |
| androgen receptor binding:0 | 18/61,988 | 51/16,348,907 | 93.11 | 3.51e-28 | 9.09e-27 |
| molecular imaging:0 | 19/61,988 | 806/16,348,907 | 6.22 | 8.89e-10 | 8.76e-09 |
| Cysteine:0 | 35/61,988 | 25,836/16,348,907 | 0.36 | 3.93e-13 | 4.97e-12 |
| Trisomy 7:0 | 11/61,988 | 146/16,348,907 | 19.87 | 3.37e-11 | 3.74e-10 |
| CYP17A1 gene|CYP17A1:0 | 73/61,988 | 1,594/16,348,907 | 12.09 | 2.46e-51 | 1.15e-49 |
| Paracrine Communication:0 | 20/61,988 | 457/16,348,907 | 11.55 | 6.88e-15 | 9.76e-14 |
| Enlargement of lymph nodes:0 | 44/61,988 | 3,420/16,348,907 | 3.39 | 1.30e-11 | 1.49e-10 |
| Image Cytometry:0 | 15/61,988 | 401/16,348,907 | 9.87 | 1.26e-10 | 1.34e-09 |
| Histamine Release:0 | 1/61,988 | 10,377/16,348,907 | 0.03 | 6.36e-16 | 9.59e-15 |
| NADH:0 | 9/61,988 | 8,815/16,348,907 | 0.27 | 1.34e-06 | 9.34e-06 |
| Histone Acetylation:0 | 35/61,988 | 1,342/16,348,907 | 6.88 | 5.22e-18 | 8.85e-17 |
| Phosphorylation:0 | 618/61,988 | 62,763/16,348,907 | 2.61 | 3.25e-93 | 2.53e-91 |
| erbB-2 Receptor|ERBB2:0 | 86/61,988 | 6,216/16,348,907 | 3.65 | 4.59e-23 | 9.86e-22 |
| TAP-144|SCTR|SNCG:0 | 4/61,988 | 1/16,348,907 | 1055.04 | 1.01e-09 | 9.90e-09 |
| Purpura, Thrombotic Thrombocytopenic:0 | 7/61,988 | 9,087/16,348,907 | 0.20 | 2.91e-08 | 2.46e-07 |
| Epidermal Growth Factor:0 | 60/61,988 | 2,455/16,348,907 | 6.45 | 2.90e-28 | 7.54e-27 |
| abiraterone:0 | 287/61,988 | 590/16,348,907 | 128.89 | 0.00e+00 | 0.00e+00 |
| Electrocardiogram:0 | 7/61,988 | 18,423/16,348,907 | 0.10 | 1.74e-21 | 3.50e-20 |
| Headache:0 | 17/61,988 | 29,574/16,348,907 | 0.15 | 1.11e-28 | 2.95e-27 |
| Paroxysmal atrial fibrillation:0 | 2/61,988 | 6,229/16,348,907 | 0.08 | 3.80e-08 | 3.18e-07 |
| Australia:0 | 28/61,988 | 2,205/16,348,907 | 3.35 | 7.80e-08 | 6.28e-07 |
| Carcinoid Tumor:0 | 76/61,988 | 9,615/16,348,907 | 2.09 | 1.04e-08 | 9.22e-08 |
| Corticotropin-Releasing Hormone:0 | 8/61,988 | 22,269/16,348,907 | 0.09 | 4.05e-26 | 9.86e-25 |
| G-3139 oligonucleotide:0 | 11/61,988 | 358/16,348,907 | 8.11 | 2.41e-07 | 1.85e-06 |
| RB1 gene|RB1:0 | 35/61,988 | 2,355/16,348,907 | 3.92 | 3.73e-11 | 4.13e-10 |
| Graft Survival:0 | 1/61,988 | 7,547/16,348,907 | 0.03 | 2.58e-11 | 2.88e-10 |
| Colon Carcinoma:0 | 111/61,988 | 10,214/16,348,907 | 2.87 | 3.04e-21 | 6.07e-20 |
| Hemangioma:0 | 18/61,988 | 16,746/16,348,907 | 0.28 | 3.49e-11 | 3.87e-10 |
| TAP-144|SCTR:0 | 8/61,988 | 53/16,348,907 | 39.82 | 1.02e-10 | 1.10e-09 |
| bone metabolism:0 | 67/61,988 | 6,733/16,348,907 | 2.63 | 7.51e-12 | 8.74e-11 |
| Disseminated adenocarcinoma:0 | 8/61,988 | 51/16,348,907 | 41.38 | 7.74e-11 | 8.38e-10 |
| Nucleoproteins:0 | 1/61,988 | 4,523/16,348,907 | 0.06 | 1.28e-06 | 8.96e-06 |
| Dendritic Cell Vaccine:0 | 17/61,988 | 886/16,348,907 | 5.06 | 1.18e-07 | 9.36e-07 |
| Encephalitis:0 | 5/61,988 | 16,483/16,348,907 | 0.08 | 1.35e-20 | 2.64e-19 |
| VICTIM:0 | 7/61,988 | 21,487/16,348,907 | 0.09 | 5.50e-26 | 1.33e-24 |
| malignant state:0 | 9/61,988 | 139/16,348,907 | 17.08 | 7.15e-09 | 6.45e-08 |
| skills:0 | 21/61,988 | 16,422/16,348,907 | 0.34 | 2.45e-09 | 2.32e-08 |
| RC 3095:0 | 10/61,988 | 250/16,348,907 | 10.55 | 8.19e-08 | 6.58e-07 |
| At risk for suicide:0 | 1/61,988 | 5,364/16,348,907 | 0.05 | 7.52e-08 | 6.07e-07 |
| DNA analysis:0 | 35/61,988 | 3,254/16,348,907 | 2.84 | 1.08e-07 | 8.61e-07 |
| Carpal Tunnel Syndrome:0 | 1/61,988 | 10,205/16,348,907 | 0.03 | 1.35e-15 | 2.01e-14 |
| JNK Mitogen-Activated Protein Kinases|JUN:0 | 49/61,988 | 4,157/16,348,907 | 3.11 | 1.87e-11 | 2.11e-10 |
| AOD use:0 | 1/61,988 | 8,954/16,348,907 | 0.03 | 1.64e-13 | 2.14e-12 |
| tamsulosin:0 | 51/61,988 | 3,152/16,348,907 | 4.27 | 6.05e-17 | 9.68e-16 |
| TRH gene|TRH:0 | 3/61,988 | 8,700/16,348,907 | 0.09 | 6.69e-11 | 7.27e-10 |
| Paraffin Embedding:0 | 17/61,988 | 772/16,348,907 | 5.81 | 1.75e-08 | 1.51e-07 |
| Abscess of prostate:0 | 14/61,988 | 384/16,348,907 | 9.62 | 7.09e-10 | 7.03e-09 |
| antagonists:0 | 50/61,988 | 6,139/16,348,907 | 2.15 | 1.26e-06 | 8.81e-06 |
| phenethyl isothiocyanate:0 | 47/61,988 | 1,577/16,348,907 | 7.87 | 6.03e-26 | 1.46e-24 |
| Refractory Neoplasm:0 | 22/61,988 | 318/16,348,907 | 18.25 | 3.45e-20 | 6.58e-19 |
| Zinc measurement:0 | 22/61,988 | 797/16,348,907 | 7.28 | 2.32e-12 | 2.78e-11 |
| Dihydrotestosterone Assay:0 | 34/61,988 | 143/16,348,907 | 62.74 | 7.59e-47 | 3.24e-45 |
| Clinical Trials, Phase II:0 | 126/61,988 | 2,618/16,348,907 | 12.72 | 1.01e-89 | 7.49e-88 |
| Transition Zone PSA Density:0 | 6/61,988 | 14/16,348,907 | 113.04 | 1.08e-10 | 1.15e-09 |
| Polyamines:0 | 113/61,988 | 15,856/16,348,907 | 1.88 | 1.31e-09 | 1.27e-08 |
| Botanicals:0 | 15/61,988 | 652/16,348,907 | 6.07 | 6.82e-08 | 5.55e-07 |
| Osteoclasts:0 | 151/61,988 | 15,216/16,348,907 | 2.62 | 1.79e-24 | 4.06e-23 |
| Preservative free ingredient:0 | 25/61,988 | 2,059/16,348,907 | 3.20 | 8.23e-07 | 5.93e-06 |
| C-reactive protein:0 | 78/61,988 | 36,920/16,348,907 | 0.56 | 1.51e-08 | 1.32e-07 |
| Atypical proliferation:0 | 64/61,988 | 300/16,348,907 | 56.32 | 4.88e-84 | 3.46e-82 |
| organ development:0 | 15/61,988 | 779/16,348,907 | 5.08 | 6.13e-07 | 4.48e-06 |
| Pancreatitis, Chronic:0 | 19/61,988 | 19,284/16,348,907 | 0.26 | 1.10e-13 | 1.46e-12 |
| Antimalarials:0 | 2/61,988 | 8,591/16,348,907 | 0.06 | 7.44e-12 | 8.66e-11 |
| human CAP|CTAA1|LNPEP|SERPINB6|PTPLA|CAP1|SORBS1|BRD4:0 | 14/61,988 | 27/16,348,907 | 136.79 | 3.85e-24 | 8.61e-23 |
| Xenopus:0 | 9/61,988 | 11,600/16,348,907 | 0.20 | 3.15e-10 | 3.25e-09 |
| HIV Infections:0 | 33/61,988 | 63,295/16,348,907 | 0.14 | 6.19e-63 | 3.47e-61 |
| Bax protein|BAX:0 | 29/61,988 | 1,193/16,348,907 | 6.41 | 1.90e-14 | 2.63e-13 |
| Stat3 protein|STAT3:0 | 10/61,988 | 325/16,348,907 | 8.12 | 8.32e-07 | 5.99e-06 |
| Wounds and Injuries:0 | 52/61,988 | 88,259/16,348,907 | 0.15 | 1.81e-82 | 1.26e-80 |
| Mastication:0 | 4/61,988 | 7,781/16,348,907 | 0.14 | 9.92e-09 | 8.82e-08 |
| Toes:0 | 1/61,988 | 6,088/16,348,907 | 0.04 | 3.92e-09 | 3.63e-08 |
| vitamin analog:0 | 15/61,988 | 432/16,348,907 | 9.16 | 3.38e-10 | 3.47e-09 |
| Bypass:0 | 8/61,988 | 15,328/16,348,907 | 0.14 | 4.61e-16 | 7.01e-15 |
| Racemases:0 | 56/61,988 | 337/16,348,907 | 43.87 | 2.59e-68 | 1.55e-66 |
| Infertility:0 | 69/61,988 | 41,348/16,348,907 | 0.44 | 5.06e-15 | 7.26e-14 |
| Normal body mass index:0 | 21/61,988 | 1,152/16,348,907 | 4.81 | 9.77e-09 | 8.70e-08 |
| Age related macular degeneration:0 | 10/61,988 | 23,211/16,348,907 | 0.11 | 9.69e-26 | 2.33e-24 |
| Infections, Hospital:0 | 2/61,988 | 11,298/16,348,907 | 0.05 | 4.72e-16 | 7.18e-15 |
| early detection of colorectal cancer:0 | 26/61,988 | 1,323/16,348,907 | 5.18 | 3.88e-11 | 4.29e-10 |
| Positron-Emission Tomography:0 | 345/61,988 | 24,142/16,348,907 | 3.78 | 1.25e-90 | 9.44e-89 |
| Hamman-Rich syndrome:0 | 4/61,988 | 14,347/16,348,907 | 0.07 | 1.64e-18 | 2.85e-17 |
| Bladder control:0 | 85/61,988 | 485/16,348,907 | 46.29 | 1.52e-104 | 1.29e-102 |
| Open approach:0 | 96/61,988 | 9,668/16,348,907 | 2.62 | 4.17e-16 | 6.35e-15 |
| Karnofsky Performance Status:0 | 13/61,988 | 307/16,348,907 | 11.17 | 5.02e-10 | 5.06e-09 |
| Dissection:0 | 175/61,988 | 22,460/16,348,907 | 2.06 | 1.58e-17 | 2.60e-16 |
| Right atrial structure:0 | 1/61,988 | 9,088/16,348,907 | 0.03 | 7.28e-14 | 9.69e-13 |
| Serotonin Uptake Inhibitors:0 | 9/61,988 | 15,966/16,348,907 | 0.15 | 3.74e-16 | 5.71e-15 |
| Cardiomyopathies:0 | 6/61,988 | 24,678/16,348,907 | 0.06 | 5.08e-32 | 1.49e-30 |
| EAF2:0 | 11/61,988 | 65/16,348,907 | 44.64 | 1.02e-14 | 1.43e-13 |
| CYTOCHROME C:0 | 102/61,988 | 10,006/16,348,907 | 2.69 | 7.61e-18 | 1.28e-16 |
| Seedling:0 | 1/61,988 | 6,636/16,348,907 | 0.04 | 6.61e-10 | 6.57e-09 |
| chromatin immunoprecipitation:0 | 55/61,988 | 5,455/16,348,907 | 2.66 | 3.27e-10 | 3.37e-09 |
| HOXB13 gene|HOXB13:0 | 9/61,988 | 14/16,348,907 | 169.57 | 1.22e-16 | 1.92e-15 |
| NOS2A protein, human|NOS2:0 | 57/61,988 | 46,952/16,348,907 | 0.32 | 6.46e-26 | 1.56e-24 |
| Cell Cycle Arrest:0 | 478/61,988 | 14,182/16,348,907 | 8.95 | 1.23e-269 | 2.66e-267 |
| DNA Methyltransferase:0 | 21/61,988 | 1,562/16,348,907 | 3.55 | 1.29e-06 | 9.01e-06 |
| Heparin:0 | 50/61,988 | 50,120/16,348,907 | 0.26 | 2.59e-33 | 7.87e-32 |
| Chromogranin A|CGA:0 | 62/61,988 | 353/16,348,907 | 46.37 | 8.67e-77 | 5.71e-75 |
| Intraocular pressure disorder:0 | 3/61,988 | 24,294/16,348,907 | 0.03 | 2.54e-35 | 8.08e-34 |
| Breast:0 | 3,608/61,988 | 108,991/16,348,907 | 9.21 | 0.00e+00 | 0.00e+00 |
| cDNA Microarray device:0 | 44/61,988 | 1,599/16,348,907 | 7.26 | 4.33e-23 | 9.32e-22 |
| PCSK6:0 | 12/61,988 | 311/16,348,907 | 10.18 | 6.25e-09 | 5.67e-08 |
| terazosine:0 | 38/61,988 | 1,907/16,348,907 | 5.26 | 9.69e-16 | 1.45e-14 |
| GDF15 gene|GDF15:0 | 22/61,988 | 509/16,348,907 | 11.40 | 4.05e-16 | 6.18e-15 |
| Protein C|SPANXC:0 | 5/61,988 | 11,999/16,348,907 | 0.11 | 5.70e-14 | 7.66e-13 |
| Coronary Occlusion:0 | 3/61,988 | 5,881/16,348,907 | 0.13 | 1.06e-06 | 7.47e-06 |
| Urea:0 | 31/61,988 | 26,100/16,348,907 | 0.31 | 2.81e-15 | 4.09e-14 |
| Hepatitis A:0 | 2/61,988 | 5,178/16,348,907 | 0.10 | 1.21e-06 | 8.54e-06 |
| Low Density Lipoprotein Receptor:0 | 10/61,988 | 9,473/16,348,907 | 0.28 | 6.14e-07 | 4.48e-06 |
| Lymphography:0 | 65/61,988 | 1,559/16,348,907 | 11.01 | 1.55e-43 | 6.12e-42 |
| Cholecystectomy:0 | 8/61,988 | 9,340/16,348,907 | 0.23 | 7.13e-08 | 5.78e-07 |
| Corpora Cavernosa:0 | 19/61,988 | 984/16,348,907 | 5.09 | 2.00e-08 | 1.72e-07 |
| Suicide attempt:0 | 1/61,988 | 6,608/16,348,907 | 0.04 | 6.45e-10 | 6.43e-09 |
| Aredia:0 | 11/61,988 | 91/16,348,907 | 31.89 | 2.90e-13 | 3.71e-12 |
| Lactate:0 | 44/61,988 | 30,371/16,348,907 | 0.38 | 6.57e-14 | 8.78e-13 |
| Cytarabine:0 | 14/61,988 | 11,592/16,348,907 | 0.32 | 3.00e-07 | 2.28e-06 |
| donepezil:0 | 1/61,988 | 4,718/16,348,907 | 0.06 | 6.20e-07 | 4.53e-06 |
| Psychotherapy, Multiple:0 | 159/61,988 | 11,764/16,348,907 | 3.57 | 5.61e-40 | 2.04e-38 |
| Temporal Arteritis:0 | 4/61,988 | 7,457/16,348,907 | 0.14 | 4.06e-08 | 3.38e-07 |
| Hormone preparation:0 | 6/61,988 | 51/16,348,907 | 31.03 | 8.93e-08 | 7.15e-07 |
| NPSA:0 | 7/61,988 | 14/16,348,907 | 131.89 | 1.22e-12 | 1.49e-11 |
| Equine laminitis:0 | 27/61,988 | 2,404/16,348,907 | 2.96 | 1.31e-06 | 9.12e-06 |
| BCL-XL Protein:0 | 10/61,988 | 338/16,348,907 | 7.80 | 1.17e-06 | 8.24e-06 |
| Fluoroimmunoassay:0 | 13/61,988 | 515/16,348,907 | 6.66 | 1.80e-07 | 1.40e-06 |
| Alpha linolenic acid intake:0 | 5/61,988 | 39/16,348,907 | 33.82 | 7.38e-07 | 5.35e-06 |
| Transcriptional Regulation:0 | 108/61,988 | 9,809/16,348,907 | 2.91 | 4.07e-21 | 8.10e-20 |
| Structure of venule:0 | 2/61,988 | 5,997/16,348,907 | 0.09 | 7.46e-08 | 6.02e-07 |
| Apoptosis Inhibitor:0 | 14/61,988 | 433/16,348,907 | 8.53 | 3.11e-09 | 2.91e-08 |
| Teens:0 | 2/61,988 | 10,597/16,348,907 | 0.05 | 5.83e-15 | 8.31e-14 |
| Valeriana jatamansi:0 | 5/61,988 | 26/16,348,907 | 50.72 | 1.20e-07 | 9.50e-07 |
| Obturator lymph node group:0 | 9/61,988 | 40/16,348,907 | 59.35 | 2.80e-13 | 3.59e-12 |
| CAROTID:0 | 4/61,988 | 19,664/16,348,907 | 0.05 | 1.10e-26 | 2.74e-25 |
| PSIP1 gene|PSIP1:0 | 14/61,988 | 696/16,348,907 | 5.31 | 8.71e-07 | 6.26e-06 |
| Colitis:0 | 11/61,988 | 17,745/16,348,907 | 0.16 | 4.42e-17 | 7.12e-16 |
| ITK gene|ITK:0 | 40/61,988 | 1,505/16,348,907 | 7.01 | 1.25e-20 | 2.45e-19 |
| ETS Family Protein:0 | 18/61,988 | 391/16,348,907 | 12.14 | 6.62e-14 | 8.84e-13 |
| Deep Vein Thrombosis:0 | 53/61,988 | 27,708/16,348,907 | 0.50 | 3.57e-08 | 2.99e-07 |
| Photochemotherapy:0 | 172/61,988 | 23,345/16,348,907 | 1.95 | 4.01e-15 | 5.79e-14 |
| PSAT1:0 | 6/61,988 | 49/16,348,907 | 32.30 | 7.18e-08 | 5.82e-07 |
| ACPP gene|ACPP:0 | 74/61,988 | 158/16,348,907 | 123.67 | 1.85e-118 | 1.87e-116 |
| Ribosomes:0 | 4/61,988 | 13,082/16,348,907 | 0.08 | 1.61e-16 | 2.52e-15 |
| Finding / disorder:0 | 31/61,988 | 2,121/16,348,907 | 3.86 | 6.88e-10 | 6.83e-09 |
| RNASEL:0 | 41/61,988 | 99/16,348,907 | 109.30 | 1.36e-64 | 7.79e-63 |
| Prostatic acid phosphatase antigen:0 | 5/61,988 | 10/16,348,907 | 131.88 | 2.24e-09 | 2.12e-08 |
| Acetylcholine:0 | 9/61,988 | 46,175/16,348,907 | 0.05 | 7.50e-62 | 4.12e-60 |
| NG-Nitroarginine Methyl Ester:0 | 2/61,988 | 7,086/16,348,907 | 0.07 | 1.53e-09 | 1.47e-08 |
| invasive growth:0 | 22/61,988 | 1,149/16,348,907 | 5.05 | 1.86e-09 | 1.78e-08 |
| Chromosomes, Human, Pair 3:0 | 37/61,988 | 3,232/16,348,907 | 3.02 | 1.03e-08 | 9.18e-08 |
| Cell Cycle Checkpoint:0 | 24/61,988 | 1,086/16,348,907 | 5.83 | 2.14e-11 | 2.40e-10 |
| Nested Case-Control Studies:0 | 21/61,988 | 391/16,348,907 | 14.17 | 3.06e-17 | 4.98e-16 |
| Pentoxifylline:0 | 3/61,988 | 10,509/16,348,907 | 0.08 | 1.21e-13 | 1.59e-12 |
| Atrial Natriuretic Factor:0 | 17/61,988 | 32,015/16,348,907 | 0.14 | 3.78e-32 | 1.11e-30 |
| Carbamazepine:0 | 2/61,988 | 15,123/16,348,907 | 0.03 | 5.57e-22 | 1.15e-20 |
| Androstenediols:0 | 10/61,988 | 228/16,348,907 | 11.57 | 3.59e-08 | 3.01e-07 |
| Clinical Trials:0 | 967/61,988 | 74,283/16,348,907 | 3.47 | 3.78e-223 | 6.83e-221 |
| Boys:0 | 67/61,988 | 83,324/16,348,907 | 0.21 | 1.32e-64 | 7.55e-63 |
| L12ADT:0 | 4/61,988 | 8/16,348,907 | 131.88 | 9.83e-08 | 7.85e-07 |
| Arthroplasty, Replacement, Knee:0 | 7/61,988 | 15,405/16,348,907 | 0.12 | 5.16e-17 | 8.28e-16 |
| 17q:0 | 17/61,988 | 370/16,348,907 | 12.12 | 3.34e-13 | 4.24e-12 |
| Neoplastic Cell:0 | 362/61,988 | 13,088/16,348,907 | 7.33 | 7.98e-178 | 1.19e-175 |
| Epithelial Mesenchymal Transition Tumor of the Mouse Mammary Gland:0 | 22/61,988 | 378/16,348,907 | 15.36 | 1.10e-18 | 1.93e-17 |
| Epidermal growth factor receptor inhibitor:0 | 74/61,988 | 8,251/16,348,907 | 2.37 | 7.75e-11 | 8.38e-10 |
| Bone Matrix:0 | 36/61,988 | 2,644/16,348,907 | 3.59 | 2.02e-10 | 2.12e-09 |
| Lymphocyte antigen CD66A:0 | 12/61,988 | 145/16,348,907 | 21.83 | 1.55e-12 | 1.87e-11 |
| Liposomes:0 | 114/61,988 | 47,071/16,348,907 | 0.64 | 3.04e-07 | 2.30e-06 |
| Pelvic Neoplasms:0 | 50/61,988 | 832/16,348,907 | 15.86 | 4.86e-41 | 1.83e-39 |
| HCT116 Cells:0 | 41/61,988 | 3,651/16,348,907 | 2.96 | 2.94e-09 | 2.77e-08 |
| Leukotriene B4:0 | 5/61,988 | 8,582/16,348,907 | 0.15 | 5.76e-09 | 5.25e-08 |
| Interleukin-2|IL2:0 | 13/61,988 | 11,492/16,348,907 | 0.30 | 1.15e-07 | 9.11e-07 |
| Cerebellar Nuclei:0 | 1/61,988 | 6,920/16,348,907 | 0.04 | 2.19e-10 | 2.29e-09 |
| Urination:0 | 143/61,988 | 4,559/16,348,907 | 8.29 | 4.43e-78 | 2.95e-76 |
| Hypercalcemia:0 | 136/61,988 | 15,116/16,348,907 | 2.38 | 1.43e-18 | 2.49e-17 |
| Disease Outcome:0 | 56/61,988 | 2,020/16,348,907 | 7.32 | 4.41e-29 | 1.18e-27 |
| Contraction:0 | 67/61,988 | 128,982/16,348,907 | 0.14 | 1.67e-127 | 1.82e-125 |
| Antigen assay:0 | 336/61,988 | 2,919/16,348,907 | 30.52 | 0.00e+00 | 0.00e+00 |
| Stage A2:0 | 5/61,988 | 5/16,348,907 | 263.76 | 1.91e-10 | 2.00e-09 |
| Mechanical ventilation:0 | 2/61,988 | 12,782/16,348,907 | 0.04 | 2.12e-18 | 3.66e-17 |
| MMP9 gene|MMP9:0 | 18/61,988 | 526/16,348,907 | 9.03 | 7.63e-12 | 8.88e-11 |
| CDC2 gene|CDK1|POLD1:0 | 41/61,988 | 2,874/16,348,907 | 3.76 | 2.95e-12 | 3.52e-11 |
| Cytotoxic Chemotherapy:0 | 114/61,988 | 3,047/16,348,907 | 9.88 | 3.01e-70 | 1.83e-68 |
| Ovalbumin:0 | 3/61,988 | 10,708/16,348,907 | 0.07 | 5.97e-14 | 8.01e-13 |
| MAPK8 gene|MAPK8:0 | 190/61,988 | 24,551/16,348,907 | 2.04 | 1.62e-18 | 2.82e-17 |
| EB 1089:0 | 22/61,988 | 492/16,348,907 | 11.80 | 2.07e-16 | 3.22e-15 |
| Cell division phases:0 | 105/61,988 | 3,200/16,348,907 | 8.67 | 1.32e-59 | 7.06e-58 |
| beta-microseminoprotein:0 | 9/61,988 | 52/16,348,907 | 45.65 | 2.27e-12 | 2.73e-11 |
| CDKN1B gene|CDKN1B:0 | 69/61,988 | 2,344/16,348,907 | 7.77 | 5.70e-37 | 1.92e-35 |
| Tissue Microarray:0 | 267/61,988 | 2,648/16,348,907 | 26.70 | 4.03e-266 | 8.56e-264 |
| Helminthiasis:0 | 2/61,988 | 7,033/16,348,907 | 0.07 | 2.27e-09 | 2.15e-08 |
| Health Care Systems:0 | 29/61,988 | 2,562/16,348,907 | 2.99 | 4.66e-07 | 3.45e-06 |
| Urethra excision:0 | 30/61,988 | 178/16,348,907 | 44.47 | 1.56e-37 | 5.34e-36 |
| Cavia:0 | 20/61,988 | 91,408/16,348,907 | 0.06 | 1.49e-118 | 1.51e-116 |
| annual screening:0 | 17/61,988 | 209/16,348,907 | 21.46 | 4.87e-17 | 7.84e-16 |
| Ring device:0 | 19/61,988 | 18,530/16,348,907 | 0.27 | 8.79e-13 | 1.08e-11 |
| Entire sympathetic nerve:0 | 3/61,988 | 17,878/16,348,907 | 0.04 | 4.10e-25 | 9.60e-24 |
| Cytoplasm:0 | 467/61,988 | 75,115/16,348,907 | 1.64 | 4.67e-23 | 1.00e-21 |
| Gossypol:0 | 53/61,988 | 3,537/16,348,907 | 3.95 | 3.28e-16 | 5.03e-15 |
| Biopsy of rectum:0 | 30/61,988 | 696/16,348,907 | 11.37 | 2.23e-21 | 4.47e-20 |
| Pancreatic carcinoma:0 | 374/61,988 | 47,753/16,348,907 | 2.07 | 5.33e-36 | 1.74e-34 |
| Fluorodeoxyglucose F18:0 | 38/61,988 | 2,457/16,348,907 | 4.08 | 1.80e-12 | 2.18e-11 |
| BCL-2 Protein|BCL2:0 | 37/61,988 | 1,872/16,348,907 | 5.22 | 2.91e-15 | 4.23e-14 |
| receptor expression:0 | 289/61,988 | 8,538/16,348,907 | 8.96 | 3.51e-164 | 4.92e-162 |
| Forkhead Transcription Factors:0 | 19/61,988 | 1,032/16,348,907 | 4.86 | 4.14e-08 | 3.45e-07 |
| Hydrogen Peroxide:0 | 100/61,988 | 58,759/16,348,907 | 0.45 | 4.53e-20 | 8.56e-19 |
| fungus:0 | 14/61,988 | 18,807/16,348,907 | 0.20 | 3.52e-16 | 5.39e-15 |
| CLOCK:0 | 2/61,988 | 5,524/16,348,907 | 0.10 | 4.43e-07 | 3.29e-06 |
| Hormone Receptor:0 | 45/61,988 | 2,658/16,348,907 | 4.47 | 7.98e-16 | 1.20e-14 |
| Cell Growth:0 | 1,354/61,988 | 44,816/16,348,907 | 8.12 | 0.00e+00 | 0.00e+00 |
| Polymers:0 | 38/61,988 | 25,862/16,348,907 | 0.39 | 7.81e-12 | 9.09e-11 |
| Monoclonal Antibodies|BGLAP:0 | 12/61,988 | 14/16,348,907 | 226.11 | 7.75e-23 | 1.65e-21 |
| SMUG1:0 | 29/61,988 | 1,835/16,348,907 | 4.17 | 4.32e-10 | 4.39e-09 |
| Empty rectum:0 | 5/61,988 | 15/16,348,907 | 87.92 | 1.14e-08 | 1.01e-07 |
| Carcinogenesis Mechanism:0 | 5/61,988 | 8/16,348,907 | 164.85 | 9.65e-10 | 9.43e-09 |
| Brothers:0 | 56/61,988 | 6,533/16,348,907 | 2.26 | 5.81e-08 | 4.75e-07 |
| Lecithin:0 | 16/61,988 | 25,302/16,348,907 | 0.17 | 1.35e-23 | 2.96e-22 |
| Well Differentiated Prostate Adenocarcinoma:0 | 5/61,988 | 8/16,348,907 | 164.85 | 9.65e-10 | 9.43e-09 |
| PTEN Phosphohydrolase|PTEN:0 | 24/61,988 | 441/16,348,907 | 14.36 | 1.32e-19 | 2.42e-18 |
| Division (procedure):0 | 449/61,988 | 36,693/16,348,907 | 3.24 | 5.93e-96 | 4.69e-94 |
| demethylation:0 | 13/61,988 | 592/16,348,907 | 5.79 | 8.26e-07 | 5.94e-06 |
| Kupffer Cells:0 | 2/61,988 | 7,235/16,348,907 | 0.07 | 1.12e-09 | 1.09e-08 |
| heart rate:0 | 3/61,988 | 17,291/16,348,907 | 0.05 | 3.58e-24 | 8.02e-23 |
| Stable Disease:0 | 198/61,988 | 9,400/16,348,907 | 5.57 | 1.29e-78 | 8.67e-77 |
| Forskolin:0 | 32/61,988 | 19,277/16,348,907 | 0.44 | 1.07e-07 | 8.53e-07 |
| Urogenital sinus:0 | 51/61,988 | 421/16,348,907 | 31.98 | 5.15e-56 | 2.61e-54 |
| Integrin alphaVbeta3:0 | 25/61,988 | 1,746/16,348,907 | 3.78 | 4.22e-08 | 3.51e-07 |
| Exanthema:0 | 41/61,988 | 28,632/16,348,907 | 0.38 | 2.25e-13 | 2.90e-12 |
| PRUNE2:0 | 7/61,988 | 68/16,348,907 | 27.15 | 1.74e-08 | 1.50e-07 |
| Fibrinolytic Agents:0 | 2/61,988 | 9,502/16,348,907 | 0.06 | 3.01e-13 | 3.84e-12 |
| racial differences:0 | 63/61,988 | 1,455/16,348,907 | 11.43 | 3.59e-43 | 1.40e-41 |
| Carcinogens:0 | 520/61,988 | 29,931/16,348,907 | 4.61 | 5.73e-169 | 8.22e-167 |
| Citalopram:0 | 1/61,988 | 6,879/16,348,907 | 0.04 | 3.43e-10 | 3.53e-09 |
| lycopene:0 | 239/61,988 | 5,675/16,348,907 | 11.15 | 4.24e-156 | 5.72e-154 |
| Sphincter:0 | 57/61,988 | 5,506/16,348,907 | 2.73 | 6.12e-11 | 6.68e-10 |
| End stage renal failure:0 | 42/61,988 | 47,038/16,348,907 | 0.23 | 3.02e-34 | 9.35e-33 |
| Glycol:0 | 40/61,988 | 3,502/16,348,907 | 3.01 | 2.88e-09 | 2.71e-08 |
| Macrophages, Peritoneal:0 | 7/61,988 | 19,042/16,348,907 | 0.10 | 2.21e-22 | 4.62e-21 |
| Insulin:0 | 112/61,988 | 109,430/16,348,907 | 0.27 | 9.93e-70 | 6.01e-68 |
| Ventricular Premature Complexes:0 | 1/61,988 | 6,102/16,348,907 | 0.04 | 3.93e-09 | 3.64e-08 |
| Diagnostic:0 | 118/61,988 | 10,130/16,348,907 | 3.08 | 7.85e-25 | 1.82e-23 |
| Hepatitis:0 | 20/61,988 | 16,775/16,348,907 | 0.31 | 3.22e-10 | 3.31e-09 |
| Interleukin-1 beta:0 | 83/61,988 | 96,977/16,348,907 | 0.22 | 1.01e-71 | 6.27e-70 |
| Functional RNA:0 | 136/61,988 | 9,580/16,348,907 | 3.75 | 1.49e-36 | 4.97e-35 |
| Epithelial Cell Proliferation:0 | 38/61,988 | 1,730/16,348,907 | 5.80 | 4.76e-17 | 7.66e-16 |
| Intervertebral disc structure:0 | 1/61,988 | 6,239/16,348,907 | 0.04 | 2.82e-09 | 2.65e-08 |
| Epidermal Growth Factor Receptor:0 | 84/61,988 | 7,705/16,348,907 | 2.88 | 1.44e-16 | 2.26e-15 |
| Meiosis:0 | 2/61,988 | 6,763/16,348,907 | 0.08 | 6.85e-09 | 6.20e-08 |
| Emission:0 | 24/61,988 | 21,549/16,348,907 | 0.29 | 1.27e-13 | 1.67e-12 |
| Extent:0 | 95/61,988 | 7,729/16,348,907 | 3.25 | 7.65e-22 | 1.56e-20 |
| Sequential Treatment:0 | 24/61,988 | 1,620/16,348,907 | 3.91 | 4.22e-08 | 3.50e-07 |
| Brain Stem:0 | 9/61,988 | 35,259/16,348,907 | 0.07 | 8.08e-45 | 3.28e-43 |
| Cytoplasmic:0 | 171/61,988 | 21,988/16,348,907 | 2.05 | 4.78e-17 | 7.70e-16 |
| 7q31.1:0 | 8/61,988 | 29/16,348,907 | 72.77 | 1.45e-12 | 1.76e-11 |
| Respiration:0 | 18/61,988 | 53,579/16,348,907 | 0.09 | 8.98e-63 | 5.01e-61 |
| TACSTD2 gene|TACSTD2:0 | 14/61,988 | 673/16,348,907 | 5.49 | 5.93e-07 | 4.34e-06 |
| matrigel:0 | 87/61,988 | 3,052/16,348,907 | 7.53 | 4.11e-45 | 1.69e-43 |
| Infraclass Eutheria:0 | 38/61,988 | 29,696/16,348,907 | 0.34 | 7.10e-16 | 1.07e-14 |
| Eye diseases:0 | 3/61,988 | 6,613/16,348,907 | 0.12 | 1.00e-07 | 7.99e-07 |
| Selenite:0 | 31/61,988 | 2,704/16,348,907 | 3.02 | 1.47e-07 | 1.15e-06 |
| Tryptophan:0 | 15/61,988 | 22,300/16,348,907 | 0.18 | 3.12e-20 | 5.98e-19 |
| WDR77:0 | 9/61,988 | 49/16,348,907 | 48.45 | 1.41e-12 | 1.71e-11 |
| Organoselenium Compounds:0 | 10/61,988 | 218/16,348,907 | 12.10 | 2.40e-08 | 2.05e-07 |
| Seeks information:0 | 10/61,988 | 250/16,348,907 | 10.55 | 8.19e-08 | 6.58e-07 |
| Residual Tumor:0 | 118/61,988 | 8,307/16,348,907 | 3.75 | 5.62e-32 | 1.65e-30 |
| Urinary Fistula:0 | 14/61,988 | 434/16,348,907 | 8.51 | 3.20e-09 | 2.99e-08 |
| Eyelash:0 | 1/61,988 | 5,901/16,348,907 | 0.04 | 8.10e-09 | 7.28e-08 |
| Thrombin:0 | 40/61,988 | 41,771/16,348,907 | 0.25 | 6.63e-29 | 1.77e-27 |
| Intermittent Claudication:0 | 1/61,988 | 6,039/16,348,907 | 0.04 | 5.81e-09 | 5.29e-08 |
| Acetaminophen:0 | 20/61,988 | 20,926/16,348,907 | 0.25 | 3.56e-15 | 5.15e-14 |
| [X]Painful micturition, unspecified:0 | 80/61,988 | 1,245/16,348,907 | 16.97 | 9.99e-67 | 5.84e-65 |
| androgen receptor activity:0 | 259/61,988 | 494/16,348,907 | 138.85 | 0.00e+00 | 0.00e+00 |
| Rats, Sprague-Dawley:0 | 40/61,988 | 25,325/16,348,907 | 0.42 | 1.64e-10 | 1.72e-09 |
| Fatty Acids, Nonesterified:0 | 10/61,988 | 20,621/16,348,907 | 0.13 | 6.78e-22 | 1.39e-20 |
| Angiotensin-Converting Enzyme Inhibitors:0 | 20/61,988 | 35,503/16,348,907 | 0.15 | 1.46e-34 | 4.55e-33 |
| atrial natriuretic factor precursor (79-98):0 | 11/61,988 | 118/16,348,907 | 24.59 | 3.94e-12 | 4.68e-11 |
| Radioactive implant:0 | 18/61,988 | 81/16,348,907 | 58.63 | 4.60e-25 | 1.07e-23 |
| Immunohistochemistry:0 | 856/61,988 | 40,249/16,348,907 | 5.67 | 0.00e+00 | 0.00e+00 |
| Entire interstitial tissue of prostate:0 | 121/61,988 | 347/16,348,907 | 92.15 | 1.03e-179 | 1.56e-177 |
| Atrophy of prostate:0 | 17/61,988 | 79/16,348,907 | 56.77 | 1.52e-23 | 3.33e-22 |
| Common Carcinoma:0 | 14/61,988 | 205/16,348,907 | 18.02 | 2.56e-13 | 3.29e-12 |
| Ultrasonic Therapy:0 | 19/61,988 | 1,184/16,348,907 | 4.23 | 3.21e-07 | 2.42e-06 |
| Dinoprost:0 | 8/61,988 | 18,230/16,348,907 | 0.12 | 3.82e-20 | 7.27e-19 |
| Free prostate-specific antigen:0 | 176/61,988 | 244/16,348,907 | 190.78 | 5.07e-305 | 1.23e-302 |
| Blastocyst structure:0 | 1/61,988 | 10,456/16,348,907 | 0.03 | 4.38e-16 | 6.66e-15 |
| Signal Pathways:0 | 524/61,988 | 44,299/16,348,907 | 3.14 | 1.96e-106 | 1.72e-104 |
| Bone marrow biopsy:0 | 32/61,988 | 1,697/16,348,907 | 4.98 | 6.85e-13 | 8.50e-12 |
| Copper:0 | 50/61,988 | 37,378/16,348,907 | 0.35 | 1.27e-18 | 2.23e-17 |
| Internal carotid artery structure:0 | 1/61,988 | 9,499/16,348,907 | 0.03 | 1.71e-14 | 2.37e-13 |
| Interleukin-4:0 | 53/61,988 | 48,859/16,348,907 | 0.29 | 3.44e-30 | 9.49e-29 |
| Encounter due to In vitro fertilization:0 | 9/61,988 | 9,996/16,348,907 | 0.24 | 4.86e-08 | 4.02e-07 |
| Bands:0 | 45/61,988 | 28,626/16,348,907 | 0.41 | 8.10e-12 | 9.41e-11 |
| Taxanes:0 | 92/61,988 | 1,843/16,348,907 | 13.18 | 2.54e-67 | 1.50e-65 |
| Hip Replacement, Total:0 | 5/61,988 | 13,757/16,348,907 | 0.10 | 1.65e-16 | 2.57e-15 |
| Acetylcholinesterase:0 | 3/61,988 | 20,902/16,348,907 | 0.04 | 8.79e-30 | 2.41e-28 |
| Penicillins:0 | 6/61,988 | 16,359/16,348,907 | 0.10 | 2.28e-19 | 4.15e-18 |
| Focal Adhesion Kinase 1|PTK2:0 | 43/61,988 | 2,331/16,348,907 | 4.87 | 1.90e-16 | 2.95e-15 |
| PCA3 gene|PCA3:0 | 54/61,988 | 100/16,348,907 | 142.54 | 1.42e-89 | 1.05e-87 |
| Polymerase:0 | 58/61,988 | 5,194/16,348,907 | 2.95 | 2.40e-12 | 2.87e-11 |
| Inferior vena cava structure:0 | 8/61,988 | 8,445/16,348,907 | 0.25 | 8.21e-07 | 5.91e-06 |
| Radiation-Sensitizing Agents:0 | 50/61,988 | 1,463/16,348,907 | 9.02 | 4.47e-30 | 1.23e-28 |
| Blood Tests:0 | 24/61,988 | 1,659/16,348,907 | 3.82 | 6.46e-08 | 5.26e-07 |
| Multiple malignancy:0 | 191/61,988 | 3,248/16,348,907 | 15.55 | 4.75e-150 | 6.13e-148 |
| Parasites:0 | 8/61,988 | 30,835/16,348,907 | 0.07 | 3.11e-39 | 1.12e-37 |
| Malondialdehyde:0 | 12/61,988 | 19,359/16,348,907 | 0.16 | 1.84e-18 | 3.20e-17 |
| Upper arm:0 | 66/61,988 | 7,888/16,348,907 | 2.21 | 1.25e-08 | 1.10e-07 |
| Chromogranin A:0 | 163/61,988 | 5,036/16,348,907 | 8.56 | 1.16e-90 | 8.74e-89 |
| Protein-Serine-Threonine Kinases:0 | 114/61,988 | 7,263/16,348,907 | 4.15 | 1.27e-34 | 3.97e-33 |
| Drosophila melanogaster:0 | 1/61,988 | 6,056/16,348,907 | 0.04 | 5.94e-09 | 5.40e-08 |
| Mitogen-Activated Protein Kinases:0 | 316/61,988 | 43,130/16,348,907 | 1.94 | 4.25e-26 | 1.03e-24 |
| Myeloid Leukemia, Chronic:0 | 50/61,988 | 33,835/16,348,907 | 0.39 | 5.54e-15 | 7.93e-14 |
| Microsomes, Liver:0 | 33/61,988 | 30,850/16,348,907 | 0.28 | 8.70e-20 | 1.62e-18 |
| Pharyngeal structure:0 | 102/61,988 | 7,801/16,348,907 | 3.45 | 3.06e-25 | 7.20e-24 |
| 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine:0 | 45/61,988 | 1,450/16,348,907 | 8.19 | 1.35e-25 | 3.22e-24 |
| Synovial:0 | 2/61,988 | 12,257/16,348,907 | 0.04 | 2.02e-17 | 3.31e-16 |
| Rhabdomyosarcoma, Embryonal:0 | 46/61,988 | 1,505/16,348,907 | 8.07 | 7.28e-26 | 1.75e-24 |
| Radical cystectomy:0 | 230/61,988 | 6,773/16,348,907 | 8.99 | 2.50e-131 | 2.82e-129 |
| Somatotropin deficiency:0 | 6/61,988 | 8,798/16,348,907 | 0.18 | 1.59e-08 | 1.38e-07 |
| pM category:0 | 102/61,988 | 2,231/16,348,907 | 12.08 | 6.07e-71 | 3.73e-69 |
| Aberrant DNA Methylation:0 | 23/61,988 | 585/16,348,907 | 10.37 | 6.14e-16 | 9.28e-15 |
| GLI2 gene|GLI2:0 | 18/61,988 | 959/16,348,907 | 4.95 | 7.03e-08 | 5.70e-07 |
| urology:0 | 212/61,988 | 1,547/16,348,907 | 36.26 | 1.76e-237 | 3.32e-235 |
| rhenium-188 HEDP:0 | 6/61,988 | 32/16,348,907 | 49.46 | 7.23e-09 | 6.52e-08 |
| Testing:0 | 492/61,988 | 96,106/16,348,907 | 1.35 | 2.15e-10 | 2.24e-09 |
| Entire bony skeleton:0 | 16/61,988 | 682/16,348,907 | 6.19 | 1.95e-08 | 1.68e-07 |
| risk factors:0 | 37/61,988 | 3,816/16,348,907 | 2.56 | 5.58e-07 | 4.10e-06 |
| Stimulant:0 | 4/61,988 | 12,887/16,348,907 | 0.08 | 3.27e-16 | 5.00e-15 |
| Operation on prostate:0 | 103/61,988 | 333/16,348,907 | 81.71 | 1.11e-148 | 1.39e-146 |
| Radioimmunoassay:0 | 145/61,988 | 14,040/16,348,907 | 2.73 | 3.72e-25 | 8.73e-24 |
| Frank hematuria:0 | 48/61,988 | 1,368/16,348,907 | 9.26 | 2.02e-29 | 5.47e-28 |
| Biopsy needle:0 | 23/61,988 | 368/16,348,907 | 16.49 | 4.13e-20 | 7.83e-19 |
| Selenomethionine:0 | 33/61,988 | 1,487/16,348,907 | 5.86 | 3.88e-15 | 5.61e-14 |
| Chromosomes, Human, Pair 1:0 | 46/61,988 | 4,401/16,348,907 | 2.76 | 2.96e-09 | 2.78e-08 |
| Electric Stimulation:0 | 22/61,988 | 30,604/16,348,907 | 0.19 | 2.68e-26 | 6.57e-25 |
| sodium-iodide symporter:0 | 35/61,988 | 1,350/16,348,907 | 6.84 | 6.22e-18 | 1.05e-16 |
| rosiglitazone:0 | 15/61,988 | 13,610/16,348,907 | 0.29 | 4.53e-09 | 4.16e-08 |
| Chloroplasts:0 | 3/61,988 | 16,041/16,348,907 | 0.05 | 4.05e-22 | 8.38e-21 |
| Male gender:0 | 675/61,988 | 45,860/16,348,907 | 3.91 | 4.39e-182 | 6.77e-180 |
| Laceration:0 | 9/61,988 | 11,561/16,348,907 | 0.21 | 4.49e-10 | 4.57e-09 |
| stable cell line:0 | 25/61,988 | 1,673/16,348,907 | 3.94 | 1.90e-08 | 1.64e-07 |
| tacrolimus binding protein 4|FKBP4:0 | 17/61,988 | 586/16,348,907 | 7.65 | 3.31e-10 | 3.41e-09 |
| Leprosy:0 | 3/61,988 | 11,171/16,348,907 | 0.07 | 9.98e-15 | 1.40e-13 |
| PC12 Cells:0 | 7/61,988 | 14,343/16,348,907 | 0.13 | 1.48e-15 | 2.19e-14 |
| Hydrocortisone:0 | 136/61,988 | 53,406/16,348,907 | 0.67 | 8.93e-07 | 6.40e-06 |
| Case-Control Studies:0 | 74/61,988 | 5,857/16,348,907 | 3.34 | 5.25e-18 | 8.90e-17 |
| Hormonal resistance:0 | 40/61,988 | 467/16,348,907 | 22.60 | 8.63e-39 | 3.06e-37 |
| Ionizing radiation:0 | 64/61,988 | 3,253/16,348,907 | 5.19 | 4.30e-25 | 1.00e-23 |
| Structure of beta Cell of islet:0 | 3/61,988 | 11,615/16,348,907 | 0.07 | 2.49e-15 | 3.65e-14 |
| Organism:0 | 86/61,988 | 94,684/16,348,907 | 0.24 | 7.10e-67 | 4.16e-65 |
| oxidized low density lipoprotein:0 | 4/61,988 | 13,161/16,348,907 | 0.08 | 1.12e-16 | 1.77e-15 |
| MYH14:0 | 6/61,988 | 10,182/16,348,907 | 0.16 | 2.34e-10 | 2.43e-09 |
| Programmed Cell Death, Type II:0 | 24/61,988 | 1,119/16,348,907 | 5.66 | 3.86e-11 | 4.27e-10 |
| Schwann Cells:0 | 9/61,988 | 10,071/16,348,907 | 0.24 | 3.48e-08 | 2.93e-07 |
| Down-Regulation:0 | 685/61,988 | 35,195/16,348,907 | 5.18 | 9.90e-249 | 1.96e-246 |
| Mare:0 | 2/61,988 | 7,775/16,348,907 | 0.07 | 1.28e-10 | 1.36e-09 |
| NODE:0 | 306/61,988 | 20,800/16,348,907 | 3.89 | 2.01e-83 | 1.42e-81 |
| MG 132|PRB3:0 | 8/61,988 | 24/16,348,907 | 87.93 | 4.02e-13 | 5.07e-12 |
| PDLIM4:0 | 5/61,988 | 15/16,348,907 | 87.92 | 1.14e-08 | 1.01e-07 |
| Immunotherapeutic agent:0 | 20/61,988 | 583/16,348,907 | 9.05 | 5.18e-13 | 6.48e-12 |
| Dysmyelopoietic Syndromes:0 | 35/61,988 | 27,883/16,348,907 | 0.33 | 3.08e-15 | 4.48e-14 |
| STAT3 gene|STAT3:0 | 250/61,988 | 21,298/16,348,907 | 3.10 | 3.72e-51 | 1.73e-49 |
| Lights, manufactured:0 | 1/61,988 | 5,515/16,348,907 | 0.05 | 3.46e-08 | 2.91e-07 |
| RNASEL gene|RNASEL:0 | 11/61,988 | 17/16,348,907 | 170.69 | 4.52e-20 | 8.55e-19 |
| Genome Scan:0 | 7/61,988 | 126/16,348,907 | 14.65 | 9.00e-07 | 6.44e-06 |
| AR gene|AR:0 | 1,184/61,988 | 4,311/16,348,907 | 73.83 | 0.00e+00 | 0.00e+00 |
| TNM category pT:0 | 23/61,988 | 107/16,348,907 | 56.71 | 2.60e-31 | 7.43e-30 |
| Acyclovir:0 | 6/61,988 | 12,139/16,348,907 | 0.13 | 2.74e-13 | 3.52e-12 |
| vascular bed:0 | 6/61,988 | 10,564/16,348,907 | 0.15 | 6.01e-11 | 6.56e-10 |
| Insulin-Like Growth Factor I:0 | 542/61,988 | 73,504/16,348,907 | 1.95 | 2.65e-44 | 1.06e-42 |
| Angiogenesis:0 | 710/61,988 | 41,445/16,348,907 | 4.56 | 7.60e-227 | 1.38e-224 |
| Apoptosis Inhibiting Proteins:0 | 50/61,988 | 1,855/16,348,907 | 7.11 | 1.25e-25 | 2.99e-24 |
| Ganglia, Spinal:0 | 14/61,988 | 28,145/16,348,907 | 0.13 | 3.69e-29 | 9.94e-28 |
| GLI1 gene|GLI1:0 | 42/61,988 | 2,402/16,348,907 | 4.61 | 2.46e-15 | 3.61e-14 |
| Alanine Transaminase:0 | 14/61,988 | 12,636/16,348,907 | 0.29 | 1.69e-08 | 1.46e-07 |
| MAP Kinase Kinase 4:0 | 8/61,988 | 105/16,348,907 | 20.10 | 1.49e-08 | 1.30e-07 |
| DNA Modification Methylases:0 | 26/61,988 | 1,397/16,348,907 | 4.91 | 1.20e-10 | 1.28e-09 |
| Neuroendocrine Tumors:0 | 110/61,988 | 15,294/16,348,907 | 1.90 | 1.05e-09 | 1.02e-08 |
| prior androgen therapy:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| Prostascint:0 | 53/61,988 | 113/16,348,907 | 123.81 | 2.36e-85 | 1.69e-83 |
| sperm cell:0 | 14/61,988 | 33,859/16,348,907 | 0.11 | 1.38e-37 | 4.73e-36 |
| Carcinoma of Male Breast:0 | 49/61,988 | 1,350/16,348,907 | 9.58 | 1.24e-30 | 3.47e-29 |
| Cell Cycle Regulation:0 | 110/61,988 | 5,772/16,348,907 | 5.03 | 1.18e-40 | 4.38e-39 |
| filtration:0 | 3/61,988 | 6,230/16,348,907 | 0.13 | 2.58e-07 | 1.97e-06 |
| BRCA2 Mutation:0 | 49/61,988 | 866/16,348,907 | 14.93 | 4.34e-39 | 1.55e-37 |
| multicatalytic endopeptidase complex:0 | 176/61,988 | 20,158/16,348,907 | 2.31 | 3.01e-22 | 6.27e-21 |
| Oils, Volatile:0 | 18/61,988 | 15,299/16,348,907 | 0.31 | 1.46e-09 | 1.41e-08 |
| Multiple Trauma:0 | 2/61,988 | 6,040/16,348,907 | 0.09 | 7.81e-08 | 6.29e-07 |
| Amphotericin B:0 | 4/61,988 | 16,214/16,348,907 | 0.07 | 2.95e-21 | 5.91e-20 |
| Extracellular Matrix Proteins:0 | 67/61,988 | 8,561/16,348,907 | 2.07 | 9.40e-08 | 7.52e-07 |
| Heat Shock Protein 27:0 | 36/61,988 | 2,037/16,348,907 | 4.66 | 1.67e-13 | 2.18e-12 |
| Thermogenesis:0 | 1/61,988 | 6,106/16,348,907 | 0.04 | 3.94e-09 | 3.64e-08 |
| VEGF gene|VEGFA:0 | 78/61,988 | 6,193/16,348,907 | 3.32 | 8.18e-19 | 1.44e-17 |
| Androgens:0 | 4,106/61,988 | 38,318/16,348,907 | 30.20 | 0.00e+00 | 0.00e+00 |
| Subcapsular orchidectomy:0 | 28/61,988 | 68/16,348,907 | 108.65 | 1.47e-44 | 5.95e-43 |
| Urinary tract obstruction:0 | 118/61,988 | 3,002/16,348,907 | 10.38 | 6.97e-75 | 4.49e-73 |
| Human Glandular Kallikrein 2|HK2:0 | 100/61,988 | 525/16,348,907 | 50.32 | 6.45e-126 | 7.00e-124 |
| Tumor Cells, Cultured:0 | 24/61,988 | 928/16,348,907 | 6.82 | 9.09e-13 | 1.12e-11 |
| Breast fluid:0 | 7/61,988 | 77/16,348,907 | 23.98 | 3.85e-08 | 3.21e-07 |
| Carotenoids:0 | 132/61,988 | 13,825/16,348,907 | 2.52 | 4.48e-20 | 8.49e-19 |
| Adrenal Medulla:0 | 6/61,988 | 8,069/16,348,907 | 0.20 | 1.51e-07 | 1.18e-06 |
| Mycobacterium Infections:0 | 1/61,988 | 5,781/16,348,907 | 0.05 | 1.83e-08 | 1.58e-07 |
| Spheroids, Cellular:0 | 37/61,988 | 1,955/16,348,907 | 4.99 | 1.05e-14 | 1.48e-13 |
| nornitrogen mustard:0 | 4/61,988 | 10/16,348,907 | 105.50 | 1.98e-07 | 1.53e-06 |
| histone acetyltransferase:0 | 28/61,988 | 2,140/16,348,907 | 3.45 | 4.29e-08 | 3.56e-07 |
| Constipation:0 | 13/61,988 | 12,387/16,348,907 | 0.28 | 1.15e-08 | 1.02e-07 |
| Drug Combinations:0 | 42/61,988 | 4,231/16,348,907 | 2.62 | 5.50e-08 | 4.51e-07 |
| Traumatic Brain Injury:0 | 3/61,988 | 32,268/16,348,907 | 0.02 | 6.35e-48 | 2.79e-46 |
| Strabismus:0 | 1/61,988 | 5,707/16,348,907 | 0.05 | 1.67e-08 | 1.45e-07 |
| Partial excision of bladder NOS:0 | 22/61,988 | 862/16,348,907 | 6.73 | 1.01e-11 | 1.16e-10 |
| Amylases:0 | 8/61,988 | 12,306/16,348,907 | 0.17 | 6.64e-12 | 7.76e-11 |
| CD82 gene|CD82:0 | 63/61,988 | 1,272/16,348,907 | 13.08 | 1.80e-46 | 7.62e-45 |
| Trans-Activation (Genetics):0 | 206/61,988 | 7,069/16,348,907 | 7.71 | 5.56e-106 | 4.85e-104 |
| Recurrence:0 | 96/61,988 | 4,587/16,348,907 | 5.53 | 7.63e-39 | 2.71e-37 |
| Caenorhabditis elegans:0 | 2/61,988 | 10,949/16,348,907 | 0.05 | 2.11e-15 | 3.10e-14 |
| CDKN1A:0 | 20/61,988 | 849/16,348,907 | 6.21 | 3.29e-10 | 3.39e-09 |
| retinamide:0 | 24/61,988 | 418/16,348,907 | 15.15 | 4.10e-20 | 7.79e-19 |
| Detected:0 | 90/61,988 | 9,886/16,348,907 | 2.40 | 3.29e-13 | 4.18e-12 |
| Validation:0 | 253/61,988 | 13,925/16,348,907 | 4.81 | 5.79e-87 | 4.21e-85 |
| Bladder neck obstruction:0 | 12/61,988 | 399/16,348,907 | 7.93 | 8.68e-08 | 6.96e-07 |
| Perineal approach:0 | 13/61,988 | 31/16,348,907 | 110.62 | 1.48e-21 | 2.99e-20 |
| Pelvic lymphadenectomy:0 | 340/61,988 | 1,935/16,348,907 | 46.59 | 0.00e+00 | 0.00e+00 |
| Gastroenteritis:0 | 1/61,988 | 10,404/16,348,907 | 0.03 | 6.52e-16 | 9.84e-15 |
| Trigeminal Neuralgia:0 | 3/61,988 | 6,454/16,348,907 | 0.12 | 1.32e-07 | 1.04e-06 |
| Perceived quality of life:0 | 43/61,988 | 2,057/16,348,907 | 5.52 | 2.54e-18 | 4.36e-17 |
| promatrilysin:0 | 8/61,988 | 106/16,348,907 | 19.91 | 1.60e-08 | 1.39e-07 |
| Somatostatin analog|TAT:0 | 7/61,988 | 1/16,348,907 | 1846.41 | 8.74e-17 | 1.39e-15 |
| Malignant Cystosarcoma Phyllodes:0 | 12/61,988 | 455/16,348,907 | 6.96 | 3.38e-07 | 2.54e-06 |
| Clodronate:0 | 49/61,988 | 2,493/16,348,907 | 5.19 | 1.37e-19 | 2.52e-18 |
| Phenytoin:0 | 5/61,988 | 14,284/16,348,907 | 0.09 | 2.97e-17 | 4.84e-16 |
| Ganglia:0 | 13/61,988 | 22,470/16,348,907 | 0.15 | 5.43e-22 | 1.12e-20 |
| Intervention regimes:0 | 628/61,988 | 130,152/16,348,907 | 1.28 | 5.80e-09 | 5.28e-08 |
| Plants:0 | 177/61,988 | 108,775/16,348,907 | 0.43 | 5.25e-39 | 1.87e-37 |
| Arteries:0 | 47/61,988 | 76,487/16,348,907 | 0.16 | 6.29e-70 | 3.82e-68 |
| Growth Cones:0 | 1/61,988 | 4,578/16,348,907 | 0.06 | 1.37e-06 | 9.55e-06 |
| Therapeutic Intervention:0 | 99/61,988 | 6,756/16,348,907 | 3.87 | 4.28e-28 | 1.11e-26 |
| Microbial Biofilms:0 | 1/61,988 | 8,859/16,348,907 | 0.03 | 2.37e-13 | 3.06e-12 |
| Nitrate:0 | 2/61,988 | 14,037/16,348,907 | 0.04 | 3.01e-20 | 5.77e-19 |
| Epidermal Growth Factor|EGF:0 | 268/61,988 | 39,398/16,348,907 | 1.80 | 2.86e-18 | 4.92e-17 |
| Lipoproteins:0 | 38/61,988 | 42,716/16,348,907 | 0.23 | 2.50e-31 | 7.18e-30 |
| Ankylosing spondylitis:0 | 6/61,988 | 21,286/16,348,907 | 0.07 | 8.45e-27 | 2.11e-25 |
| MSMB protein, human|MSMB:0 | 32/61,988 | 156/16,348,907 | 54.13 | 2.26e-42 | 8.70e-41 |
| Corticotropin|POMC:0 | 37/61,988 | 25,898/16,348,907 | 0.38 | 2.70e-12 | 3.23e-11 |
| Chronic pelvic pain syndrome:0 | 28/61,988 | 1,514/16,348,907 | 4.88 | 2.76e-11 | 3.08e-10 |
| phosphoric diester hydrolase:0 | 8/61,988 | 13,772/16,348,907 | 0.15 | 6.72e-14 | 8.97e-13 |
| Dinoprostone:0 | 77/61,988 | 47,360/16,348,907 | 0.43 | 1.10e-17 | 1.83e-16 |
| Intubation:0 | 1/61,988 | 10,918/16,348,907 | 0.02 | 1.08e-16 | 1.71e-15 |
| Methylene blue:0 | 7/61,988 | 8,418/16,348,907 | 0.22 | 2.75e-07 | 2.09e-06 |
| Differential Diagnosis:0 | 90/61,988 | 10,879/16,348,907 | 2.18 | 4.76e-11 | 5.24e-10 |
| Early Detection Research Network:0 | 4/61,988 | 7/16,348,907 | 150.72 | 6.58e-08 | 5.36e-07 |
| Malignant neoplasm of kidney:0 | 271/61,988 | 6,073/16,348,907 | 11.82 | 7.95e-183 | 1.23e-180 |
| Caffeine:0 | 20/61,988 | 24,588/16,348,907 | 0.21 | 7.63e-20 | 1.43e-18 |
| Amputation:0 | 9/61,988 | 11,461/16,348,907 | 0.21 | 6.19e-10 | 6.18e-09 |
| Insulin-Like Growth Factor Receptor:0 | 45/61,988 | 2,246/16,348,907 | 5.29 | 1.99e-18 | 3.45e-17 |
| Dental Cementum:0 | 3/61,988 | 8,359/16,348,907 | 0.09 | 1.86e-10 | 1.94e-09 |
| soft tissue:0 | 202/61,988 | 20,368/16,348,907 | 2.62 | 5.19e-32 | 1.52e-30 |
| Losartan:0 | 7/61,988 | 17,302/16,348,907 | 0.11 | 7.62e-20 | 1.42e-18 |
| Tobramycin:0 | 2/61,988 | 5,244/16,348,907 | 0.10 | 1.30e-06 | 9.11e-06 |
| Mannitol:0 | 3/61,988 | 9,095/16,348,907 | 0.09 | 1.64e-11 | 1.86e-10 |
| Musculoskeletal Diseases:0 | 1/61,988 | 5,706/16,348,907 | 0.05 | 1.67e-08 | 1.45e-07 |
| Firm prostate:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| macrophage:0 | 160/61,988 | 139,690/16,348,907 | 0.30 | 2.08e-79 | 1.41e-77 |
| electrode:0 | 23/61,988 | 21,123/16,348,907 | 0.29 | 1.11e-13 | 1.46e-12 |
| Yeasts:0 | 3/61,988 | 7,402/16,348,907 | 0.11 | 6.20e-09 | 5.63e-08 |
| Systemic Scleroderma:0 | 9/61,988 | 29,948/16,348,907 | 0.08 | 1.03e-36 | 3.46e-35 |
| Fibroblasts:0 | 450/61,988 | 149,590/16,348,907 | 0.79 | 3.82e-07 | 2.86e-06 |
| BID gene|BID:0 | 34/61,988 | 1,949/16,348,907 | 4.60 | 1.09e-12 | 1.33e-11 |
| Tumor Necrosis Factor-alpha:0 | 133/61,988 | 99,753/16,348,907 | 0.35 | 7.31e-48 | 3.20e-46 |
| treatment method:0 | 74/61,988 | 7,505/16,348,907 | 2.60 | 1.33e-12 | 1.62e-11 |
| Mood Disorders:0 | 6/61,988 | 15,037/16,348,907 | 0.11 | 2.00e-17 | 3.28e-16 |
| SPOP gene|SPOP:0 | 8/61,988 | 49/16,348,907 | 43.07 | 5.81e-11 | 6.34e-10 |
| Vitamin D3 Receptor|VDR:0 | 37/61,988 | 1,779/16,348,907 | 5.49 | 6.33e-16 | 9.55e-15 |
| Mental health problem:0 | 1/61,988 | 5,683/16,348,907 | 0.05 | 2.64e-08 | 2.24e-07 |
| pregabalin:0 | 1/61,988 | 4,776/16,348,907 | 0.06 | 6.66e-07 | 4.84e-06 |
| Graves' Disease:0 | 4/61,988 | 20,112/16,348,907 | 0.05 | 2.78e-27 | 7.01e-26 |
| Honvan:0 | 16/61,988 | 35/16,348,907 | 120.60 | 1.09e-26 | 2.70e-25 |
| Prostate induration:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| Paroxetine:0 | 3/61,988 | 7,480/16,348,907 | 0.11 | 4.28e-09 | 3.94e-08 |
| Irritable Bowel Syndrome:0 | 1/61,988 | 22,761/16,348,907 | 0.01 | 5.32e-36 | 1.74e-34 |
| Dopamine:0 | 26/61,988 | 98,385/16,348,907 | 0.07 | 2.93e-122 | 3.07e-120 |
| Cyclosporine:0 | 37/61,988 | 79,771/16,348,907 | 0.12 | 4.20e-83 | 2.96e-81 |
| JAZF1:0 | 10/61,988 | 131/16,348,907 | 20.14 | 2.33e-10 | 2.42e-09 |
| Heparin, Low-Molecular-Weight:0 | 18/61,988 | 25,463/16,348,907 | 0.19 | 2.72e-22 | 5.65e-21 |
| Urinary outflow obstruction:0 | 9/61,988 | 61/16,348,907 | 38.92 | 8.27e-12 | 9.59e-11 |
| Pain relief:0 | 111/61,988 | 12,843/16,348,907 | 2.28 | 1.78e-14 | 2.46e-13 |
| Pelvic lymphadenopathy:0 | 8/61,988 | 27/16,348,907 | 78.16 | 8.90e-13 | 1.10e-11 |
| Proteasome Inhibition:0 | 11/61,988 | 313/16,348,907 | 9.27 | 6.60e-08 | 5.37e-07 |
| Interstitial brachytherapy:0 | 154/61,988 | 1,094/16,348,907 | 37.22 | 1.17e-174 | 1.73e-172 |
| advanced disease:0 | 677/61,988 | 17,023/16,348,907 | 10.59 | 0.00e+00 | 0.00e+00 |
| Interleukin-10:0 | 51/61,988 | 40,504/16,348,907 | 0.33 | 1.54e-21 | 3.10e-20 |
| Radioimmunoconjugates:0 | 23/61,988 | 961/16,348,907 | 6.31 | 1.20e-11 | 1.37e-10 |
| Hormonal:0 | 32/61,988 | 883/16,348,907 | 9.56 | 1.48e-20 | 2.87e-19 |
| Microarray Analysis:0 | 153/61,988 | 6,031/16,348,907 | 6.70 | 2.21e-71 | 1.36e-69 |
| selenomethylselenocysteine:0 | 18/61,988 | 366/16,348,907 | 12.97 | 2.27e-14 | 3.12e-13 |
| Seizures, Focal:0 | 1/61,988 | 6,153/16,348,907 | 0.04 | 4.12e-09 | 3.80e-08 |
| kahalalide F:0 | 7/61,988 | 85/16,348,907 | 21.72 | 7.26e-08 | 5.87e-07 |
| Aspirin:0 | 142/61,988 | 69,399/16,348,907 | 0.54 | 3.77e-16 | 5.76e-15 |
| Compete:0 | 55/61,988 | 4,036/16,348,907 | 3.60 | 4.29e-15 | 6.17e-14 |
| Antidepressive Agents, Tricyclic:0 | 9/61,988 | 9,473/16,348,907 | 0.25 | 2.25e-07 | 1.72e-06 |
| T-Lymphocyte:0 | 290/61,988 | 147,455/16,348,907 | 0.52 | 4.73e-36 | 1.55e-34 |
| Streptozocin:0 | 6/61,988 | 21,207/16,348,907 | 0.07 | 1.24e-26 | 3.07e-25 |
| partial response:0 | 212/61,988 | 8,543/16,348,907 | 6.56 | 1.76e-96 | 1.40e-94 |
| Recanalization:0 | 1/61,988 | 4,666/16,348,907 | 0.06 | 9.39e-07 | 6.70e-06 |
| Epidermal Growth Factor Receptor|EGF:0 | 73/61,988 | 5,503/16,348,907 | 3.50 | 7.06e-19 | 1.25e-17 |
| Needle guide:0 | 7/61,988 | 109/16,348,907 | 16.94 | 3.57e-07 | 2.68e-06 |
| Lower urinary tract symptoms:0 | 418/61,988 | 7,699/16,348,907 | 14.41 | 4.63e-313 | 1.14e-310 |
| NOS3 protein, human|NOS3:0 | 75/61,988 | 45,385/16,348,907 | 0.44 | 1.24e-16 | 1.95e-15 |
| Hypoxemia:0 | 4/61,988 | 7,626/16,348,907 | 0.14 | 1.99e-08 | 1.71e-07 |
| Primary Gleason pattern:0 | 12/61,988 | 16/16,348,907 | 197.85 | 2.42e-22 | 5.06e-21 |
| 11p11.2:0 | 5/61,988 | 25/16,348,907 | 52.75 | 1.01e-07 | 8.08e-07 |
| Transfer RNA:0 | 9/61,988 | 13,831/16,348,907 | 0.17 | 3.80e-13 | 4.81e-12 |
| Extrinsic asthma NOS:0 | 4/61,988 | 7,007/16,348,907 | 0.15 | 1.48e-07 | 1.16e-06 |
| Immunoblotting:0 | 54/61,988 | 6,692/16,348,907 | 2.13 | 7.23e-07 | 5.24e-06 |
| Brain tissue:0 | 17/61,988 | 22,468/16,348,907 | 0.20 | 5.85e-19 | 1.04e-17 |
| WDTC1:0 | 6/61,988 | 15,796/16,348,907 | 0.10 | 1.24e-18 | 2.18e-17 |
| Genomic Instability:0 | 55/61,988 | 3,926/16,348,907 | 3.70 | 1.42e-15 | 2.11e-14 |
| Entire retroperitoneal lymph node:0 | 13/61,988 | 396/16,348,907 | 8.66 | 9.45e-09 | 8.42e-08 |
| DAB2IP:0 | 17/61,988 | 167/16,348,907 | 26.86 | 1.49e-18 | 2.59e-17 |
| Disorder of artery:0 | 1/61,988 | 7,932/16,348,907 | 0.03 | 5.92e-12 | 6.94e-11 |
| Cleft Lip:0 | 2/61,988 | 5,393/16,348,907 | 0.10 | 6.09e-07 | 4.46e-06 |
| B-Lymphocytes:0 | 65/61,988 | 72,947/16,348,907 | 0.23 | 1.40e-52 | 6.67e-51 |
| offender:0 | 1/61,988 | 6,822/16,348,907 | 0.04 | 3.16e-10 | 3.26e-09 |
| Cardiopulmonary Resuscitation:0 | 3/61,988 | 7,255/16,348,907 | 0.11 | 8.41e-09 | 7.54e-08 |
| WWOX:0 | 24/61,988 | 870/16,348,907 | 7.28 | 2.43e-13 | 3.13e-12 |
| SERPINB5 gene|SERPINB5:0 | 6/61,988 | 84/16,348,907 | 18.84 | 1.38e-06 | 9.58e-06 |
| Hypoxia-Inducible Factor 1:0 | 75/61,988 | 4,011/16,348,907 | 4.94 | 8.63e-28 | 2.22e-26 |
| Fentanyl:0 | 12/61,988 | 15,583/16,348,907 | 0.20 | 1.96e-13 | 2.54e-12 |
| Bombesin Receptor|GRPR:0 | 7/61,988 | 56/16,348,907 | 32.97 | 5.04e-09 | 4.61e-08 |
| Stromal Cell-Derived Factor 1|CXCL12:0 | 44/61,988 | 3,775/16,348,907 | 3.08 | 2.67e-10 | 2.76e-09 |
| Carbachol:0 | 6/61,988 | 15,909/16,348,907 | 0.10 | 8.81e-19 | 1.55e-17 |
| Genetic Markers:0 | 45/61,988 | 2,333/16,348,907 | 5.09 | 7.87e-18 | 1.32e-16 |
| atorvastatin:0 | 19/61,988 | 19,900/16,348,907 | 0.25 | 1.81e-14 | 2.50e-13 |
| Red meat:0 | 22/61,988 | 372/16,348,907 | 15.60 | 8.00e-19 | 1.41e-17 |
| radiosensitization:0 | 25/61,988 | 953/16,348,907 | 6.92 | 2.29e-13 | 2.95e-12 |
| Seed Implantation:0 | 187/61,988 | 579/16,348,907 | 85.44 | 1.93e-271 | 4.25e-269 |
| Pre-Eclampsia:0 | 7/61,988 | 39,960/16,348,907 | 0.05 | 1.65e-54 | 8.15e-53 |
| Cleft Palate:0 | 1/61,988 | 9,607/16,348,907 | 0.03 | 1.20e-14 | 1.68e-13 |
| Atrial Fibrillation:0 | 7/61,988 | 74,235/16,348,907 | 0.02 | 2.75e-109 | 2.46e-107 |
| Temporal Lobe:0 | 4/61,988 | 14,755/16,348,907 | 0.07 | 4.01e-19 | 7.23e-18 |
| Transient Ischemic Attack:0 | 6/61,988 | 13,164/16,348,907 | 0.12 | 9.25e-15 | 1.30e-13 |
| leiomyosarcoma:0 | 89/61,988 | 7,886/16,348,907 | 2.98 | 2.47e-18 | 4.25e-17 |
| Goserelin Acetate|EREG|ESR1:0 | 7/61,988 | 8/16,348,907 | 230.80 | 6.87e-14 | 9.16e-13 |
| TPD52 gene|TPD52:0 | 12/61,988 | 134/16,348,907 | 23.62 | 6.50e-13 | 8.08e-12 |
| Inspiration function:0 | 5/61,988 | 17,447/16,348,907 | 0.08 | 3.95e-22 | 8.16e-21 |
| Antibodies, Bispecific:0 | 22/61,988 | 1,477/16,348,907 | 3.93 | 1.38e-07 | 1.08e-06 |
| Iodine 125 brachytherapy:0 | 71/61,988 | 253/16,348,907 | 74.10 | 1.86e-100 | 1.51e-98 |
| CyberKnife:0 | 69/61,988 | 1,255/16,348,907 | 14.52 | 1.49e-53 | 7.20e-52 |
| preference:0 | 105/61,988 | 15,853/16,348,907 | 1.75 | 1.41e-07 | 1.10e-06 |
| EGFR gene|EGFR:0 | 102/61,988 | 8,606/16,348,907 | 3.13 | 3.21e-22 | 6.66e-21 |
| Capsaicin:0 | 22/61,988 | 22,496/16,348,907 | 0.26 | 6.28e-16 | 9.48e-15 |
| PCAF gene|KAT2B:0 | 23/61,988 | 1,363/16,348,907 | 4.45 | 8.06e-09 | 7.24e-08 |
| Mitoxantrone:0 | 221/61,988 | 7,341/16,348,907 | 7.96 | 3.05e-116 | 2.98e-114 |
| Nephrotic Syndrome:0 | 8/61,988 | 16,074/16,348,907 | 0.13 | 4.54e-17 | 7.33e-16 |
| Structure of parietal fascia of pelvis:0 | 7/61,988 | 67/16,348,907 | 27.56 | 1.58e-08 | 1.37e-07 |
| Urethral catheter:0 | 34/61,988 | 505/16,348,907 | 17.77 | 5.72e-30 | 1.57e-28 |
| SMAD3 gene|SMAD3:0 | 44/61,988 | 4,617/16,348,907 | 2.51 | 1.04e-07 | 8.30e-07 |
| Chromosomal Instability:0 | 39/61,988 | 2,610/16,348,907 | 3.94 | 2.56e-12 | 3.06e-11 |
| Microglia:0 | 4/61,988 | 22,855/16,348,907 | 0.05 | 1.16e-31 | 3.36e-30 |
| AKT Signaling Pathway:0 | 38/61,988 | 1,023/16,348,907 | 9.80 | 1.82e-24 | 4.13e-23 |
| Nociception:0 | 6/61,988 | 7,696/16,348,907 | 0.21 | 5.64e-07 | 4.14e-06 |
| 5-aza-2'-deoxycytidine:0 | 93/61,988 | 5,033/16,348,907 | 4.88 | 1.16e-33 | 3.57e-32 |
| skin disorder:0 | 30/61,988 | 24,450/16,348,907 | 0.32 | 7.61e-14 | 1.01e-12 |
| Radiotherapy, Adjuvant:0 | 224/61,988 | 4,265/16,348,907 | 13.90 | 1.09e-165 | 1.55e-163 |
| Gonadorelin|PLOD1:0 | 97/61,988 | 39/16,348,907 | 657.00 | 1.45e-201 | 2.40e-199 |
| Alleles:0 | 163/61,988 | 19,033/16,348,907 | 2.26 | 4.30e-20 | 8.16e-19 |
| Prostatic cyst:0 | 9/61,988 | 157/16,348,907 | 15.12 | 1.94e-08 | 1.67e-07 |
| Impaired cognition:0 | 20/61,988 | 43,849/16,348,907 | 0.12 | 1.61e-46 | 6.80e-45 |
| Experimental Design:0 | 45/61,988 | 2,919/16,348,907 | 4.07 | 2.00e-14 | 2.76e-13 |
| Malignant neoplasm of pancreas:0 | 56/61,988 | 1,446/16,348,907 | 10.22 | 3.72e-36 | 1.23e-34 |
| SLC5A5 gene|SLC5A5:0 | 18/61,988 | 429/16,348,907 | 11.07 | 2.95e-13 | 3.77e-12 |
| docetaxel:0 | 1,579/61,988 | 22,855/16,348,907 | 18.67 | 0.00e+00 | 0.00e+00 |
| Sclera:0 | 1/61,988 | 6,123/16,348,907 | 0.04 | 3.98e-09 | 3.68e-08 |
| Recurrent Carcinoma:0 | 167/61,988 | 7,864/16,348,907 | 5.61 | 4.44e-67 | 2.61e-65 |
| Time:0 | 170/61,988 | 22,307/16,348,907 | 2.01 | 3.40e-16 | 5.20e-15 |
| SPATA7|HSD11B1L:0 | 7/61,988 | 46/16,348,907 | 40.14 | 1.45e-09 | 1.40e-08 |
| PAGE4:0 | 12/61,988 | 32/16,348,907 | 98.92 | 1.59e-19 | 2.91e-18 |
| Western society:0 | 35/61,988 | 1,521/16,348,907 | 6.07 | 2.05e-16 | 3.18e-15 |
| beta-Lactamase:0 | 3/61,988 | 9,488/16,348,907 | 0.08 | 4.02e-12 | 4.76e-11 |
| elk-1 protein|ELK1:0 | 9/61,988 | 256/16,348,907 | 9.27 | 1.02e-06 | 7.22e-06 |
| Cardiac function:0 | 4/61,988 | 16,044/16,348,907 | 0.07 | 6.30e-21 | 1.24e-19 |
| Soy Foods:0 | 6/61,988 | 83/16,348,907 | 19.07 | 1.29e-06 | 9.03e-06 |
| palladium-bacteriopheophorbide:0 | 6/61,988 | 23/16,348,907 | 68.81 | 1.28e-09 | 1.24e-08 |
| Hemiparesis:0 | 2/61,988 | 5,610/16,348,907 | 0.09 | 3.07e-07 | 2.32e-06 |
| gene therapy:0 | 289/61,988 | 17,854/16,348,907 | 4.28 | 7.11e-88 | 5.19e-86 |
| Syncope:0 | 4/61,988 | 11,073/16,348,907 | 0.10 | 1.74e-13 | 2.26e-12 |
| Retinoblastoma Genes:0 | 23/61,988 | 1,060/16,348,907 | 5.72 | 7.80e-11 | 8.44e-10 |
| Myocardium:0 | 12/61,988 | 51,212/16,348,907 | 0.06 | 6.08e-66 | 3.53e-64 |
| Puboprostatic ligament:0 | 13/61,988 | 25/16,348,907 | 137.17 | 1.58e-22 | 3.32e-21 |
| Relaxation:0 | 11/61,988 | 18,549/16,348,907 | 0.16 | 3.18e-18 | 5.44e-17 |
| Patient observation:0 | 279/61,988 | 1,373/16,348,907 | 53.83 | 0.00e+00 | 0.00e+00 |
| Pathological accumulation of air in tissues:0 | 7/61,988 | 10,373/16,348,907 | 0.18 | 6.27e-10 | 6.25e-09 |
| Prostate Urothelial Carcinoma:0 | 19/61,988 | 45/16,348,907 | 111.39 | 6.85e-31 | 1.92e-29 |
| [D]Urinary system symptoms NOS:0 | 13/61,988 | 183/16,348,907 | 18.74 | 1.13e-12 | 1.38e-11 |
| ZEB1:0 | 32/61,988 | 1,544/16,348,907 | 5.47 | 6.00e-14 | 8.04e-13 |
| kinase activity:0 | 66/61,988 | 6,238/16,348,907 | 2.79 | 8.18e-13 | 1.01e-11 |
| Memory:0 | 8/61,988 | 13,655/16,348,907 | 0.15 | 9.31e-14 | 1.23e-12 |
| Beta Carotene:0 | 102/61,988 | 11,609/16,348,907 | 2.32 | 7.94e-14 | 1.06e-12 |
| Glial Fibrillary Acidic Protein:0 | 2/61,988 | 9,543/16,348,907 | 0.06 | 3.14e-13 | 4.00e-12 |
| Materials:0 | 55/61,988 | 28,268/16,348,907 | 0.51 | 3.84e-08 | 3.21e-07 |
| Birth Weight:0 | 9/61,988 | 13,104/16,348,907 | 0.18 | 3.67e-12 | 4.35e-11 |
| Gelatinase B:0 | 219/61,988 | 21,600/16,348,907 | 2.68 | 6.91e-36 | 2.24e-34 |
| Serum acid phosphatase measurement:0 | 17/61,988 | 27/16,348,907 | 166.11 | 4.03e-30 | 1.11e-28 |
| fluorodeoxyglucose positron emission tomography:0 | 62/61,988 | 5,933/16,348,907 | 2.76 | 6.39e-12 | 7.48e-11 |
| Magnetic Resonance Angiography:0 | 5/61,988 | 7,679/16,348,907 | 0.17 | 1.15e-07 | 9.07e-07 |
| Restenosis:0 | 2/61,988 | 13,333/16,348,907 | 0.04 | 3.71e-19 | 6.69e-18 |
| Biopsy of prostate:0 | 198/61,988 | 316/16,348,907 | 165.78 | 0.00e+00 | 0.00e+00 |
| HYPERTHYROID:0 | 3/61,988 | 6,452/16,348,907 | 0.12 | 1.32e-07 | 1.03e-06 |
| Prostatic Neoplasms:0 | 2,156/61,988 | 3,143/16,348,907 | 187.40 | 0.00e+00 | 0.00e+00 |
| Capsid Proteins:0 | 10/61,988 | 16,125/16,348,907 | 0.16 | 1.56e-15 | 2.32e-14 |
| Samarium SM 153 lexidronam:0 | 28/61,988 | 228/16,348,907 | 32.40 | 1.20e-31 | 3.46e-30 |
| Irrigation:0 | 23/61,988 | 16,339/16,348,907 | 0.37 | 2.33e-08 | 1.99e-07 |
| Worried:0 | 27/61,988 | 2,042/16,348,907 | 3.49 | 6.02e-08 | 4.91e-07 |
| Tubulin:0 | 89/61,988 | 13,063/16,348,907 | 1.80 | 5.08e-07 | 3.75e-06 |
| Tumor Suppressor Proteins:0 | 49/61,988 | 2,295/16,348,907 | 5.63 | 5.14e-21 | 1.02e-19 |
| bicalutamide:0 | 588/61,988 | 1,877/16,348,907 | 83.40 | 0.00e+00 | 0.00e+00 |
| Laser vaporization:0 | 29/61,988 | 1,650/16,348,907 | 4.64 | 3.98e-11 | 4.40e-10 |
| Nicardipine:0 | 3/61,988 | 5,813/16,348,907 | 0.14 | 1.00e-06 | 7.12e-06 |
| Immunoperoxidase Techniques:0 | 16/61,988 | 721/16,348,907 | 5.85 | 4.09e-08 | 3.41e-07 |
| beta-adrenergic receptor:0 | 2/61,988 | 5,576/16,348,907 | 0.09 | 3.00e-07 | 2.27e-06 |
| Cyanobacterium:0 | 2/61,988 | 14,949/16,348,907 | 0.04 | 7.38e-22 | 1.51e-20 |
| Urogenital organ:0 | 15/61,988 | 203/16,348,907 | 19.49 | 1.23e-14 | 1.72e-13 |
| conjunctiva:0 | 11/61,988 | 16,281/16,348,907 | 0.18 | 4.20e-15 | 6.06e-14 |
| Somatotropin|ELANE:0 | 7/61,988 | 34/16,348,907 | 54.31 | 2.20e-10 | 2.30e-09 |
| ovarian neoplasm:0 | 59/61,988 | 7,227/16,348,907 | 2.15 | 1.49e-07 | 1.16e-06 |
| Cancer Cell Growth:0 | 757/61,988 | 6,349/16,348,907 | 31.82 | 0.00e+00 | 0.00e+00 |
| Androgens, Synthetic:0 | 57/61,988 | 319/16,348,907 | 47.17 | 4.05e-71 | 2.49e-69 |
| Huntington Disease:0 | 3/61,988 | 13,382/16,348,907 | 0.06 | 4.06e-18 | 6.92e-17 |
| Cell Aging:0 | 61/61,988 | 4,977/16,348,907 | 3.23 | 1.42e-14 | 1.98e-13 |
| Biological function, NOS:0 | 163/61,988 | 15,496/16,348,907 | 2.78 | 6.96e-29 | 1.85e-27 |
| hair:0 | 17/61,988 | 23,415/16,348,907 | 0.19 | 3.40e-20 | 6.50e-19 |
| Anchorage-Independent Growth:0 | 125/61,988 | 3,285/16,348,907 | 10.05 | 1.17e-77 | 7.79e-76 |
| EPHA2 gene|EPHA2:0 | 32/61,988 | 1,275/16,348,907 | 6.62 | 3.75e-16 | 5.73e-15 |
| Birth:0 | 46/61,988 | 44,134/16,348,907 | 0.27 | 2.47e-28 | 6.42e-27 |
| Large prostate:0 | 258/61,988 | 1,200/16,348,907 | 56.94 | 0.00e+00 | 0.00e+00 |
| Psychiatric inpatient:0 | 4/61,988 | 8,111/16,348,907 | 0.13 | 3.62e-09 | 3.37e-08 |
| Sirolimus (substance):0 | 183/61,988 | 28,562/16,348,907 | 1.69 | 6.25e-11 | 6.82e-10 |
| M Phase Arrest:0 | 15/61,988 | 570/16,348,907 | 6.94 | 1.24e-08 | 1.10e-07 |
| 5-oxo-6,8,11,14-eicosatetraenoic acid:0 | 4/61,988 | 18/16,348,907 | 58.61 | 1.41e-06 | 9.79e-06 |
| protein C activator peptide|PCAP:0 | 5/61,988 | 22/16,348,907 | 59.95 | 5.79e-08 | 4.74e-07 |
| AKT1 gene|AKT1:0 | 21/61,988 | 774/16,348,907 | 7.16 | 9.84e-12 | 1.13e-10 |
| Somatostatin analog|SST:0 | 67/61,988 | 4,095/16,348,907 | 4.32 | 5.53e-22 | 1.14e-20 |
| Glucagon:0 | 7/61,988 | 14,558/16,348,907 | 0.13 | 7.56e-16 | 1.14e-14 |
| Pancreaticoduodenectomy:0 | 4/61,988 | 8,301/16,348,907 | 0.13 | 1.83e-09 | 1.75e-08 |
| Ibandronate:0 | 35/61,988 | 1,862/16,348,907 | 4.96 | 6.51e-14 | 8.70e-13 |
| Clusterin:0 | 22/61,988 | 1,283/16,348,907 | 4.52 | 1.28e-08 | 1.12e-07 |
| Lymphocele:0 | 66/61,988 | 1,485/16,348,907 | 11.73 | 8.20e-46 | 3.41e-44 |
| Hashimoto Disease:0 | 2/61,988 | 5,723/16,348,907 | 0.09 | 2.19e-07 | 1.68e-06 |
| Pathological aspects:0 | 23/61,988 | 848/16,348,907 | 7.16 | 1.05e-12 | 1.29e-11 |
| Epilepsy:0 | 18/61,988 | 98,304/16,348,907 | 0.05 | 5.36e-132 | 6.08e-130 |
| Entire ascending aorta:0 | 1/61,988 | 5,403/16,348,907 | 0.05 | 4.94e-08 | 4.07e-07 |
| 17q24.3:0 | 5/61,988 | 11/16,348,907 | 119.89 | 3.24e-09 | 3.03e-08 |
| Prostatic plexus:0 | 6/61,988 | 19/16,348,907 | 83.30 | 4.84e-10 | 4.88e-09 |
| Myelin Basic Proteins:0 | 3/61,988 | 7,060/16,348,907 | 0.11 | 1.68e-08 | 1.45e-07 |
| Methotrexate:0 | 97/61,988 | 55,579/16,348,907 | 0.46 | 3.33e-18 | 5.69e-17 |
| TMPRSS2 gene|TMPRSS2:0 | 164/61,988 | 267/16,348,907 | 162.43 | 1.18e-275 | 2.67e-273 |
| Hernia:0 | 28/61,988 | 32,741/16,348,907 | 0.23 | 5.18e-25 | 1.21e-23 |
| pomegranate juice:0 | 7/61,988 | 74/16,348,907 | 24.95 | 2.99e-08 | 2.53e-07 |
| Allografting:0 | 13/61,988 | 16,059/16,348,907 | 0.21 | 2.65e-13 | 3.40e-12 |
| SRC gene|SRC:0 | 31/61,988 | 923/16,348,907 | 8.86 | 4.57e-19 | 8.22e-18 |
| Micrometastasis:0 | 106/61,988 | 5,758/16,348,907 | 4.86 | 5.57e-38 | 1.93e-36 |
| Lead measurement:0 | 6/61,988 | 8,162/16,348,907 | 0.19 | 1.09e-07 | 8.66e-07 |
| Electroencephalography:0 | 3/61,988 | 12,215/16,348,907 | 0.06 | 2.97e-16 | 4.57e-15 |
| Platelet aggregation:0 | 9/61,988 | 21,541/16,348,907 | 0.11 | 3.19e-24 | 7.17e-23 |
| Ventral Tegmental Area:0 | 1/61,988 | 9,654/16,348,907 | 0.03 | 1.30e-14 | 1.81e-13 |
| Pilocarpine:0 | 1/61,988 | 5,813/16,348,907 | 0.05 | 1.17e-08 | 1.03e-07 |
| Nonsteroidal antiandrogen:0 | 114/61,988 | 247/16,348,907 | 121.95 | 6.06e-181 | 9.26e-179 |
| PIK3CA:0 | 13/61,988 | 601/16,348,907 | 5.71 | 9.72e-07 | 6.92e-06 |
| Signaling Protein:0 | 42/61,988 | 3,799/16,348,907 | 2.92 | 2.96e-09 | 2.78e-08 |
| Erinaceidae:0 | 59/61,988 | 5,173/16,348,907 | 3.01 | 6.81e-13 | 8.45e-12 |
| Refractory Disease:0 | 57/61,988 | 2,639/16,348,907 | 5.70 | 2.09e-24 | 4.73e-23 |
| Urologic Diseases:0 | 124/61,988 | 2,323/16,348,907 | 14.10 | 2.36e-93 | 1.84e-91 |
| Growth arrest:0 | 173/61,988 | 5,707/16,348,907 | 8.01 | 7.50e-92 | 5.75e-90 |
| NCOR2 gene|NCOR2:0 | 20/61,988 | 671/16,348,907 | 7.86 | 6.00e-12 | 7.03e-11 |
| Globin:0 | 1/61,988 | 5,831/16,348,907 | 0.05 | 1.19e-08 | 1.05e-07 |
| Malaria:0 | 16/61,988 | 53,071/16,348,907 | 0.08 | 3.04e-64 | 1.73e-62 |
| Gastric acid secretion:0 | 1/61,988 | 7,084/16,348,907 | 0.04 | 1.04e-10 | 1.12e-09 |
| Head of femur:0 | 12/61,988 | 11,408/16,348,907 | 0.28 | 4.26e-08 | 3.53e-07 |
| Radiotherapy Systems, Linear Accelerator:0 | 85/61,988 | 1,574/16,348,907 | 14.26 | 5.87e-65 | 3.38e-63 |
| CASP8 and FADD-like apoptosis regulating protein:0 | 35/61,988 | 1,659/16,348,907 | 5.57 | 2.50e-15 | 3.67e-14 |
| Urologic Surgical Procedures:0 | 26/61,988 | 466/16,348,907 | 14.72 | 2.30e-21 | 4.61e-20 |
| Intracavernous injection:0 | 18/61,988 | 399/16,348,907 | 11.90 | 9.18e-14 | 1.22e-12 |
| Mouse Cell Line:0 | 46/61,988 | 5,093/16,348,907 | 2.38 | 2.61e-07 | 1.99e-06 |
| Dental Implants:0 | 2/61,988 | 6,678/16,348,907 | 0.08 | 6.28e-09 | 5.70e-08 |
| valsartan:0 | 2/61,988 | 5,218/16,348,907 | 0.10 | 1.26e-06 | 8.82e-06 |
| Cognitive Therapy:0 | 9/61,988 | 15,789/16,348,907 | 0.15 | 7.42e-16 | 1.12e-14 |
| ZNF77:0 | 12/61,988 | 461/16,348,907 | 6.87 | 3.86e-07 | 2.89e-06 |
| Prostate:0 | 34,102/61,988 | 82,025/16,348,907 | 242.52 | 0.00e+00 | 0.00e+00 |
| NF-kappa B:0 | 445/61,988 | 61,562/16,348,907 | 1.91 | 1.00e-34 | 3.13e-33 |
| Conscious:0 | 1/61,988 | 21,359/16,348,907 | 0.01 | 1.43e-33 | 4.39e-32 |
| Ulcerative Colitis:0 | 29/61,988 | 49,700/16,348,907 | 0.15 | 3.64e-47 | 1.56e-45 |
| Cephalosporins:0 | 3/61,988 | 8,335/16,348,907 | 0.09 | 2.84e-10 | 2.93e-09 |
| Primates:0 | 40/61,988 | 33,961/16,348,907 | 0.31 | 1.15e-19 | 2.12e-18 |
| ELAC2 gene|ELAC2:0 | 8/61,988 | 11/16,348,907 | 191.84 | 3.02e-15 | 4.39e-14 |
| Prostatic fluid sample:0 | 5/61,988 | 14/16,348,907 | 94.20 | 8.55e-09 | 7.65e-08 |
| Stress Disorders, Post-Traumatic:0 | 5/61,988 | 38,052/16,348,907 | 0.03 | 2.43e-54 | 1.20e-52 |
| APEX1 protein, human|APEX1:0 | 213/61,988 | 15,580/16,348,907 | 3.61 | 1.08e-53 | 5.26e-52 |
| HT29 Cells:0 | 61/61,988 | 7,417/16,348,907 | 2.17 | 7.35e-08 | 5.94e-07 |
| Anatomic structures:0 | 227/61,988 | 28,966/16,348,907 | 2.07 | 1.41e-22 | 2.98e-21 |
| Cadherins:0 | 137/61,988 | 8,715/16,348,907 | 4.15 | 2.60e-41 | 9.86e-40 |
| Local:0 | 46/61,988 | 511/16,348,907 | 23.76 | 2.89e-45 | 1.19e-43 |
| Structure of cortex of kidney:0 | 3/61,988 | 5,735/16,348,907 | 0.14 | 1.42e-06 | 9.86e-06 |
| PIM1 gene|PIM1:0 | 45/61,988 | 838/16,348,907 | 14.17 | 4.13e-35 | 1.30e-33 |
| Relationships:0 | 255/61,988 | 23,029/16,348,907 | 2.93 | 7.61e-48 | 3.33e-46 |
| AKR1C3:0 | 43/61,988 | 389/16,348,907 | 29.17 | 6.22e-46 | 2.60e-44 |
| inpatient:0 | 51/61,988 | 26,102/16,348,907 | 0.51 | 1.79e-07 | 1.39e-06 |
| Dutasteride 0.5 MG:0 | 5/61,988 | 10/16,348,907 | 131.88 | 2.24e-09 | 2.12e-08 |
| plant growth/development:0 | 1/61,988 | 5,024/16,348,907 | 0.05 | 2.11e-07 | 1.63e-06 |
| Cytotoxic T-Lymphocyte-Associated Protein 4:0 | 39/61,988 | 3,624/16,348,907 | 2.84 | 2.11e-08 | 1.80e-07 |
| Ataxia:0 | 3/61,988 | 6,704/16,348,907 | 0.12 | 6.99e-08 | 5.68e-07 |
| cyclin B1|CCNB1:0 | 40/61,988 | 1,487/16,348,907 | 7.10 | 8.34e-21 | 1.64e-19 |
| ACAT1|SLC25A5:0 | 20/61,988 | 479/16,348,907 | 11.02 | 1.59e-14 | 2.21e-13 |
| Fatty degeneration:0 | 4/61,988 | 8,633/16,348,907 | 0.12 | 6.67e-10 | 6.63e-09 |
| Triglycerides:0 | 41/61,988 | 49,742/16,348,907 | 0.22 | 2.23e-38 | 7.81e-37 |
| Ventricular Septal Defects:0 | 1/61,988 | 7,930/16,348,907 | 0.03 | 5.91e-12 | 6.93e-11 |
| Prostate cancer recurrent:0 | 713/61,988 | 1,240/16,348,907 | 153.41 | 0.00e+00 | 0.00e+00 |
| Mitral Valve Stenosis:0 | 1/61,988 | 7,687/16,348,907 | 0.03 | 1.18e-11 | 1.35e-10 |
| CANCER OCCULT:0 | 12/61,988 | 348/16,348,907 | 9.10 | 2.06e-08 | 1.77e-07 |
| Ventricular Dysfunction, Left:0 | 2/61,988 | 12,554/16,348,907 | 0.04 | 6.84e-18 | 1.15e-16 |
| Prostate cancer stage III:0 | 10/61,988 | 14/16,348,907 | 188.42 | 1.10e-18 | 1.94e-17 |
| Hyperthyroidism:0 | 6/61,988 | 17,484/16,348,907 | 0.09 | 5.12e-21 | 1.01e-19 |
| therapeutic use:0 | 32/61,988 | 2,943/16,348,907 | 2.87 | 2.92e-07 | 2.22e-06 |
| Mean blood pressure:0 | 1/61,988 | 12,748/16,348,907 | 0.02 | 9.85e-20 | 1.82e-18 |
| Trimethoprim-Sulfamethoxazole Combination:0 | 7/61,988 | 11,794/16,348,907 | 0.16 | 6.31e-12 | 7.38e-11 |
| Bypass surgery:0 | 1/61,988 | 4,710/16,348,907 | 0.06 | 6.18e-07 | 4.51e-06 |
| Staining method:0 | 62/61,988 | 6,607/16,348,907 | 2.48 | 4.17e-10 | 4.25e-09 |
| Adenylate Cyclase:0 | 26/61,988 | 31,469/16,348,907 | 0.22 | 1.07e-24 | 2.46e-23 |
| Anticonvulsants:0 | 8/61,988 | 15,380/16,348,907 | 0.14 | 3.23e-16 | 4.95e-15 |
| Medulla:0 | 10/61,988 | 20,620/16,348,907 | 0.13 | 6.77e-22 | 1.39e-20 |
| Atopy:0 | 4/61,988 | 8,581/16,348,907 | 0.12 | 9.89e-10 | 9.65e-09 |
| Stricture:0 | 105/61,988 | 13,552/16,348,907 | 2.05 | 4.86e-11 | 5.34e-10 |
| conserved helix-loop-helix ubiquitous kinase:0 | 16/61,988 | 580/16,348,907 | 7.28 | 2.17e-09 | 2.06e-08 |
| Cdc25C protein|CDC25C:0 | 5/61,988 | 38/16,348,907 | 34.71 | 6.57e-07 | 4.78e-06 |
| negative regulation of cyclin dependent protein kinase activity:0 | 35/61,988 | 1,221/16,348,907 | 7.56 | 3.12e-19 | 5.64e-18 |
| MG 132:0 | 44/61,988 | 3,393/16,348,907 | 3.42 | 1.02e-11 | 1.17e-10 |
| Common carotid artery:0 | 1/61,988 | 4,519/16,348,907 | 0.06 | 1.28e-06 | 8.94e-06 |
| Glycine:0 | 36/61,988 | 24,989/16,348,907 | 0.38 | 9.85e-12 | 1.13e-10 |
| Methimazole:0 | 1/61,988 | 4,833/16,348,907 | 0.05 | 4.38e-07 | 3.26e-06 |
| Epothilones:0 | 24/61,988 | 468/16,348,907 | 13.53 | 4.79e-19 | 8.60e-18 |
| Brown Fat:0 | 1/61,988 | 9,266/16,348,907 | 0.03 | 3.49e-14 | 4.74e-13 |
| Phacoemulsification:0 | 1/61,988 | 6,231/16,348,907 | 0.04 | 2.79e-09 | 2.63e-08 |
| Muscle - Striated (Skeletal) (MMHCC):0 | 22/61,988 | 30,400/16,348,907 | 0.19 | 5.09e-26 | 1.23e-24 |
| SRD5A2 gene|SRD5A2:0 | 42/61,988 | 176/16,348,907 | 62.98 | 1.53e-57 | 7.90e-56 |
| Cholecystokinin|CCK:0 | 3/61,988 | 9,616/16,348,907 | 0.08 | 2.90e-12 | 3.46e-11 |
| N-Cadherins:0 | 66/61,988 | 3,639/16,348,907 | 4.79 | 5.68e-24 | 1.26e-22 |
| Neuronal Plasticity:0 | 1/61,988 | 4,861/16,348,907 | 0.05 | 4.53e-07 | 3.36e-06 |
| Interleukin-3:0 | 6/61,988 | 8,012/16,348,907 | 0.20 | 2.18e-07 | 1.67e-06 |
| 1,4,7-triazacyclononane-N,N',N''-triacetic acid:0 | 12/61,988 | 148/16,348,907 | 21.39 | 1.94e-12 | 2.34e-11 |
| human leukocyte interferon|DNAJC5:0 | 7/61,988 | 31/16,348,907 | 59.56 | 1.25e-10 | 1.33e-09 |
| Homelessness:0 | 1/61,988 | 7,632/16,348,907 | 0.03 | 1.76e-11 | 1.98e-10 |
| Multiple Myeloma:0 | 318/61,988 | 49,760/16,348,907 | 1.69 | 9.04e-18 | 1.51e-16 |
| [D]Slowing of urinary stream:0 | 6/61,988 | 43/16,348,907 | 36.80 | 3.53e-08 | 2.97e-07 |
| Allergens:0 | 3/61,988 | 16,957/16,348,907 | 0.05 | 1.03e-23 | 2.26e-22 |
| Physical and emotional exhaustion state:0 | 1/61,988 | 4,552/16,348,907 | 0.06 | 1.32e-06 | 9.20e-06 |
| granulosa cell:0 | 8/61,988 | 18,285/16,348,907 | 0.12 | 2.55e-20 | 4.91e-19 |
| Coronary Stenosis:0 | 2/61,988 | 7,107/16,348,907 | 0.07 | 1.55e-09 | 1.49e-08 |
| diagnostic use:0 | 15/61,988 | 439/16,348,907 | 9.01 | 4.18e-10 | 4.25e-09 |
| Spleen:0 | 180/61,988 | 137,561/16,348,907 | 0.34 | 3.79e-67 | 2.23e-65 |
| Neisseria meningitidis:0 | 1/61,988 | 4,594/16,348,907 | 0.06 | 8.80e-07 | 6.32e-06 |
| Cancer Diagnosis:0 | 1,083/61,988 | 3,927/16,348,907 | 74.01 | 0.00e+00 | 0.00e+00 |
| Injury to kidney NOS:0 | 2/61,988 | 5,761/16,348,907 | 0.09 | 1.48e-07 | 1.16e-06 |
| TGFBR2 protein, human|TGFBR2:0 | 17/61,988 | 376/16,348,907 | 11.93 | 4.27e-13 | 5.38e-12 |
| radiation toxicity:0 | 36/61,988 | 721/16,348,907 | 13.18 | 2.15e-27 | 5.45e-26 |
| Catenins:0 | 30/61,988 | 2,075/16,348,907 | 3.81 | 1.63e-09 | 1.57e-08 |
| Amygdaloid structure:0 | 2/61,988 | 24,001/16,348,907 | 0.02 | 3.24e-36 | 1.07e-34 |
| magnetic resonance spectroscopic imaging:0 | 49/61,988 | 206/16,348,907 | 62.78 | 8.61e-67 | 5.04e-65 |
| Nematoda:0 | 1/61,988 | 15,896/16,348,907 | 0.02 | 7.93e-25 | 1.83e-23 |
| Adrenergic beta-Agonists:0 | 3/61,988 | 6,136/16,348,907 | 0.13 | 3.64e-07 | 2.73e-06 |
| Tension:0 | 13/61,988 | 26,487/16,348,907 | 0.13 | 1.26e-27 | 3.22e-26 |
| Essential Hypertension:0 | 3/61,988 | 32,632/16,348,907 | 0.02 | 1.40e-48 | 6.20e-47 |
| Antiphospholipid Antibodies:0 | 1/61,988 | 5,657/16,348,907 | 0.05 | 2.52e-08 | 2.15e-07 |
| Androgens measurement:0 | 53/61,988 | 357/16,348,907 | 39.19 | 2.12e-62 | 1.18e-60 |
| Synovial Fluid:0 | 1/61,988 | 8,250/16,348,907 | 0.03 | 2.05e-12 | 2.47e-11 |
| 2-methoxyestradiol:0 | 35/61,988 | 1,557/16,348,907 | 5.93 | 4.04e-16 | 6.17e-15 |
| Neuroglia:0 | 10/61,988 | 21,448/16,348,907 | 0.12 | 4.61e-23 | 9.89e-22 |
| Sexual Dysfunction:0 | 113/61,988 | 4,011/16,348,907 | 7.44 | 1.47e-57 | 7.61e-56 |
| Signet ring cell:0 | 27/61,988 | 893/16,348,907 | 7.98 | 9.72e-16 | 1.45e-14 |
| proto-oncogene proteins pim|PIM1:0 | 11/61,988 | 166/16,348,907 | 17.48 | 1.22e-10 | 1.30e-09 |
| Supernumerary mandibular left first primary molar:0 | 15/61,988 | 333/16,348,907 | 11.88 | 1.05e-11 | 1.20e-10 |
| Metalloproteases:0 | 111/61,988 | 12,450/16,348,907 | 2.35 | 2.81e-15 | 4.09e-14 |
| Natural Products:0 | 60/61,988 | 6,041/16,348,907 | 2.62 | 9.48e-11 | 1.02e-09 |
| Guillain-Barre Syndrome:0 | 3/61,988 | 9,932/16,348,907 | 0.08 | 1.03e-12 | 1.26e-11 |
| Disabled Homolog 2 Protein|DAB2:0 | 11/61,988 | 199/16,348,907 | 14.58 | 7.54e-10 | 7.46e-09 |
| Xylocaine gel:0 | 14/61,988 | 207/16,348,907 | 17.84 | 2.89e-13 | 3.70e-12 |
| Magnetic resonance imaging guidance:0 | 5/61,988 | 29/16,348,907 | 45.48 | 1.95e-07 | 1.51e-06 |
| Ito cell:0 | 2/61,988 | 8,238/16,348,907 | 0.06 | 3.22e-11 | 3.58e-10 |
| disease characteristic:0 | 27/61,988 | 613/16,348,907 | 11.62 | 1.26e-19 | 2.32e-18 |
| Diabetic Nephropathy:0 | 2/61,988 | 18,684/16,348,907 | 0.03 | 1.18e-27 | 3.00e-26 |
| nervous system disorder:0 | 28/61,988 | 28,697/16,348,907 | 0.26 | 5.26e-20 | 9.93e-19 |
| Fusion Gene:0 | 77/61,988 | 3,748/16,348,907 | 5.42 | 5.28e-31 | 1.48e-29 |
| Melatonin:0 | 84/61,988 | 49,828/16,348,907 | 0.44 | 1.52e-17 | 2.50e-16 |
| CDK5RAP1:0 | 72/61,988 | 165/16,348,907 | 115.22 | 1.68e-113 | 1.57e-111 |
| Protein Expression:0 | 122/61,988 | 8,415/16,348,907 | 3.83 | 8.59e-34 | 2.64e-32 |
| Photon radiation therapy:0 | 8/61,988 | 81/16,348,907 | 26.05 | 2.23e-09 | 2.12e-08 |
| Entire arteriole:0 | 1/61,988 | 5,256/16,348,907 | 0.05 | 1.07e-07 | 8.47e-07 |
| atrial natriuretic factor prohormone (1-30), human:0 | 9/61,988 | 124/16,348,907 | 19.15 | 2.79e-09 | 2.63e-08 |
| Gonadorelin|TRH:0 | 5/61,988 | 6/16,348,907 | 219.80 | 3.49e-10 | 3.57e-09 |
| Cancer Survivor:0 | 181/61,988 | 3,396/16,348,907 | 14.10 | 2.72e-135 | 3.14e-133 |
| Degenerative polyarthritis:0 | 24/61,988 | 72,359/16,348,907 | 0.09 | 6.58e-85 | 4.70e-83 |
| OR51E2:0 | 13/61,988 | 65/16,348,907 | 52.76 | 5.59e-18 | 9.45e-17 |
| Hypercholesterolemia, Familial:0 | 2/61,988 | 8,544/16,348,907 | 0.06 | 1.11e-11 | 1.28e-10 |
| Cataract Extraction:0 | 1/61,988 | 9,076/16,348,907 | 0.03 | 7.24e-14 | 9.64e-13 |
| Phagocytosis:0 | 19/61,988 | 23,618/16,348,907 | 0.21 | 3.96e-19 | 7.15e-18 |
| Cell Cycle Proteins:0 | 69/61,988 | 2,773/16,348,907 | 6.57 | 1.08e-32 | 3.21e-31 |
| Physical shape:0 | 7/61,988 | 7,852/16,348,907 | 0.24 | 1.27e-06 | 8.89e-06 |
| prostatein:0 | 7/61,988 | 76/16,348,907 | 24.29 | 3.54e-08 | 2.98e-07 |
| Toxin:0 | 48/61,988 | 40,594/16,348,907 | 0.31 | 3.04e-23 | 6.61e-22 |
| Photosensitizing Agents:0 | 59/61,988 | 4,931/16,348,907 | 3.16 | 1.00e-13 | 1.32e-12 |
| Luciferases|EREG|ESR1:0 | 132/61,988 | 154/16,348,907 | 226.55 | 1.89e-236 | 3.54e-234 |
| Xenopus laevis:0 | 11/61,988 | 11,627/16,348,907 | 0.25 | 6.01e-09 | 5.46e-08 |
| Pelvic lymph node group:0 | 135/61,988 | 621/16,348,907 | 57.46 | 3.02e-176 | 4.47e-174 |
| Medicare:0 | 69/61,988 | 3,813/16,348,907 | 4.78 | 6.25e-25 | 1.45e-23 |
| 3 (or 17)-beta-hydroxysteroid dehydrogenase:0 | 38/61,988 | 1,840/16,348,907 | 5.45 | 3.23e-16 | 4.94e-15 |
| Phototherapy:0 | 94/61,988 | 14,259/16,348,907 | 1.74 | 7.92e-07 | 5.72e-06 |
| Arteriovenous fistula:0 | 1/61,988 | 8,738/16,348,907 | 0.03 | 3.28e-13 | 4.18e-12 |
| Estrogen Receptor beta|EREG|ESR1:0 | 26/61,988 | 1,986/16,348,907 | 3.45 | 1.26e-07 | 9.90e-07 |
| Tracer:0 | 71/61,988 | 9,032/16,348,907 | 2.07 | 4.44e-08 | 3.68e-07 |
| Group Psychotherapy:0 | 47/61,988 | 5,083/16,348,907 | 2.44 | 7.63e-08 | 6.15e-07 |
| univariate analysis:0 | 22/61,988 | 1,204/16,348,907 | 4.82 | 4.23e-09 | 3.90e-08 |
| Islets of Langerhans:0 | 9/61,988 | 18,654/16,348,907 | 0.13 | 6.37e-20 | 1.20e-18 |
| Turtles:0 | 1/61,988 | 6,862/16,348,907 | 0.04 | 3.33e-10 | 3.42e-09 |
| Cerebral Infarction:0 | 4/61,988 | 13,474/16,348,907 | 0.08 | 3.94e-17 | 6.36e-16 |
| ewes:0 | 1/61,988 | 11,754/16,348,907 | 0.02 | 3.80e-18 | 6.48e-17 |
| Arginine:0 | 43/61,988 | 43,072/16,348,907 | 0.26 | 8.17e-29 | 2.17e-27 |
| Peptides:0 | 359/61,988 | 68,924/16,348,907 | 1.38 | 1.05e-08 | 9.35e-08 |
| Tacrolimus:0 | 9/61,988 | 18,513/16,348,907 | 0.13 | 8.63e-20 | 1.61e-18 |
| Malignant neoplasm of endocrine gland:0 | 23/61,988 | 485/16,348,907 | 12.51 | 1.30e-17 | 2.15e-16 |
| Cyclin D1|CCND1:0 | 247/61,988 | 12,653/16,348,907 | 5.17 | 4.87e-91 | 3.71e-89 |
| cancer angiogenesis:0 | 27/61,988 | 389/16,348,907 | 18.31 | 1.86e-24 | 4.22e-23 |
| hepcidin:0 | 2/61,988 | 7,146/16,348,907 | 0.07 | 1.62e-09 | 1.55e-08 |
| Lung diseases:0 | 19/61,988 | 28,836/16,348,907 | 0.17 | 3.29e-26 | 8.05e-25 |
| pT3 stage:0 | 8/61,988 | 15/16,348,907 | 140.68 | 1.93e-14 | 2.67e-13 |
| myopodin:0 | 8/61,988 | 90/16,348,907 | 23.45 | 4.82e-09 | 4.41e-08 |
| Hydrocephalus:0 | 2/61,988 | 15,505/16,348,907 | 0.03 | 1.28e-22 | 2.70e-21 |
| Scleroderma:0 | 6/61,988 | 8,732/16,348,907 | 0.18 | 2.27e-08 | 1.94e-07 |
| Cyclic AMP:0 | 39/61,988 | 37,786/16,348,907 | 0.27 | 9.70e-25 | 2.23e-23 |
| Neomycin resistance gene:0 | 26/61,988 | 1,766/16,348,907 | 3.88 | 1.34e-08 | 1.18e-07 |
| Cartilage:0 | 16/61,988 | 39,892/16,348,907 | 0.11 | 1.81e-44 | 7.30e-43 |
| eosinophil:0 | 8/61,988 | 20,090/16,348,907 | 0.10 | 5.31e-23 | 1.14e-21 |
| Erythromycin:0 | 3/61,988 | 13,774/16,348,907 | 0.06 | 9.74e-19 | 1.71e-17 |
| destruction; bone:0 | 57/61,988 | 2,980/16,348,907 | 5.05 | 5.62e-22 | 1.15e-20 |
| Cessation of life:0 | 1,243/61,988 | 124,741/16,348,907 | 2.66 | 1.11e-190 | 1.77e-188 |
| Prostate cancer stage II:0 | 8/61,988 | 12/16,348,907 | 175.85 | 5.01e-15 | 7.19e-14 |
| Cell of bone:0 | 61/61,988 | 2,831/16,348,907 | 5.69 | 6.02e-26 | 1.46e-24 |
| Testosterone 5-alpha-Reductase:0 | 117/61,988 | 1,652/16,348,907 | 18.71 | 3.00e-101 | 2.47e-99 |
| HSPB1 gene|HSPB1:0 | 52/61,988 | 4,096/16,348,907 | 3.35 | 3.22e-13 | 4.09e-12 |
| Testosterone increased:0 | 8/61,988 | 144/16,348,907 | 14.65 | 1.50e-07 | 1.17e-06 |
| Basal Cell:0 | 250/61,988 | 5,052/16,348,907 | 13.10 | 7.07e-179 | 1.06e-176 |
| Los Angeles:0 | 31/61,988 | 816/16,348,907 | 10.02 | 1.59e-20 | 3.08e-19 |
| Nephrostomy:0 | 18/61,988 | 400/16,348,907 | 11.87 | 9.56e-14 | 1.27e-12 |
| Cochlear structure:0 | 1/61,988 | 22,375/16,348,907 | 0.01 | 2.32e-35 | 7.41e-34 |
| Prostate implant brachytherapy:0 | 5/61,988 | 8/16,348,907 | 164.85 | 9.65e-10 | 9.43e-09 |
| Tumor-Associated Vasculature:0 | 82/61,988 | 778/16,348,907 | 27.83 | 1.83e-84 | 1.30e-82 |
| Atherogenesis:0 | 4/61,988 | 7,828/16,348,907 | 0.13 | 1.01e-08 | 9.01e-08 |
| Brain Injuries:0 | 1/61,988 | 22,308/16,348,907 | 0.01 | 3.44e-35 | 1.09e-33 |
| Manganese:0 | 8/61,988 | 11,093/16,348,907 | 0.19 | 3.25e-10 | 3.35e-09 |
| Radiotherapy, Interstitial:0 | 19/61,988 | 196/16,348,907 | 25.57 | 3.43e-20 | 6.54e-19 |
| Learning:0 | 9/61,988 | 14,207/16,348,907 | 0.17 | 1.01e-13 | 1.33e-12 |
| Lipoid nephrosis:0 | 1/61,988 | 5,515/16,348,907 | 0.05 | 3.46e-08 | 2.91e-07 |
| Nucleolar Organizer Region:0 | 25/61,988 | 1,491/16,348,907 | 4.42 | 2.11e-09 | 2.01e-08 |
| Prostate finding:0 | 23/61,988 | 31/16,348,907 | 195.75 | 1.82e-41 | 6.92e-40 |
| Leuprolide Acetate|PGR|PR@|PRH2|TMEM37|ERVK-10:0 | 21/61,988 | 25/16,348,907 | 221.62 | 8.35e-39 | 2.96e-37 |
| Estrogen Receptor beta:0 | 135/61,988 | 3,835/16,348,907 | 9.30 | 1.05e-79 | 7.13e-78 |
| Audiological observations:0 | 3/61,988 | 9,152/16,348,907 | 0.09 | 1.13e-11 | 1.30e-10 |
| Serotonin:0 | 55/61,988 | 85,111/16,348,907 | 0.17 | 1.22e-75 | 7.88e-74 |
| Ions:0 | 91/61,988 | 93,385/16,348,907 | 0.26 | 3.08e-62 | 1.70e-60 |
| ATP phosphohydrolase|DNAH8:0 | 11/61,988 | 11,279/16,348,907 | 0.26 | 1.47e-08 | 1.29e-07 |
| Megavoltage radiation therapy:0 | 7/61,988 | 81/16,348,907 | 22.80 | 5.33e-08 | 4.38e-07 |
| Sclerotherapy:0 | 5/61,988 | 8,655/16,348,907 | 0.15 | 4.05e-09 | 3.74e-08 |
| Radiotherapy, Conformal:0 | 610/61,988 | 3,376/16,348,907 | 48.12 | 0.00e+00 | 0.00e+00 |
| RU 23908:0 | 8/61,988 | 17/16,348,907 | 124.13 | 4.23e-14 | 5.73e-13 |
| Bone structure of ilium:0 | 53/61,988 | 5,140/16,348,907 | 2.72 | 3.17e-10 | 3.27e-09 |
| Paw:0 | 5/61,988 | 8,222/16,348,907 | 0.16 | 1.52e-08 | 1.32e-07 |
| Nevus, Blue:0 | 15/61,988 | 686/16,348,907 | 5.77 | 1.29e-07 | 1.01e-06 |
| CAR receptor:0 | 12/61,988 | 427/16,348,907 | 7.41 | 1.76e-07 | 1.36e-06 |
| MAPK3 gene|MAPK3:0 | 41/61,988 | 3,754/16,348,907 | 2.88 | 6.28e-09 | 5.70e-08 |
| Alteplase:0 | 22/61,988 | 31,590/16,348,907 | 0.18 | 1.06e-27 | 2.71e-26 |
| Anaplasia:0 | 65/61,988 | 3,922/16,348,907 | 4.37 | 1.17e-21 | 2.38e-20 |
| S-allylmercaptocysteine:0 | 7/61,988 | 95/16,348,907 | 19.44 | 1.48e-07 | 1.16e-06 |
| Tumor Immunity:0 | 57/61,988 | 2,629/16,348,907 | 5.72 | 1.75e-24 | 3.98e-23 |
| Transurethral resection of bladder neoplasm:0 | 11/61,988 | 340/16,348,907 | 8.53 | 1.47e-07 | 1.15e-06 |
| Gastrin releasing peptide:0 | 70/61,988 | 2,963/16,348,907 | 6.24 | 7.93e-32 | 2.31e-30 |
| Neurons, Afferent:0 | 12/61,988 | 13,094/16,348,907 | 0.24 | 3.46e-10 | 3.55e-09 |
| Autologous bone marrow transplant:0 | 1/61,988 | 4,786/16,348,907 | 0.06 | 4.28e-07 | 3.19e-06 |
| Metastasis Suppression:0 | 6/61,988 | 80/16,348,907 | 19.78 | 1.05e-06 | 7.47e-06 |
| Mesangial Cells:0 | 5/61,988 | 11,555/16,348,907 | 0.11 | 3.29e-13 | 4.18e-12 |
| Ultrasonography, Doppler, Color:0 | 26/61,988 | 2,235/16,348,907 | 3.07 | 1.09e-06 | 7.67e-06 |
| Neuropathy:0 | 34/61,988 | 25,696/16,348,907 | 0.35 | 2.21e-13 | 2.85e-12 |
| A-23187:0 | 8/61,988 | 11,786/16,348,907 | 0.18 | 3.37e-11 | 3.75e-10 |
| Vocal cord structure:0 | 3/61,988 | 6,276/16,348,907 | 0.13 | 2.67e-07 | 2.03e-06 |
| Rats, Inbred SHR:0 | 2/61,988 | 35,149/16,348,907 | 0.01 | 2.18e-54 | 1.08e-52 |
| Congenital Abnormality:0 | 52/61,988 | 94,082/16,348,907 | 0.15 | 1.61e-90 | 1.21e-88 |
| Executives:0 | 1/61,988 | 5,138/16,348,907 | 0.05 | 1.49e-07 | 1.16e-06 |
| Neutralizing antibody:0 | 49/61,988 | 5,153/16,348,907 | 2.51 | 1.98e-08 | 1.70e-07 |
| Musculoskeletal torsion, function:0 | 1/61,988 | 6,265/16,348,907 | 0.04 | 2.92e-09 | 2.75e-08 |
| Acinar Pattern:0 | 5/61,988 | 14/16,348,907 | 94.20 | 8.55e-09 | 7.65e-08 |
| Scanning:0 | 623/61,988 | 64,067/16,348,907 | 2.58 | 5.39e-92 | 4.14e-90 |
| ETV1 gene|ETV1:0 | 37/61,988 | 379/16,348,907 | 25.76 | 6.25e-38 | 2.17e-36 |
| Synoviocytes:0 | 3/61,988 | 7,324/16,348,907 | 0.11 | 9.05e-09 | 8.08e-08 |
| 1-Phosphatidylinositol 3-Kinase|PI3:0 | 21/61,988 | 1,490/16,348,907 | 3.72 | 6.21e-07 | 4.53e-06 |
| Entire tibialis anterior:0 | 1/61,988 | 6,105/16,348,907 | 0.04 | 3.94e-09 | 3.64e-08 |
| Oligonucleotides, Antisense:0 | 158/61,988 | 8,265/16,348,907 | 5.05 | 9.15e-58 | 4.76e-56 |
| Sedatives:0 | 7/61,988 | 7,924/16,348,907 | 0.23 | 9.21e-07 | 6.58e-06 |
| Photoreceptors:0 | 1/61,988 | 11,423/16,348,907 | 0.02 | 1.78e-17 | 2.92e-16 |
| Lymphatic Metastasis:0 | 37/61,988 | 1,534/16,348,907 | 6.36 | 6.87e-18 | 1.16e-16 |
| Hepatic Encephalopathy:0 | 2/61,988 | 8,909/16,348,907 | 0.06 | 2.58e-12 | 3.08e-11 |
| Nitric Oxide Synthase:0 | 27/61,988 | 27,141/16,348,907 | 0.26 | 1.19e-18 | 2.08e-17 |
| Chlormadinone Acetate:0 | 55/61,988 | 842/16,348,907 | 17.24 | 8.77e-47 | 3.74e-45 |
| Urinary symptoms:0 | 145/61,988 | 1,682/16,348,907 | 22.79 | 2.37e-136 | 2.76e-134 |
| XPR1:0 | 7/61,988 | 58/16,348,907 | 31.83 | 6.30e-09 | 5.71e-08 |
| Entire eyelid:0 | 3/61,988 | 6,785/16,348,907 | 0.12 | 4.84e-08 | 4.00e-07 |
| Cholecalciferol:0 | 66/61,988 | 8,697/16,348,907 | 2.00 | 4.75e-07 | 3.51e-06 |
| Elevation procedure:0 | 105/61,988 | 1,993/16,348,907 | 13.92 | 8.57e-79 | 5.76e-77 |
| Entire atrium:0 | 3/61,988 | 14,916/16,348,907 | 0.05 | 1.98e-20 | 3.83e-19 |
| Somatostatin analog:0 | 62/61,988 | 2,244/16,348,907 | 7.29 | 6.16e-32 | 1.80e-30 |
| C11 Chalcone:0 | 7/61,988 | 94/16,348,907 | 19.64 | 1.38e-07 | 1.08e-06 |
| Hypermethylation:0 | 89/61,988 | 2,597/16,348,907 | 9.05 | 2.89e-52 | 1.37e-50 |
| LOX gene|LOX:0 | 18/61,988 | 422/16,348,907 | 11.25 | 2.27e-13 | 2.92e-12 |
| Taurine:0 | 7/61,988 | 17,855/16,348,907 | 0.10 | 1.43e-20 | 2.79e-19 |
| Interleukin-5:0 | 6/61,988 | 12,834/16,348,907 | 0.12 | 3.81e-14 | 5.17e-13 |
| Hip Prosthesis:0 | 30/61,988 | 1,408/16,348,907 | 5.62 | 1.81e-13 | 2.35e-12 |
| Tumor Necrosis Factor Receptor Superfamily, Member 10B|TNFRSF10B:0 | 40/61,988 | 1,590/16,348,907 | 6.64 | 8.03e-20 | 1.50e-18 |
| AR:0 | 77/61,988 | 315/16,348,907 | 64.55 | 9.05e-105 | 7.75e-103 |
| Peptide Receptor:0 | 23/61,988 | 1,442/16,348,907 | 4.21 | 2.19e-08 | 1.88e-07 |
| Physical object:0 | 1/61,988 | 4,616/16,348,907 | 0.06 | 8.88e-07 | 6.37e-06 |
| Mandible:0 | 41/61,988 | 39,102/16,348,907 | 0.28 | 4.23e-25 | 9.90e-24 |
| TAP-144:0 | 5/61,988 | 14/16,348,907 | 94.20 | 8.55e-09 | 7.65e-08 |
| Bronchoalveolar Lavage Fluid:0 | 1/61,988 | 11,220/16,348,907 | 0.02 | 3.65e-17 | 5.93e-16 |
| Mesenchyma:0 | 64/61,988 | 5,515/16,348,907 | 3.06 | 3.58e-14 | 4.87e-13 |
| Fetus:0 | 5/61,988 | 22,753/16,348,907 | 0.06 | 2.79e-30 | 7.72e-29 |
| TRYPSIN:0 | 54/61,988 | 34,580/16,348,907 | 0.41 | 4.36e-14 | 5.89e-13 |
| mycophenolate mofetil:0 | 4/61,988 | 13,174/16,348,907 | 0.08 | 1.13e-16 | 1.78e-15 |
| 16q:0 | 32/61,988 | 390/16,348,907 | 21.65 | 8.16e-31 | 2.28e-29 |
| Skin lesion:0 | 11/61,988 | 10,334/16,348,907 | 0.28 | 2.16e-07 | 1.66e-06 |
| Disseminated Malignant Neoplasm:0 | 45/61,988 | 1,421/16,348,907 | 8.36 | 6.14e-26 | 1.48e-24 |
| Liver Failure, Acute:0 | 12/61,988 | 13,490/16,348,907 | 0.23 | 1.01e-10 | 1.08e-09 |
| Suprapubic:0 | 19/61,988 | 314/16,348,907 | 15.96 | 1.23e-16 | 1.94e-15 |
| Oestrogen therapy:0 | 142/61,988 | 2,250/16,348,907 | 16.68 | 5.31e-116 | 5.12e-114 |
| Plasma Cells:0 | 7/61,988 | 7,894/16,348,907 | 0.23 | 1.31e-06 | 9.13e-06 |
| Therapeutic regimen:0 | 31/61,988 | 2,470/16,348,907 | 3.31 | 2.11e-08 | 1.81e-07 |
| sulforafan:0 | 78/61,988 | 3,867/16,348,907 | 5.33 | 6.98e-31 | 1.96e-29 |
| Second Degree Relative:0 | 22/61,988 | 497/16,348,907 | 11.68 | 2.53e-16 | 3.91e-15 |
| Lisinopril:0 | 1/61,988 | 5,333/16,348,907 | 0.05 | 7.23e-08 | 5.85e-07 |
| Entire face:0 | 3/61,988 | 7,429/16,348,907 | 0.11 | 4.19e-09 | 3.86e-08 |
| Gastric mucosa:0 | 14/61,988 | 20,792/16,348,907 | 0.18 | 5.42e-19 | 9.69e-18 |
| X-Linked Inhibitor of Apoptosis Protein|XIAP:0 | 7/61,988 | 104/16,348,907 | 17.75 | 2.64e-07 | 2.01e-06 |
| Logistic Regression:0 | 135/61,988 | 7,898/16,348,907 | 4.52 | 1.76e-44 | 7.07e-43 |
| Hypotension:0 | 12/61,988 | 16,287/16,348,907 | 0.19 | 3.09e-14 | 4.22e-13 |
| peripheral blood:0 | 118/61,988 | 16,275/16,348,907 | 1.91 | 1.83e-10 | 1.92e-09 |
| Prostate Brachytherapy Needles:0 | 4/61,988 | 4/16,348,907 | 263.76 | 1.41e-08 | 1.23e-07 |
| High Grade Intraepithelial Neoplasia:0 | 23/61,988 | 810/16,348,907 | 7.49 | 4.27e-13 | 5.38e-12 |
| gamma-Tocopherol:0 | 30/61,988 | 1,526/16,348,907 | 5.19 | 1.28e-12 | 1.57e-11 |
| serotonin transporter:0 | 1/61,988 | 5,737/16,348,907 | 0.05 | 1.71e-08 | 1.48e-07 |
| Antiandrogen therapy:0 | 185/61,988 | 531/16,348,907 | 92.16 | 9.79e-274 | 2.18e-271 |
| ethinyl estradiol sulfonate:0 | 7/61,988 | 24/16,348,907 | 76.93 | 2.66e-11 | 2.98e-10 |
| Diptera:0 | 2/61,988 | 12,310/16,348,907 | 0.04 | 1.31e-17 | 2.16e-16 |
| Otitis Media:0 | 3/61,988 | 8,839/16,348,907 | 0.09 | 4.97e-11 | 5.46e-10 |
| BAD gene|BAD:0 | 53/61,988 | 2,510/16,348,907 | 5.57 | 2.19e-22 | 4.57e-21 |
| Cancer-Predisposing Gene:0 | 142/61,988 | 4,315/16,348,907 | 8.70 | 4.10e-80 | 2.80e-78 |
| Hematological Disease:0 | 10/61,988 | 11,355/16,348,907 | 0.23 | 3.73e-09 | 3.46e-08 |
| NF-Kappa B p65:0 | 39/61,988 | 4,136/16,348,907 | 2.49 | 6.88e-07 | 5.00e-06 |
| Nystagmus:0 | 1/61,988 | 4,504/16,348,907 | 0.06 | 1.26e-06 | 8.87e-06 |
| Coffee intake:0 | 10/61,988 | 193/16,348,907 | 13.67 | 7.97e-09 | 7.17e-08 |
| Transplanted tissue:0 | 49/61,988 | 51,196/16,348,907 | 0.25 | 3.32e-35 | 1.06e-33 |
| Liver tissue:0 | 18/61,988 | 18,941/16,348,907 | 0.25 | 6.72e-14 | 8.97e-13 |
| Inflammatory Bowel Diseases:0 | 36/61,988 | 53,108/16,348,907 | 0.18 | 2.34e-46 | 9.86e-45 |
| Lipid Peroxidation:0 | 9/61,988 | 11,517/16,348,907 | 0.21 | 4.35e-10 | 4.43e-09 |
| TERT gene|TERT:0 | 71/61,988 | 5,086/16,348,907 | 3.68 | 1.53e-19 | 2.81e-18 |
| Muromonab-CD3:0 | 5/61,988 | 11,575/16,348,907 | 0.11 | 3.38e-13 | 4.29e-12 |
| Factor VIII:0 | 8/61,988 | 9,823/16,348,907 | 0.21 | 1.46e-08 | 1.28e-07 |
| Hypnotics:0 | 2/61,988 | 5,611/16,348,907 | 0.09 | 3.07e-07 | 2.32e-06 |
| Angioplasty:0 | 1/61,988 | 15,057/16,348,907 | 0.02 | 2.27e-23 | 4.97e-22 |
| Pylorus:0 | 1/61,988 | 5,281/16,348,907 | 0.05 | 1.11e-07 | 8.80e-07 |
| Supernumerary mandibular left second molar:0 | 4/61,988 | 6,356/16,348,907 | 0.17 | 1.07e-06 | 7.55e-06 |
| mevalonate pathway:0 | 18/61,988 | 345/16,348,907 | 13.76 | 8.67e-15 | 1.22e-13 |
| coenzyme Q10:0 | 2/61,988 | 6,217/16,348,907 | 0.08 | 3.75e-08 | 3.14e-07 |
| S100B:0 | 1/61,988 | 8,641/16,348,907 | 0.03 | 4.74e-13 | 5.95e-12 |
| Acute radiation proctitis:0 | 11/61,988 | 33/16,348,907 | 87.93 | 1.53e-17 | 2.51e-16 |
| Primary infection NOS:0 | 4/61,988 | 7,934/16,348,907 | 0.13 | 7.25e-09 | 6.54e-08 |
| Minerals:0 | 5/61,988 | 11,725/16,348,907 | 0.11 | 1.61e-13 | 2.10e-12 |
| Retrograde urethrography:0 | 7/61,988 | 131/16,348,907 | 14.09 | 1.15e-06 | 8.12e-06 |
| Dormancy:0 | 19/61,988 | 1,194/16,348,907 | 4.20 | 3.63e-07 | 2.72e-06 |
| ERBB2|NEU1|NEURL1:0 | 104/61,988 | 4,784/16,348,907 | 5.74 | 2.50e-43 | 9.78e-42 |
| Acute infectious disease:0 | 4/61,988 | 9,556/16,348,907 | 0.11 | 3.09e-11 | 3.45e-10 |
| Poisoning:0 | 3/61,988 | 11,433/16,348,907 | 0.07 | 5.18e-15 | 7.42e-14 |
| neoplasm/cancer invasiveness:0 | 24/61,988 | 181/16,348,907 | 34.98 | 4.43e-28 | 1.14e-26 |
| KLK14:0 | 8/61,988 | 70/16,348,907 | 30.15 | 7.68e-10 | 7.59e-09 |
| Na(+)-K(+)-Exchanging ATPase:0 | 9/61,988 | 9,668/16,348,907 | 0.25 | 1.20e-07 | 9.50e-07 |
| OBSTRUCTIVE SYMPTOM:0 | 73/61,988 | 883/16,348,907 | 21.83 | 2.42e-68 | 1.45e-66 |
| nilutamide:0 | 79/61,988 | 289/16,348,907 | 72.19 | 8.53e-111 | 7.77e-109 |
| Compartments:0 | 308/61,988 | 56,087/16,348,907 | 1.45 | 8.40e-10 | 8.29e-09 |
| cetuximab|EGFR:0 | 15/61,988 | 381/16,348,907 | 10.39 | 6.37e-11 | 6.93e-10 |
| Shell:0 | 9/61,988 | 15,293/16,348,907 | 0.16 | 3.95e-15 | 5.72e-14 |
| Chronic prostatitis:0 | 93/61,988 | 2,750/16,348,907 | 8.93 | 4.60e-54 | 2.25e-52 |
| ABT 627:0 | 8/61,988 | 125/16,348,907 | 16.88 | 5.34e-08 | 4.38e-07 |
| Viremia:0 | 5/61,988 | 12,925/16,348,907 | 0.10 | 2.58e-15 | 3.78e-14 |
| Locomotion:0 | 9/61,988 | 9,664/16,348,907 | 0.25 | 1.20e-07 | 9.48e-07 |
| Growth Factor Receptors:0 | 64/61,988 | 3,070/16,348,907 | 5.50 | 2.16e-26 | 5.32e-25 |
| Youth:0 | 7/61,988 | 39,079/16,348,907 | 0.05 | 2.66e-53 | 1.29e-51 |
| Naltrexone:0 | 1/61,988 | 11,123/16,348,907 | 0.02 | 5.28e-17 | 8.47e-16 |
| Heterocyclic Amines:0 | 19/61,988 | 880/16,348,907 | 5.70 | 3.55e-09 | 3.31e-08 |
| Fluorides:0 | 18/61,988 | 19,834/16,348,907 | 0.24 | 6.09e-15 | 8.66e-14 |
| Basal cell hyperplasia:0 | 26/61,988 | 180/16,348,907 | 38.11 | 3.62e-31 | 1.03e-29 |
| AR protein, human|AR:0 | 113/61,988 | 652/16,348,907 | 45.79 | 6.90e-138 | 8.10e-136 |
| Superficial Bladder Cancer:0 | 90/61,988 | 2,708/16,348,907 | 8.78 | 8.73e-52 | 4.11e-50 |
| Blood capillaries:0 | 50/61,988 | 35,266/16,348,907 | 0.37 | 1.92e-16 | 2.98e-15 |
| Sodium Dodecyl Sulfate:0 | 7/61,988 | 10,706/16,348,907 | 0.17 | 2.42e-10 | 2.51e-09 |
| Botulinum Toxin Type A:0 | 1/61,988 | 4,576/16,348,907 | 0.06 | 1.37e-06 | 9.52e-06 |
| Entire coronary sinus:0 | 1/61,988 | 5,283/16,348,907 | 0.05 | 1.11e-07 | 8.83e-07 |
| Epigenetic Process:0 | 63/61,988 | 3,895/16,348,907 | 4.27 | 1.56e-20 | 3.04e-19 |
| Estrogens:0 | 1,215/61,988 | 98,867/16,348,907 | 3.29 | 4.30e-259 | 8.91e-257 |
| Slide:0 | 101/61,988 | 10,864/16,348,907 | 2.45 | 4.13e-15 | 5.95e-14 |
| Bronchoalveolar Lavage:0 | 5/61,988 | 7,477/16,348,907 | 0.18 | 2.21e-07 | 1.70e-06 |
| Sickle Cell Anemia:0 | 6/61,988 | 33,065/16,348,907 | 0.05 | 4.99e-45 | 2.04e-43 |
| Erectile dysfunction:0 | 549/61,988 | 22,316/16,348,907 | 6.54 | 2.81e-245 | 5.47e-243 |
| Perineal prostatectomy:0 | 23/61,988 | 48/16,348,907 | 126.42 | 4.18e-38 | 1.45e-36 |
| Receptors, Cell Surface:0 | 69/61,988 | 7,797/16,348,907 | 2.34 | 5.39e-10 | 5.42e-09 |
| Students, Medical:0 | 3/61,988 | 7,181/16,348,907 | 0.11 | 1.21e-08 | 1.07e-07 |
| Entire prostatic fascia:0 | 11/61,988 | 32/16,348,907 | 90.68 | 1.15e-17 | 1.90e-16 |
| HIGH SENSITIVITY:0 | 76/61,988 | 6,654/16,348,907 | 3.01 | 3.63e-16 | 5.56e-15 |
| Prostate Lymphoma:0 | 10/61,988 | 13/16,348,907 | 202.91 | 6.46e-19 | 1.15e-17 |
| Bradykinin:0 | 20/61,988 | 20,704/16,348,907 | 0.25 | 6.48e-15 | 9.21e-14 |
| BCL-2 Protein:0 | 139/61,988 | 7,357/16,348,907 | 4.99 | 1.77e-50 | 8.10e-49 |
| AKAP12:0 | 9/61,988 | 187/16,348,907 | 12.70 | 8.10e-08 | 6.51e-07 |
| Vimentin:0 | 52/61,988 | 4,262/16,348,907 | 3.22 | 1.36e-12 | 1.65e-11 |
| Oncology Group:0 | 21/61,988 | 255/16,348,907 | 21.73 | 8.54e-21 | 1.68e-19 |
| Self Administration:0 | 3/61,988 | 10,664/16,348,907 | 0.07 | 5.83e-14 | 7.82e-13 |
| Ursodeoxycholic Acid:0 | 3/61,988 | 7,661/16,348,907 | 0.10 | 2.11e-09 | 2.01e-08 |
| Squamous metaplasia:0 | 18/61,988 | 881/16,348,907 | 5.39 | 2.04e-08 | 1.75e-07 |
| Therapy-Associated Cancer:0 | 5/61,988 | 36/16,348,907 | 36.63 | 5.14e-07 | 3.79e-06 |
| Preoptic Areas:0 | 1/61,988 | 5,387/16,348,907 | 0.05 | 4.92e-08 | 4.06e-07 |
| Chronic inflammation:0 | 161/61,988 | 15,739/16,348,907 | 2.70 | 2.58e-27 | 6.53e-26 |
| Retinal Diseases:0 | 8/61,988 | 17,498/16,348,907 | 0.12 | 3.99e-19 | 7.20e-18 |
| Soft tissue lesion:0 | 16/61,988 | 530/16,348,907 | 7.96 | 6.24e-10 | 6.23e-09 |
| Stereotactic radiotherapy:0 | 108/61,988 | 4,918/16,348,907 | 5.80 | 2.59e-45 | 1.07e-43 |
| Adipose tissue:0 | 50/61,988 | 43,666/16,348,907 | 0.30 | 9.81e-26 | 2.35e-24 |
| Systemic infection:0 | 1/61,988 | 6,228/16,348,907 | 0.04 | 2.78e-09 | 2.62e-08 |
| Verapamil:0 | 15/61,988 | 26,283/16,348,907 | 0.15 | 8.81e-26 | 2.12e-24 |
| oncoprotein p21:0 | 15/61,988 | 249/16,348,907 | 15.89 | 2.02e-13 | 2.62e-12 |
| 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole:0 | 36/61,988 | 3,439/16,348,907 | 2.76 | 1.36e-07 | 1.07e-06 |
| ADAM9:0 | 11/61,988 | 297/16,348,907 | 9.77 | 3.96e-08 | 3.30e-07 |
| Normal cell:0 | 444/61,988 | 15,779/16,348,907 | 7.47 | 1.54e-220 | 2.75e-218 |
| Urokinase|PLG:0 | 15/61,988 | 344/16,348,907 | 11.50 | 1.62e-11 | 1.84e-10 |
| Vaccines, Attenuated:0 | 4/61,988 | 7,504/16,348,907 | 0.14 | 2.75e-08 | 2.34e-07 |
| Memory impairment:0 | 2/61,988 | 13,896/16,348,907 | 0.04 | 4.05e-20 | 7.70e-19 |
| Hereditary Diseases:0 | 32/61,988 | 25,666/16,348,907 | 0.33 | 2.89e-14 | 3.94e-13 |
| Inferior Colliculus:0 | 190/61,988 | 31,602/16,348,907 | 1.59 | 3.07e-09 | 2.88e-08 |
| Rectal pain:0 | 10/61,988 | 141/16,348,907 | 18.71 | 4.56e-10 | 4.63e-09 |
| Hypoplasia:0 | 6/61,988 | 16,242/16,348,907 | 0.10 | 3.17e-19 | 5.74e-18 |
| Lymphoid Cells:0 | 7/61,988 | 8,145/16,348,907 | 0.23 | 4.95e-07 | 3.66e-06 |
| Testosterone measurement:0 | 73/61,988 | 1,052/16,348,907 | 18.32 | 2.88e-63 | 1.62e-61 |
| Transitional epithelium:0 | 19/61,988 | 588/16,348,907 | 8.52 | 5.27e-12 | 6.21e-11 |
| Tomography, Optical Coherence:0 | 16/61,988 | 12,770/16,348,907 | 0.33 | 1.12e-07 | 8.84e-07 |
| Steroid 17-alpha-monooxygenase|CYP17A1:0 | 123/61,988 | 1,391/16,348,907 | 23.37 | 3.43e-117 | 3.41e-115 |
| Diastasis:0 | 49/61,988 | 36,223/16,348,907 | 0.36 | 7.95e-18 | 1.33e-16 |
| Avodart:0 | 7/61,988 | 32/16,348,907 | 57.70 | 1.52e-10 | 1.60e-09 |
| Androgen Suppression:0 | 376/61,988 | 1,047/16,348,907 | 95.29 | 0.00e+00 | 0.00e+00 |
| Acute myocardial infarction:0 | 25/61,988 | 70,477/16,348,907 | 0.09 | 6.24e-81 | 4.28e-79 |
| Matrigel Invasion Assay:0 | 10/61,988 | 80/16,348,907 | 32.97 | 2.57e-12 | 3.07e-11 |
| Rectourinary fistula:0 | 9/61,988 | 24/16,348,907 | 98.92 | 5.56e-15 | 7.95e-14 |
| Immunoassay:0 | 96/61,988 | 10,682/16,348,907 | 2.37 | 1.27e-13 | 1.68e-12 |
| Atresia:0 | 4/61,988 | 12,187/16,348,907 | 0.09 | 3.79e-15 | 5.49e-14 |
| CRISP-3 protein:0 | 11/61,988 | 60/16,348,907 | 48.36 | 4.64e-15 | 6.67e-14 |
| GGCT:0 | 9/61,988 | 158/16,348,907 | 15.03 | 2.05e-08 | 1.75e-07 |
| Acute respiratory failure:0 | 1/61,988 | 6,487/16,348,907 | 0.04 | 9.20e-10 | 9.05e-09 |
| VEGFA:0 | 176/61,988 | 18,757/16,348,907 | 2.48 | 1.25e-25 | 2.98e-24 |
| Radioimmunotherapy:0 | 41/61,988 | 2,624/16,348,907 | 4.12 | 1.82e-13 | 2.36e-12 |
| Androgen Receptor|AR:0 | 2,483/61,988 | 13,713/16,348,907 | 49.71 | 0.00e+00 | 0.00e+00 |
| androgen binding:0 | 7/61,988 | 43/16,348,907 | 42.94 | 9.50e-10 | 9.31e-09 |
| Bone Diseases:0 | 139/61,988 | 7,501/16,348,907 | 4.90 | 1.49e-49 | 6.74e-48 |
| Cerebrovascular Circulation:0 | 1/61,988 | 17,649/16,348,907 | 0.01 | 1.07e-27 | 2.72e-26 |
| Staphylococcus aureus:0 | 7/61,988 | 31,303/16,348,907 | 0.06 | 5.42e-41 | 2.03e-39 |
| Selective Estrogen Receptor Modulators:0 | 62/61,988 | 4,129/16,348,907 | 3.96 | 1.01e-18 | 1.77e-17 |
| caveolin 1:0 | 106/61,988 | 7,004/16,348,907 | 4.00 | 4.66e-31 | 1.31e-29 |
| PTGS2 gene|PTGS2:0 | 43/61,988 | 2,038/16,348,907 | 5.57 | 1.83e-18 | 3.18e-17 |
| Malignant neoplasm of gastrointestinal tract:0 | 57/61,988 | 5,283/16,348,907 | 2.85 | 1.33e-11 | 1.52e-10 |
| BCL1 Oncogene:0 | 47/61,988 | 2,305/16,348,907 | 5.38 | 1.84e-19 | 3.36e-18 |
| Dyspnea:0 | 22/61,988 | 17,378/16,348,907 | 0.33 | 6.61e-10 | 6.57e-09 |
| zinc transporter:0 | 25/61,988 | 668/16,348,907 | 9.87 | 1.03e-16 | 1.63e-15 |
| Estrogenic effect:0 | 18/61,988 | 1,159/16,348,907 | 4.10 | 1.02e-06 | 7.22e-06 |
| Rat Cell Line:0 | 91/61,988 | 5,998/16,348,907 | 4.01 | 5.51e-27 | 1.38e-25 |
| Burn injury:0 | 5/61,988 | 22,243/16,348,907 | 0.06 | 1.65e-29 | 4.47e-28 |
| BRCA1 gene|BRCA1:0 | 192/61,988 | 11,821/16,348,907 | 4.29 | 3.20e-59 | 1.70e-57 |
| Lactoferrin:0 | 14/61,988 | 15,063/16,348,907 | 0.24 | 1.79e-11 | 2.02e-10 |
| Measurement:0 | 177/61,988 | 30,952/16,348,907 | 1.51 | 2.63e-07 | 2.01e-06 |
| Provenge:0 | 18/61,988 | 28/16,348,907 | 169.60 | 6.23e-32 | 1.82e-30 |
| Chondrocytes:0 | 6/61,988 | 28,053/16,348,907 | 0.06 | 2.81e-37 | 9.54e-36 |
| Total Peripheral Resistance:0 | 1/61,988 | 4,941/16,348,907 | 0.05 | 3.08e-07 | 2.33e-06 |
| AMACR gene|AMACR:0 | 24/61,988 | 66/16,348,907 | 95.94 | 2.45e-37 | 8.33e-36 |
| Dorsal grey horn:0 | 3/61,988 | 12,578/16,348,907 | 0.06 | 6.99e-17 | 1.12e-15 |
| Proteoglycan:0 | 36/61,988 | 22,352/16,348,907 | 0.42 | 4.29e-09 | 3.94e-08 |
| cancer radiation therapy:0 | 7/61,988 | 49/16,348,907 | 37.68 | 2.16e-09 | 2.06e-08 |
| Triptorelin|TYRP1:0 | 31/61,988 | 61/16,348,907 | 134.10 | 1.85e-51 | 8.63e-50 |
| Antipsychotic Agents:0 | 8/61,988 | 43,217/16,348,907 | 0.05 | 2.02e-58 | 1.07e-56 |
| Glutamine:0 | 40/61,988 | 22,670/16,348,907 | 0.47 | 5.25e-08 | 4.32e-07 |
| Adrenergic Receptor:0 | 47/61,988 | 34,819/16,348,907 | 0.36 | 2.67e-17 | 4.35e-16 |
| Prostate infection:0 | 13/61,988 | 84/16,348,907 | 40.83 | 1.10e-16 | 1.75e-15 |
| c-myc Genes|MYC:0 | 239/61,988 | 18,126/16,348,907 | 3.49 | 2.45e-57 | 1.26e-55 |
| Periodontitis:0 | 6/61,988 | 25,059/16,348,907 | 0.06 | 1.21e-32 | 3.61e-31 |
| beta-Galactosidase|GLA:0 | 4/61,988 | 4/16,348,907 | 263.76 | 1.41e-08 | 1.23e-07 |
| Needle device:0 | 88/61,988 | 4,224/16,348,907 | 5.50 | 1.30e-35 | 4.16e-34 |
| Cancer of Rectum:0 | 205/61,988 | 23,945/16,348,907 | 2.26 | 8.83e-25 | 2.03e-23 |
| Virion:0 | 6/61,988 | 17,570/16,348,907 | 0.09 | 3.55e-21 | 7.08e-20 |
| Dihydrofolate Reductase|DHFR:0 | 5/61,988 | 6,923/16,348,907 | 0.19 | 1.08e-06 | 7.63e-06 |
| peptide hormone:0 | 62/61,988 | 4,578/16,348,907 | 3.57 | 1.10e-16 | 1.74e-15 |
| Free testosterone:0 | 92/61,988 | 2,177/16,348,907 | 11.16 | 2.33e-61 | 1.27e-59 |
| Lymphocyte antigen CD82|CD82:0 | 20/61,988 | 181/16,348,907 | 29.15 | 3.25e-22 | 6.75e-21 |
| Dendrites:0 | 5/61,988 | 19,037/16,348,907 | 0.07 | 2.19e-24 | 4.95e-23 |
| Uterine Cancer:0 | 34/61,988 | 1,725/16,348,907 | 5.20 | 4.03e-14 | 5.46e-13 |
| Urinary Diversion:0 | 137/61,988 | 3,551/16,348,907 | 10.20 | 1.17e-85 | 8.41e-84 |
| RASSF1:0 | 10/61,988 | 182/16,348,907 | 14.49 | 4.68e-09 | 4.29e-08 |
| 1-Phosphatidylinositol 3-Kinase:0 | 183/61,988 | 17,867/16,348,907 | 2.71 | 7.25e-31 | 2.03e-29 |
| Granulocyte Colony-Stimulating Factor:0 | 23/61,988 | 15,790/16,348,907 | 0.38 | 8.66e-08 | 6.95e-07 |
| Sodium Chloride:0 | 102/61,988 | 131,341/16,348,907 | 0.20 | 8.70e-104 | 7.33e-102 |
| Hepatitis B:0 | 9/61,988 | 15,017/16,348,907 | 0.16 | 7.25e-15 | 1.03e-13 |
| Steroids:0 | 631/61,988 | 56,869/16,348,907 | 2.95 | 3.74e-116 | 3.64e-114 |
| Hypertensive:0 | 23/61,988 | 68,876/16,348,907 | 0.09 | 1.09e-80 | 7.45e-79 |
| Phase I/II Trial:0 | 14/61,988 | 148/16,348,907 | 24.95 | 3.93e-15 | 5.69e-14 |
| HK2 gene|HK2:0 | 47/61,988 | 411/16,348,907 | 30.18 | 1.11e-50 | 5.09e-49 |
| Alpha tocopheryl succinate:0 | 16/61,988 | 519/16,348,907 | 8.13 | 4.66e-10 | 4.72e-09 |
| Cell Surface Proteins:0 | 34/61,988 | 2,915/16,348,907 | 3.08 | 2.57e-08 | 2.18e-07 |
| 5-Alpha reductase inhibitor:0 | 115/61,988 | 837/16,348,907 | 36.30 | 8.46e-130 | 9.46e-128 |
| Entire ear:0 | 7/61,988 | 21,238/16,348,907 | 0.09 | 1.05e-25 | 2.51e-24 |
| Vesico-Ureteral Reflux:0 | 8/61,988 | 8,822/16,348,907 | 0.24 | 3.36e-07 | 2.53e-06 |
| Carcinosarcoma:0 | 52/61,988 | 4,105/16,348,907 | 3.34 | 3.49e-13 | 4.42e-12 |
| VAV3 gene|VAV3:0 | 17/61,988 | 319/16,348,907 | 14.06 | 3.43e-14 | 4.67e-13 |
| Physical therapy:0 | 16/61,988 | 11,805/16,348,907 | 0.36 | 1.32e-06 | 9.23e-06 |
| Memorial Sloan-Kettering Cancer Center:0 | 23/61,988 | 191/16,348,907 | 31.77 | 4.24e-26 | 1.03e-24 |
| Weighing patient:0 | 71/61,988 | 2,364/16,348,907 | 7.93 | 1.59e-38 | 5.60e-37 |
| Dermatitis, Atopic:0 | 4/61,988 | 35,920/16,348,907 | 0.03 | 2.11e-52 | 1.00e-50 |
| Prior Hormone Therapy:0 | 18/61,988 | 39/16,348,907 | 121.76 | 6.60e-30 | 1.81e-28 |
| [X]Injury of blood vessel(s) of unspecified body region:0 | 2/61,988 | 5,348/16,348,907 | 0.10 | 9.24e-07 | 6.60e-06 |
| Households:0 | 7/61,988 | 11,485/16,348,907 | 0.16 | 1.70e-11 | 1.92e-10 |
| Delirium:0 | 4/61,988 | 11,265/16,348,907 | 0.09 | 8.62e-14 | 1.14e-12 |
| R-flurbiprofen:0 | 7/61,988 | 130/16,348,907 | 14.20 | 1.10e-06 | 7.75e-06 |
| Radiation-Induced Change:0 | 77/61,988 | 2,853/16,348,907 | 7.13 | 1.42e-38 | 5.01e-37 |
| Ceramics:0 | 2/61,988 | 9,239/16,348,907 | 0.06 | 9.11e-13 | 1.12e-11 |
| Incontinence:0 | 332/61,988 | 9,316/16,348,907 | 9.44 | 7.80e-195 | 1.27e-192 |
| Transcription, Genetic:0 | 864/61,988 | 90,323/16,348,907 | 2.54 | 3.20e-123 | 3.39e-121 |
| Peptidyl-Dipeptidase A:0 | 13/61,988 | 22,478/16,348,907 | 0.15 | 5.48e-22 | 1.13e-20 |
| Myosin Heavy Chains:0 | 7/61,988 | 8,891/16,348,907 | 0.21 | 5.51e-08 | 4.52e-07 |
| Surface Enhanced Laser Desorption Ionization Mass Spectrometry:0 | 14/61,988 | 309/16,348,907 | 11.95 | 4.69e-11 | 5.17e-10 |
| Nurses:0 | 58/61,988 | 32,452/16,348,907 | 0.47 | 1.05e-10 | 1.12e-09 |
| Urologic Neoplasms:0 | 35/61,988 | 359/16,348,907 | 25.73 | 5.97e-36 | 1.94e-34 |
| Aminoglutethimide:0 | 46/61,988 | 2,301/16,348,907 | 5.28 | 9.17e-19 | 1.62e-17 |
| Tumor Markers:0 | 361/61,988 | 5,491/16,348,907 | 17.44 | 7.45e-298 | 1.76e-295 |
| Performance Status:0 | 120/61,988 | 5,009/16,348,907 | 6.33 | 6.86e-54 | 3.34e-52 |
| Agent Orange:0 | 12/61,988 | 161/16,348,907 | 19.66 | 4.88e-12 | 5.76e-11 |
| Entire portal vein:0 | 2/61,988 | 11,822/16,348,907 | 0.04 | 8.02e-17 | 1.28e-15 |
| Adenocarcinoma of the prostate metastatic:0 | 79/61,988 | 107/16,348,907 | 194.97 | 1.76e-138 | 2.09e-136 |
| Urothelial Cell:0 | 27/61,988 | 1,967/16,348,907 | 3.62 | 2.89e-08 | 2.45e-07 |
| Palate:0 | 3/61,988 | 14,988/16,348,907 | 0.05 | 1.35e-20 | 2.63e-19 |
| Tuberculosis:0 | 31/61,988 | 90,519/16,348,907 | 0.09 | 6.91e-105 | 5.94e-103 |
| Holmium:YAG laser device:0 | 31/61,988 | 1,019/16,348,907 | 8.03 | 6.58e-18 | 1.11e-16 |
| Screening procedure:0 | 789/61,988 | 59,844/16,348,907 | 3.51 | 2.58e-185 | 4.03e-183 |
| Gait:0 | 3/61,988 | 6,524/16,348,907 | 0.12 | 9.25e-08 | 7.40e-07 |
| SUBCUTANEOUS TUMOR:0 | 29/61,988 | 610/16,348,907 | 12.54 | 7.96e-22 | 1.62e-20 |
| Fluoxetine:0 | 2/61,988 | 17,857/16,348,907 | 0.03 | 2.04e-26 | 5.02e-25 |
| Nkx-3.1 protein|NKX3-1:0 | 57/61,988 | 135/16,348,907 | 111.46 | 1.52e-89 | 1.12e-87 |
| AMACR protein, human|AMACR:0 | 58/61,988 | 140/16,348,907 | 109.37 | 1.08e-90 | 8.23e-89 |
| Adenoviruses:0 | 172/61,988 | 14,506/16,348,907 | 3.13 | 2.83e-36 | 9.39e-35 |
| Ultrasonic guidance procedure:0 | 38/61,988 | 849/16,348,907 | 11.81 | 3.34e-27 | 8.41e-26 |
| Dairy Products:0 | 35/61,988 | 827/16,348,907 | 11.17 | 2.01e-24 | 4.55e-23 |
| Estracyt:0 | 102/61,988 | 287/16,348,907 | 93.89 | 1.71e-152 | 2.26e-150 |
| Entire facial nerve:0 | 2/61,988 | 5,977/16,348,907 | 0.09 | 7.38e-08 | 5.96e-07 |
| sarcoma:0 | 305/61,988 | 41,508/16,348,907 | 1.94 | 2.19e-25 | 5.18e-24 |
| Selenium:0 | 304/61,988 | 23,060/16,348,907 | 3.49 | 2.06e-72 | 1.29e-70 |
| Sleep Apnea Syndromes:0 | 6/61,988 | 10,816/16,348,907 | 0.15 | 2.15e-11 | 2.42e-10 |
| Dermis:0 | 9/61,988 | 9,975/16,348,907 | 0.24 | 4.77e-08 | 3.95e-07 |
| Kidney Transplantation:0 | 38/61,988 | 21,569/16,348,907 | 0.46 | 1.14e-07 | 9.06e-07 |
| epigallocatechin gallate:0 | 157/61,988 | 15,409/16,348,907 | 2.69 | 1.65e-26 | 4.06e-25 |
| Chest Pain:0 | 3/61,988 | 15,084/16,348,907 | 0.05 | 9.42e-21 | 1.85e-19 |
| Entire prostate:0 | 61/61,988 | 109/16,348,907 | 147.74 | 1.03e-101 | 8.60e-100 |
| Acute suppurative arthritis due to bacteria:0 | 4/61,988 | 7,302/16,348,907 | 0.14 | 5.39e-08 | 4.43e-07 |
| NCOA4 gene|NCOA4:0 | 5/61,988 | 21/16,348,907 | 62.80 | 4.73e-08 | 3.92e-07 |
| Methylation:0 | 118/61,988 | 5,655/16,348,907 | 5.51 | 3.30e-47 | 1.42e-45 |
| Gonadotropin-Releasing Hormone Receptor:0 | 124/61,988 | 3,242/16,348,907 | 10.11 | 2.70e-77 | 1.78e-75 |
| Recombinant DNA:0 | 12/61,988 | 11,217/16,348,907 | 0.28 | 7.78e-08 | 6.27e-07 |
| Complementary therapies:0 | 27/61,988 | 1,841/16,348,907 | 3.87 | 7.72e-09 | 6.95e-08 |
| ITGB2 gene|ITGB2:0 | 2/61,988 | 5,248/16,348,907 | 0.10 | 1.31e-06 | 9.16e-06 |
| polyphenols:0 | 91/61,988 | 9,715/16,348,907 | 2.47 | 5.06e-14 | 6.81e-13 |
| Listeria monocytogenes:0 | 1/61,988 | 5,333/16,348,907 | 0.05 | 7.23e-08 | 5.85e-07 |
| Residual function:0 | 1/61,988 | 4,610/16,348,907 | 0.06 | 8.85e-07 | 6.35e-06 |
| CPA4 gene|CPA4:0 | 4/61,988 | 14/16,348,907 | 75.36 | 5.97e-07 | 4.37e-06 |
| Infestation:0 | 7/61,988 | 9,567/16,348,907 | 0.19 | 8.45e-09 | 7.57e-08 |
| Total urinary incontinence:0 | 11/61,988 | 131/16,348,907 | 22.15 | 1.13e-11 | 1.30e-10 |
| Bacterial Endocarditis:0 | 3/61,988 | 12,510/16,348,907 | 0.06 | 1.02e-16 | 1.62e-15 |
| Steroid hormone:0 | 201/61,988 | 9,653/16,348,907 | 5.51 | 5.81e-79 | 3.91e-77 |
| abarelix:0 | 28/61,988 | 102/16,348,907 | 72.43 | 2.19e-40 | 8.04e-39 |
| Chronic liver disease NOS:0 | 4/61,988 | 18,493/16,348,907 | 0.06 | 8.15e-25 | 1.88e-23 |
| Ovary:0 | 445/61,988 | 63,209/16,348,907 | 1.86 | 2.01e-32 | 5.95e-31 |
| Reverse Transcriptase Polymerase Chain Reaction:0 | 333/61,988 | 19,373/16,348,907 | 4.55 | 1.24e-107 | 1.09e-105 |
| Management procedure:0 | 532/61,988 | 87,451/16,348,907 | 1.61 | 3.99e-24 | 8.91e-23 |
| RNase L|RNASEL:0 | 25/61,988 | 850/16,348,907 | 7.76 | 1.98e-14 | 2.74e-13 |
| NKX3-1 gene|NKX3-1:0 | 100/61,988 | 278/16,348,907 | 95.02 | 5.57e-150 | 7.17e-148 |
| Arthritis, Psoriatic:0 | 1/61,988 | 11,231/16,348,907 | 0.02 | 3.73e-17 | 6.05e-16 |
| TACSTD2 protein, human|TACSTD2:0 | 54/61,988 | 1,802/16,348,907 | 7.91 | 1.14e-29 | 3.11e-28 |
| Hormone-refractory prostate cancer:0 | 1,488/61,988 | 3,646/16,348,907 | 110.26 | 0.00e+00 | 0.00e+00 |
| Hypoglycemic Agents:0 | 5/61,988 | 8,449/16,348,907 | 0.16 | 7.86e-09 | 7.07e-08 |
| DN-101:0 | 7/61,988 | 10/16,348,907 | 184.64 | 2.06e-13 | 2.67e-12 |
| Adverse event:0 | 182/61,988 | 25,166/16,348,907 | 1.91 | 3.51e-15 | 5.09e-14 |
| Anandron:0 | 35/61,988 | 134/16,348,907 | 68.93 | 1.99e-49 | 8.93e-48 |
| lissamine rhodamine B:0 | 46/61,988 | 675/16,348,907 | 17.99 | 3.52e-40 | 1.29e-38 |
| 8q24:0 | 105/61,988 | 542/16,348,907 | 51.18 | 8.23e-133 | 9.36e-131 |
| Urinary tract:0 | 130/61,988 | 4,833/16,348,907 | 7.11 | 1.02e-63 | 5.78e-62 |
| Avulsed wound:0 | 3/61,988 | 6,821/16,348,907 | 0.12 | 3.31e-08 | 2.79e-07 |
| Glucagon-Like Peptide 1:0 | 1/61,988 | 6,583/16,348,907 | 0.04 | 6.40e-10 | 6.38e-09 |
| Starch:0 | 8/61,988 | 14,654/16,348,907 | 0.14 | 5.00e-15 | 7.18e-14 |
| Interleukin 2 Receptor:0 | 6/61,988 | 7,575/16,348,907 | 0.21 | 7.60e-07 | 5.50e-06 |
| Dipyridamole:0 | 8/61,988 | 8,580/16,348,907 | 0.25 | 6.10e-07 | 4.46e-06 |
| Narcotic Antagonists:0 | 4/61,988 | 6,419/16,348,907 | 0.16 | 1.12e-06 | 7.88e-06 |
| Animal fat:0 | 16/61,988 | 404/16,348,907 | 10.45 | 1.37e-11 | 1.56e-10 |
| School child:0 | 1/61,988 | 15,822/16,348,907 | 0.02 | 1.17e-24 | 2.67e-23 |
| Sedation:0 | 5/61,988 | 11,355/16,348,907 | 0.12 | 6.54e-13 | 8.12e-12 |
| Dietary Supplements:0 | 24/61,988 | 1,025/16,348,907 | 6.18 | 6.76e-12 | 7.89e-11 |
| Cancer Treatment:0 | 929/61,988 | 14,359/16,348,907 | 17.31 | 0.00e+00 | 0.00e+00 |
| Protein Overexpression:0 | 48/61,988 | 2,895/16,348,907 | 4.38 | 1.96e-16 | 3.04e-15 |
| Contact Inhibition:0 | 15/61,988 | 794/16,348,907 | 4.98 | 7.72e-07 | 5.57e-06 |
| Interferon-alpha:0 | 42/61,988 | 31,276/16,348,907 | 0.35 | 8.87e-16 | 1.33e-14 |
| Brain Edema:0 | 1/61,988 | 6,056/16,348,907 | 0.04 | 5.94e-09 | 5.40e-08 |
| Cytokinesis of the fertilized ovum:0 | 241/61,988 | 37,468/16,348,907 | 1.70 | 3.87e-14 | 5.25e-13 |
| Left atrial structure:0 | 2/61,988 | 10,491/16,348,907 | 0.05 | 8.32e-15 | 1.18e-13 |
| T-Lymphocytes, Cytotoxic:0 | 85/61,988 | 12,428/16,348,907 | 1.80 | 5.91e-07 | 4.33e-06 |
| Erythrocytes:0 | 82/61,988 | 129,624/16,348,907 | 0.17 | 5.22e-116 | 5.06e-114 |
| Morphine:0 | 34/61,988 | 53,357/16,348,907 | 0.17 | 3.05e-48 | 1.34e-46 |
| Epirubicin:0 | 49/61,988 | 5,942/16,348,907 | 2.18 | 1.31e-06 | 9.14e-06 |
| Craniocerebral Trauma:0 | 2/61,988 | 15,264/16,348,907 | 0.03 | 2.51e-22 | 5.23e-21 |
| Specific antigen:0 | 61/61,988 | 4,234/16,348,907 | 3.80 | 1.23e-17 | 2.04e-16 |
| Liver damage:0 | 14/61,988 | 11,372/16,348,907 | 0.32 | 5.26e-07 | 3.87e-06 |
| Glucocorticoids:0 | 101/61,988 | 49,055/16,348,907 | 0.54 | 1.34e-11 | 1.53e-10 |
| CXCL12 gene|CXCL12:0 | 23/61,988 | 915/16,348,907 | 6.63 | 4.65e-12 | 5.49e-11 |
| Blotting, Western:0 | 181/61,988 | 12,727/16,348,907 | 3.76 | 3.78e-48 | 1.67e-46 |
| Fatty Liver:0 | 7/61,988 | 15,346/16,348,907 | 0.12 | 4.98e-17 | 8.00e-16 |
| Autism spectrum disorder:0 | 3/61,988 | 23,464/16,348,907 | 0.03 | 7.06e-34 | 2.17e-32 |
| Diabetes Mellitus:0 | 141/61,988 | 70,996/16,348,907 | 0.52 | 1.23e-17 | 2.04e-16 |
| Mycotoxins:0 | 4/61,988 | 8,150/16,348,907 | 0.13 | 3.73e-09 | 3.46e-08 |
| Prednisone 5 MG:0 | 9/61,988 | 15/16,348,907 | 158.27 | 1.94e-16 | 3.02e-15 |
| PTEN gene|PTEN:0 | 603/61,988 | 16,075/16,348,907 | 9.98 | 0.00e+00 | 0.00e+00 |
| Syphilis:0 | 4/61,988 | 9,037/16,348,907 | 0.12 | 1.70e-10 | 1.79e-09 |
| Growth delay:0 | 43/61,988 | 1,496/16,348,907 | 7.59 | 2.68e-23 | 5.84e-22 |
| Stenosis, unspecified:0 | 38/61,988 | 48,746/16,348,907 | 0.21 | 3.68e-39 | 1.32e-37 |
| Cholestasis:0 | 5/61,988 | 11,909/16,348,907 | 0.11 | 8.05e-14 | 1.07e-12 |
| Hospitals:0 | 401/61,988 | 81,268/16,348,907 | 1.30 | 4.02e-07 | 3.00e-06 |
| Early Diagnosis:0 | 504/61,988 | 18,626/16,348,907 | 7.19 | 7.64e-243 | 1.48e-240 |
| Axon:0 | 11/61,988 | 44,507/16,348,907 | 0.07 | 8.48e-57 | 4.32e-55 |
| ATP phosphohydrolase:0 | 21/61,988 | 21,057/16,348,907 | 0.26 | 1.06e-14 | 1.48e-13 |
| Ro 28-2653:0 | 5/61,988 | 37/16,348,907 | 35.64 | 5.82e-07 | 4.27e-06 |
| Entire lumbar disc:0 | 1/61,988 | 7,267/16,348,907 | 0.04 | 7.90e-11 | 8.54e-10 |
| Cardiopulmonary:0 | 1/61,988 | 6,633/16,348,907 | 0.04 | 6.58e-10 | 6.55e-09 |
| Doxorubicin:0 | 361/61,988 | 45,594/16,348,907 | 2.09 | 1.01e-35 | 3.24e-34 |
| agonists:0 | 764/61,988 | 90,321/16,348,907 | 2.25 | 1.26e-85 | 9.04e-84 |
| Overtreated:0 | 6/61,988 | 48/16,348,907 | 32.97 | 6.42e-08 | 5.23e-07 |
| IMMUNOHISTOCHEMICAL:0 | 142/61,988 | 6,908/16,348,907 | 5.43 | 1.09e-55 | 5.50e-54 |
| Psychotic Disorders:0 | 2/61,988 | 33,047/16,348,907 | 0.02 | 7.42e-51 | 3.42e-49 |
| Osteosclerosis:0 | 20/61,988 | 999/16,348,907 | 5.28 | 4.81e-09 | 4.41e-08 |
| Silence:0 | 272/61,988 | 16,378/16,348,907 | 4.40 | 3.97e-85 | 2.84e-83 |
| Tissue fiber:0 | 35/61,988 | 44,822/16,348,907 | 0.21 | 3.96e-36 | 1.30e-34 |
| Allelic Imbalance:0 | 23/61,988 | 579/16,348,907 | 10.48 | 4.98e-16 | 7.55e-15 |
| Misoprostol:0 | 3/61,988 | 9,987/16,348,907 | 0.08 | 6.92e-13 | 8.59e-12 |
| PROTECTION:0 | 121/61,988 | 50,769/16,348,907 | 0.63 | 4.31e-08 | 3.57e-07 |
| Culture Media, Conditioned:0 | 44/61,988 | 2,677/16,348,907 | 4.34 | 4.51e-15 | 6.49e-14 |
| 3' Untranslated Regions:0 | 109/61,988 | 8,846/16,348,907 | 3.25 | 6.92e-25 | 1.60e-23 |
| Hereditary Malignant Neoplasm:0 | 71/61,988 | 4,972/16,348,907 | 3.77 | 4.74e-20 | 8.95e-19 |
| Pregnant Women:0 | 10/61,988 | 65,502/16,348,907 | 0.04 | 6.69e-91 | 5.08e-89 |
| Variation (Genetics):0 | 46/61,988 | 4,278/16,348,907 | 2.84 | 1.27e-09 | 1.23e-08 |
| Fibril:0 | 1/61,988 | 7,362/16,348,907 | 0.04 | 5.45e-11 | 5.96e-10 |
| Leuprolide Acetate:0 | 130/61,988 | 1,845/16,348,907 | 18.62 | 5.00e-112 | 4.65e-110 |
| Bladder neck sclerosis:0 | 7/61,988 | 51/16,348,907 | 36.20 | 2.79e-09 | 2.62e-08 |
| MCAM gene|MCAM:0 | 17/61,988 | 1,060/16,348,907 | 4.23 | 1.31e-06 | 9.18e-06 |
| Generalized Anxiety Disorder:0 | 1/61,988 | 7,854/16,348,907 | 0.03 | 8.80e-12 | 1.02e-10 |
| Synovial Membrane:0 | 2/61,988 | 16,277/16,348,907 | 0.03 | 6.82e-24 | 1.51e-22 |
| HIV:0 | 22/61,988 | 45,079/16,348,907 | 0.13 | 1.81e-46 | 7.64e-45 |
| Head and neck structure:0 | 306/61,988 | 25,931/16,348,907 | 3.12 | 1.12e-62 | 6.20e-61 |
| Histone H3:0 | 63/61,988 | 4,130/16,348,907 | 4.03 | 2.55e-19 | 4.63e-18 |
| Gastric ulcer:0 | 9/61,988 | 12,559/16,348,907 | 0.19 | 1.80e-11 | 2.03e-10 |
| L-Selenomethionine:0 | 10/61,988 | 81/16,348,907 | 32.57 | 2.87e-12 | 3.43e-11 |
| Stress:0 | 127/61,988 | 69,387/16,348,907 | 0.48 | 1.71e-20 | 3.31e-19 |
| High Risk Populations:0 | 59/61,988 | 5,836/16,348,907 | 2.67 | 6.99e-11 | 7.58e-10 |
| MMP:0 | 50/61,988 | 5,953/16,348,907 | 2.22 | 5.03e-07 | 3.72e-06 |
| Amphetamine:0 | 51/61,988 | 44,263/16,348,907 | 0.30 | 8.59e-26 | 2.07e-24 |
| TRPM2:0 | 8/61,988 | 79/16,348,907 | 26.71 | 1.86e-09 | 1.78e-08 |
| Chlorpromazine:0 | 2/61,988 | 8,523/16,348,907 | 0.06 | 1.09e-11 | 1.25e-10 |
| Hyperlipidemia:0 | 376/61,988 | 17,455/16,348,907 | 5.71 | 1.34e-150 | 1.75e-148 |
| Prostatic nodule:0 | 32/61,988 | 43/16,348,907 | 196.37 | 3.90e-57 | 1.99e-55 |
| Estimated blood loss:0 | 26/61,988 | 432/16,348,907 | 15.88 | 3.84e-22 | 7.95e-21 |
| Ionophores:0 | 11/61,988 | 10,445/16,348,907 | 0.28 | 1.61e-07 | 1.25e-06 |
| Body of uterus:0 | 88/61,988 | 7,923/16,348,907 | 2.93 | 9.63e-18 | 1.60e-16 |
| Crosstalk:0 | 91/61,988 | 5,877/16,348,907 | 4.09 | 1.37e-27 | 3.49e-26 |
| Driving While Intoxicated:0 | 19/61,988 | 766/16,348,907 | 6.54 | 3.95e-10 | 4.03e-09 |
| TXNL4B:0 | 9/61,988 | 113/16,348,907 | 21.01 | 1.30e-09 | 1.26e-08 |
| Intestinal Diseases:0 | 6/61,988 | 7,493/16,348,907 | 0.21 | 1.07e-06 | 7.55e-06 |
| Radioimmunodetection:0 | 46/61,988 | 1,079/16,348,907 | 11.25 | 1.04e-31 | 3.02e-30 |
| oncoprotein p21|CDKN1A|SLC12A9:0 | 19/61,988 | 763/16,348,907 | 6.57 | 3.71e-10 | 3.79e-09 |
| Absence of pain sensation:0 | 9/61,988 | 16,178/16,348,907 | 0.15 | 1.93e-16 | 3.00e-15 |
| Biopsy gun:0 | 20/61,988 | 186/16,348,907 | 28.37 | 5.36e-22 | 1.10e-20 |
| Prostatic acinus:0 | 43/61,988 | 84/16,348,907 | 135.10 | 7.16e-71 | 4.39e-69 |
| ERG gene|ERG:0 | 249/61,988 | 1,893/16,348,907 | 34.83 | 1.44e-274 | 3.24e-272 |
| Carcinogens, Environmental:0 | 12/61,988 | 507/16,348,907 | 6.24 | 1.02e-06 | 7.22e-06 |
| Peritonitis:0 | 7/61,988 | 17,909/16,348,907 | 0.10 | 9.68e-21 | 1.90e-19 |
| Sildenafil citrate:0 | 28/61,988 | 1,601/16,348,907 | 4.61 | 9.49e-11 | 1.02e-09 |
| Paraneoplastic Syndromes:0 | 35/61,988 | 2,478/16,348,907 | 3.73 | 1.40e-10 | 1.48e-09 |
| high throughput analysis:0 | 18/61,988 | 1,084/16,348,907 | 4.38 | 4.01e-07 | 3.00e-06 |
| Vasculitis:0 | 8/61,988 | 20,241/16,348,907 | 0.10 | 3.97e-23 | 8.58e-22 |
| Hypertension, Pulmonary:0 | 3/61,988 | 32,936/16,348,907 | 0.02 | 4.73e-49 | 2.12e-47 |
| EAF2 gene|EAF2:0 | 5/61,988 | 23/16,348,907 | 57.34 | 7.03e-08 | 5.70e-07 |
| Immune Sera|ESR1|ERAL1:0 | 3/61,988 | 1/16,348,907 | 791.27 | 2.15e-07 | 1.65e-06 |
| Prostate cancer stage B:0 | 35/61,988 | 42/16,348,907 | 219.91 | 1.35e-63 | 7.63e-62 |
| 1q25:0 | 5/61,988 | 37/16,348,907 | 35.64 | 5.82e-07 | 4.27e-06 |
| Maximal urinary flow rate:0 | 8/61,988 | 97/16,348,907 | 21.75 | 8.34e-09 | 7.48e-08 |
| Meningitis:0 | 11/61,988 | 22,154/16,348,907 | 0.13 | 2.75e-23 | 5.99e-22 |
| White American:0 | 26/61,988 | 500/16,348,907 | 13.72 | 1.21e-20 | 2.36e-19 |
| histrelin:0 | 10/61,988 | 71/16,348,907 | 37.15 | 8.70e-13 | 1.07e-11 |
| Acquired Immunodeficiency Syndrome:0 | 86/61,988 | 95,671/16,348,907 | 0.24 | 3.19e-68 | 1.90e-66 |
| Immunoglobulins:0 | 47/61,988 | 46,117/16,348,907 | 0.27 | 3.44e-30 | 9.49e-29 |
| T-Cell Receptor:0 | 18/61,988 | 19,039/16,348,907 | 0.25 | 4.96e-14 | 6.69e-13 |
| Acetazolamide:0 | 1/61,988 | 6,316/16,348,907 | 0.04 | 1.92e-09 | 1.84e-08 |
| Ingestion:0 | 9/61,988 | 11,900/16,348,907 | 0.20 | 1.21e-10 | 1.29e-09 |
| Transcription Repressor/Corepressor:0 | 88/61,988 | 11,959/16,348,907 | 1.94 | 1.76e-08 | 1.52e-07 |
| QUANTUM:0 | 2/61,988 | 5,557/16,348,907 | 0.09 | 2.99e-07 | 2.27e-06 |
| Gleason Pattern 4:0 | 11/61,988 | 17/16,348,907 | 170.69 | 4.52e-20 | 8.55e-19 |
| Fructose:0 | 6/61,988 | 10,648/16,348,907 | 0.15 | 4.24e-11 | 4.69e-10 |
| sphingosine kinase-1:0 | 20/61,988 | 1,281/16,348,907 | 4.12 | 2.43e-07 | 1.86e-06 |
| Cystectomy:0 | 165/61,988 | 4,129/16,348,907 | 10.56 | 5.19e-105 | 4.48e-103 |
| Vasodilation:0 | 5/61,988 | 21,463/16,348,907 | 0.06 | 2.85e-28 | 7.42e-27 |
| Co-morbid conditions:0 | 44/61,988 | 3,682/16,348,907 | 3.15 | 1.26e-10 | 1.34e-09 |
| serine repeat antigen, Plasmodium:0 | 22/61,988 | 550/16,348,907 | 10.55 | 1.85e-15 | 2.73e-14 |
| Bipolar Disorder:0 | 7/61,988 | 34,877/16,348,907 | 0.05 | 1.40e-46 | 5.95e-45 |
| Prognostic Factor:0 | 576/61,988 | 20,896/16,348,907 | 7.33 | 2.89e-281 | 6.61e-279 |
| BAX gene|BAX:0 | 313/61,988 | 19,223/16,348,907 | 4.31 | 1.25e-95 | 9.86e-94 |
| Stratum corneum:0 | 3/61,988 | 6,500/16,348,907 | 0.12 | 1.38e-07 | 1.08e-06 |
| DELIVER:0 | 77/61,988 | 4,901/16,348,907 | 4.15 | 5.60e-24 | 1.24e-22 |
| Cytostat:0 | 15/61,988 | 609/16,348,907 | 6.50 | 2.89e-08 | 2.45e-07 |
| PubMed:0 | 135/61,988 | 6,212/16,348,907 | 5.74 | 1.10e-55 | 5.54e-54 |
| pT2 stage:0 | 6/61,988 | 15/16,348,907 | 105.51 | 1.50e-10 | 1.59e-09 |
| Therapeutic radioisotope:0 | 6/61,988 | 49/16,348,907 | 32.30 | 7.18e-08 | 5.82e-07 |
| ID1:0 | 25/61,988 | 1,505/16,348,907 | 4.38 | 2.52e-09 | 2.39e-08 |
| Bromocriptine:0 | 25/61,988 | 16,163/16,348,907 | 0.41 | 2.46e-07 | 1.88e-06 |
| Suramin:0 | 137/61,988 | 5,616/16,348,907 | 6.45 | 3.68e-62 | 2.03e-60 |
| Impotence:0 | 133/61,988 | 4,113/16,348,907 | 8.54 | 2.83e-74 | 1.82e-72 |
| Hypogonadism:0 | 184/61,988 | 4,420/16,348,907 | 11.01 | 8.69e-120 | 8.92e-118 |
| cell homeostasis:0 | 30/61,988 | 2,608/16,348,907 | 3.03 | 2.16e-07 | 1.66e-06 |
| Cytotoxic agent:0 | 160/61,988 | 6,824/16,348,907 | 6.20 | 5.40e-70 | 3.28e-68 |
| Sodium Nitroprusside:0 | 9/61,988 | 13,185/16,348,907 | 0.18 | 2.61e-12 | 3.12e-11 |
| Labels:0 | 136/61,988 | 19,114/16,348,907 | 1.88 | 2.90e-11 | 3.23e-10 |
| I Kappa B-Alpha:0 | 102/61,988 | 9,353/16,348,907 | 2.88 | 9.20e-20 | 1.71e-18 |
| radiation resistance:0 | 12/61,988 | 443/16,348,907 | 7.15 | 2.57e-07 | 1.96e-06 |
| Diabetic:0 | 132/61,988 | 148,453/16,348,907 | 0.23 | 4.18e-106 | 3.66e-104 |
| Plasticity:0 | 26/61,988 | 34,522/16,348,907 | 0.20 | 1.23e-28 | 3.25e-27 |
| androstan-3-one:0 | 11/61,988 | 153/16,348,907 | 18.97 | 5.39e-11 | 5.91e-10 |
| Entire paraventricular nucleus:0 | 1/61,988 | 5,996/16,348,907 | 0.04 | 5.63e-09 | 5.14e-08 |
| Nodular hyperplasia:0 | 39/61,988 | 2,401/16,348,907 | 4.29 | 2.18e-13 | 2.82e-12 |
| Polyp of urethra:0 | 21/61,988 | 126/16,348,907 | 43.97 | 1.19e-26 | 2.95e-25 |
| Temporomandibular Joint Disorders:0 | 2/61,988 | 6,459/16,348,907 | 0.08 | 1.96e-08 | 1.69e-07 |
| KLK3 gene|KLK3:0 | 2,606/61,988 | 9,016/16,348,907 | 79.53 | 0.00e+00 | 0.00e+00 |
| Low Back Pain:0 | 13/61,988 | 18,774/16,348,907 | 0.18 | 6.95e-17 | 1.11e-15 |
| Cancer Vaccines:0 | 186/61,988 | 2,979/16,348,907 | 16.51 | 1.43e-150 | 1.86e-148 |
| Estramustine:0 | 327/61,988 | 1,158/16,348,907 | 74.87 | 0.00e+00 | 0.00e+00 |
| S100P gene|S100P:0 | 18/61,988 | 627/16,348,907 | 7.57 | 1.19e-10 | 1.27e-09 |
| Alprostadil:0 | 20/61,988 | 13,971/16,348,907 | 0.38 | 3.95e-07 | 2.96e-06 |
| Reconstructive Surgical Procedures:0 | 142/61,988 | 65,162/16,348,907 | 0.57 | 5.41e-13 | 6.77e-12 |
| PROSTATE CALCIFICATION:0 | 11/61,988 | 45/16,348,907 | 64.48 | 2.84e-16 | 4.38e-15 |
| Fetal Growth Retardation:0 | 1/61,988 | 10,582/16,348,907 | 0.02 | 3.08e-16 | 4.73e-15 |
| beta-lapachone:0 | 22/61,988 | 942/16,348,907 | 6.16 | 5.19e-11 | 5.69e-10 |
| Angina Pectoris:0 | 6/61,988 | 10,871/16,348,907 | 0.15 | 2.21e-11 | 2.49e-10 |
| uptake:0 | 126/61,988 | 53,645/16,348,907 | 0.62 | 7.11e-09 | 6.42e-08 |
| Leptin|HSD3B1:0 | 9/61,988 | 17/16,348,907 | 139.65 | 4.61e-16 | 7.01e-15 |
| Penile Prosthesis:0 | 36/61,988 | 981/16,348,907 | 9.68 | 4.26e-23 | 9.18e-22 |
| Chromosome Pairing:0 | 5/61,988 | 37,079/16,348,907 | 0.04 | 9.24e-53 | 4.43e-51 |
| Hypophysectomy, Chemical:0 | 4/61,988 | 12/16,348,907 | 87.92 | 3.57e-07 | 2.68e-06 |
| PIK3CA|PIK3CB|PIK3CD|PIK3CG:0 | 137/61,988 | 6,650/16,348,907 | 5.44 | 6.72e-54 | 3.28e-52 |
| Sjogren's Syndrome:0 | 3/61,988 | 11,129/16,348,907 | 0.07 | 1.49e-14 | 2.07e-13 |
| Inflammatory disorder:0 | 52/61,988 | 26,207/16,348,907 | 0.52 | 2.54e-07 | 1.94e-06 |
| Need for isolation:0 | 47/61,988 | 24,893/16,348,907 | 0.50 | 1.19e-07 | 9.37e-07 |
| Entire pelvic lymph node:0 | 33/61,988 | 144/16,348,907 | 60.47 | 4.73e-45 | 1.94e-43 |
| Suppression treatment:0 | 12/61,988 | 81/16,348,907 | 39.08 | 2.65e-15 | 3.86e-14 |
| UROLOGIC PROBLEM:0 | 8/61,988 | 195/16,348,907 | 10.82 | 1.34e-06 | 9.34e-06 |
| Antiplatelet therapy:0 | 3/61,988 | 6,138/16,348,907 | 0.13 | 3.64e-07 | 2.73e-06 |
| tadalafil:0 | 39/61,988 | 2,920/16,348,907 | 3.52 | 6.35e-11 | 6.92e-10 |
| Racial group:0 | 291/61,988 | 14,629/16,348,907 | 5.27 | 7.92e-109 | 7.04e-107 |
| Bicarbonates:0 | 5/61,988 | 12,959/16,348,907 | 0.10 | 2.64e-15 | 3.86e-14 |
| phenoxodiol:0 | 9/61,988 | 161/16,348,907 | 14.75 | 2.39e-08 | 2.04e-07 |
| Levodopa:0 | 8/61,988 | 35,782/16,348,907 | 0.06 | 9.30e-47 | 3.96e-45 |
| Apolipoproteins B|APOB:0 | 2/61,988 | 10,176/16,348,907 | 0.05 | 2.43e-14 | 3.33e-13 |
| GLIPR1:0 | 13/61,988 | 100/16,348,907 | 34.29 | 8.60e-16 | 1.29e-14 |
| HOXB13:0 | 44/61,988 | 205/16,348,907 | 56.65 | 2.05e-58 | 1.08e-56 |
| Troponin:0 | 1/61,988 | 5,858/16,348,907 | 0.05 | 1.23e-08 | 1.08e-07 |
| Transforming Growth Factor alpha:0 | 65/61,988 | 6,818/16,348,907 | 2.52 | 8.92e-11 | 9.63e-10 |
| beta-2 Adrenergic Receptors:0 | 4/61,988 | 7,174/16,348,907 | 0.15 | 7.46e-08 | 6.02e-07 |
| Myocardial Ischemia:0 | 45/61,988 | 46,323/16,348,907 | 0.26 | 1.22e-31 | 3.53e-30 |
| Cryoablation of prostate:0 | 7/61,988 | 43/16,348,907 | 42.94 | 9.50e-10 | 9.31e-09 |
| Dialysis Solutions:0 | 1/61,988 | 7,094/16,348,907 | 0.04 | 1.05e-10 | 1.12e-09 |
| Leg:0 | 11/61,988 | 10,740/16,348,907 | 0.27 | 6.58e-08 | 5.36e-07 |
| Fishes:0 | 39/61,988 | 47,006/16,348,907 | 0.22 | 3.52e-36 | 1.16e-34 |
| EHF gene|EHF:0 | 7/61,988 | 123/16,348,907 | 15.01 | 7.72e-07 | 5.58e-06 |
| Young adult:0 | 59/61,988 | 46,051/16,348,907 | 0.34 | 6.30e-24 | 1.39e-22 |
| Enhancer:0 | 69/61,988 | 7,241/16,348,907 | 2.51 | 2.44e-11 | 2.73e-10 |
| cancer regression:0 | 11/61,988 | 127/16,348,907 | 22.85 | 8.27e-12 | 9.59e-11 |
| Pelvic organ:0 | 23/61,988 | 1,187/16,348,907 | 5.11 | 6.49e-10 | 6.47e-09 |
| Assessment procedure:0 | 506/61,988 | 96,769/16,348,907 | 1.38 | 5.93e-12 | 6.94e-11 |
| Nuclear Matrix-Associated Proteins:0 | 37/61,988 | 672/16,348,907 | 14.53 | 1.57e-29 | 4.28e-28 |
| Generalized illness:0 | 54/61,988 | 4,079/16,348,907 | 3.49 | 2.32e-14 | 3.18e-13 |
| Tetanus:0 | 2/61,988 | 5,368/16,348,907 | 0.10 | 6.02e-07 | 4.40e-06 |
| Edetic Acid:0 | 11/61,988 | 17,584/16,348,907 | 0.16 | 8.73e-17 | 1.39e-15 |
| Thalamic structure:0 | 1/61,988 | 15,961/16,348,907 | 0.02 | 8.68e-25 | 2.00e-23 |
| Carotid Body:0 | 1/61,988 | 5,714/16,348,907 | 0.05 | 1.68e-08 | 1.45e-07 |
| Receptors, Eph Family:0 | 15/61,988 | 744/16,348,907 | 5.32 | 3.50e-07 | 2.63e-06 |
| Sarcoidosis:0 | 11/61,988 | 26,298/16,348,907 | 0.11 | 2.47e-29 | 6.68e-28 |
| Reason for:0 | 47/61,988 | 5,498/16,348,907 | 2.26 | 8.13e-07 | 5.86e-06 |
| Calcineurin:0 | 7/61,988 | 9,681/16,348,907 | 0.19 | 6.20e-09 | 5.63e-08 |
| Iron:0 | 61/61,988 | 86,457/16,348,907 | 0.19 | 5.27e-73 | 3.34e-71 |
| Cytomegalovirus Infections:0 | 7/61,988 | 17,799/16,348,907 | 0.10 | 1.36e-20 | 2.65e-19 |
| prostate gland development:0 | 5/61,988 | 17/16,348,907 | 77.58 | 1.92e-08 | 1.65e-07 |
| Chickens:0 | 1/61,988 | 8,393/16,348,907 | 0.03 | 9.31e-13 | 1.15e-11 |
| Epithelial proliferation:0 | 41/61,988 | 1,812/16,348,907 | 5.97 | 1.06e-18 | 1.86e-17 |
| Lobectomy:0 | 10/61,988 | 11,415/16,348,907 | 0.23 | 2.65e-09 | 2.51e-08 |
| Urinary complication:0 | 11/61,988 | 333/16,348,907 | 8.71 | 1.20e-07 | 9.49e-07 |
| Fatty-acid synthase:0 | 97/61,988 | 5,011/16,348,907 | 5.11 | 1.38e-36 | 4.63e-35 |
| Infiltration:0 | 281/61,988 | 43,522/16,348,907 | 1.71 | 2.34e-16 | 3.61e-15 |
| Resins, Plant:0 | 14/61,988 | 10,987/16,348,907 | 0.34 | 1.19e-06 | 8.40e-06 |
| Intravenous pyelogram:0 | 37/61,988 | 2,431/16,348,907 | 4.02 | 5.46e-12 | 6.43e-11 |
| Human Glandular Kallikrein 2|KLK2:0 | 20/61,988 | 61/16,348,907 | 86.50 | 1.31e-30 | 3.65e-29 |
| TIMP2 protein, human|TIMP2:0 | 32/61,988 | 2,738/16,348,907 | 3.08 | 6.17e-08 | 5.04e-07 |
| prenatal:0 | 5/61,988 | 11,422/16,348,907 | 0.12 | 4.50e-13 | 5.65e-12 |
| Muscle function:0 | 12/61,988 | 14,779/16,348,907 | 0.21 | 2.46e-12 | 2.95e-11 |
| peer:0 | 6/61,988 | 8,117/16,348,907 | 0.19 | 1.58e-07 | 1.23e-06 |
| Caudal:0 | 18/61,988 | 14,282/16,348,907 | 0.33 | 2.45e-08 | 2.09e-07 |
| Recombinant Interferon-gamma|CALR:0 | 9/61,988 | 20/16,348,907 | 118.70 | 1.46e-15 | 2.17e-14 |
| DNA Repair Gene:0 | 55/61,988 | 2,976/16,348,907 | 4.88 | 1.30e-20 | 2.54e-19 |
| metaplastic cell transformation:0 | 44/61,988 | 1,506/16,348,907 | 7.71 | 4.54e-24 | 1.01e-22 |
| Somatomedins|BP3:0 | 10/61,988 | 51/16,348,907 | 51.72 | 4.47e-14 | 6.04e-13 |
| Acinar Prostate Adenocarcinoma:0 | 11/61,988 | 16/16,348,907 | 181.36 | 2.75e-20 | 5.28e-19 |
| Calcitonin Gene-Related Peptide:0 | 15/61,988 | 18,800/16,348,907 | 0.21 | 1.63e-15 | 2.41e-14 |
| Up-Regulation (Physiology):0 | 302/61,988 | 22,987/16,348,907 | 3.48 | 1.25e-71 | 7.74e-70 |
| Liver Cirrhosis:0 | 22/61,988 | 26,587/16,348,907 | 0.22 | 4.19e-21 | 8.33e-20 |
| Autoimmunity:0 | 23/61,988 | 14,850/16,348,907 | 0.41 | 8.83e-07 | 6.33e-06 |
| matriptase:0 | 33/61,988 | 1,088/16,348,907 | 8.00 | 6.36e-19 | 1.13e-17 |
| Secondary malignant neoplasm of lung:0 | 201/61,988 | 13,625/16,348,907 | 3.90 | 1.30e-55 | 6.54e-54 |
| Ischemic stroke:0 | 10/61,988 | 44,460/16,348,907 | 0.06 | 8.26e-58 | 4.31e-56 |
| Anxiety Disorders:0 | 3/61,988 | 14,864/16,348,907 | 0.05 | 1.91e-20 | 3.70e-19 |
| src-Family Kinases:0 | 49/61,988 | 3,795/16,348,907 | 3.41 | 8.38e-13 | 1.03e-11 |
| Coronary Artery Bypass Surgery:0 | 2/61,988 | 36,304/16,348,907 | 0.01 | 4.14e-56 | 2.10e-54 |
| Heme:0 | 9/61,988 | 14,199/16,348,907 | 0.17 | 1.00e-13 | 1.32e-12 |
| Addictive Behavior:0 | 5/61,988 | 9,713/16,348,907 | 0.14 | 1.46e-10 | 1.55e-09 |
| Epinephrine:0 | 15/61,988 | 45,013/16,348,907 | 0.09 | 5.17e-53 | 2.49e-51 |
| Parasitemia:0 | 1/61,988 | 6,777/16,348,907 | 0.04 | 4.91e-10 | 4.95e-09 |
| Fibroblast Growth Factor Receptors:0 | 56/61,988 | 4,214/16,348,907 | 3.51 | 6.71e-15 | 9.53e-14 |
| Frozen Sections:0 | 98/61,988 | 8,271/16,348,907 | 3.13 | 2.08e-21 | 4.18e-20 |
| Attention deficit hyperactivity disorder:0 | 2/61,988 | 58,657/16,348,907 | 0.01 | 1.26e-92 | 9.81e-91 |
| Fascia of individual pelvic organ:0 | 8/61,988 | 32/16,348,907 | 65.94 | 2.86e-12 | 3.41e-11 |
| Conservative therapy:0 | 99/61,988 | 7,174/16,348,907 | 3.64 | 3.29e-26 | 8.06e-25 |
| KRT6A|PCSK1|BTG2|ACTR1B|CBX8:0 | 6/61,988 | 20/16,348,907 | 79.13 | 6.27e-10 | 6.25e-09 |
| Risk Reduction:0 | 85/61,988 | 4,050/16,348,907 | 5.54 | 1.11e-34 | 3.46e-33 |
| Injury wounds:0 | 13/61,988 | 11,938/16,348,907 | 0.29 | 3.64e-08 | 3.05e-07 |
| G1 Arrest:0 | 51/61,988 | 1,073/16,348,907 | 12.55 | 3.97e-37 | 1.34e-35 |
| Secondary malignant neoplasm of bone:0 | 2,429/61,988 | 17,034/16,348,907 | 39.10 | 0.00e+00 | 0.00e+00 |
| Receptors, Metabotropic Glutamate:0 | 3/61,988 | 6,268/16,348,907 | 0.13 | 2.65e-07 | 2.02e-06 |
| HISTORY OF SYMPTOMS & DISEASES:FINDING:POINT IN TIME:HEREDITARY:NOMINAL:0 | 25/61,988 | 1,182/16,348,907 | 5.58 | 2.04e-11 | 2.30e-10 |
| Cerebral hemisphere hemorrhage:0 | 6/61,988 | 15,342/16,348,907 | 0.10 | 7.15e-18 | 1.20e-16 |
| Physiologic Organization:0 | 15/61,988 | 17,641/16,348,907 | 0.22 | 4.97e-14 | 6.70e-13 |
| Arthrogryposis:0 | 20/61,988 | 1,126/16,348,907 | 4.69 | 3.27e-08 | 2.76e-07 |
| Lung Transplantation:0 | 1/61,988 | 5,836/16,348,907 | 0.05 | 1.19e-08 | 1.05e-07 |
| Total thyroidectomy:0 | 2/61,988 | 5,449/16,348,907 | 0.10 | 6.52e-07 | 4.75e-06 |
| UVRAG|TP63|CKAP4:0 | 102/61,988 | 4,488/16,348,907 | 6.00 | 3.80e-44 | 1.51e-42 |
| KLK3|PLAG1|PROS1|NPEPPS|PSAT1:0 | 137/61,988 | 363/16,348,907 | 99.76 | 3.36e-207 | 5.73e-205 |
| Stroma:0 | 988/61,988 | 54,679/16,348,907 | 4.83 | 0.00e+00 | 0.00e+00 |
| silybin:0 | 72/61,988 | 3,579/16,348,907 | 5.31 | 1.42e-28 | 3.74e-27 |
| Mouse Intraepithelial Neoplasia:0 | 4/61,988 | 11/16,348,907 | 95.91 | 2.69e-07 | 2.04e-06 |
| Steryl-sulfatase:0 | 22/61,988 | 1,570/16,348,907 | 3.70 | 3.74e-07 | 2.80e-06 |
| Nuclear Hormone Receptors:0 | 23/61,988 | 1,554/16,348,907 | 3.90 | 8.09e-08 | 6.51e-07 |
| Moving:0 | 3/61,988 | 8,308/16,348,907 | 0.10 | 2.73e-10 | 2.83e-09 |
| Retinal Detachment:0 | 1/61,988 | 9,387/16,348,907 | 0.03 | 2.44e-14 | 3.35e-13 |
| Prolactin|PGR|PR@|PRH2|TMEM37|ERVK-10:0 | 8/61,988 | 107/16,348,907 | 19.72 | 1.71e-08 | 1.48e-07 |
| Signs and Symptoms, Respiratory:0 | 6/61,988 | 7,312/16,348,907 | 0.22 | 1.38e-06 | 9.62e-06 |
| Tissue membrane:0 | 87/61,988 | 79,269/16,348,907 | 0.29 | 1.48e-47 | 6.42e-46 |
| CANCER WORKUP:0 | 7/61,988 | 41/16,348,907 | 45.03 | 7.05e-10 | 7.00e-09 |
| Malignant neoplasm of brain:0 | 64/61,988 | 3,745/16,348,907 | 4.51 | 5.24e-22 | 1.08e-20 |
| cDNA Microarray procedure:0 | 12/61,988 | 332/16,348,907 | 9.53 | 1.25e-08 | 1.10e-07 |
| Octreotide|PLXNA2:0 | 9/61,988 | 36/16,348,907 | 65.95 | 1.23e-13 | 1.61e-12 |
| Thioctic Acid:0 | 6/61,988 | 8,508/16,348,907 | 0.19 | 4.26e-08 | 3.53e-07 |
| kallikrein 10:0 | 6/61,988 | 55/16,348,907 | 28.77 | 1.35e-07 | 1.06e-06 |
| Combined Modality Therapy:0 | 633/61,988 | 57,532/16,348,907 | 2.92 | 5.33e-115 | 5.07e-113 |
| Bupivacaine:0 | 9/61,988 | 13,970/16,348,907 | 0.17 | 2.86e-13 | 3.67e-12 |
| African race:0 | 166/61,988 | 18,751/16,348,907 | 2.34 | 9.42e-22 | 1.91e-20 |
| Recipient, Transplant:0 | 92/61,988 | 54,994/16,348,907 | 0.44 | 1.76e-19 | 3.22e-18 |
| Albumins:0 | 36/61,988 | 25,581/16,348,907 | 0.37 | 2.01e-12 | 2.42e-11 |
| CATALASE:0 | 27/61,988 | 17,074/16,348,907 | 0.42 | 1.90e-07 | 1.47e-06 |
| Aspartate Transaminase:0 | 11/61,988 | 10,748/16,348,907 | 0.27 | 6.59e-08 | 5.36e-07 |
| Prostatic Intraepithelial Neoplasia of the Mouse Prostate Gland:0 | 60/61,988 | 106/16,348,907 | 149.43 | 2.64e-100 | 2.15e-98 |
| Whole Body Imaging:0 | 32/61,988 | 1,291/16,348,907 | 6.54 | 5.25e-16 | 7.95e-15 |
| Entire left seminal vesicle:0 | 5/61,988 | 32/16,348,907 | 41.21 | 3.03e-07 | 2.29e-06 |
| Rats, Inbred ACI:0 | 18/61,988 | 397/16,348,907 | 11.96 | 8.46e-14 | 1.12e-12 |
| steroid hormone receptor:0 | 75/61,988 | 1,392/16,348,907 | 14.23 | 1.85e-57 | 9.53e-56 |
| Pollutant:0 | 2/61,988 | 6,946/16,348,907 | 0.08 | 3.28e-09 | 3.06e-08 |
| Histologic:0 | 27/61,988 | 442/16,348,907 | 16.12 | 4.32e-23 | 9.30e-22 |
| Somatostatin Receptor:0 | 32/61,988 | 2,716/16,348,907 | 3.11 | 5.17e-08 | 4.26e-07 |
| Pulmonary artery structure:0 | 3/61,988 | 8,547/16,348,907 | 0.09 | 9.22e-11 | 9.93e-10 |
| Malignant Carcinoid Syndrome:0 | 19/61,988 | 430/16,348,907 | 11.66 | 2.72e-14 | 3.73e-13 |
| ALCAM gene|ALCAM:0 | 11/61,988 | 409/16,348,907 | 7.09 | 8.57e-07 | 6.16e-06 |
| Stratification:0 | 81/61,988 | 3,430/16,348,907 | 6.24 | 1.53e-36 | 5.12e-35 |
| Curcumin:0 | 183/61,988 | 25,265/16,348,907 | 1.91 | 2.61e-15 | 3.82e-14 |
| BRCA2 Protein|BRCA2:0 | 12/61,988 | 147/16,348,907 | 21.53 | 1.80e-12 | 2.17e-11 |
| caspase-3:0 | 343/61,988 | 20,964/16,348,907 | 4.33 | 3.62e-105 | 3.13e-103 |
| Mycobacterium tuberculosis:0 | 5/61,988 | 19,195/16,348,907 | 0.07 | 1.01e-24 | 2.33e-23 |
| SKP2 gene|SKP2:0 | 21/61,988 | 919/16,348,907 | 6.03 | 2.06e-10 | 2.15e-09 |
| Phagocytes:0 | 8/61,988 | 10,762/16,348,907 | 0.20 | 8.44e-10 | 8.33e-09 |
| terminal deoxynucleotidyl transferase nick end labeling:0 | 22/61,988 | 698/16,348,907 | 8.32 | 1.87e-13 | 2.43e-12 |
| Cognitive function: planning:0 | 7/61,988 | 131/16,348,907 | 14.09 | 1.15e-06 | 8.12e-06 |
| Lymphocyte antigen CD66A|CEACAM1:0 | 14/61,988 | 664/16,348,907 | 5.56 | 5.08e-07 | 3.75e-06 |
| Thalassemia:0 | 1/61,988 | 6,434/16,348,907 | 0.04 | 1.36e-09 | 1.31e-08 |
| Selenium and Vitamin E Efficacy Trial:0 | 63/61,988 | 7,268/16,348,907 | 2.29 | 9.11e-09 | 8.13e-08 |
| Obstetric Labor, Premature:0 | 2/61,988 | 7,598/16,348,907 | 0.07 | 2.62e-10 | 2.72e-09 |
| Bladder Adenocarcinoma:0 | 8/61,988 | 82/16,348,907 | 25.73 | 2.44e-09 | 2.31e-08 |
| Mitosis:0 | 156/61,988 | 17,328/16,348,907 | 2.38 | 2.98e-21 | 5.96e-20 |
| Polysaccharides:0 | 90/61,988 | 51,669/16,348,907 | 0.46 | 4.18e-17 | 6.76e-16 |
| Cancer of Pelvis:0 | 39/61,988 | 346/16,348,907 | 29.75 | 4.06e-42 | 1.56e-40 |
| Structure of articular cartilage:0 | 1/61,988 | 11,844/16,348,907 | 0.02 | 2.63e-18 | 4.52e-17 |
| N-Myc Downstream Regulated Protein 1|NDRG1:0 | 22/61,988 | 566/16,348,907 | 10.25 | 3.25e-15 | 4.71e-14 |
| Neoadjuvant Therapy:0 | 441/61,988 | 10,341/16,348,907 | 11.32 | 1.20e-288 | 2.80e-286 |
| Glucosephosphate Dehydrogenase:0 | 1/61,988 | 4,739/16,348,907 | 0.06 | 6.32e-07 | 4.61e-06 |
| Osteoporosis:0 | 392/61,988 | 51,099/16,348,907 | 2.03 | 7.52e-36 | 2.43e-34 |
| Cell physiology:0 | 361/61,988 | 46,073/16,348,907 | 2.07 | 6.75e-35 | 2.12e-33 |
| Laryngeal Masks:0 | 1/61,988 | 5,241/16,348,907 | 0.05 | 1.05e-07 | 8.32e-07 |
| perilla alcohol:0 | 12/61,988 | 397/16,348,907 | 7.97 | 8.24e-08 | 6.61e-07 |
| androgen biosynthesis:0 | 42/61,988 | 194/16,348,907 | 57.14 | 5.65e-56 | 2.86e-54 |
| Saccades:0 | 1/61,988 | 4,535/16,348,907 | 0.06 | 1.29e-06 | 9.04e-06 |
| Dactinomycin|MYC:0 | 5/61,988 | 6/16,348,907 | 219.80 | 3.49e-10 | 3.57e-09 |
| glandular epithelium:0 | 80/61,988 | 2,051/16,348,907 | 10.30 | 4.06e-51 | 1.88e-49 |
| American:0 | 138/61,988 | 11,187/16,348,907 | 3.26 | 4.40e-31 | 1.24e-29 |
| mutation analysis:0 | 46/61,988 | 3,884/16,348,907 | 3.13 | 6.48e-11 | 7.04e-10 |
| Thrombectomy:0 | 1/61,988 | 4,755/16,348,907 | 0.06 | 6.44e-07 | 4.69e-06 |
| Mesenteric Arteries:0 | 1/61,988 | 8,887/16,348,907 | 0.03 | 1.51e-13 | 1.97e-12 |
| Prostate mass:0 | 6/61,988 | 14/16,348,907 | 113.04 | 1.08e-10 | 1.15e-09 |
| Castration:0 | 766/61,988 | 4,619/16,348,907 | 44.27 | 0.00e+00 | 0.00e+00 |
| PECAM1 gene|PECAM1:0 | 35/61,988 | 2,487/16,348,907 | 3.71 | 1.53e-10 | 1.62e-09 |
| Labyrinth:0 | 6/61,988 | 15,615/16,348,907 | 0.10 | 2.49e-18 | 4.29e-17 |
| PROSTATE SPECIFIC:0 | 135/61,988 | 196/16,348,907 | 182.05 | 2.35e-232 | 4.35e-230 |
| Prostatic Glandular Cell:0 | 11/61,988 | 38/16,348,907 | 76.36 | 5.70e-17 | 9.12e-16 |
| Phosphodiesterase 5 inhibitor:0 | 72/61,988 | 3,804/16,348,907 | 5.00 | 4.75e-27 | 1.19e-25 |
| 1-amino-3-fluorocyclobutane-1-carboxylic acid:0 | 6/61,988 | 10/16,348,907 | 158.26 | 2.25e-11 | 2.53e-10 |
| Thrombomodulin|THBD:0 | 1/61,988 | 4,604/16,348,907 | 0.06 | 8.83e-07 | 6.33e-06 |
| Medical center:0 | 79/61,988 | 7,680/16,348,907 | 2.72 | 2.14e-14 | 2.95e-13 |
| beta-Lactams:0 | 2/61,988 | 5,655/16,348,907 | 0.09 | 2.11e-07 | 1.62e-06 |
| samarium ethylenediaminetetramethylenephosphonate:0 | 9/61,988 | 68/16,348,907 | 34.91 | 2.00e-11 | 2.25e-10 |
| Prodrugs:0 | 28/61,988 | 1,010/16,348,907 | 7.31 | 2.34e-15 | 3.44e-14 |
| VIABLE CELLS:0 | 66/61,988 | 4,542/16,348,907 | 3.84 | 3.99e-19 | 7.20e-18 |
| Experimental Autoimmune Encephalomyelitis:0 | 1/61,988 | 8,356/16,348,907 | 0.03 | 1.44e-12 | 1.75e-11 |
| CXCL1 gene|CXCL1:0 | 9/61,988 | 208/16,348,907 | 11.41 | 1.92e-07 | 1.49e-06 |
| Imaging Device:0 | 55/61,988 | 1,386/16,348,907 | 10.47 | 4.68e-36 | 1.53e-34 |
| Genetic Predisposition to Disease:0 | 37/61,988 | 2,750/16,348,907 | 3.55 | 1.58e-10 | 1.66e-09 |
| Death (finding):0 | 446/61,988 | 31,124/16,348,907 | 3.80 | 4.97e-117 | 4.93e-115 |
| [M]Unspecified tumor cell NOS:0 | 2,310/61,988 | 75,073/16,348,907 | 8.39 | 0.00e+00 | 0.00e+00 |
| Bladder stenosis:0 | 17/61,988 | 90/16,348,907 | 49.83 | 1.09e-22 | 2.31e-21 |
| Promoter Regions (Genetics):0 | 114/61,988 | 6,625/16,348,907 | 4.54 | 4.23e-38 | 1.47e-36 |
| Medical Castration:0 | 95/61,988 | 178/16,348,907 | 140.98 | 6.76e-156 | 9.08e-154 |
| Neurovascular bundle:0 | 157/61,988 | 843/16,348,907 | 49.24 | 2.94e-195 | 4.81e-193 |
| DNA, Complementary:0 | 234/61,988 | 22,436/16,348,907 | 2.76 | 3.96e-40 | 1.45e-38 |
| Entire olfactory bulb:0 | 1/61,988 | 9,936/16,348,907 | 0.03 | 4.21e-15 | 6.07e-14 |
| Orthomyxoviridae:0 | 4/61,988 | 11,219/16,348,907 | 0.09 | 1.30e-13 | 1.71e-12 |
| Thyrotropin:0 | 16/61,988 | 13,729/16,348,907 | 0.31 | 1.23e-08 | 1.08e-07 |
| Overweight:0 | 85/61,988 | 36,917/16,348,907 | 0.61 | 8.00e-07 | 5.77e-06 |
| leukemia:0 | 441/61,988 | 53,501/16,348,907 | 2.18 | 2.74e-47 | 1.18e-45 |
| THIN FILM:0 | 2/61,988 | 6,081/16,348,907 | 0.09 | 5.20e-08 | 4.28e-07 |
| Prosencephalon:0 | 1/61,988 | 22,614/16,348,907 | 0.01 | 1.16e-35 | 3.73e-34 |
| Suicide Gene Therapy:0 | 40/61,988 | 474/16,348,907 | 22.27 | 1.49e-38 | 5.24e-37 |
| Stroke, Acute:0 | 2/61,988 | 11,484/16,348,907 | 0.05 | 2.28e-16 | 3.54e-15 |
| Amyotrophic Lateral Sclerosis:0 | 8/61,988 | 35,595/16,348,907 | 0.06 | 1.94e-46 | 8.17e-45 |
| dihydroxy-vitamin D3:0 | 102/61,988 | 4,786/16,348,907 | 5.63 | 8.19e-42 | 3.12e-40 |
| Substance P:0 | 12/61,988 | 34,092/16,348,907 | 0.09 | 8.30e-40 | 3.02e-38 |
| Nasal Polyps:0 | 2/61,988 | 6,232/16,348,907 | 0.08 | 3.82e-08 | 3.19e-07 |
| Lithium:0 | 5/61,988 | 24,098/16,348,907 | 0.05 | 2.83e-32 | 8.36e-31 |
| Cancer Prognosis:0 | 22/61,988 | 208/16,348,907 | 27.91 | 6.71e-24 | 1.48e-22 |
| Pneumothorax:0 | 2/61,988 | 7,607/16,348,907 | 0.07 | 2.63e-10 | 2.73e-09 |
| Coronary Arteriosclerosis:0 | 36/61,988 | 101,100/16,348,907 | 0.09 | 1.57e-115 | 1.50e-113 |
| CDK2 gene|CDK2:0 | 86/61,988 | 4,776/16,348,907 | 4.75 | 1.68e-30 | 4.67e-29 |
| caspase:0 | 183/61,988 | 12,222/16,348,907 | 3.96 | 1.14e-51 | 5.34e-50 |
| Entire gastrocnemius:0 | 1/61,988 | 13,338/16,348,907 | 0.02 | 1.09e-20 | 2.14e-19 |
| Gamma Cameras:0 | 36/61,988 | 3,322/16,348,907 | 2.86 | 6.04e-08 | 4.93e-07 |
| Proteomics:0 | 35/61,988 | 2,851/16,348,907 | 3.24 | 4.71e-09 | 4.31e-08 |
| Excitation:0 | 5/61,988 | 8,513/16,348,907 | 0.15 | 8.33e-09 | 7.47e-08 |
| Revascularization - action:0 | 5/61,988 | 24,538/16,348,907 | 0.05 | 4.52e-33 | 1.36e-31 |
| DNA Fragmentation:0 | 51/61,988 | 3,362/16,348,907 | 4.00 | 7.29e-16 | 1.10e-14 |
| Swollen prostate:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| Child Development Disorders:0 | 1/61,988 | 8,686/16,348,907 | 0.03 | 3.12e-13 | 3.97e-12 |
| Bulimia:0 | 1/61,988 | 7,635/16,348,907 | 0.03 | 1.76e-11 | 1.99e-10 |
| Short stature:0 | 3/61,988 | 6,540/16,348,907 | 0.12 | 9.29e-08 | 7.44e-07 |
| Disease recurrence:0 | 154/61,988 | 2,600/16,348,907 | 15.66 | 8.70e-122 | 9.10e-120 |
| Author:0 | 442/61,988 | 57,164/16,348,907 | 2.05 | 5.37e-41 | 2.02e-39 |
| Virus Diseases:0 | 84/61,988 | 71,852/16,348,907 | 0.31 | 1.68e-40 | 6.22e-39 |
| Retinoblastoma Protein:0 | 58/61,988 | 2,684/16,348,907 | 5.70 | 8.17e-25 | 1.88e-23 |
| Taxotere:0 | 107/61,988 | 1,690/16,348,907 | 16.73 | 5.26e-88 | 3.85e-86 |
| growth hormone-releasing hormone receptor:0 | 15/61,988 | 487/16,348,907 | 8.13 | 1.63e-09 | 1.56e-08 |
| Nerve-Sparing Prostatectomy:0 | 93/61,988 | 233/16,348,907 | 105.43 | 4.02e-143 | 4.90e-141 |
| Dialysis procedure:0 | 14/61,988 | 21,075/16,348,907 | 0.18 | 2.99e-19 | 5.42e-18 |
| Respiratory Failure:0 | 7/61,988 | 12,928/16,348,907 | 0.14 | 1.64e-13 | 2.14e-12 |
| Antiretroviral Therapy, Highly Active:0 | 5/61,988 | 8,395/16,348,907 | 0.16 | 1.14e-08 | 1.01e-07 |
| Induced Hyperthermia:0 | 30/61,988 | 2,601/16,348,907 | 3.04 | 2.04e-07 | 1.58e-06 |
| Cell Nucleus:0 | 95/61,988 | 8,243/16,348,907 | 3.04 | 4.93e-20 | 9.32e-19 |
| Cyclosporine|RIT2:0 | 4/61,988 | 5/16,348,907 | 211.01 | 2.53e-08 | 2.15e-07 |
| athymia:0 | 17/61,988 | 753/16,348,907 | 5.96 | 1.23e-08 | 1.08e-07 |
| wave:0 | 27/61,988 | 23,746/16,348,907 | 0.30 | 1.37e-14 | 1.91e-13 |
| Leukemia, Myelocytic, Acute:0 | 93/61,988 | 65,224/16,348,907 | 0.38 | 3.81e-29 | 1.02e-27 |
| Uveitis:0 | 1/61,988 | 15,813/16,348,907 | 0.02 | 1.16e-24 | 2.65e-23 |
| Flare:0 | 81/61,988 | 4,483/16,348,907 | 4.77 | 6.36e-29 | 1.70e-27 |
| Paraffin:0 | 149/61,988 | 11,560/16,348,907 | 3.41 | 2.13e-35 | 6.81e-34 |
| KLK10 gene|KLK10:0 | 6/61,988 | 56/16,348,907 | 28.26 | 1.49e-07 | 1.16e-06 |
| Primary Carcinoma:0 | 178/61,988 | 15,209/16,348,907 | 3.09 | 8.53e-37 | 2.87e-35 |
| Clinical Trials, Phase III:0 | 45/61,988 | 798/16,348,907 | 14.88 | 5.62e-36 | 1.83e-34 |
| Urine specimen:0 | 70/61,988 | 2,827/16,348,907 | 6.54 | 5.10e-33 | 1.54e-31 |
| Growth acceleration:0 | 26/61,988 | 1,546/16,348,907 | 4.44 | 9.58e-10 | 9.38e-09 |
| Polysomnography:0 | 1/61,988 | 5,289/16,348,907 | 0.05 | 7.06e-08 | 5.73e-07 |
| Gonadotropin releasing hormone antagonist:0 | 64/61,988 | 1,354/16,348,907 | 12.48 | 5.18e-46 | 2.17e-44 |
| Tumor Biology:0 | 7/61,988 | 122/16,348,907 | 15.13 | 7.33e-07 | 5.31e-06 |
| Thoracotomy:0 | 2/61,988 | 9,289/16,348,907 | 0.06 | 6.11e-13 | 7.62e-12 |
| OGX-011:0 | 14/61,988 | 59/16,348,907 | 62.60 | 3.61e-20 | 6.88e-19 |
| Multiple System Atrophy:0 | 1/61,988 | 5,614/16,348,907 | 0.05 | 2.41e-08 | 2.06e-07 |
| Urethral Diseases:0 | 16/61,988 | 543/16,348,907 | 7.77 | 8.73e-10 | 8.61e-09 |
| Atlases:0 | 26/61,988 | 1,656/16,348,907 | 4.14 | 3.79e-09 | 3.51e-08 |
| Paclitaxel:0 | 410/61,988 | 38,401/16,348,907 | 2.83 | 1.31e-71 | 8.10e-70 |
| Defibrillators:0 | 1/61,988 | 5,368/16,348,907 | 0.05 | 7.57e-08 | 6.11e-07 |
| Gastrin|GAST:0 | 4/61,988 | 9,718/16,348,907 | 0.11 | 1.53e-11 | 1.73e-10 |
| Blood flow:0 | 46/61,988 | 56,850/16,348,907 | 0.21 | 2.65e-44 | 1.06e-42 |
| cyclooxygenase 2:0 | 213/61,988 | 37,191/16,348,907 | 1.51 | 1.77e-08 | 1.53e-07 |
| Advanced cancer:0 | 1,013/61,988 | 28,658/16,348,907 | 9.46 | 0.00e+00 | 0.00e+00 |
| Analog:0 | 78/61,988 | 9,175/16,348,907 | 2.24 | 2.71e-10 | 2.81e-09 |
| Congestive heart failure:0 | 26/61,988 | 43,135/16,348,907 | 0.16 | 1.93e-40 | 7.11e-39 |
| antisense therapy:0 | 10/61,988 | 173/16,348,907 | 15.25 | 2.95e-09 | 2.77e-08 |
| CC 5013:0 | 5/61,988 | 42/16,348,907 | 31.40 | 1.03e-06 | 7.33e-06 |
| Spinal Dysraphism:0 | 1/61,988 | 5,403/16,348,907 | 0.05 | 4.94e-08 | 4.07e-07 |
| Nuclear Proteins|AR:0 | 9/61,988 | 21/16,348,907 | 113.05 | 2.08e-15 | 3.06e-14 |
| TP53 gene|TP53:0 | 1,032/61,988 | 108,855/16,348,907 | 2.53 | 1.12e-144 | 1.39e-142 |
| Orgasm:0 | 21/61,988 | 811/16,348,907 | 6.83 | 2.27e-11 | 2.54e-10 |
| Fibrosis, Liver:0 | 2/61,988 | 17,065/16,348,907 | 0.03 | 3.72e-25 | 8.73e-24 |
| Imaging Techniques:0 | 104/61,988 | 5,126/16,348,907 | 5.36 | 8.49e-41 | 3.16e-39 |
| PSCA:0 | 20/61,988 | 84/16,348,907 | 62.82 | 3.29e-28 | 8.53e-27 |
| Respiration Disorders:0 | 7/61,988 | 18,555/16,348,907 | 0.10 | 1.27e-21 | 2.57e-20 |
| Radiofrequency ablation:0 | 26/61,988 | 16,915/16,348,907 | 0.41 | 1.16e-07 | 9.15e-07 |
| Infectious disease of lung:0 | 5/61,988 | 8,789/16,348,907 | 0.15 | 2.97e-09 | 2.78e-08 |
| Functional assessment:0 | 34/61,988 | 3,249/16,348,907 | 2.76 | 2.99e-07 | 2.27e-06 |
| Organ:0 | 1,173/61,988 | 129,821/16,348,907 | 2.41 | 7.26e-150 | 9.23e-148 |
| Scanning/Transmission Electron Microscopes:0 | 1/61,988 | 4,559/16,348,907 | 0.06 | 1.33e-06 | 9.28e-06 |
| Mail:0 | 55/61,988 | 4,698/16,348,907 | 3.09 | 1.50e-12 | 1.82e-11 |
| Adenovirus Vector:0 | 66/61,988 | 2,652/16,348,907 | 6.57 | 2.36e-31 | 6.78e-30 |
| Polyneuropathy:0 | 1/61,988 | 5,576/16,348,907 | 0.05 | 3.73e-08 | 3.12e-07 |
| Host-Tumor Interaction:0 | 7/61,988 | 93/16,348,907 | 19.85 | 1.29e-07 | 1.02e-06 |
| MYC gene|MYC:0 | 151/61,988 | 8,634/16,348,907 | 4.62 | 1.06e-50 | 4.87e-49 |
| Octreotide|OXT:0 | 4/61,988 | 6/16,348,907 | 175.84 | 4.20e-08 | 3.49e-07 |
| Azithromycin:0 | 1/61,988 | 10,563/16,348,907 | 0.02 | 3.04e-16 | 4.68e-15 |
| disorder control:0 | 77/61,988 | 4,228/16,348,907 | 4.81 | 8.66e-28 | 2.22e-26 |
| Second Primary Cancers:0 | 274/61,988 | 6,073/16,348,907 | 11.95 | 5.31e-186 | 8.35e-184 |
| Sun Exposure:0 | 20/61,988 | 1,023/16,348,907 | 5.16 | 7.06e-09 | 6.38e-08 |
| Female breast:0 | 69/61,988 | 1,023/16,348,907 | 17.81 | 4.03e-59 | 2.13e-57 |
| voriconazole:0 | 1/61,988 | 5,275/16,348,907 | 0.05 | 1.10e-07 | 8.72e-07 |
| Cicatrix:0 | 14/61,988 | 16,629/16,348,907 | 0.22 | 1.78e-13 | 2.31e-12 |
| Polycystic Ovary Syndrome:0 | 19/61,988 | 40,526/16,348,907 | 0.12 | 1.19e-42 | 4.61e-41 |
| Lens, Crystalline:0 | 6/61,988 | 33,999/16,348,907 | 0.05 | 1.30e-46 | 5.54e-45 |
| Pamphlets:0 | 13/61,988 | 555/16,348,907 | 6.18 | 4.10e-07 | 3.06e-06 |
| Flow:0 | 19/61,988 | 16,174/16,348,907 | 0.31 | 5.19e-10 | 5.22e-09 |
| HNF1B:0 | 12/61,988 | 435/16,348,907 | 7.28 | 2.13e-07 | 1.64e-06 |
| Megestrol Acetate:0 | 36/61,988 | 2,501/16,348,907 | 3.80 | 4.67e-11 | 5.14e-10 |
| Prostate Embryonal Rhabdomyosarcoma:0 | 5/61,988 | 18/16,348,907 | 73.27 | 2.44e-08 | 2.09e-07 |
| Midazolam:0 | 10/61,988 | 15,325/16,348,907 | 0.17 | 2.19e-14 | 3.01e-13 |
| myometrium:0 | 7/61,988 | 11,935/16,348,907 | 0.15 | 4.67e-12 | 5.51e-11 |
| Vascular anomaly:0 | 4/61,988 | 6,866/16,348,907 | 0.15 | 2.03e-07 | 1.57e-06 |
| Androsterone:0 | 18/61,988 | 588/16,348,907 | 8.08 | 4.40e-11 | 4.86e-10 |
| Serine Protease:0 | 250/61,988 | 13,678/16,348,907 | 4.84 | 1.83e-86 | 1.33e-84 |
| Screening Tests:0 | 58/61,988 | 6,476/16,348,907 | 2.36 | 7.68e-09 | 6.91e-08 |
| penis:0 | 252/61,988 | 15,693/16,348,907 | 4.25 | 3.37e-76 | 2.20e-74 |
| CDH1 gene|CDH1:0 | 22/61,988 | 1,243/16,348,907 | 4.67 | 7.38e-09 | 6.65e-08 |
| Hard prostate:0 | 9/61,988 | 10/16,348,907 | 237.40 | 1.40e-17 | 2.30e-16 |
| Oligonucleotides:0 | 79/61,988 | 9,418/16,348,907 | 2.21 | 4.59e-10 | 4.66e-09 |
| secretory protein:0 | 39/61,988 | 3,939/16,348,907 | 2.61 | 1.70e-07 | 1.32e-06 |
| ESR1 protein, human|ESR1:0 | 190/61,988 | 20,573/16,348,907 | 2.44 | 1.10e-26 | 2.73e-25 |
| Deglutition Disorders:0 | 5/61,988 | 17,665/16,348,907 | 0.07 | 1.97e-22 | 4.11e-21 |
| Septic Shock:0 | 7/61,988 | 18,488/16,348,907 | 0.10 | 1.21e-21 | 2.45e-20 |
| Cyclin D1|LMOD1|BBS9:0 | 50/61,988 | 3,310/16,348,907 | 3.99 | 1.62e-15 | 2.40e-14 |
| Iron deficiency:0 | 2/61,988 | 9,269/16,348,907 | 0.06 | 9.57e-13 | 1.18e-11 |
| Domestic Sheep:0 | 6/61,988 | 30,073/16,348,907 | 0.05 | 2.29e-40 | 8.41e-39 |
| Microinjections:0 | 1/61,988 | 4,486/16,348,907 | 0.06 | 1.26e-06 | 8.84e-06 |
| Acetate:0 | 333/61,988 | 18,826/16,348,907 | 4.68 | 7.57e-111 | 6.94e-109 |
| fosfestrol:0 | 85/61,988 | 224/16,348,907 | 100.22 | 2.08e-129 | 2.31e-127 |
| COLLAGENASE:0 | 21/61,988 | 14,543/16,348,907 | 0.38 | 3.20e-07 | 2.41e-06 |
| Cholinergic Receptors:0 | 3/61,988 | 10,158/16,348,907 | 0.08 | 3.39e-13 | 4.30e-12 |
| Leukocytes:0 | 143/61,988 | 61,338/16,348,907 | 0.61 | 3.52e-10 | 3.61e-09 |
| antiangiogenesis therapy:0 | 26/61,988 | 895/16,348,907 | 7.66 | 7.99e-15 | 1.13e-13 |
| Flavonoids:0 | 156/61,988 | 21,421/16,348,907 | 1.92 | 1.90e-13 | 2.46e-12 |
| Helicobacter pylori:0 | 10/61,988 | 21,931/16,348,907 | 0.12 | 8.24e-24 | 1.82e-22 |
| Gene Expression Profiling:0 | 50/61,988 | 2,732/16,348,907 | 4.83 | 1.01e-18 | 1.77e-17 |
| Disorder of soft tissue:0 | 35/61,988 | 432/16,348,907 | 21.38 | 2.25e-33 | 6.84e-32 |
| Ablation:0 | 1,158/61,988 | 35,852/16,348,907 | 8.66 | 0.00e+00 | 0.00e+00 |
| Longitudinal Studies:0 | 766/61,988 | 50,484/16,348,907 | 4.04 | 5.62e-214 | 9.88e-212 |
| Clonidine:0 | 9/61,988 | 20,330/16,348,907 | 0.12 | 1.92e-22 | 4.03e-21 |
| Doxazosin:0 | 58/61,988 | 4,209/16,348,907 | 3.64 | 4.96e-16 | 7.52e-15 |
| 10q:0 | 29/61,988 | 426/16,348,907 | 17.96 | 6.30e-26 | 1.52e-24 |
| Proprotein Convertase 1|KRT6A|PCSK1|BTG2|ACTR1B|CBX8:0 | 468/61,988 | 1,009/16,348,907 | 123.25 | 0.00e+00 | 0.00e+00 |
| oblimersen:0 | 16/61,988 | 255/16,348,907 | 16.55 | 1.78e-14 | 2.47e-13 |
| Hydrogen, Homeopathic preparation:0 | 2/61,988 | 5,836/16,348,907 | 0.09 | 1.57e-07 | 1.22e-06 |
| Fluorescent in Situ Hybridization:0 | 216/61,988 | 14,341/16,348,907 | 3.98 | 4.57e-61 | 2.48e-59 |
| topiramate:0 | 1/61,988 | 9,134/16,348,907 | 0.03 | 7.65e-14 | 1.02e-12 |
| Cancer Prevention Trial:0 | 7/61,988 | 35/16,348,907 | 52.75 | 2.64e-10 | 2.73e-09 |
| Fenretinide:0 | 45/61,988 | 2,080/16,348,907 | 5.71 | 1.20e-19 | 2.22e-18 |
| Frequency of micturition:0 | 18/61,988 | 731/16,348,907 | 6.50 | 1.26e-09 | 1.22e-08 |
| apoptogenic cytochrome c release channel activity:0 | 172/61,988 | 5,269/16,348,907 | 8.63 | 4.06e-96 | 3.23e-94 |
| Growth stimulant:0 | 28/61,988 | 822/16,348,907 | 8.99 | 1.59e-17 | 2.61e-16 |
| Replacement blood transfusion:0 | 9/61,988 | 25/16,348,907 | 94.96 | 7.54e-15 | 1.07e-13 |
| Estrogen Receptor alpha:0 | 187/61,988 | 17,690/16,348,907 | 2.79 | 3.95e-33 | 1.20e-31 |
| Histamine:0 | 15/61,988 | 39,491/16,348,907 | 0.10 | 6.46e-45 | 2.64e-43 |
| REG3A|ASAP2|MRPS30|PAPOLA|PDAP1|TUSC2|ASAP1:0 | 38/61,988 | 1,005/16,348,907 | 9.98 | 1.00e-24 | 2.31e-23 |
| Platinum Compounds:0 | 19/61,988 | 1,180/16,348,907 | 4.25 | 3.05e-07 | 2.31e-06 |
| Magnetic resonance imaging unit:0 | 22/61,988 | 918/16,348,907 | 6.32 | 3.23e-11 | 3.59e-10 |
| Erythrocyte Membrane:0 | 7/61,988 | 9,271/16,348,907 | 0.20 | 2.24e-08 | 1.92e-07 |
| glutathione S-transferase pi:0 | 33/61,988 | 1,341/16,348,907 | 6.49 | 2.27e-16 | 3.52e-15 |
| Traumatic Rupture:0 | 2/61,988 | 10,573/16,348,907 | 0.05 | 5.78e-15 | 8.25e-14 |
| HSP90 Heat-Shock Proteins|HSP90AA1:0 | 86/61,988 | 8,829/16,348,907 | 2.57 | 3.19e-14 | 4.35e-13 |
| Heart Ventricle:0 | 1/61,988 | 11,109/16,348,907 | 0.02 | 5.16e-17 | 8.28e-16 |
| Aggressive behavior:0 | 593/61,988 | 27,698/16,348,907 | 5.69 | 2.73e-235 | 5.08e-233 |
| Vertebrates:0 | 46/61,988 | 46,550/16,348,907 | 0.26 | 2.70e-31 | 7.71e-30 |
| Cyclin-Dependent Kinase Inhibitor Proteins:0 | 61/61,988 | 2,206/16,348,907 | 7.30 | 1.81e-31 | 5.22e-30 |
| Splenectomy:0 | 8/61,988 | 13,191/16,348,907 | 0.16 | 4.99e-13 | 6.26e-12 |
| Condoms, Male:0 | 18/61,988 | 14,953/16,348,907 | 0.32 | 4.66e-09 | 4.28e-08 |
| Helicobacter Infections:0 | 3/61,988 | 12,472/16,348,907 | 0.06 | 9.95e-17 | 1.58e-15 |
| Muscle, Smooth, Vascular:0 | 6/61,988 | 12,385/16,348,907 | 0.13 | 1.41e-13 | 1.85e-12 |
| Entire fetus:0 | 3/61,988 | 11,682/16,348,907 | 0.07 | 1.71e-15 | 2.52e-14 |
| Pulmonary arterial hypertension:0 | 1/61,988 | 15,930/16,348,907 | 0.02 | 8.21e-25 | 1.89e-23 |
| In Situ Hybridization:0 | 151/61,988 | 24,228/16,348,907 | 1.65 | 1.43e-08 | 1.25e-07 |
| Central gray substance of midbrain:0 | 1/61,988 | 6,291/16,348,907 | 0.04 | 1.90e-09 | 1.82e-08 |
| mesalamine:0 | 5/61,988 | 6,884/16,348,907 | 0.19 | 1.06e-06 | 7.51e-06 |
| Mutant:0 | 18/61,988 | 21,170/16,348,907 | 0.22 | 1.10e-16 | 1.74e-15 |
| Therapies, Investigational:0 | 26/61,988 | 1,105/16,348,907 | 6.21 | 8.32e-13 | 1.03e-11 |
| Brachytherapy Systems:0 | 10/61,988 | 75/16,348,907 | 35.17 | 1.43e-12 | 1.74e-11 |
| Urogenital Diseases:0 | 34/61,988 | 451/16,348,907 | 19.89 | 1.70e-31 | 4.91e-30 |
| Areae:0 | 482/61,988 | 68,353/16,348,907 | 1.87 | 4.98e-35 | 1.57e-33 |
| Estradiol:0 | 485/61,988 | 78,673/16,348,907 | 1.63 | 3.29e-23 | 7.13e-22 |
| Antibody Formation:0 | 41/61,988 | 22,333/16,348,907 | 0.48 | 1.97e-07 | 1.52e-06 |
| 6-O-galloylglucose:0 | 6/61,988 | 76/16,348,907 | 20.82 | 7.95e-07 | 5.74e-06 |
| Dementia:0 | 23/61,988 | 70,232/16,348,907 | 0.09 | 1.21e-82 | 8.46e-81 |
| Operon:0 | 2/61,988 | 15,621/16,348,907 | 0.03 | 9.16e-23 | 1.94e-21 |
| Immunoconjugates:0 | 25/61,988 | 960/16,348,907 | 6.87 | 2.67e-13 | 3.43e-12 |
| Gonadorelin|GNRH1:0 | 443/61,988 | 18,242/16,348,907 | 6.44 | 3.83e-196 | 6.30e-194 |
| Genes, rRNA:0 | 6/61,988 | 21,335/16,348,907 | 0.07 | 5.74e-27 | 1.44e-25 |
| Tendon structure:0 | 3/61,988 | 7,180/16,348,907 | 0.11 | 1.21e-08 | 1.07e-07 |
| Entire membranous urethra:0 | 13/61,988 | 141/16,348,907 | 24.32 | 5.07e-14 | 6.83e-13 |
| Nuclear Receptor Coactivator 4|AR:0 | 6/61,988 | 19/16,348,907 | 83.30 | 4.84e-10 | 4.88e-09 |
| Cyclin-Dependent Kinase 4|CDK4:0 | 45/61,988 | 1,947/16,348,907 | 6.10 | 1.04e-20 | 2.03e-19 |
| Pain management:0 | 100/61,988 | 13,619/16,348,907 | 1.94 | 2.19e-09 | 2.08e-08 |
| CHKA gene|CHKA:0 | 23/61,988 | 536/16,348,907 | 11.32 | 1.02e-16 | 1.62e-15 |
| Schools, Medical:0 | 7/61,988 | 8,600/16,348,907 | 0.21 | 1.44e-07 | 1.12e-06 |
| sural:0 | 11/61,988 | 376/16,348,907 | 7.72 | 3.86e-07 | 2.89e-06 |
| Saphenous Vein:0 | 1/61,988 | 5,794/16,348,907 | 0.05 | 1.16e-08 | 1.03e-07 |
| Soy Proteins:0 | 135/61,988 | 4,607/16,348,907 | 7.74 | 2.22e-70 | 1.36e-68 |
| CDC25C:0 | 21/61,988 | 813/16,348,907 | 6.81 | 2.37e-11 | 2.65e-10 |
| Prenatal Diagnosis:0 | 2/61,988 | 5,195/16,348,907 | 0.10 | 1.23e-06 | 8.63e-06 |
| Cervical spine:0 | 12/61,988 | 15,690/16,348,907 | 0.20 | 1.43e-13 | 1.87e-12 |
| Chromosome abnormality:0 | 125/61,988 | 19,185/16,348,907 | 1.72 | 2.73e-08 | 2.32e-07 |
| Hypersensitivity:0 | 43/61,988 | 46,309/16,348,907 | 0.24 | 7.38e-33 | 2.21e-31 |
| Dopamine Receptor:0 | 3/61,988 | 12,517/16,348,907 | 0.06 | 1.03e-16 | 1.63e-15 |
| Somatomedins:0 | 354/61,988 | 19,992/16,348,907 | 4.69 | 7.52e-118 | 7.55e-116 |
| Problem drinker:0 | 3/61,988 | 17,564/16,348,907 | 0.05 | 1.19e-24 | 2.73e-23 |
| Bombesin Antagonist:0 | 17/61,988 | 127/16,348,907 | 35.31 | 2.13e-20 | 4.11e-19 |
| Etanercept:0 | 2/61,988 | 13,242/16,348,907 | 0.04 | 5.40e-19 | 9.66e-18 |
| Ultraviolet B Radiation:0 | 8/61,988 | 10,970/16,348,907 | 0.19 | 4.45e-10 | 4.53e-09 |
| Adenosis:0 | 11/61,988 | 291/16,348,907 | 9.97 | 3.24e-08 | 2.74e-07 |
| Glutamate-Ammonia Ligase:0 | 3/61,988 | 6,488/16,348,907 | 0.12 | 1.36e-07 | 1.07e-06 |
| Prostatectomy, Retropubic:0 | 271/61,988 | 610/16,348,907 | 117.68 | 0.00e+00 | 0.00e+00 |
| ETS1 gene|ETS1:0 | 109/61,988 | 3,178/16,348,907 | 9.06 | 1.24e-63 | 7.00e-62 |
| Myocytes, Smooth Muscle:0 | 111/61,988 | 97,507/16,348,907 | 0.30 | 3.91e-56 | 1.99e-54 |
| Mastodynia:0 | 31/61,988 | 829/16,348,907 | 9.87 | 2.45e-20 | 4.71e-19 |
| Anti-Arrhythmia Agents:0 | 5/61,988 | 17,292/16,348,907 | 0.08 | 8.21e-22 | 1.67e-20 |
| Entire axial skeleton:0 | 27/61,988 | 1,077/16,348,907 | 6.61 | 7.31e-14 | 9.73e-13 |
| Hemodynamics:0 | 8/61,988 | 37,608/16,348,907 | 0.06 | 9.99e-50 | 4.53e-48 |
| Tumor necrosis factor receptor 11b:0 | 80/61,988 | 9,247/16,348,907 | 2.28 | 9.56e-11 | 1.03e-09 |
| Goserelin Acetate:0 | 68/61,988 | 308/16,348,907 | 58.29 | 4.44e-90 | 3.29e-88 |
| casein kinase II:0 | 46/61,988 | 3,560/16,348,907 | 3.41 | 3.97e-12 | 4.70e-11 |
| Candidiasis:0 | 2/61,988 | 8,780/16,348,907 | 0.06 | 3.63e-12 | 4.32e-11 |
| Lobe:0 | 483/61,988 | 41,342/16,348,907 | 3.10 | 1.75e-96 | 1.40e-94 |
| ELL:0 | 9/61,988 | 191/16,348,907 | 12.43 | 9.62e-08 | 7.69e-07 |
| CYP19A1 gene|CYP19A1:0 | 23/61,988 | 1,117/16,348,907 | 5.43 | 2.09e-10 | 2.19e-09 |
| Oligosaccharides:0 | 11/61,988 | 14,713/16,348,907 | 0.20 | 7.53e-13 | 9.31e-12 |
| Endorectal:0 | 286/61,988 | 1,305/16,348,907 | 58.06 | 0.00e+00 | 0.00e+00 |
| Solid tumor:0 | 1,007/61,988 | 33,165/16,348,907 | 8.12 | 0.00e+00 | 0.00e+00 |
| Voluntary Workers:0 | 103/61,988 | 52,274/16,348,907 | 0.52 | 1.57e-13 | 2.06e-12 |
| phosphoprotein 32|ANP32A:0 | 10/61,988 | 147/16,348,907 | 17.94 | 6.68e-10 | 6.63e-09 |
| Hormone manipulation:0 | 154/61,988 | 531/16,348,907 | 76.68 | 1.11e-217 | 1.97e-215 |
| Isoflurane:0 | 5/61,988 | 14,813/16,348,907 | 0.09 | 5.41e-18 | 9.17e-17 |
| Retinoblastoma:0 | 110/61,988 | 13,359/16,348,907 | 2.17 | 5.09e-13 | 6.38e-12 |
| Simian B disease:0 | 2/61,988 | 11,138/16,348,907 | 0.05 | 1.01e-15 | 1.51e-14 |
| Implants:0 | 332/61,988 | 44,210/16,348,907 | 1.99 | 4.47e-29 | 1.20e-27 |
| Tumorigenicity:0 | 330/61,988 | 8,583/16,348,907 | 10.19 | 3.00e-203 | 5.05e-201 |
| CYP24A1:0 | 24/61,988 | 696/16,348,907 | 9.10 | 2.34e-15 | 3.44e-14 |
| Extraction:0 | 76/61,988 | 45,536/16,348,907 | 0.44 | 1.96e-16 | 3.04e-15 |
| Prostatic obstruction:0 | 44/61,988 | 721/16,348,907 | 16.11 | 1.38e-36 | 4.63e-35 |
| Ankylosis:0 | 2/61,988 | 13,559/16,348,907 | 0.04 | 1.17e-19 | 2.16e-18 |
| telomerase activity:0 | 56/61,988 | 3,842/16,348,907 | 3.85 | 1.55e-16 | 2.43e-15 |
| Hepatitis B Virus:0 | 3/61,988 | 17,893/16,348,907 | 0.04 | 4.17e-25 | 9.74e-24 |
| Nutraceuticals:0 | 16/61,988 | 555/16,348,907 | 7.61 | 1.18e-09 | 1.15e-08 |
| Tissue Integrity:0 | 11/61,988 | 354/16,348,907 | 8.20 | 2.17e-07 | 1.66e-06 |
| Vital capacity:0 | 2/61,988 | 5,196/16,348,907 | 0.10 | 1.23e-06 | 8.63e-06 |
| Neuron-Specific Enolase:0 | 66/61,988 | 5,541/16,348,907 | 3.14 | 4.52e-15 | 6.50e-14 |
| Receptor Inhibition:0 | 16/61,988 | 726/16,348,907 | 5.81 | 4.49e-08 | 3.72e-07 |
| Numerical Chromosomal Abnormality:0 | 12/61,988 | 363/16,348,907 | 8.72 | 3.22e-08 | 2.72e-07 |
| Specimen:0 | 100/61,988 | 6,593/16,348,907 | 4.01 | 1.80e-29 | 4.87e-28 |
| Nitric Oxide:0 | 84/61,988 | 147,628/16,348,907 | 0.15 | 1.16e-139 | 1.38e-137 |
| Lateral Geniculate Body:0 | 1/61,988 | 6,492/16,348,907 | 0.04 | 9.21e-10 | 9.05e-09 |
| Alveolar ventilation function:0 | 21/61,988 | 14,343/16,348,907 | 0.39 | 4.01e-07 | 2.99e-06 |
| homocysteine:0 | 17/61,988 | 25,184/16,348,907 | 0.18 | 9.83e-23 | 2.09e-21 |
| Drug eluting stent:0 | 2/61,988 | 11,120/16,348,907 | 0.05 | 9.88e-16 | 1.48e-14 |
| Oxidoreductase:0 | 330/61,988 | 36,175/16,348,907 | 2.41 | 4.76e-44 | 1.89e-42 |
| Prostaglandins G:0 | 10/61,988 | 251/16,348,907 | 10.51 | 8.49e-08 | 6.81e-07 |
| Vascular constriction (function):0 | 2/61,988 | 21,099/16,348,907 | 0.02 | 1.21e-31 | 3.50e-30 |
| Matrilysin:0 | 46/61,988 | 2,573/16,348,907 | 4.72 | 5.47e-17 | 8.76e-16 |
| Myopathy:0 | 13/61,988 | 17,500/16,348,907 | 0.20 | 3.15e-15 | 4.57e-14 |
| Crystallins:0 | 2/61,988 | 6,197/16,348,907 | 0.09 | 3.69e-08 | 3.09e-07 |
| procollagen type I carboxy terminal peptide:0 | 25/61,988 | 983/16,348,907 | 6.71 | 4.41e-13 | 5.55e-12 |
| Weaning:0 | 1/61,988 | 8,914/16,348,907 | 0.03 | 1.54e-13 | 2.01e-12 |
| LIPOPROTEIN LIPASE|LPL:0 | 10/61,988 | 11,404/16,348,907 | 0.23 | 2.64e-09 | 2.50e-08 |
| Abdominal aorta structure:0 | 2/61,988 | 8,042/16,348,907 | 0.07 | 6.59e-11 | 7.16e-10 |
| Agitation:0 | 2/61,988 | 6,924/16,348,907 | 0.08 | 3.19e-09 | 2.99e-08 |
| Null cell:0 | 43/61,988 | 1,976/16,348,907 | 5.74 | 6.19e-19 | 1.10e-17 |
| Glyburide:0 | 4/61,988 | 11,347/16,348,907 | 0.09 | 6.04e-14 | 8.09e-13 |
| ETV4 gene|ETV4:0 | 23/61,988 | 120/16,348,907 | 50.57 | 2.71e-30 | 7.50e-29 |
| canine cell line:0 | 15/61,988 | 753/16,348,907 | 5.25 | 4.05e-07 | 3.03e-06 |
| Antimicrobial susceptibility:0 | 675/61,988 | 87,620/16,348,907 | 2.04 | 3.86e-61 | 2.10e-59 |
| United States:0 | 31/61,988 | 2,551/16,348,907 | 3.21 | 4.26e-08 | 3.53e-07 |
| stricture; bladder, neck:0 | 7/61,988 | 24/16,348,907 | 76.93 | 2.66e-11 | 2.98e-10 |
| Gene Fusion:0 | 20/61,988 | 311/16,348,907 | 16.97 | 6.49e-18 | 1.09e-16 |
| Relative Risk:0 | 22/61,988 | 880/16,348,907 | 6.60 | 1.48e-11 | 1.68e-10 |
| Catecholamines:0 | 12/61,988 | 26,511/16,348,907 | 0.12 | 1.29e-28 | 3.39e-27 |
| Herpesvirus 4, Human:0 | 9/61,988 | 18,480/16,348,907 | 0.13 | 8.56e-20 | 1.59e-18 |
| Biopsy finding:0 | 12/61,988 | 377/16,348,907 | 8.40 | 4.80e-08 | 3.97e-07 |
| Renin|REN:0 | 1/61,988 | 8,207/16,348,907 | 0.03 | 1.94e-12 | 2.34e-11 |
| TNF-related apoptosis-inducing ligand|TNF:0 | 11/61,988 | 427/16,348,907 | 6.80 | 1.29e-06 | 9.00e-06 |
| Gelatinase A:0 | 213/61,988 | 17,325/16,348,907 | 3.25 | 8.91e-47 | 3.80e-45 |
| Long-Term Survivors:0 | 101/61,988 | 5,500/16,348,907 | 4.85 | 3.46e-36 | 1.14e-34 |
| Major Histocompatibility Complex:0 | 9/61,988 | 11,754/16,348,907 | 0.20 | 2.35e-10 | 2.44e-09 |
| Dehydration:0 | 4/61,988 | 9,966/16,348,907 | 0.11 | 7.84e-12 | 9.12e-11 |
| Synapses:0 | 3/61,988 | 18,932/16,348,907 | 0.04 | 7.68e-27 | 1.92e-25 |
| indole-3-carbinol:0 | 29/61,988 | 747/16,348,907 | 10.24 | 1.51e-19 | 2.78e-18 |
| diagnostic procedure:0 | 95/61,988 | 9,671/16,348,907 | 2.59 | 9.63e-16 | 1.44e-14 |
| Immunocompromised Host:0 | 12/61,988 | 13,348/16,348,907 | 0.24 | 1.94e-10 | 2.03e-09 |
| angiogram:0 | 15/61,988 | 36,525/16,348,907 | 0.11 | 2.07e-40 | 7.62e-39 |
| Ecosystem:0 | 3/61,988 | 6,302/16,348,907 | 0.13 | 2.76e-07 | 2.10e-06 |
| fluorescence activated cell sorter device:0 | 66/61,988 | 4,177/16,348,907 | 4.17 | 6.40e-21 | 1.26e-19 |
| Luc Gene:0 | 19/61,988 | 1,213/16,348,907 | 4.13 | 4.57e-07 | 3.38e-06 |
| Antiviral Agents:0 | 1/61,988 | 7,865/16,348,907 | 0.03 | 8.98e-12 | 1.04e-10 |
| FOLH1 gene|FOLH1:0 | 147/61,988 | 607/16,348,907 | 64.02 | 7.80e-198 | 1.29e-195 |
| Structure of paraurethral ducts:0 | 6/61,988 | 68/16,348,907 | 23.27 | 4.32e-07 | 3.21e-06 |
| HIV-1:0 | 12/61,988 | 34,936/16,348,907 | 0.09 | 5.45e-41 | 2.04e-39 |
| Liver diseases:0 | 48/61,988 | 37,138/16,348,907 | 0.34 | 2.17e-19 | 3.96e-18 |
| Nutritional status:0 | 5/61,988 | 8,215/16,348,907 | 0.16 | 1.51e-08 | 1.32e-07 |
| ANXA7:0 | 9/61,988 | 217/16,348,907 | 10.94 | 2.70e-07 | 2.06e-06 |
| Bradycardia:0 | 1/61,988 | 6,199/16,348,907 | 0.04 | 2.73e-09 | 2.58e-08 |
| Posterior Fossa:0 | 1/61,988 | 5,325/16,348,907 | 0.05 | 7.17e-08 | 5.81e-07 |
| PREDICTED:0 | 98/61,988 | 5,726/16,348,907 | 4.52 | 7.95e-33 | 2.38e-31 |
| CYP3A4 gene|CYP3A4:0 | 28/61,988 | 975/16,348,907 | 7.58 | 1.01e-15 | 1.50e-14 |
| Myelin:0 | 1/61,988 | 8,722/16,348,907 | 0.03 | 3.21e-13 | 4.09e-12 |
| Zonal:0 | 507/61,988 | 67,299/16,348,907 | 2.00 | 6.41e-44 | 2.54e-42 |
| cooperative study:0 | 11/61,988 | 414/16,348,907 | 7.01 | 9.61e-07 | 6.84e-06 |
| membrane attack complex location:0 | 29/61,988 | 837/16,348,907 | 9.14 | 2.78e-18 | 4.78e-17 |
| Local disease:0 | 623/61,988 | 4,549/16,348,907 | 36.48 | 0.00e+00 | 0.00e+00 |
| Bacteria:0 | 70/61,988 | 122,648/16,348,907 | 0.15 | 5.79e-116 | 5.57e-114 |
| Entire midbrain:0 | 2/61,988 | 14,841/16,348,907 | 0.04 | 1.06e-21 | 2.14e-20 |
| Uroflowmetry:0 | 16/61,988 | 309/16,348,907 | 13.66 | 2.91e-13 | 3.72e-12 |
| MAP9:0 | 13/61,988 | 52/16,348,907 | 65.95 | 4.35e-19 | 7.83e-18 |
| N-telopeptide:0 | 8/61,988 | 142/16,348,907 | 14.86 | 1.35e-07 | 1.06e-06 |
| Rifampin:0 | 3/61,988 | 15,580/16,348,907 | 0.05 | 1.57e-21 | 3.16e-20 |
| Processed meat:0 | 11/61,988 | 189/16,348,907 | 15.35 | 4.50e-10 | 4.57e-09 |
| Prosthesis:0 | 36/61,988 | 32,796/16,348,907 | 0.29 | 2.39e-20 | 4.60e-19 |
| MULTISECTION:FINDING:POINT IN TIME:PROSTATE:NARRATIVE:COMPUTERIZED TOMOGRAPHY:0 | 8/61,988 | 9/16,348,907 | 234.47 | 9.77e-16 | 1.46e-14 |
| Prostatic Tissue:0 | 2,253/61,988 | 5,110/16,348,907 | 120.63 | 0.00e+00 | 0.00e+00 |
| Ethnic group:0 | 231/61,988 | 23,819/16,348,907 | 2.56 | 4.36e-35 | 1.37e-33 |
| 2,2'-azobis(2-(2-imidazolin-2-yl) propane) dihydrochloride:0 | 7/61,988 | 20/16,348,907 | 92.32 | 9.12e-12 | 1.05e-10 |
| EGR1:0 | 35/61,988 | 3,286/16,348,907 | 2.81 | 1.36e-07 | 1.06e-06 |
| Sex Counseling:0 | 7/61,988 | 133/16,348,907 | 13.88 | 1.27e-06 | 8.90e-06 |
| Lanugo:0 | 85/61,988 | 6,845/16,348,907 | 3.28 | 5.51e-20 | 1.04e-18 |
| Luteinizing Hormone:0 | 127/61,988 | 16,830/16,348,907 | 1.99 | 3.03e-12 | 3.61e-11 |
| Slinging procedure:0 | 29/61,988 | 2,506/16,348,907 | 3.05 | 3.02e-07 | 2.29e-06 |
| Urothelium:0 | 301/61,988 | 9,808/16,348,907 | 8.13 | 8.28e-160 | 1.13e-157 |
| Buserelin:0 | 84/61,988 | 2,378/16,348,907 | 9.33 | 2.14e-50 | 9.74e-49 |
| Mesenchymal Stem Cells:0 | 46/61,988 | 30,359/16,348,907 | 0.40 | 4.01e-13 | 5.06e-12 |
| glutaric acid:0 | 10/61,988 | 293/16,348,907 | 9.00 | 3.35e-07 | 2.52e-06 |
| bone sialoprotein:0 | 26/61,988 | 2,059/16,348,907 | 3.33 | 2.46e-07 | 1.88e-06 |
| Cricetinae:0 | 47/61,988 | 36,063/16,348,907 | 0.34 | 1.41e-18 | 2.47e-17 |
| Nitrogen:0 | 15/61,988 | 22,805/16,348,907 | 0.17 | 6.14e-21 | 1.21e-19 |
| glutamate carboxypeptidase II, human:0 | 15/61,988 | 38/16,348,907 | 104.13 | 2.48e-24 | 5.59e-23 |
| Phosphatidylethanolamines:0 | 12/61,988 | 11,423/16,348,907 | 0.28 | 4.30e-08 | 3.56e-07 |
| Carbon:0 | 30/61,988 | 25,351/16,348,907 | 0.31 | 5.90e-15 | 8.41e-14 |
| Insulin Resistance:0 | 83/61,988 | 63,707/16,348,907 | 0.34 | 5.33e-32 | 1.56e-30 |
| caspase-8:0 | 119/61,988 | 5,662/16,348,907 | 5.55 | 6.79e-48 | 2.98e-46 |
| Mouse Pancreatic Intraepithelial Neoplasia-2:0 | 52/61,988 | 2,783/16,348,907 | 4.93 | 8.93e-20 | 1.66e-18 |
| Candidate Disease Gene:0 | 878/61,988 | 53,728/16,348,907 | 4.36 | 1.75e-266 | 3.75e-264 |
| alpha-Melanocyte stimulating hormone:0 | 1/61,988 | 4,699/16,348,907 | 0.06 | 6.15e-07 | 4.49e-06 |
| Parenchyma:0 | 65/61,988 | 31,429/16,348,907 | 0.54 | 8.63e-08 | 6.92e-07 |
| Bone Screws:0 | 2/61,988 | 15,853/16,348,907 | 0.03 | 2.84e-23 | 6.19e-22 |
| Poorly Differentiated Prostate Adenocarcinoma:0 | 7/61,988 | 11/16,348,907 | 167.86 | 3.37e-13 | 4.27e-12 |
| Parenteral Nutrition, Total:0 | 1/61,988 | 6,115/16,348,907 | 0.04 | 3.96e-09 | 3.66e-08 |
| pars compacta:0 | 1/61,988 | 8,800/16,348,907 | 0.03 | 2.18e-13 | 2.82e-12 |
| Peritoneal Dialysis:0 | 2/61,988 | 8,453/16,348,907 | 0.06 | 1.61e-11 | 1.83e-10 |
| Thermal techniques:0 | 51/61,988 | 752/16,348,907 | 17.90 | 2.90e-44 | 1.15e-42 |
| Platelet-Derived Growth Factor Receptor|PDGFRB:0 | 14/61,988 | 493/16,348,907 | 7.49 | 1.51e-08 | 1.31e-07 |
| diallyl trisulfide:0 | 22/61,988 | 929/16,348,907 | 6.25 | 4.02e-11 | 4.45e-10 |
| Tool:0 | 389/61,988 | 55,288/16,348,907 | 1.86 | 1.77e-28 | 4.64e-27 |
| Invasive Malignant Neoplasm:0 | 141/61,988 | 4,876/16,348,907 | 7.64 | 9.96e-73 | 6.30e-71 |
| Shock:0 | 34/61,988 | 43,186/16,348,907 | 0.21 | 1.30e-34 | 4.05e-33 |
| Systemic arterial pressure:0 | 34/61,988 | 84,167/16,348,907 | 0.11 | 2.26e-92 | 1.74e-90 |
| Chest:0 | 88/61,988 | 44,721/16,348,907 | 0.52 | 7.32e-12 | 8.53e-11 |
| Trunk of posterior segmental artery:0 | 24/61,988 | 1,223/16,348,907 | 5.18 | 2.19e-10 | 2.28e-09 |
| Antimitotic Agents:0 | 20/61,988 | 990/16,348,907 | 5.33 | 4.15e-09 | 3.83e-08 |
| Cyclooxygenase 2 Inhibitors:0 | 129/61,988 | 10,626/16,348,907 | 3.21 | 1.48e-28 | 3.90e-27 |
| Cell marker:0 | 55/61,988 | 3,239/16,348,907 | 4.48 | 4.97e-19 | 8.91e-18 |
| Primary Lesion:0 | 54/61,988 | 4,919/16,348,907 | 2.90 | 2.43e-11 | 2.72e-10 |
| Atherosclerosis:0 | 59/61,988 | 73,537/16,348,907 | 0.21 | 2.78e-57 | 1.43e-55 |
| Urinary Incontinence:0 | 306/61,988 | 14,456/16,348,907 | 5.61 | 5.24e-121 | 5.46e-119 |
| RNA, Small Interfering:0 | 655/61,988 | 33,696/16,348,907 | 5.17 | 1.32e-237 | 2.51e-235 |
| Radiotherapy department:0 | 7/61,988 | 82/16,348,907 | 22.52 | 5.76e-08 | 4.72e-07 |
| PTRF:0 | 9/61,988 | 139/16,348,907 | 17.08 | 7.15e-09 | 6.45e-08 |
| Metastasis Suppressor Genes:0 | 68/61,988 | 355/16,348,907 | 50.57 | 2.40e-86 | 1.73e-84 |
| Lymph node excision:0 | 203/61,988 | 8,391/16,348,907 | 6.40 | 1.35e-90 | 1.02e-88 |
| Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:0 | 262/61,988 | 344/16,348,907 | 201.72 | 0.00e+00 | 0.00e+00 |
| Ketoconazole:0 | 171/61,988 | 10,163/16,348,907 | 4.45 | 5.95e-55 | 2.97e-53 |
| FADD gene|FADD:0 | 29/61,988 | 1,334/16,348,907 | 5.74 | 2.80e-13 | 3.59e-12 |
| Entire hippocampus:0 | 16/61,988 | 102,020/16,348,907 | 0.04 | 1.47e-140 | 1.75e-138 |
| cell stroma:0 | 11/61,988 | 199/16,348,907 | 14.58 | 7.54e-10 | 7.46e-09 |
| Adaptation:0 | 20/61,988 | 19,257/16,348,907 | 0.27 | 4.22e-13 | 5.32e-12 |
| Therapeutic vaccine:0 | 73/61,988 | 1,464/16,348,907 | 13.17 | 9.29e-54 | 4.51e-52 |
| DNMT1:0 | 34/61,988 | 1,702/16,348,907 | 5.27 | 2.79e-14 | 3.81e-13 |
| Problem, prostate:0 | 10/61,988 | 26/16,348,907 | 101.46 | 1.37e-16 | 2.16e-15 |
| Nitric Oxide Synthase Type I:0 | 3/61,988 | 6,261/16,348,907 | 0.13 | 2.63e-07 | 2.01e-06 |
| TRPV6:0 | 19/61,988 | 561/16,348,907 | 8.93 | 2.41e-12 | 2.89e-11 |
| Cooley's anemia:0 | 2/61,988 | 5,768/16,348,907 | 0.09 | 1.49e-07 | 1.16e-06 |
| Hepatitis, Chronic:0 | 2/61,988 | 10,561/16,348,907 | 0.05 | 9.04e-15 | 1.27e-13 |
| Pneumonia, Pneumocystis carinii:0 | 1/61,988 | 5,524/16,348,907 | 0.05 | 3.48e-08 | 2.93e-07 |
| Enterocytes:0 | 3/61,988 | 10,101/16,348,907 | 0.08 | 4.92e-13 | 6.17e-12 |
| Ribavirin:0 | 4/61,988 | 25,217/16,348,907 | 0.04 | 2.04e-35 | 6.53e-34 |
| Uterus - Cervix (MMHCC):0 | 103/61,988 | 10,435/16,348,907 | 2.61 | 4.66e-17 | 7.52e-16 |
| Motility:0 | 183/61,988 | 22,771/16,348,907 | 2.12 | 1.78e-19 | 3.25e-18 |
| Synaptic Vesicles:0 | 1/61,988 | 5,057/16,348,907 | 0.05 | 2.19e-07 | 1.68e-06 |
| cohort:0 | 1,939/61,988 | 121,378/16,348,907 | 4.32 | 0.00e+00 | 0.00e+00 |
| Magnetic Resonance Imaging:0 | 1,843/61,988 | 130,520/16,348,907 | 3.81 | 0.00e+00 | 0.00e+00 |
| Donor person:0 | 61/61,988 | 32,687/16,348,907 | 0.49 | 5.47e-10 | 5.49e-09 |
| SPOP:0 | 19/61,988 | 117/16,348,907 | 42.84 | 4.59e-24 | 1.02e-22 |
| Itraconazole:0 | 7/61,988 | 8,032/16,348,907 | 0.23 | 6.75e-07 | 4.90e-06 |
| Goserelin|EREG|ESR1:0 | 31/61,988 | 57/16,348,907 | 143.51 | 3.50e-52 | 1.65e-50 |
| Leptocyte:0 | 147/61,988 | 15,796/16,348,907 | 2.46 | 2.36e-21 | 4.74e-20 |
| Caries:0 | 1/61,988 | 13,263/16,348,907 | 0.02 | 1.61e-20 | 3.13e-19 |
| Sodium:0 | 26/61,988 | 34,109/16,348,907 | 0.20 | 4.38e-28 | 1.13e-26 |
| inhibitor-of-apoptosis protein:0 | 17/61,988 | 555/16,348,907 | 8.08 | 1.49e-10 | 1.58e-09 |
| Follicle:0 | 5/61,988 | 8,990/16,348,907 | 0.15 | 1.52e-09 | 1.46e-08 |
| thymolphthalein monophosphate:0 | 5/61,988 | 11/16,348,907 | 119.89 | 3.24e-09 | 3.03e-08 |
| Cryosurgery:0 | 335/61,988 | 6,267/16,348,907 | 14.17 | 3.40e-249 | 6.84e-247 |
| Southwest Oncology Group:0 | 34/61,988 | 731/16,348,907 | 12.27 | 5.08e-25 | 1.18e-23 |
| Reporter:0 | 133/61,988 | 11,671/16,348,907 | 3.01 | 6.48e-27 | 1.62e-25 |
| Proscar:0 | 8/61,988 | 101/16,348,907 | 20.89 | 1.12e-08 | 9.93e-08 |
| epitheliasin|TMPRSS2:0 | 63/61,988 | 246/16,348,907 | 67.61 | 3.71e-87 | 2.70e-85 |
| Predisposition:0 | 64/61,988 | 7,028/16,348,907 | 2.40 | 7.40e-10 | 7.33e-09 |
| Mitogen-Activated Protein Kinases|SGSM3:0 | 42/61,988 | 3,979/16,348,907 | 2.79 | 1.06e-08 | 9.41e-08 |
| Angiotensin II:0 | 30/61,988 | 65,381/16,348,907 | 0.12 | 1.24e-68 | 7.48e-67 |
| Skeletal muscle structure:0 | 24/61,988 | 54,023/16,348,907 | 0.12 | 1.34e-57 | 6.95e-56 |
| Interferons:0 | 60/61,988 | 62,340/16,348,907 | 0.25 | 1.61e-42 | 6.19e-41 |
| Androgen Response Element:0 | 100/61,988 | 270/16,348,907 | 97.84 | 4.78e-151 | 6.25e-149 |
| Markers, Radiopaque:0 | 15/61,988 | 400/16,348,907 | 9.89 | 1.22e-10 | 1.30e-09 |
| Nimodipine:0 | 1/61,988 | 5,579/16,348,907 | 0.05 | 3.75e-08 | 3.14e-07 |
| Urologic Oncology:0 | 7/61,988 | 14/16,348,907 | 131.89 | 1.22e-12 | 1.49e-11 |
| 2-pyrrolino-DOX:0 | 4/61,988 | 12/16,348,907 | 87.92 | 3.57e-07 | 2.68e-06 |
| Bone Tissue:0 | 41/61,988 | 4,445/16,348,907 | 2.43 | 5.40e-07 | 3.97e-06 |
| DUSP10:0 | 8/61,988 | 85/16,348,907 | 24.83 | 3.17e-09 | 2.97e-08 |
| DELETION:0 | 126/61,988 | 20,760/16,348,907 | 1.60 | 8.18e-07 | 5.89e-06 |
| FGFR1 gene|FGFR1:0 | 30/61,988 | 1,083/16,348,907 | 7.31 | 2.48e-16 | 3.83e-15 |
| CERS2:0 | 10/61,988 | 73/16,348,907 | 36.13 | 1.12e-12 | 1.37e-11 |
| Nifedipine:0 | 7/61,988 | 24,785/16,348,907 | 0.07 | 5.14e-31 | 1.45e-29 |
| BRCA2 gene|BRCA2:0 | 152/61,988 | 4,922/16,348,907 | 8.16 | 5.49e-82 | 3.80e-80 |
| Histocompatibility Antigens Class II:0 | 9/61,988 | 12,056/16,348,907 | 0.20 | 8.99e-11 | 9.70e-10 |
| Oxytocin:0 | 11/61,988 | 31,200/16,348,907 | 0.09 | 1.66e-36 | 5.53e-35 |
| Motor Neurons:0 | 4/61,988 | 27,207/16,348,907 | 0.04 | 1.50e-38 | 5.29e-37 |
| Cyclins:0 | 56/61,988 | 3,194/16,348,907 | 4.63 | 5.96e-20 | 1.12e-18 |
| Oligodendroglia:0 | 1/61,988 | 11,923/16,348,907 | 0.02 | 2.90e-18 | 4.97e-17 |
| Pudendal artery:0 | 9/61,988 | 102/16,348,907 | 23.27 | 5.59e-10 | 5.60e-09 |
| Ascorbic Acid:0 | 90/61,988 | 40,315/16,348,907 | 0.59 | 4.90e-08 | 4.05e-07 |
| bicalutamide 150 MG:0 | 24/61,988 | 37/16,348,907 | 171.14 | 3.68e-42 | 1.41e-40 |
| Tumor Necrosis Factor-alpha|TNF:0 | 64/61,988 | 39,958/16,348,907 | 0.42 | 1.64e-15 | 2.43e-14 |
| Anticholesteremic Agents:0 | 20/61,988 | 1,335/16,348,907 | 3.95 | 4.55e-07 | 3.37e-06 |
| Nitroglycerin:0 | 6/61,988 | 12,680/16,348,907 | 0.12 | 5.09e-14 | 6.85e-13 |
| Estrogen Antagonists:0 | 115/61,988 | 9,641/16,348,907 | 3.15 | 4.78e-25 | 1.11e-23 |
| Genes, Suppressor:0 | 21/61,988 | 964/16,348,907 | 5.75 | 4.72e-10 | 4.78e-09 |
| Fatigue:0 | 163/61,988 | 26,582/16,348,907 | 1.62 | 1.12e-08 | 9.89e-08 |
| Prostatic gland:0 | 6/61,988 | 12/16,348,907 | 131.88 | 5.18e-11 | 5.68e-10 |
| Colorectal Neoplasms:0 | 53/61,988 | 6,571/16,348,907 | 2.13 | 9.59e-07 | 6.83e-06 |
| Human Glandular Kallikrein 2:0 | 40/61,988 | 112/16,348,907 | 94.25 | 6.50e-61 | 3.52e-59 |
| Neurotransmitters:0 | 23/61,988 | 25,852/16,348,907 | 0.23 | 1.59e-19 | 2.91e-18 |
| receptor binding sites:0 | 17/61,988 | 1,017/16,348,907 | 4.41 | 7.61e-07 | 5.50e-06 |
| Human Cell Line:0 | 2,358/61,988 | 74,082/16,348,907 | 8.69 | 0.00e+00 | 0.00e+00 |
| Insulin|INS:0 | 104/61,988 | 63,586/16,348,907 | 0.43 | 4.16e-23 | 8.98e-22 |
| Cell Proliferation:0 | 2,210/61,988 | 80,896/16,348,907 | 7.43 | 0.00e+00 | 0.00e+00 |
| Rectal examination:0 | 83/61,988 | 310/16,348,907 | 70.71 | 1.15e-115 | 1.11e-113 |
| vitamin E succinate:0 | 23/61,988 | 658/16,348,907 | 9.22 | 6.70e-15 | 9.52e-14 |
| Corpora amylacea:0 | 9/61,988 | 145/16,348,907 | 16.37 | 1.01e-08 | 8.99e-08 |
| polyestradiol phosphate:0 | 37/61,988 | 156/16,348,907 | 62.59 | 8.42e-51 | 3.88e-49 |
| Inguinal part of abdomen:0 | 11/61,988 | 131/16,348,907 | 22.15 | 1.13e-11 | 1.30e-10 |
| Urothelial carcinoma urethra:0 | 8/61,988 | 26/16,348,907 | 81.16 | 6.89e-13 | 8.55e-12 |
| Blood Platelets:0 | 20/61,988 | 32,989/16,348,907 | 0.16 | 3.89e-31 | 1.10e-29 |
| Proton Pump Inhibitors:0 | 8/61,988 | 10,286/16,348,907 | 0.21 | 4.24e-09 | 3.90e-08 |
| SPDEF:0 | 31/61,988 | 201/16,348,907 | 40.70 | 1.18e-37 | 4.07e-36 |
| Opaque marker:0 | 12/61,988 | 504/16,348,907 | 6.28 | 9.57e-07 | 6.82e-06 |
| fluorodeoxyglucose:0 | 34/61,988 | 2,356/16,348,907 | 3.81 | 1.48e-10 | 1.56e-09 |
| Spinal Cord Diseases:0 | 9/61,988 | 8,831/16,348,907 | 0.27 | 1.36e-06 | 9.46e-06 |
| Neoplasms, Experimental:0 | 44/61,988 | 2,685/16,348,907 | 4.32 | 4.99e-15 | 7.16e-14 |
| Genitourinary Cancer:0 | 145/61,988 | 439/16,348,907 | 87.32 | 4.26e-212 | 7.41e-210 |
| mTOR Inhibitor:0 | 25/61,988 | 1,147/16,348,907 | 5.75 | 1.10e-11 | 1.27e-10 |
| Exercise stress test:0 | 3/61,988 | 14,198/16,348,907 | 0.06 | 2.37e-19 | 4.31e-18 |
| Estrogen Receptors:0 | 141/61,988 | 11,006/16,348,907 | 3.38 | 2.48e-33 | 7.53e-32 |
| Cryoprobe:0 | 11/61,988 | 429/16,348,907 | 6.76 | 1.34e-06 | 9.35e-06 |
| NPPB:0 | 1/61,988 | 5,961/16,348,907 | 0.04 | 8.59e-09 | 7.67e-08 |
| Advice:0 | 125/61,988 | 11,114/16,348,907 | 2.97 | 6.28e-25 | 1.46e-23 |
| Excitability:0 | 2/61,988 | 18,691/16,348,907 | 0.03 | 1.19e-27 | 3.04e-26 |
| Intracranial Hemorrhages:0 | 1/61,988 | 6,566/16,348,907 | 0.04 | 9.91e-10 | 9.67e-09 |
| KLK2 gene|KLK2:0 | 19/61,988 | 35/16,348,907 | 143.22 | 1.49e-32 | 4.44e-31 |
| gene polymorphism:0 | 94/61,988 | 11,200/16,348,907 | 2.22 | 9.84e-12 | 1.13e-10 |
| Horseradish Peroxidase:0 | 15/61,988 | 14,752/16,348,907 | 0.27 | 1.76e-10 | 1.85e-09 |
| Single tumor:0 | 25/61,988 | 971/16,348,907 | 6.79 | 3.40e-13 | 4.32e-12 |
| Rod Photoreceptors:0 | 1/61,988 | 5,997/16,348,907 | 0.04 | 5.64e-09 | 5.14e-08 |
| Oxidase:0 | 8/61,988 | 10,784/16,348,907 | 0.20 | 8.51e-10 | 8.40e-09 |
| Rectum:0 | 560/61,988 | 19,685/16,348,907 | 7.56 | 4.99e-280 | 1.14e-277 |
| Gene Amplification:0 | 28/61,988 | 1,378/16,348,907 | 5.36 | 3.33e-12 | 3.96e-11 |
| Medical Imaging:0 | 1,260/61,988 | 145,462/16,348,907 | 2.31 | 8.29e-148 | 1.04e-145 |
| Tumor Burden:0 | 65/61,988 | 1,857/16,348,907 | 9.24 | 3.58e-39 | 1.29e-37 |
| Fibromyalgia:0 | 4/61,988 | 21,318/16,348,907 | 0.05 | 3.86e-29 | 1.04e-27 |
| Protein-tyrosine kinase inhibitor:0 | 115/61,988 | 12,674/16,348,907 | 2.40 | 2.46e-16 | 3.80e-15 |
| Catheterization:0 | 67/61,988 | 8,096/16,348,907 | 2.18 | 1.24e-08 | 1.09e-07 |
| S Phase:0 | 59/61,988 | 4,852/16,348,907 | 3.21 | 5.20e-14 | 6.99e-13 |
| ixabepilone:0 | 24/61,988 | 793/16,348,907 | 7.98 | 3.59e-14 | 4.88e-13 |
| Minor pelvis:0 | 34/61,988 | 592/16,348,907 | 15.16 | 7.82e-28 | 2.01e-26 |
| Neoplasm progression:0 | 3,611/61,988 | 37,131/16,348,907 | 27.17 | 0.00e+00 | 0.00e+00 |
| HDAC1 gene|HDAC1:0 | 27/61,988 | 2,119/16,348,907 | 3.36 | 1.23e-07 | 9.70e-07 |
| Eosinophilia:0 | 6/61,988 | 9,618/16,348,907 | 0.16 | 1.16e-09 | 1.12e-08 |
| THBS1 gene|THBS1:0 | 13/61,988 | 545/16,348,907 | 6.29 | 3.36e-07 | 2.53e-06 |
| Insulin-Like Growth Factor Binding Protein 3:0 | 201/61,988 | 6,361/16,348,907 | 8.36 | 1.53e-109 | 1.38e-107 |
| Mycelium:0 | 2/61,988 | 6,477/16,348,907 | 0.08 | 1.27e-08 | 1.12e-07 |
| Difluoromethylornithine|TH:0 | 5/61,988 | 14/16,348,907 | 94.20 | 8.55e-09 | 7.65e-08 |
| AKR1C1|AKR1C1:0 | 11/61,988 | 228/16,348,907 | 12.73 | 2.92e-09 | 2.75e-08 |
| Calcitriol:0 | 123/61,988 | 9,538/16,348,907 | 3.41 | 1.49e-29 | 4.06e-28 |
| Integrin alpha6|ITGA6:0 | 14/61,988 | 341/16,348,907 | 10.83 | 1.62e-10 | 1.70e-09 |
| Immunotherapy, Active:0 | 37/61,988 | 897/16,348,907 | 10.88 | 2.34e-25 | 5.51e-24 |
| Stage B:0 | 5/61,988 | 32/16,348,907 | 41.21 | 3.03e-07 | 2.29e-06 |
| Embolization, Therapeutic:0 | 41/61,988 | 29,910/16,348,907 | 0.36 | 9.41e-15 | 1.32e-13 |
| Scoliosis, unspecified:0 | 1/61,988 | 8,508/16,348,907 | 0.03 | 6.54e-13 | 8.12e-12 |
| Acoustic Neuroma:0 | 4/61,988 | 6,496/16,348,907 | 0.16 | 7.83e-07 | 5.65e-06 |
| Genistein:0 | 340/61,988 | 20,100/16,348,907 | 4.48 | 4.96e-108 | 4.40e-106 |
| Milk:0 | 14/61,988 | 15,301/16,348,907 | 0.24 | 9.85e-12 | 1.13e-10 |
| Entire pelvic cavity:0 | 13/61,988 | 444/16,348,907 | 7.72 | 3.45e-08 | 2.91e-07 |
| NCOA2 gene|NCOA2:0 | 15/61,988 | 435/16,348,907 | 9.10 | 3.70e-10 | 3.79e-09 |
| Decubitus ulcer:0 | 2/61,988 | 8,423/16,348,907 | 0.06 | 1.55e-11 | 1.76e-10 |
| Staff:0 | 19/61,988 | 13,285/16,348,907 | 0.38 | 8.68e-07 | 6.24e-06 |
| Debridement:0 | 12/61,988 | 15,279/16,348,907 | 0.21 | 5.06e-13 | 6.35e-12 |
| caspase-7:0 | 21/61,988 | 618/16,348,907 | 8.96 | 1.64e-13 | 2.14e-12 |
| E2F3:0 | 14/61,988 | 441/16,348,907 | 8.37 | 3.89e-09 | 3.61e-08 |
| Urethral Neoplasms:0 | 18/61,988 | 127/16,348,907 | 37.39 | 6.47e-22 | 1.33e-20 |
| BCL2 gene|BCL2:0 | 73/61,988 | 3,721/16,348,907 | 5.18 | 2.62e-28 | 6.83e-27 |
| Transitional Cell Neoplasm:0 | 13/61,988 | 492/16,348,907 | 6.97 | 1.09e-07 | 8.64e-07 |
| Image analysis:0 | 94/61,988 | 6,124/16,348,907 | 4.05 | 3.58e-28 | 9.25e-27 |
| Alcoholic Liver Diseases:0 | 3/61,988 | 6,594/16,348,907 | 0.12 | 9.74e-08 | 7.78e-07 |
| Tumor Suppression:0 | 52/61,988 | 1,050/16,348,907 | 13.07 | 1.17e-38 | 4.15e-37 |
| Nephrogenic adenoma:0 | 24/61,988 | 450/16,348,907 | 14.07 | 2.04e-19 | 3.73e-18 |
| Peripheral Neuropathy:0 | 16/61,988 | 11,821/16,348,907 | 0.36 | 1.33e-06 | 9.26e-06 |
| Ductal Breast Carcinoma:0 | 68/61,988 | 1,672/16,348,907 | 10.74 | 8.23e-45 | 3.34e-43 |
| Buprenorphine:0 | 1/61,988 | 9,591/16,348,907 | 0.03 | 1.18e-14 | 1.65e-13 |
| Green Fluorescent Proteins|UBTF:0 | 3/61,988 | 2/16,348,907 | 395.63 | 5.36e-07 | 3.94e-06 |
| GTP-Binding Proteins:0 | 38/61,988 | 20,571/16,348,907 | 0.49 | 8.98e-07 | 6.43e-06 |
| glucose transport:0 | 5/61,988 | 7,869/16,348,907 | 0.17 | 5.85e-08 | 4.78e-07 |
| Stains:0 | 19/61,988 | 1,228/16,348,907 | 4.08 | 5.46e-07 | 4.01e-06 |
| Peplomycin|PAEP|PREP|PTPN22:0 | 6/61,988 | 3/16,348,907 | 527.54 | 2.42e-13 | 3.11e-12 |
| Pericardial sac structure:0 | 2/61,988 | 5,342/16,348,907 | 0.10 | 9.15e-07 | 6.55e-06 |
| Somatic mutation:0 | 64/61,988 | 4,263/16,348,907 | 3.96 | 2.87e-19 | 5.20e-18 |
| Duodenal Ulcer:0 | 189/61,988 | 19,063/16,348,907 | 2.62 | 5.35e-30 | 1.47e-28 |
| Atypia:0 | 40/61,988 | 1,292/16,348,907 | 8.17 | 6.70e-23 | 1.43e-21 |
| Lignin:0 | 1/61,988 | 4,851/16,348,907 | 0.05 | 4.47e-07 | 3.32e-06 |
| Rectum finding:0 | 4/61,988 | 6/16,348,907 | 175.84 | 4.20e-08 | 3.49e-07 |
| Magnetic resonance imaging of pelvis:0 | 8/61,988 | 115/16,348,907 | 18.35 | 2.90e-08 | 2.46e-07 |
| Estrogenic:0 | 89/61,988 | 5,465/16,348,907 | 4.30 | 1.69e-28 | 4.44e-27 |
| Bacterial Infections:0 | 24/61,988 | 20,604/16,348,907 | 0.31 | 1.68e-12 | 2.04e-11 |
| Breast neoplasm screening:0 | 19/61,988 | 806/16,348,907 | 6.22 | 8.89e-10 | 8.76e-09 |
| Ptosis:0 | 14/61,988 | 12,843/16,348,907 | 0.29 | 9.42e-09 | 8.40e-08 |
| isosilybin:0 | 5/61,988 | 36/16,348,907 | 36.63 | 5.14e-07 | 3.79e-06 |
| GPX1:0 | 13/61,988 | 354/16,348,907 | 9.69 | 2.62e-09 | 2.47e-08 |
| cancer surgery:0 | 24/61,988 | 1,254/16,348,907 | 5.05 | 3.55e-10 | 3.64e-09 |
| Phytotherapy:0 | 22/61,988 | 792/16,348,907 | 7.33 | 2.06e-12 | 2.48e-11 |
| Phospholipase A2:0 | 22/61,988 | 14,755/16,348,907 | 0.39 | 4.06e-07 | 3.03e-06 |
| Sterile coverings:0 | 3/61,988 | 7,396/16,348,907 | 0.11 | 6.16e-09 | 5.59e-08 |
| Biliary Atresia:0 | 1/61,988 | 6,116/16,348,907 | 0.04 | 3.96e-09 | 3.66e-08 |
| Insurance Coverage:0 | 51/61,988 | 3,386/16,348,907 | 3.97 | 9.57e-16 | 1.43e-14 |
| ERBB2 gene|ERBB2:0 | 133/61,988 | 11,298/16,348,907 | 3.11 | 3.56e-28 | 9.22e-27 |
| SRD5A1:0 | 14/61,988 | 113/16,348,907 | 32.68 | 1.25e-16 | 1.97e-15 |
| EP300 gene|EP300:0 | 18/61,988 | 777/16,348,907 | 6.11 | 3.16e-09 | 2.96e-08 |
| Microscopy, Electron, Scanning:0 | 4/61,988 | 9,467/16,348,907 | 0.11 | 4.41e-11 | 4.86e-10 |
| Prostate and urinary bladder:0 | 9/61,988 | 24/16,348,907 | 98.92 | 5.56e-15 | 7.95e-14 |
| CpG Islands:0 | 111/61,988 | 3,724/16,348,907 | 7.87 | 6.69e-59 | 3.54e-57 |
| Methane:0 | 3/61,988 | 5,714/16,348,907 | 0.14 | 1.41e-06 | 9.77e-06 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase activity:0 | 9/61,988 | 62/16,348,907 | 38.29 | 9.44e-12 | 1.09e-10 |
| NFKB1:0 | 66/61,988 | 5,144/16,348,907 | 3.39 | 1.50e-16 | 2.35e-15 |
| Sensors:0 | 43/61,988 | 22,174/16,348,907 | 0.51 | 1.31e-06 | 9.13e-06 |
| Plenaxis:0 | 5/61,988 | 9/16,348,907 | 146.54 | 1.50e-09 | 1.44e-08 |
| Gleason Pattern 5:0 | 14/61,988 | 24/16,348,907 | 153.88 | 1.07e-24 | 2.45e-23 |
| Comorbidity:0 | 35/61,988 | 1,771/16,348,907 | 5.21 | 1.60e-14 | 2.22e-13 |
| fluoroethylcholine:0 | 12/61,988 | 30/16,348,907 | 105.52 | 8.39e-20 | 1.56e-18 |
| Magnesium:0 | 12/61,988 | 21,165/16,348,907 | 0.15 | 4.78e-21 | 9.48e-20 |
| Upper gastrointestinal hemorrhage:0 | 2/61,988 | 5,860/16,348,907 | 0.09 | 1.05e-07 | 8.32e-07 |
| Tinnitus:0 | 2/61,988 | 9,270/16,348,907 | 0.06 | 9.59e-13 | 1.18e-11 |
| Cataract:0 | 10/61,988 | 23,097/16,348,907 | 0.11 | 2.08e-25 | 4.91e-24 |
| Pneumonia:0 | 26/61,988 | 83,170/16,348,907 | 0.08 | 3.97e-99 | 3.19e-97 |
| Tumor Cell Invasion:0 | 161/61,988 | 4,558/16,348,907 | 9.34 | 6.63e-95 | 5.21e-93 |
| Proto-Oncogene Proteins c-myc|MYC:0 | 72/61,988 | 5,926/16,348,907 | 3.21 | 1.03e-16 | 1.63e-15 |
| X-Ray Computed Tomography:0 | 239/61,988 | 28,334/16,348,907 | 2.23 | 9.70e-28 | 2.48e-26 |
| CA2:0 | 90/61,988 | 129,513/16,348,907 | 0.18 | 6.48e-110 | 5.86e-108 |
| loss; bone:0 | 239/61,988 | 18,786/16,348,907 | 3.36 | 1.00e-54 | 4.99e-53 |
| Rhabdomyosarcoma:0 | 150/61,988 | 11,067/16,348,907 | 3.58 | 5.99e-38 | 2.08e-36 |
| beta catenin:0 | 289/61,988 | 29,409/16,348,907 | 2.60 | 1.90e-44 | 7.65e-43 |
| High-Risk Cancer:0 | 1,296/61,988 | 7,468/16,348,907 | 46.73 | 0.00e+00 | 0.00e+00 |
| Fine-needle biopsy:0 | 12/61,988 | 494/16,348,907 | 6.41 | 7.82e-07 | 5.64e-06 |
| Androstanediol:0 | 13/61,988 | 323/16,348,907 | 10.62 | 9.07e-10 | 8.93e-09 |
| Tomato sauce:0 | 7/61,988 | 18/16,348,907 | 102.58 | 4.97e-12 | 5.86e-11 |
| prostate stem cell antigen:0 | 80/61,988 | 193/16,348,907 | 109.46 | 1.89e-124 | 2.02e-122 |
| Very low:0 | 50/61,988 | 5,084/16,348,907 | 2.60 | 4.35e-09 | 4.00e-08 |
| Radical retropubic prostatectomy:0 | 963/61,988 | 2,101/16,348,907 | 122.78 | 0.00e+00 | 0.00e+00 |
| Harbor:0 | 31/61,988 | 2,417/16,348,907 | 3.38 | 1.31e-08 | 1.15e-07 |
| Cancer Intervention:0 | 7/61,988 | 31/16,348,907 | 59.56 | 1.25e-10 | 1.33e-09 |
| UGT2B17:0 | 15/61,988 | 149/16,348,907 | 26.56 | 1.77e-16 | 2.75e-15 |
| Extent of disease:0 | 5/61,988 | 11/16,348,907 | 119.89 | 3.24e-09 | 3.03e-08 |
| Glutamate Receptor:0 | 3/61,988 | 8,278/16,348,907 | 0.10 | 2.65e-10 | 2.75e-09 |
| MAP1LC3B:0 | 12/61,988 | 343/16,348,907 | 9.23 | 1.77e-08 | 1.53e-07 |
| Utilities:0 | 65/61,988 | 4,126/16,348,907 | 4.16 | 1.45e-20 | 2.82e-19 |
| Irradiation cystitis:0 | 32/61,988 | 283/16,348,907 | 29.84 | 6.82e-35 | 2.14e-33 |
| Seizures:0 | 46/61,988 | 57,336/16,348,907 | 0.21 | 5.45e-45 | 2.23e-43 |
| PAK6 gene|PAK6:0 | 9/61,988 | 170/16,348,907 | 13.96 | 3.72e-08 | 3.12e-07 |
| amidronate:0 | 103/61,988 | 7,720/16,348,907 | 3.52 | 4.11e-26 | 1.00e-24 |
| Diversion procedure:0 | 57/61,988 | 4,464/16,348,907 | 3.37 | 1.96e-14 | 2.70e-13 |
| S-Phase Fraction:0 | 52/61,988 | 2,829/16,348,907 | 4.85 | 1.75e-19 | 3.20e-18 |
| Elderly man:0 | 23/61,988 | 1,297/16,348,907 | 4.68 | 3.29e-09 | 3.07e-08 |
| Multiple Sclerosis:0 | 25/61,988 | 93,770/16,348,907 | 0.07 | 2.42e-116 | 2.38e-114 |
| Hemoglobin:0 | 76/61,988 | 43,112/16,348,907 | 0.46 | 3.43e-14 | 4.67e-13 |
| decursin:0 | 11/61,988 | 334/16,348,907 | 8.69 | 1.24e-07 | 9.75e-07 |
| Virus:0 | 92/61,988 | 67,078/16,348,907 | 0.36 | 1.97e-31 | 5.66e-30 |
| FK-506:0 | 10/61,988 | 11,219/16,348,907 | 0.23 | 4.96e-09 | 4.54e-08 |
| Esophagus:0 | 274/61,988 | 39,005/16,348,907 | 1.86 | 1.92e-20 | 3.71e-19 |
| epithelial to mesenchymal transition:0 | 84/61,988 | 2,290/16,348,907 | 9.69 | 1.32e-51 | 6.19e-50 |
| Facilitation:0 | 5/61,988 | 8,321/16,348,907 | 0.16 | 1.09e-08 | 9.65e-08 |
| STEAP1:0 | 30/61,988 | 136/16,348,907 | 58.21 | 1.16e-40 | 4.30e-39 |
| Diabetic Retinopathy:0 | 14/61,988 | 21,356/16,348,907 | 0.17 | 1.10e-19 | 2.03e-18 |
| Urinalysis:0 | 32/61,988 | 2,596/16,348,907 | 3.25 | 1.90e-08 | 1.63e-07 |
| naftopidil:0 | 13/61,988 | 534/16,348,907 | 6.42 | 2.69e-07 | 2.04e-06 |
| Pregnancy:0 | 31/61,988 | 98,117/16,348,907 | 0.08 | 2.87e-116 | 2.81e-114 |
| delta-catenin:0 | 14/61,988 | 331/16,348,907 | 11.16 | 1.11e-10 | 1.19e-09 |
| Arabidopsis thaliana:0 | 3/61,988 | 13,218/16,348,907 | 0.06 | 8.53e-18 | 1.42e-16 |
| External auditory canal structure:0 | 1/61,988 | 4,711/16,348,907 | 0.06 | 6.18e-07 | 4.51e-06 |
| Stents:0 | 46/61,988 | 51,189/16,348,907 | 0.24 | 4.65e-37 | 1.57e-35 |
| European American:0 | 27/61,988 | 1,338/16,348,907 | 5.32 | 9.30e-12 | 1.07e-10 |
| Measurable Disease:0 | 144/61,988 | 1,465/16,348,907 | 25.98 | 6.17e-143 | 7.46e-141 |
| Systemic Therapy:0 | 199/61,988 | 10,219/16,348,907 | 5.15 | 1.53e-73 | 9.75e-72 |
| Chronic inflammatory disorder:0 | 8/61,988 | 8,441/16,348,907 | 0.25 | 8.21e-07 | 5.91e-06 |
| Probes:0 | 442/61,988 | 56,887/16,348,907 | 2.06 | 2.02e-41 | 7.66e-40 |
| Hormone Antagonists:0 | 33/61,988 | 438/16,348,907 | 19.88 | 1.31e-30 | 3.65e-29 |
| TGFB1 protein, human|TGFB1:0 | 248/61,988 | 43,489/16,348,907 | 1.51 | 1.63e-09 | 1.56e-08 |
| Small prostate:0 | 63/61,988 | 181/16,348,907 | 91.89 | 2.22e-94 | 1.74e-92 |
| college student:0 | 2/61,988 | 10,231/16,348,907 | 0.05 | 2.52e-14 | 3.46e-13 |
| Estramustine phosphate:0 | 262/61,988 | 906/16,348,907 | 76.59 | 0.00e+00 | 0.00e+00 |
| Intracranial:0 | 28/61,988 | 18,191/16,348,907 | 0.41 | 4.28e-08 | 3.55e-07 |
| Bilirubin:0 | 4/61,988 | 8,559/16,348,907 | 0.12 | 9.61e-10 | 9.41e-09 |
| overdiagnosis:0 | 60/61,988 | 278/16,348,907 | 56.98 | 3.66e-79 | 2.47e-77 |
| Apolipoprotein A-I:0 | 8/61,988 | 10,133/16,348,907 | 0.21 | 5.68e-09 | 5.18e-08 |
| Premature Birth:0 | 1/61,988 | 15,951/16,348,907 | 0.02 | 8.51e-25 | 1.96e-23 |
| PGR gene|PGR:0 | 29/61,988 | 1,592/16,348,907 | 4.81 | 1.75e-11 | 1.98e-10 |
| Brucellosis:0 | 1/61,988 | 8,283/16,348,907 | 0.03 | 1.33e-12 | 1.62e-11 |
| Prostatic Urethra:0 | 283/61,988 | 942/16,348,907 | 79.59 | 0.00e+00 | 0.00e+00 |
| Suspected prostate cancer:0 | 151/61,988 | 190/16,348,907 | 210.12 | 1.21e-266 | 2.61e-264 |
| Hyperglycemia:0 | 33/61,988 | 35,522/16,348,907 | 0.24 | 1.81e-25 | 4.29e-24 |
| CAMKK2:0 | 7/61,988 | 91/16,348,907 | 20.29 | 1.12e-07 | 8.90e-07 |
| Macrophage Chemotactic Factors:0 | 89/61,988 | 4,288/16,348,907 | 5.48 | 7.00e-36 | 2.27e-34 |
| Complication, infection:0 | 45/61,988 | 4,852/16,348,907 | 2.45 | 1.33e-07 | 1.05e-06 |
| Transplantation:0 | 96/61,988 | 113,545/16,348,907 | 0.22 | 1.34e-84 | 9.57e-83 |
| Transducers:0 | 61/61,988 | 7,260/16,348,907 | 2.22 | 3.17e-08 | 2.67e-07 |
| V 70:0 | 21/61,988 | 44/16,348,907 | 125.92 | 6.82e-35 | 2.14e-33 |
| ghrelin:0 | 21/61,988 | 20,943/16,348,907 | 0.26 | 1.42e-14 | 1.98e-13 |
| epitheliasin:0 | 5/61,988 | 20/16,348,907 | 65.94 | 3.84e-08 | 3.20e-07 |
| Palliative:0 | 9/61,988 | 236/16,348,907 | 10.06 | 5.31e-07 | 3.91e-06 |
| Pulmonary Embolism:0 | 51/61,988 | 28,204/16,348,907 | 0.48 | 2.68e-09 | 2.53e-08 |
| Polypeptides:0 | 69/61,988 | 39,224/16,348,907 | 0.46 | 4.40e-13 | 5.53e-12 |
| Podocytes:0 | 2/61,988 | 8,393/16,348,907 | 0.06 | 1.52e-11 | 1.72e-10 |
| Penile Implantation:0 | 10/61,988 | 324/16,348,907 | 8.14 | 8.10e-07 | 5.84e-06 |
| Estramustine Phosphate Sodium:0 | 9/61,988 | 45/16,348,907 | 52.76 | 7.14e-13 | 8.84e-12 |
| expression vector:0 | 66/61,988 | 5,125/16,348,907 | 3.40 | 1.26e-16 | 1.98e-15 |
| DLEC1 gene|DLEC1:0 | 10/61,988 | 337/16,348,907 | 7.83 | 1.14e-06 | 8.04e-06 |
| Probability:0 | 20/61,988 | 1,191/16,348,907 | 4.43 | 7.89e-08 | 6.35e-07 |
| Pelvic cavity structure:0 | 11/61,988 | 400/16,348,907 | 7.25 | 6.95e-07 | 5.04e-06 |
| Spondylarthritis:0 | 1/61,988 | 6,137/16,348,907 | 0.04 | 4.04e-09 | 3.72e-08 |
| Saccharomycetales:0 | 1/61,988 | 4,992/16,348,907 | 0.05 | 2.08e-07 | 1.61e-06 |
| Cardiac Hypertrophy:0 | 1/61,988 | 9,792/16,348,907 | 0.03 | 5.71e-15 | 8.16e-14 |
| BTG1 gene|BTG1|PPBP:0 | 303/61,988 | 777/16,348,907 | 103.35 | 0.00e+00 | 0.00e+00 |
| Vas deferens structure:0 | 17/61,988 | 1,039/16,348,907 | 4.32 | 1.01e-06 | 7.18e-06 |
| athlete:0 | 6/61,988 | 38,102/16,348,907 | 0.04 | 5.19e-53 | 2.50e-51 |
| parent:0 | 88/61,988 | 56,632/16,348,907 | 0.41 | 1.56e-22 | 3.29e-21 |
| Coagulating gland:0 | 12/61,988 | 275/16,348,907 | 11.51 | 1.67e-09 | 1.60e-08 |
| Entire pulmonary artery:0 | 4/61,988 | 17,317/16,348,907 | 0.06 | 5.99e-23 | 1.28e-21 |
| Ligaments:0 | 3/61,988 | 8,086/16,348,907 | 0.10 | 5.36e-10 | 5.39e-09 |
| Phyllodes Tumor:0 | 44/61,988 | 1,772/16,348,907 | 6.55 | 1.98e-21 | 3.98e-20 |
| Recombinant Erythropoietin:0 | 17/61,988 | 23,175/16,348,907 | 0.19 | 6.20e-20 | 1.16e-18 |
| Cruciferous Vegetable:0 | 24/61,988 | 160/16,348,907 | 39.58 | 3.02e-29 | 8.15e-28 |
| Encephalopathies:0 | 9/61,988 | 12,372/16,348,907 | 0.19 | 3.46e-11 | 3.84e-10 |
| KCNK3:0 | 2/61,988 | 6,396/16,348,907 | 0.08 | 1.82e-08 | 1.57e-07 |
| cell motility:0 | 636/61,988 | 30,404/16,348,907 | 5.56 | 4.78e-247 | 9.37e-245 |
| Binding Protein:0 | 174/61,988 | 30,496/16,348,907 | 1.51 | 4.40e-07 | 3.27e-06 |
| Neuronal Transmission:0 | 3/61,988 | 11,694/16,348,907 | 0.07 | 1.72e-15 | 2.54e-14 |
| taxane:0 | 166/61,988 | 4,211/16,348,907 | 10.42 | 9.12e-105 | 7.79e-103 |
| Cyproterone:0 | 13/61,988 | 259/16,348,907 | 13.24 | 6.87e-11 | 7.46e-10 |
| Dutasteride:0 | 169/61,988 | 1,443/16,348,907 | 30.97 | 3.48e-179 | 5.26e-177 |
| Pelvic floor exercises:0 | 15/61,988 | 457/16,348,907 | 8.66 | 7.09e-10 | 7.03e-09 |
| Sensorineural Hearing Loss:0 | 1/61,988 | 9,588/16,348,907 | 0.03 | 1.18e-14 | 1.65e-13 |
| Sheep:0 | 16/61,988 | 64,650/16,348,907 | 0.07 | 4.87e-82 | 3.38e-80 |
| ANO7:0 | 4/61,988 | 16/16,348,907 | 65.94 | 9.40e-07 | 6.70e-06 |
| Mannose:0 | 2/61,988 | 5,474/16,348,907 | 0.10 | 4.25e-07 | 3.17e-06 |
| Sarcoplasmic Reticulum:0 | 5/61,988 | 15,289/16,348,907 | 0.09 | 9.12e-19 | 1.61e-17 |
| Apoptosis Inducing Proteins:0 | 36/61,988 | 1,136/16,348,907 | 8.36 | 4.33e-21 | 8.61e-20 |
| Bone Resorption:0 | 137/61,988 | 11,701/16,348,907 | 3.09 | 9.46e-29 | 2.51e-27 |
| Abuse:0 | 3/61,988 | 13,648/16,348,907 | 0.06 | 2.15e-18 | 3.71e-17 |
| AIDS related complex:0 | 152/61,988 | 9,047/16,348,907 | 4.44 | 5.62e-49 | 2.50e-47 |
| Carcinoma of the Large Intestine:0 | 763/61,988 | 102,181/16,348,907 | 1.98 | 8.81e-64 | 5.01e-62 |
| BAK1 gene|BAK1:0 | 52/61,988 | 2,986/16,348,907 | 4.60 | 1.59e-18 | 2.76e-17 |
| White Matter:0 | 3/61,988 | 17,781/16,348,907 | 0.04 | 5.89e-25 | 1.37e-23 |
| Sensitized cell:0 | 52/61,988 | 1,905/16,348,907 | 7.20 | 7.91e-27 | 1.98e-25 |
| Fluoroscopy:0 | 44/61,988 | 4,266/16,348,907 | 2.72 | 9.31e-09 | 8.30e-08 |
| Chromosomes, Human:0 | 44/61,988 | 3,110/16,348,907 | 3.73 | 6.40e-13 | 7.96e-12 |
| ASPARAGINASE:0 | 1/61,988 | 4,883/16,348,907 | 0.05 | 4.71e-07 | 3.48e-06 |
| Interleukin-1 alpha:0 | 39/61,988 | 25,507/16,348,907 | 0.40 | 4.73e-11 | 5.20e-10 |
| hepsin:0 | 7/61,988 | 33/16,348,907 | 55.95 | 1.83e-10 | 1.92e-09 |
| African American:0 | 530/61,988 | 24,443/16,348,907 | 5.76 | 7.89e-213 | 1.38e-210 |
| Tendinopathy:0 | 1/61,988 | 5,385/16,348,907 | 0.05 | 4.92e-08 | 4.06e-07 |
| Neoplasms, Epithelial:0 | 92/61,988 | 3,740/16,348,907 | 6.50 | 1.28e-42 | 4.95e-41 |
| Visual Acuity:0 | 1/61,988 | 12,489/16,348,907 | 0.02 | 3.08e-19 | 5.57e-18 |
| oncoprotein p21|CDKN1A|TCEAL1|NSG1|H3F3AP6:0 | 27/61,988 | 543/16,348,907 | 13.12 | 6.64e-21 | 1.31e-19 |
| Zea mays:0 | 2/61,988 | 12,948/16,348,907 | 0.04 | 1.61e-18 | 2.79e-17 |
| Gestational Age:0 | 2/61,988 | 10,552/16,348,907 | 0.05 | 8.89e-15 | 1.25e-13 |
| geldanamycin:0 | 30/61,988 | 2,712/16,348,907 | 2.92 | 4.76e-07 | 3.52e-06 |
| Zidovudine:0 | 6/61,988 | 16,903/16,348,907 | 0.09 | 4.27e-20 | 8.10e-19 |
| Ethylene:0 | 1/61,988 | 10,953/16,348,907 | 0.02 | 7.05e-17 | 1.12e-15 |
| Malignant tumor of colon:0 | 595/61,988 | 38,289/16,348,907 | 4.13 | 4.11e-171 | 5.96e-169 |
| Left ventricular structure:0 | 24/61,988 | 38,888/16,348,907 | 0.16 | 4.22e-36 | 1.39e-34 |
| Vitamin D:0 | 415/61,988 | 30,917/16,348,907 | 3.56 | 1.66e-100 | 1.36e-98 |
| Cancer of Urinary Tract:0 | 245/61,988 | 773/16,348,907 | 83.92 | 0.00e+00 | 0.00e+00 |
| Closure:0 | 8/61,988 | 11,006/16,348,907 | 0.19 | 4.53e-10 | 4.60e-09 |
| Neck Carcinoma:0 | 15/61,988 | 574/16,348,907 | 6.89 | 1.36e-08 | 1.19e-07 |
| Proteasome inhibitor:0 | 107/61,988 | 5,913/16,348,907 | 4.78 | 1.08e-37 | 3.71e-36 |
| Specimen from prostate:0 | 659/61,988 | 1,141/16,348,907 | 153.95 | 0.00e+00 | 0.00e+00 |
| E2F1 gene|E2F1|UBE2L3:0 | 65/61,988 | 3,878/16,348,907 | 4.42 | 6.68e-22 | 1.37e-20 |
| Infections, Upper Respiratory:0 | 2/61,988 | 5,419/16,348,907 | 0.10 | 6.25e-07 | 4.56e-06 |
| DNA Double Strand Break:0 | 26/61,988 | 2,180/16,348,907 | 3.15 | 6.96e-07 | 5.05e-06 |
| Therapeutic agent (substance):0 | 192/61,988 | 11,388/16,348,907 | 4.46 | 1.33e-61 | 7.29e-60 |
| Coughing:0 | 8/61,988 | 13,509/16,348,907 | 0.16 | 1.88e-13 | 2.44e-12 |
| Fibroblast Growth Factor 8:0 | 20/61,988 | 314/16,348,907 | 16.80 | 7.73e-18 | 1.30e-16 |
| Ribosomal RNA:0 | 21/61,988 | 25,593/16,348,907 | 0.22 | 2.14e-20 | 4.12e-19 |
| Nerve operations:0 | 9/61,988 | 259/16,348,907 | 9.17 | 1.12e-06 | 7.87e-06 |
| Low Birth Weights:0 | 1/61,988 | 12,477/16,348,907 | 0.02 | 3.03e-19 | 5.48e-18 |
| Macrolide Antibiotics:0 | 3/61,988 | 6,582/16,348,907 | 0.12 | 9.60e-08 | 7.67e-07 |
| BRCA1 Protein|BRCA1:0 | 13/61,988 | 319/16,348,907 | 10.75 | 7.85e-10 | 7.76e-09 |
| Endocrine Disruptors:0 | 26/61,988 | 2,126/16,348,907 | 3.23 | 4.42e-07 | 3.28e-06 |
| Adiponectin:0 | 60/61,988 | 35,021/16,348,907 | 0.45 | 2.38e-12 | 2.86e-11 |
| Tumor Necrosis Factor Receptor Superfamily, Member 10B:0 | 34/61,988 | 934/16,348,907 | 9.61 | 8.45e-22 | 1.72e-20 |
| Status Epilepticus:0 | 1/61,988 | 10,565/16,348,907 | 0.02 | 3.05e-16 | 4.68e-15 |
| Metals:0 | 45/61,988 | 35,880/16,348,907 | 0.33 | 2.35e-19 | 4.28e-18 |
| TroVax:0 | 7/61,988 | 47/16,348,907 | 39.29 | 1.66e-09 | 1.60e-08 |
| Myasthenia Gravis:0 | 2/61,988 | 17,936/16,348,907 | 0.03 | 1.39e-26 | 3.44e-25 |
| S Phase Arrest:0 | 17/61,988 | 662/16,348,907 | 6.77 | 1.95e-09 | 1.87e-08 |
| Phosphatidylethanolamine Binding Protein:0 | 23/61,988 | 1,037/16,348,907 | 5.85 | 5.15e-11 | 5.65e-10 |
| Solid organ:0 | 44/61,988 | 1,914/16,348,907 | 6.07 | 3.35e-20 | 6.41e-19 |
| Stanolone:0 | 1,054/61,988 | 15,050/16,348,907 | 18.77 | 0.00e+00 | 0.00e+00 |
| EZH2 gene|EZH2:0 | 92/61,988 | 2,252/16,348,907 | 10.79 | 3.73e-60 | 2.01e-58 |
| Cyclin-Dependent Kinases:0 | 70/61,988 | 5,126/16,348,907 | 3.60 | 8.36e-19 | 1.48e-17 |
| Actuary:0 | 37/61,988 | 713/16,348,907 | 13.69 | 1.14e-28 | 3.02e-27 |
| Hemospermia:0 | 34/61,988 | 342/16,348,907 | 26.23 | 3.11e-35 | 9.88e-34 |
| Amputation of penis NOS:0 | 12/61,988 | 298/16,348,907 | 10.62 | 3.96e-09 | 3.66e-08 |
| Hypophysectomy:0 | 37/61,988 | 1,280/16,348,907 | 7.63 | 2.35e-20 | 4.53e-19 |
| Superoxide Dismutase:0 | 54/61,988 | 50,281/16,348,907 | 0.28 | 2.97e-31 | 8.47e-30 |
| Bone lesion:0 | 108/61,988 | 2,182/16,348,907 | 13.08 | 2.37e-78 | 1.59e-76 |
| Fingers:0 | 9/61,988 | 11,085/16,348,907 | 0.21 | 1.53e-09 | 1.47e-08 |
| TNF-related apoptosis-inducing ligand:0 | 72/61,988 | 2,823/16,348,907 | 6.73 | 1.09e-34 | 3.41e-33 |
| FASN gene|FASN:0 | 42/61,988 | 427/16,348,907 | 25.96 | 5.89e-43 | 2.29e-41 |
| Thymus Gland:0 | 4/61,988 | 10,586/16,348,907 | 0.10 | 1.00e-12 | 1.23e-11 |
| CXCR4 gene|CXCR4:0 | 101/61,988 | 11,679/16,348,907 | 2.28 | 3.00e-13 | 3.83e-12 |
| Outpatients:0 | 88/61,988 | 41,949/16,348,907 | 0.55 | 1.25e-09 | 1.21e-08 |
| Zoonoses:0 | 1/61,988 | 7,914/16,348,907 | 0.03 | 5.81e-12 | 6.82e-11 |
| Jaundice, Obstructive:0 | 7/61,988 | 7,977/16,348,907 | 0.23 | 9.41e-07 | 6.71e-06 |
| glutathione S-transferase pi|GSTP1:0 | 14/61,988 | 350/16,348,907 | 10.55 | 2.24e-10 | 2.33e-09 |
| Lung Diseases, Interstitial:0 | 3/61,988 | 8,762/16,348,907 | 0.09 | 4.60e-11 | 5.07e-10 |
| Trigona:0 | 12/61,988 | 245/16,348,907 | 12.92 | 4.79e-10 | 4.85e-09 |
| [D]Acute retention of urine:0 | 129/61,988 | 1,570/16,348,907 | 21.71 | 4.74e-119 | 4.83e-117 |
| Hyperhomocysteinemia:0 | 1/61,988 | 7,498/16,348,907 | 0.04 | 2.45e-11 | 2.75e-10 |
| Phentolamine:0 | 4/61,988 | 7,319/16,348,907 | 0.14 | 5.46e-08 | 4.48e-07 |
| Neoplasm Metastasis:0 | 4,189/61,988 | 100,066/16,348,907 | 11.77 | 0.00e+00 | 0.00e+00 |
| Pseudomonas aeruginosa:0 | 8/61,988 | 28,409/16,348,907 | 0.07 | 1.47e-35 | 4.70e-34 |
| Denervation:0 | 6/61,988 | 7,924/16,348,907 | 0.20 | 2.05e-07 | 1.58e-06 |
| Question of pregnancy:0 | 6/61,988 | 15,517/16,348,907 | 0.10 | 3.52e-18 | 6.01e-17 |
| Cell Cycle Progression:0 | 293/61,988 | 12,819/16,348,907 | 6.05 | 6.12e-124 | 6.53e-122 |
| AZGP1:0 | 8/61,988 | 105/16,348,907 | 20.10 | 1.49e-08 | 1.30e-07 |
| PIK3CB:0 | 12/61,988 | 295/16,348,907 | 10.73 | 3.55e-09 | 3.31e-08 |
| Sarcosine:0 | 57/61,988 | 812/16,348,907 | 18.53 | 4.78e-50 | 2.17e-48 |
| High Density Lipoproteins:0 | 19/61,988 | 18,325/16,348,907 | 0.27 | 1.59e-12 | 1.93e-11 |
| Uric Acid:0 | 9/61,988 | 9,097/16,348,907 | 0.26 | 5.34e-07 | 3.93e-06 |
| Glycogen:0 | 7/61,988 | 22,218/16,348,907 | 0.08 | 3.16e-27 | 7.95e-26 |
| Sleep:0 | 13/61,988 | 32,212/16,348,907 | 0.11 | 4.50e-36 | 1.48e-34 |
| Biopsy sampling:0 | 19/61,988 | 234/16,348,907 | 21.42 | 7.47e-19 | 1.32e-17 |
| antitumor agent:0 | 44/61,988 | 1,733/16,348,907 | 6.70 | 8.70e-22 | 1.77e-20 |
| FOXA1:0 | 47/61,988 | 621/16,348,907 | 19.98 | 5.67e-43 | 2.21e-41 |
| Congenital bladder neck stenosis:0 | 34/61,988 | 191/16,348,907 | 46.97 | 4.77e-43 | 1.86e-41 |
| Availability of:0 | 105/61,988 | 14,249/16,348,907 | 1.95 | 8.66e-10 | 8.54e-09 |
| External radiotherapy NOS:0 | 110/61,988 | 1,058/16,348,907 | 27.47 | 4.40e-112 | 4.10e-110 |
| Heart Arrest:0 | 10/61,988 | 20,516/16,348,907 | 0.13 | 9.47e-22 | 1.92e-20 |
| Elastases:0 | 7/61,988 | 8,179/16,348,907 | 0.23 | 5.02e-07 | 3.71e-06 |
| 17q12:0 | 14/61,988 | 126/16,348,907 | 29.31 | 5.02e-16 | 7.60e-15 |
| Heart Diseases:0 | 66/61,988 | 34,418/16,348,907 | 0.51 | 6.50e-10 | 6.48e-09 |
| Congenital Heart Defects:0 | 2/61,988 | 9,029/16,348,907 | 0.06 | 1.84e-12 | 2.22e-11 |
| ST14 gene|ST14:0 | 10/61,988 | 257/16,348,907 | 10.26 | 1.05e-07 | 8.34e-07 |
| Nerve sparing:0 | 74/61,988 | 162/16,348,907 | 120.62 | 8.31e-118 | 8.32e-116 |
| hypothalamic-pituitary-gonadal axis:0 | 13/61,988 | 568/16,348,907 | 6.04 | 5.28e-07 | 3.88e-06 |
| Transitional epithelial cell:0 | 43/61,988 | 1,507/16,348,907 | 7.53 | 3.51e-23 | 7.59e-22 |
| Recurrent tumor:0 | 109/61,988 | 4,583/16,348,907 | 6.28 | 7.85e-49 | 3.49e-47 |
| Resectoscopes:0 | 11/61,988 | 390/16,348,907 | 7.44 | 5.46e-07 | 4.01e-06 |
| Transfection:0 | 263/61,988 | 17,763/16,348,907 | 3.92 | 1.68e-72 | 1.06e-70 |
| Estrogen Receptor beta|ESR2:0 | 62/61,988 | 3,735/16,348,907 | 4.38 | 9.09e-21 | 1.78e-19 |
| male germ cell-associated kinase:0 | 4/61,988 | 11/16,348,907 | 95.91 | 2.69e-07 | 2.04e-06 |
| Column:0 | 78/61,988 | 52,747/16,348,907 | 0.39 | 1.11e-22 | 2.36e-21 |
| Cystography:0 | 30/61,988 | 1,169/16,348,907 | 6.77 | 1.74e-15 | 2.57e-14 |
| Polymerase chain reaction analysis:0 | 49/61,988 | 5,472/16,348,907 | 2.36 | 1.18e-07 | 9.29e-07 |
| Prostatic secretions:0 | 75/61,988 | 461/16,348,907 | 42.96 | 2.85e-90 | 2.12e-88 |
| Back:0 | 6/61,988 | 13,410/16,348,907 | 0.12 | 4.77e-15 | 6.86e-14 |
| Ureter:0 | 154/61,988 | 16,388/16,348,907 | 2.48 | 1.28e-22 | 2.71e-21 |
| Blood Glucose:0 | 12/61,988 | 18,895/16,348,907 | 0.17 | 6.62e-18 | 1.12e-16 |
| Ultrasonography:0 | 733/61,988 | 80,080/16,348,907 | 2.43 | 2.25e-96 | 1.80e-94 |
| Urethral mucosa:0 | 8/61,988 | 143/16,348,907 | 14.76 | 1.42e-07 | 1.11e-06 |
| granule cell:0 | 2/61,988 | 13,954/16,348,907 | 0.04 | 2.75e-20 | 5.28e-19 |
| Triptorelin|GNRH1:0 | 20/61,988 | 43/16,348,907 | 122.71 | 4.03e-33 | 1.22e-31 |
| Brill-Zinsser Disease:0 | 9/61,988 | 53/16,348,907 | 44.79 | 2.65e-12 | 3.17e-11 |
| Entire dentate gyrus:0 | 1/61,988 | 17,677/16,348,907 | 0.01 | 1.08e-27 | 2.76e-26 |
| Prostate Neuroendocrine Neoplasm:0 | 4/61,988 | 4/16,348,907 | 263.76 | 1.41e-08 | 1.23e-07 |
| Primary biliary cirrhosis:0 | 4/61,988 | 15,551/16,348,907 | 0.07 | 2.37e-20 | 4.57e-19 |
| External iliac lymph node group:0 | 5/61,988 | 22/16,348,907 | 59.95 | 5.79e-08 | 4.74e-07 |
| Rhinitis:0 | 1/61,988 | 7,479/16,348,907 | 0.04 | 2.44e-11 | 2.73e-10 |
| PAWR gene|PAWR:0 | 58/61,988 | 947/16,348,907 | 16.17 | 9.18e-48 | 4.00e-46 |
| human old age (65+):0 | 72/61,988 | 3,570/16,348,907 | 5.32 | 1.23e-28 | 3.24e-27 |
| Monoamine Oxidase:0 | 6/61,988 | 11,257/16,348,907 | 0.14 | 5.71e-12 | 6.71e-11 |
| Cancer pain:0 | 64/61,988 | 5,164/16,348,907 | 3.27 | 2.00e-15 | 2.94e-14 |
| Chronic heart failure:0 | 2/61,988 | 28,381/16,348,907 | 0.02 | 2.16e-43 | 8.46e-42 |
| MET|RNMT|SLTM:0 | 58/61,988 | 5,528/16,348,907 | 2.77 | 2.55e-11 | 2.85e-10 |
| CD4 gene|CD4:0 | 86/61,988 | 54,893/16,348,907 | 0.41 | 1.49e-21 | 3.00e-20 |
| Antigen-Antibody Complex:0 | 15/61,988 | 17,771/16,348,907 | 0.22 | 3.75e-14 | 5.09e-13 |
| Androcur:0 | 8/61,988 | 66/16,348,907 | 31.97 | 5.00e-10 | 5.04e-09 |
| Joints:0 | 6/61,988 | 13,974/16,348,907 | 0.11 | 6.04e-16 | 9.13e-15 |
| Registration:0 | 67/61,988 | 2,704/16,348,907 | 6.54 | 1.08e-31 | 3.12e-30 |
| Phenols:0 | 6/61,988 | 8,835/16,348,907 | 0.18 | 1.64e-08 | 1.42e-07 |
| ITIH4:0 | 3/61,988 | 7,597/16,348,907 | 0.10 | 3.08e-09 | 2.88e-08 |
| IFI27|PSMD9|SSSCA1|DCTN6|TMED7:0 | 275/61,988 | 11,061/16,348,907 | 6.58 | 8.77e-125 | 9.48e-123 |
| Glaucoma:0 | 5/61,988 | 37,749/16,348,907 | 0.03 | 7.17e-54 | 3.49e-52 |
| equol:0 | 40/61,988 | 1,155/16,348,907 | 9.14 | 1.35e-24 | 3.08e-23 |
| Tissue, Paraffin:0 | 95/61,988 | 4,656/16,348,907 | 5.39 | 1.31e-37 | 4.49e-36 |
| Finasteride:0 | 405/61,988 | 5,752/16,348,907 | 18.69 | 0.00e+00 | 0.00e+00 |
| KLK4:0 | 22/61,988 | 293/16,348,907 | 19.81 | 6.64e-21 | 1.31e-19 |
| vinorelbine:0 | 56/61,988 | 5,241/16,348,907 | 2.82 | 2.85e-11 | 3.18e-10 |
| Prostate-specific antigen monitoring:0 | 4/61,988 | 4/16,348,907 | 263.76 | 1.41e-08 | 1.23e-07 |
| Pseudoaneurysm:0 | 5/61,988 | 13,070/16,348,907 | 0.10 | 1.89e-15 | 2.78e-14 |
| Fox Chase Cancer Center:0 | 10/61,988 | 18/16,348,907 | 146.55 | 7.29e-18 | 1.22e-16 |
| AKR1C2:0 | 17/61,988 | 300/16,348,907 | 14.95 | 1.33e-14 | 1.86e-13 |
| prior radiation therapy:0 | 29/61,988 | 556/16,348,907 | 13.76 | 7.05e-23 | 1.50e-21 |
| SOD2 gene|SOD2:0 | 26/61,988 | 1,206/16,348,907 | 5.69 | 5.47e-12 | 6.43e-11 |
| Chloramphenicol:0 | 5/61,988 | 9,730/16,348,907 | 0.14 | 1.49e-10 | 1.58e-09 |
| Arterial pulse pressure:0 | 2/61,988 | 10,552/16,348,907 | 0.05 | 8.89e-15 | 1.25e-13 |
| Hematologic Neoplasms:0 | 143/61,988 | 21,185/16,348,907 | 1.78 | 2.86e-10 | 2.95e-09 |
| Caregiver:0 | 21/61,988 | 14,764/16,348,907 | 0.37 | 1.90e-07 | 1.47e-06 |
| Palatine Tonsil:0 | 5/61,988 | 8,501/16,348,907 | 0.16 | 8.20e-09 | 7.37e-08 |
| CRK protein, human|CRK:0 | 119/61,988 | 16,919/16,348,907 | 1.86 | 9.29e-10 | 9.12e-09 |
| Captopril:0 | 4/61,988 | 25,594/16,348,907 | 0.04 | 7.58e-36 | 2.45e-34 |
| IGFBP2 protein, human|IGFBP2:0 | 44/61,988 | 2,229/16,348,907 | 5.21 | 7.97e-18 | 1.33e-16 |
| Organic solvent product:0 | 1/61,988 | 4,626/16,348,907 | 0.06 | 8.95e-07 | 6.41e-06 |
| Alpha-hemolytic streptococcus:0 | 13/61,988 | 242/16,348,907 | 14.17 | 3.09e-11 | 3.45e-10 |
| Thrombosis:0 | 41/61,988 | 49,816/16,348,907 | 0.22 | 1.59e-38 | 5.59e-37 |
| Bile Acids:0 | 20/61,988 | 17,226/16,348,907 | 0.31 | 1.04e-10 | 1.12e-09 |
| Acute leukemia:0 | 30/61,988 | 20,009/16,348,907 | 0.40 | 3.32e-09 | 3.09e-08 |
| INPP4B:0 | 8/61,988 | 112/16,348,907 | 18.84 | 2.39e-08 | 2.04e-07 |
| Vascular resistance:0 | 2/61,988 | 13,052/16,348,907 | 0.04 | 1.13e-18 | 1.98e-17 |
| Deoxycytidine:0 | 28/61,988 | 1,689/16,348,907 | 4.37 | 3.05e-10 | 3.14e-09 |
| follow-up:0 | 520/61,988 | 34,503/16,348,907 | 4.00 | 1.43e-144 | 1.76e-142 |
| Cesarean section:0 | 1/61,988 | 14,989/16,348,907 | 0.02 | 2.14e-23 | 4.67e-22 |
| Difficulty passing urine:0 | 17/61,988 | 384/16,348,907 | 11.68 | 5.88e-13 | 7.35e-12 |
| Radical perineal prostatectomy:0 | 119/61,988 | 262/16,348,907 | 120.02 | 3.98e-188 | 6.29e-186 |
| Carotid Arteries:0 | 3/61,988 | 17,221/16,348,907 | 0.05 | 5.33e-24 | 1.19e-22 |
| 17-(allylamino)-17-demethoxygeldanamycin:0 | 39/61,988 | 1,928/16,348,907 | 5.34 | 2.56e-16 | 3.95e-15 |
| PSCA gene|PSCA:0 | 111/61,988 | 276/16,348,907 | 106.26 | 8.89e-171 | 1.28e-168 |
| CDK2 protein, human|CDK2:0 | 23/61,988 | 850/16,348,907 | 7.14 | 1.10e-12 | 1.35e-11 |
| Thyroid Diseases:0 | 7/61,988 | 8,810/16,348,907 | 0.21 | 7.65e-08 | 6.17e-07 |
| adalimumab:0 | 1/61,988 | 9,514/16,348,907 | 0.03 | 1.74e-14 | 2.41e-13 |
| Choline:0 | 202/61,988 | 12,346/16,348,907 | 4.33 | 1.07e-62 | 5.95e-61 |
| Free prostate specific antigen level:0 | 17/61,988 | 21/16,348,907 | 213.56 | 1.73e-31 | 4.97e-30 |
| Discharge, Body Substance:0 | 20/61,988 | 17,536/16,348,907 | 0.30 | 4.40e-11 | 4.86e-10 |
| WASF3:0 | 9/61,988 | 115/16,348,907 | 20.64 | 1.50e-09 | 1.45e-08 |
| TNFSF10 gene|TNFSF10:0 | 51/61,988 | 1,354/16,348,907 | 9.94 | 1.55e-32 | 4.60e-31 |
| Alcohol dehydrogenase:0 | 2/61,988 | 7,880/16,348,907 | 0.07 | 8.96e-11 | 9.67e-10 |
| Plain x-ray:0 | 73/61,988 | 36,461/16,348,907 | 0.53 | 1.52e-09 | 1.47e-08 |
| Tea:0 | 63/61,988 | 2,382/16,348,907 | 6.98 | 2.08e-31 | 5.96e-30 |
| Migrants:0 | 35/61,988 | 3,582/16,348,907 | 2.58 | 9.34e-07 | 6.67e-06 |
| 3-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene:0 | 4/61,988 | 6/16,348,907 | 175.84 | 4.20e-08 | 3.49e-07 |
| PSA Velocity:0 | 21/61,988 | 35/16,348,907 | 158.30 | 1.56e-36 | 5.21e-35 |
| Multileaf collimator:0 | 50/61,988 | 644/16,348,907 | 20.49 | 4.10e-46 | 1.73e-44 |
| Residual Cancer:0 | 87/61,988 | 1,181/16,348,907 | 19.45 | 4.06e-77 | 2.68e-75 |
| Stratum germinativum:0 | 62/61,988 | 4,136/16,348,907 | 3.96 | 1.09e-18 | 1.91e-17 |
| organic disorders:0 | 275/61,988 | 2,762/16,348,907 | 26.37 | 1.17e-272 | 2.58e-270 |
| Adenosine Triphosphate:0 | 14/61,988 | 13,012/16,348,907 | 0.28 | 7.30e-09 | 6.58e-08 |
| Thyroglobulin|TG:0 | 2/61,988 | 6,967/16,348,907 | 0.08 | 2.17e-09 | 2.07e-08 |
| Receptor Activation:0 | 146/61,988 | 10,199/16,348,907 | 3.78 | 1.70e-39 | 6.17e-38 |
| Antigens, Nuclear:0 | 26/61,988 | 1,592/16,348,907 | 4.31 | 1.73e-09 | 1.66e-08 |
| Asians:0 | 130/61,988 | 12,979/16,348,907 | 2.65 | 1.47e-21 | 2.97e-20 |
| archive:0 | 26/61,988 | 2,175/16,348,907 | 3.15 | 6.67e-07 | 4.85e-06 |
| ERBB3 gene|ERBB3:0 | 46/61,988 | 2,633/16,348,907 | 4.61 | 1.26e-16 | 1.97e-15 |
| Movement:0 | 65/61,988 | 44,897/16,348,907 | 0.38 | 5.44e-20 | 1.03e-18 |
| pN1 category:0 | 32/61,988 | 720/16,348,907 | 11.73 | 4.46e-23 | 9.58e-22 |
| Receptor Protein-Tyrosine Kinases:0 | 184/61,988 | 13,263/16,348,907 | 3.67 | 1.78e-47 | 7.70e-46 |
| Intestines, Small:0 | 122/61,988 | 65,075/16,348,907 | 0.49 | 2.28e-18 | 3.93e-17 |
| Invasive bladder cancer:0 | 146/61,988 | 4,949/16,348,907 | 7.80 | 2.51e-76 | 1.64e-74 |
| Sulfur:0 | 5/61,988 | 9,845/16,348,907 | 0.13 | 1.08e-10 | 1.16e-09 |
| Entire male genitourinary tract:0 | 6/61,988 | 26/16,348,907 | 60.87 | 2.42e-09 | 2.29e-08 |
| Binge Eating:0 | 1/61,988 | 5,756/16,348,907 | 0.05 | 1.75e-08 | 1.51e-07 |
| Prostate Leiomyosarcoma:0 | 4/61,988 | 8/16,348,907 | 131.88 | 9.83e-08 | 7.85e-07 |
| ETS Family Gene:0 | 8/61,988 | 37/16,348,907 | 57.03 | 7.88e-12 | 9.17e-11 |
| Carotid Stenosis:0 | 1/61,988 | 8,274/16,348,907 | 0.03 | 1.33e-12 | 1.62e-11 |
| Nuclear accumulation:0 | 29/61,988 | 1,998/16,348,907 | 3.83 | 2.77e-09 | 2.61e-08 |
| Corticotropin|CALCA|PCYT1A:0 | 4/61,988 | 6/16,348,907 | 175.84 | 4.20e-08 | 3.49e-07 |
| Acinar Prostate Adenocarcinoma, Sarcomatoid Variant:0 | 8/61,988 | 15/16,348,907 | 140.68 | 1.93e-14 | 2.67e-13 |
| Normal growth:0 | 33/61,988 | 2,502/16,348,907 | 3.48 | 2.37e-09 | 2.25e-08 |
| Proton therapy:0 | 166/61,988 | 2,031/16,348,907 | 21.61 | 2.62e-152 | 3.44e-150 |
| CTAG2|SLC22A16|SLC6A10P:0 | 7/61,988 | 123/16,348,907 | 15.01 | 7.72e-07 | 5.58e-06 |
| glucose uptake:0 | 13/61,988 | 12,463/16,348,907 | 0.27 | 8.36e-09 | 7.49e-08 |
| Climate:0 | 4/61,988 | 8,104/16,348,907 | 0.13 | 3.61e-09 | 3.36e-08 |
| VDR gene|VDR:0 | 20/61,988 | 240/16,348,907 | 21.99 | 5.69e-20 | 1.07e-18 |
| Flutamide:0 | 616/61,988 | 5,619/16,348,907 | 29.19 | 0.00e+00 | 0.00e+00 |
| Gastritis:0 | 3/61,988 | 9,942/16,348,907 | 0.08 | 1.05e-12 | 1.28e-11 |
| Substance Use Disorders:0 | 2/61,988 | 6,578/16,348,907 | 0.08 | 8.94e-09 | 7.99e-08 |
| Obsessive-Compulsive Disorder:0 | 1/61,988 | 19,821/16,348,907 | 0.01 | 3.30e-31 | 9.40e-30 |
| Malignant neoplasm of endometrium:0 | 114/61,988 | 16,693/16,348,907 | 1.80 | 1.11e-08 | 9.85e-08 |
| Epidemiologic Studies:0 | 54/61,988 | 4,844/16,348,907 | 2.94 | 1.40e-11 | 1.60e-10 |
| Growth Factor:0 | 756/61,988 | 60,756/16,348,907 | 3.31 | 2.71e-164 | 3.82e-162 |
| Very low density lipoprotein:0 | 3/61,988 | 7,196/16,348,907 | 0.11 | 1.23e-08 | 1.08e-07 |
| Chronic infectious disease:0 | 13/61,988 | 16,102/16,348,907 | 0.21 | 1.88e-13 | 2.44e-12 |
| Shoulder:0 | 7/61,988 | 29,434/16,348,907 | 0.06 | 3.00e-38 | 1.05e-36 |
| Cell Survival:0 | 780/61,988 | 34,166/16,348,907 | 6.09 | 0.00e+00 | 0.00e+00 |
| 2,3-bis(3'-hydroxybenzyl)butyrolactone:0 | 32/61,988 | 737/16,348,907 | 11.46 | 8.69e-23 | 1.85e-21 |
| EZH2 protein, human|EZH2:0 | 33/61,988 | 524/16,348,907 | 16.62 | 2.90e-28 | 7.54e-27 |
| Marfan Syndrome:0 | 1/61,988 | 7,771/16,348,907 | 0.03 | 1.30e-11 | 1.49e-10 |
| Antihypertensive Agents:0 | 24/61,988 | 16,478/16,348,907 | 0.38 | 5.34e-08 | 4.39e-07 |
| Medullary:0 | 21/61,988 | 18,370/16,348,907 | 0.30 | 1.56e-11 | 1.77e-10 |
| glycitein:0 | 14/61,988 | 220/16,348,907 | 16.79 | 6.30e-13 | 7.85e-12 |
| dopaminergic neuron:0 | 2/61,988 | 20,951/16,348,907 | 0.03 | 2.69e-31 | 7.69e-30 |
| Alcohol abuse:0 | 3/61,988 | 5,751/16,348,907 | 0.14 | 1.44e-06 | 9.97e-06 |
| Neostriatum:0 | 7/61,988 | 83,814/16,348,907 | 0.02 | 1.01e-124 | 1.08e-122 |
| daidzein:0 | 88/61,988 | 3,062/16,348,907 | 7.59 | 7.07e-46 | 2.95e-44 |
| Tumorigenesis:0 | 1,450/61,988 | 42,358/16,348,907 | 9.22 | 0.00e+00 | 0.00e+00 |
| Granulomatous prostatitis:0 | 41/61,988 | 124/16,348,907 | 87.26 | 3.10e-61 | 1.69e-59 |
| Robot:0 | 79/61,988 | 5,128/16,348,907 | 4.07 | 4.76e-24 | 1.06e-22 |
| Alzheimer's Disease:0 | 58/61,988 | 105,318/16,348,907 | 0.14 | 1.83e-101 | 1.52e-99 |
| Skin carcinoma NOS:0 | 43/61,988 | 4,187/16,348,907 | 2.71 | 1.53e-08 | 1.33e-07 |
| Adverse effects:0 | 970/61,988 | 80,172/16,348,907 | 3.23 | 2.21e-202 | 3.71e-200 |
| Fracture:0 | 206/61,988 | 110,090/16,348,907 | 0.49 | 2.19e-30 | 6.08e-29 |
| Prostatectomy, Suprapubic:0 | 34/61,988 | 225/16,348,907 | 39.88 | 7.23e-41 | 2.70e-39 |
| Applicator - device:0 | 40/61,988 | 1,002/16,348,907 | 10.53 | 8.95e-27 | 2.23e-25 |
| Human serum albumin:0 | 11/61,988 | 10,167/16,348,907 | 0.29 | 3.98e-07 | 2.98e-06 |
| Transposition procedure:0 | 1/61,988 | 5,414/16,348,907 | 0.05 | 4.96e-08 | 4.09e-07 |
| Ejaculatory duct structure:0 | 16/61,988 | 119/16,348,907 | 35.47 | 2.59e-19 | 4.70e-18 |
| dichlorobis(ethylenediamine)rhodium(III):0 | 10/61,988 | 246/16,348,907 | 10.72 | 7.09e-08 | 5.75e-07 |
| MONONUCLEAR CELLS:0 | 31/61,988 | 24,481/16,348,907 | 0.33 | 1.83e-13 | 2.38e-12 |
| Kidney Failure:0 | 59/61,988 | 28,963/16,348,907 | 0.54 | 1.60e-07 | 1.25e-06 |
| Hay fever:0 | 6/61,988 | 9,530/16,348,907 | 0.17 | 1.62e-09 | 1.56e-08 |
| Carcinoma of bladder:0 | 22/61,988 | 717/16,348,907 | 8.10 | 3.12e-13 | 3.98e-12 |
| Radioactive destruction:0 | 13/61,988 | 71/16,348,907 | 48.30 | 1.55e-17 | 2.55e-16 |
| trophoblast:0 | 7/61,988 | 8,256/16,348,907 | 0.22 | 3.63e-07 | 2.72e-06 |
| HSPA5:0 | 72/61,988 | 4,293/16,348,907 | 4.43 | 4.32e-24 | 9.64e-23 |
| Sex hormone binding globulin measurement:0 | 7/61,988 | 121/16,348,907 | 15.26 | 6.95e-07 | 5.05e-06 |
| Aneurysm:0 | 12/61,988 | 51,128/16,348,907 | 0.06 | 8.82e-66 | 5.11e-64 |
| Cyst:0 | 52/61,988 | 35,040/16,348,907 | 0.39 | 2.04e-15 | 3.00e-14 |
| Rheumatoid Factor:0 | 1/61,988 | 6,749/16,348,907 | 0.04 | 4.68e-10 | 4.74e-09 |
| Leukocyte Elastase:0 | 1/61,988 | 8,839/16,348,907 | 0.03 | 2.29e-13 | 2.95e-12 |
| Treatment Protocols:0 | 612/61,988 | 123,150/16,348,907 | 1.31 | 1.29e-10 | 1.37e-09 |
| Warfarin:0 | 34/61,988 | 34,912/16,348,907 | 0.26 | 4.53e-24 | 1.01e-22 |
| Oncogene Proteins:0 | 119/61,988 | 8,427/16,348,907 | 3.73 | 5.21e-32 | 1.53e-30 |
| TRYPTASE:0 | 1/61,988 | 5,141/16,348,907 | 0.05 | 1.50e-07 | 1.17e-06 |
| Spinal Cord:0 | 51/61,988 | 88,108/16,348,907 | 0.15 | 6.34e-83 | 4.43e-81 |
| End Point:0 | 307/61,988 | 12,560/16,348,907 | 6.47 | 3.42e-137 | 4.00e-135 |
| Modeling:0 | 117/61,988 | 16,763/16,348,907 | 1.84 | 1.78e-09 | 1.70e-08 |
| Adenocarcinoma Cell:0 | 188/61,988 | 2,697/16,348,907 | 18.44 | 2.30e-160 | 3.15e-158 |
| Radiolabeled Monoclonal Antibodies:0 | 19/61,988 | 452/16,348,907 | 11.09 | 6.36e-14 | 8.51e-13 |
| insulin secretion:0 | 3/61,988 | 20,758/16,348,907 | 0.04 | 1.18e-29 | 3.22e-28 |
| RRBP1|RHBDL1:0 | 27/61,988 | 113/16,348,907 | 63.05 | 1.40e-37 | 4.79e-36 |
| Entire aortic arch:0 | 1/61,988 | 7,019/16,348,907 | 0.04 | 1.53e-10 | 1.61e-09 |
| mating:0 | 1/61,988 | 6,731/16,348,907 | 0.04 | 4.57e-10 | 4.64e-09 |
| depolarization:0 | 14/61,988 | 16,218/16,348,907 | 0.23 | 6.14e-13 | 7.66e-12 |
| Menopausal hot flushes:0 | 85/61,988 | 2,823/16,348,907 | 7.95 | 7.52e-46 | 3.13e-44 |
| RHOC gene|RHOC:0 | 19/61,988 | 672/16,348,907 | 7.46 | 4.75e-11 | 5.22e-10 |
| Nicotine:0 | 3/61,988 | 35,007/16,348,907 | 0.02 | 2.22e-52 | 1.05e-50 |
| Oncogenes:0 | 226/61,988 | 9,037/16,348,907 | 6.62 | 2.30e-103 | 1.93e-101 |
| Phosphoric Monoester Hydrolases:0 | 225/61,988 | 17,361/16,348,907 | 3.43 | 6.75e-53 | 3.24e-51 |
| Combination Drug Therapy:0 | 133/61,988 | 14,765/16,348,907 | 2.38 | 2.17e-18 | 3.75e-17 |
| Sugars:0 | 22/61,988 | 27,157/16,348,907 | 0.21 | 8.96e-22 | 1.82e-20 |
| in vitro Model:0 | 37/61,988 | 3,373/16,348,907 | 2.89 | 2.97e-08 | 2.52e-07 |
| KRT5:0 | 9/61,988 | 206/16,348,907 | 11.52 | 1.78e-07 | 1.38e-06 |
| Muramidase|LYZ:0 | 2/61,988 | 8,525/16,348,907 | 0.06 | 1.09e-11 | 1.25e-10 |
| Entire autonomic nerve:0 | 15/61,988 | 760/16,348,907 | 5.21 | 4.54e-07 | 3.36e-06 |
| BMX Non-Receptor Tyrosine Kinase|BMX|EPHA3:0 | 13/61,988 | 204/16,348,907 | 16.81 | 4.10e-12 | 4.85e-11 |
| Saw palmetto extract:0 | 12/61,988 | 249/16,348,907 | 12.71 | 5.71e-10 | 5.73e-09 |
| Polycystic Kidney, Autosomal Dominant:0 | 2/61,988 | 7,546/16,348,907 | 0.07 | 3.92e-10 | 4.00e-09 |
| Opioid Receptor:0 | 5/61,988 | 10,380/16,348,907 | 0.13 | 1.34e-11 | 1.52e-10 |
| Retinoblastoma Protein|RB1:0 | 72/61,988 | 6,726/16,348,907 | 2.83 | 4.57e-14 | 6.18e-13 |
| Pain Threshold:0 | 1/61,988 | 5,011/16,348,907 | 0.05 | 2.10e-07 | 1.62e-06 |
| Nicotinic Acid:0 | 1/61,988 | 8,824/16,348,907 | 0.03 | 2.24e-13 | 2.89e-12 |
| Anura:0 | 8/61,988 | 23,958/16,348,907 | 0.09 | 1.07e-28 | 2.83e-27 |
| Tumor proteins:0 | 13/61,988 | 578/16,348,907 | 5.93 | 6.38e-07 | 4.65e-06 |
| selective intervention:0 | 17/61,988 | 202/16,348,907 | 22.20 | 2.87e-17 | 4.68e-16 |
| Medical pathologist:0 | 83/61,988 | 2,558/16,348,907 | 8.57 | 3.81e-47 | 1.64e-45 |
| BMP6 gene|BMP6:0 | 12/61,988 | 221/16,348,907 | 14.32 | 1.56e-10 | 1.65e-09 |
| Gut:0 | 36/61,988 | 33,438/16,348,907 | 0.28 | 4.21e-21 | 8.38e-20 |
| ERBB2:0 | 34/61,988 | 1,338/16,348,907 | 6.71 | 3.24e-17 | 5.27e-16 |
| Molecular Target:0 | 31/61,988 | 1,757/16,348,907 | 4.66 | 7.91e-12 | 9.19e-11 |
| CALIBRATOR:0 | 11/61,988 | 388/16,348,907 | 7.48 | 5.20e-07 | 3.84e-06 |
| Leukemia, Lymphocytic, Acute:0 | 41/61,988 | 35,808/16,348,907 | 0.30 | 3.32e-21 | 6.63e-20 |
| Enkephalins:0 | 3/61,988 | 9,157/16,348,907 | 0.09 | 1.13e-11 | 1.30e-10 |
| Fibroblast Growth Factor:0 | 107/61,988 | 13,079/16,348,907 | 2.16 | 1.47e-12 | 1.79e-11 |
| Nucleus Accumbens:0 | 1/61,988 | 22,934/16,348,907 | 0.01 | 4.01e-36 | 1.32e-34 |
| Disease Progression:0 | 877/61,988 | 28,836/16,348,907 | 8.12 | 0.00e+00 | 0.00e+00 |
| STX1A:0 | 12/61,988 | 498/16,348,907 | 6.36 | 8.48e-07 | 6.10e-06 |
| Laser Delivery Systems, Fiberoptic:0 | 10/61,988 | 249/16,348,907 | 10.59 | 7.90e-08 | 6.36e-07 |
| Appendicitis:0 | 4/61,988 | 7,607/16,348,907 | 0.14 | 1.97e-08 | 1.69e-07 |
| Selenium intake:0 | 8/61,988 | 187/16,348,907 | 11.28 | 9.93e-07 | 7.06e-06 |
| Structure of mucous membrane of nose:0 | 1/61,988 | 7,586/16,348,907 | 0.03 | 1.70e-11 | 1.92e-10 |
| adjuvant therapy:0 | 331/61,988 | 14,336/16,348,907 | 6.12 | 5.66e-141 | 6.79e-139 |
| Radiation Oncologist:0 | 9/61,988 | 87/16,348,907 | 27.29 | 1.51e-10 | 1.59e-09 |
| U73122:0 | 21/61,988 | 1,148/16,348,907 | 4.83 | 9.22e-09 | 8.23e-08 |
| Heterogeneous tissue:0 | 9/61,988 | 211/16,348,907 | 11.25 | 2.16e-07 | 1.66e-06 |
| Dose-Rate:0 | 10/61,988 | 89/16,348,907 | 29.64 | 6.78e-12 | 7.91e-11 |
| Urinary pressure and flow study:0 | 26/61,988 | 1,798/16,348,907 | 3.82 | 1.90e-08 | 1.63e-07 |
| Microscopic hematuria:0 | 24/61,988 | 1,513/16,348,907 | 4.18 | 1.22e-08 | 1.07e-07 |
| Energy Metabolism:0 | 37/61,988 | 23,658/16,348,907 | 0.41 | 5.96e-10 | 5.96e-09 |
| Collagen:0 | 107/61,988 | 70,942/16,348,907 | 0.40 | 3.90e-29 | 1.05e-27 |
| Insulin-Like Growth-Factor-Binding Proteins:0 | 107/61,988 | 6,799/16,348,907 | 4.16 | 1.07e-32 | 3.19e-31 |
| Nonulcer dyspepsia:0 | 1/61,988 | 6,995/16,348,907 | 0.04 | 1.50e-10 | 1.59e-09 |
| Hand:0 | 100/61,988 | 62,883/16,348,907 | 0.42 | 6.17e-24 | 1.37e-22 |
| Epithelium:0 | 788/61,988 | 84,968/16,348,907 | 2.46 | 3.77e-106 | 3.30e-104 |
| TRANSCRIPTION FACTOR:0 | 715/61,988 | 73,851/16,348,907 | 2.57 | 1.39e-104 | 1.18e-102 |
| Small cell carcinoma of lung:0 | 371/61,988 | 29,877/16,348,907 | 3.29 | 3.19e-81 | 2.20e-79 |
| targeting:0 | 667/61,988 | 34,735/16,348,907 | 5.11 | 4.07e-239 | 7.75e-237 |
| HSP90 Heat-Shock Proteins:0 | 48/61,988 | 3,597/16,348,907 | 3.52 | 4.59e-13 | 5.76e-12 |
| Bladder tumour resection:0 | 6/61,988 | 48/16,348,907 | 32.97 | 6.42e-08 | 5.23e-07 |
| Tremor:0 | 2/61,988 | 10,634/16,348,907 | 0.05 | 6.04e-15 | 8.60e-14 |
| Urokinase|PLAU|PRAP1:0 | 114/61,988 | 5,281/16,348,907 | 5.70 | 4.90e-47 | 2.10e-45 |
| Negative Lymph Node:0 | 31/61,988 | 698/16,348,907 | 11.72 | 2.13e-22 | 4.45e-21 |
| Gastrectomy:0 | 5/61,988 | 19,080/16,348,907 | 0.07 | 1.42e-24 | 3.24e-23 |
| Colonic Neoplasms:0 | 49/61,988 | 5,074/16,348,907 | 2.55 | 1.45e-08 | 1.27e-07 |
| Suicide:0 | 38/61,988 | 20,793/16,348,907 | 0.48 | 5.71e-07 | 4.19e-06 |
| SLC45A3:0 | 4/61,988 | 15/16,348,907 | 70.34 | 7.54e-07 | 5.45e-06 |
| Hematuria:0 | 176/61,988 | 5,153/16,348,907 | 9.03 | 2.53e-101 | 2.10e-99 |
| III:0 | 23/61,988 | 1,395/16,348,907 | 4.35 | 1.22e-08 | 1.08e-07 |
| Oral anticoagulants:0 | 3/61,988 | 6,256/16,348,907 | 0.13 | 2.62e-07 | 2.00e-06 |
| SPINK1 gene|SPINK1:0 | 19/61,988 | 642/16,348,907 | 7.81 | 2.25e-11 | 2.52e-10 |
| Acute proctitis:0 | 14/61,988 | 76/16,348,907 | 48.60 | 8.31e-19 | 1.47e-17 |
| Laser enucleation of the prostate:0 | 12/61,988 | 281/16,348,907 | 11.27 | 2.11e-09 | 2.01e-08 |
| IGA Glomerulonephritis:0 | 3/61,988 | 11,801/16,348,907 | 0.07 | 1.21e-15 | 1.80e-14 |
| Connective Tissue Diseases:0 | 2/61,988 | 8,855/16,348,907 | 0.06 | 3.89e-12 | 4.62e-11 |
| Buserelin|EREG|ESR1:0 | 15/61,988 | 5/16,348,907 | 791.42 | 6.91e-33 | 2.08e-31 |
| CDKN2A gene|CDKN2A:0 | 148/61,988 | 22,351/16,348,907 | 1.75 | 4.42e-10 | 4.49e-09 |
| Hospitalized Patients:0 | 25/61,988 | 24,149/16,348,907 | 0.27 | 3.15e-16 | 4.83e-15 |
| Entire head:0 | 18/61,988 | 21,044/16,348,907 | 0.23 | 1.49e-16 | 2.33e-15 |
| Parkinsonian Disorders:0 | 1/61,988 | 11,267/16,348,907 | 0.02 | 2.38e-17 | 3.88e-16 |
| OCM:0 | 8/61,988 | 93/16,348,907 | 22.69 | 6.13e-09 | 5.57e-08 |
| Decision Making:0 | 19/61,988 | 616/16,348,907 | 8.14 | 1.14e-11 | 1.30e-10 |
| CANADIAN:0 | 81/61,988 | 10,650/16,348,907 | 2.01 | 1.56e-08 | 1.36e-07 |
| Prognosis bad:0 | 392/61,988 | 18,684/16,348,907 | 5.56 | 2.78e-153 | 3.71e-151 |
| Liver Cirrhosis, Alcoholic:0 | 1/61,988 | 4,965/16,348,907 | 0.05 | 3.18e-07 | 2.40e-06 |
| spouse:0 | 56/61,988 | 4,915/16,348,907 | 3.01 | 2.65e-12 | 3.17e-11 |
| Ventricular Function, Left:0 | 1/61,988 | 16,525/16,348,907 | 0.02 | 9.15e-26 | 2.20e-24 |
| Steroid 17-alpha-monooxygenase:0 | 14/61,988 | 708/16,348,907 | 5.22 | 1.06e-06 | 7.49e-06 |
| Adenocarcinoma, Mucinous:0 | 96/61,988 | 4,467/16,348,907 | 5.68 | 9.62e-40 | 3.49e-38 |
| Whole-Body Scintigraphy:0 | 13/61,988 | 357/16,348,907 | 9.61 | 2.88e-09 | 2.71e-08 |
| RASSF1A|RASSF1:0 | 32/61,988 | 1,874/16,348,907 | 4.51 | 8.36e-12 | 9.68e-11 |
| Osteolysis:0 | 63/61,988 | 4,226/16,348,907 | 3.93 | 7.51e-19 | 1.33e-17 |
| GSTP1 gene|GSTP1:0 | 128/61,988 | 1,800/16,348,907 | 18.79 | 8.47e-111 | 7.74e-109 |
| Entire prostatic glandular tissue:0 | 18/61,988 | 32/16,348,907 | 148.40 | 3.93e-31 | 1.11e-29 |
| FGF7 gene|FGF7:0 | 18/61,988 | 838/16,348,907 | 5.67 | 9.77e-09 | 8.69e-08 |
| Structure of retinal pigment epithelium:0 | 3/61,988 | 16,254/16,348,907 | 0.05 | 1.27e-22 | 2.68e-21 |
| kinase inhibitor:0 | 77/61,988 | 6,724/16,348,907 | 3.02 | 2.05e-16 | 3.18e-15 |
| Prostate specific antigen measurement:0 | 498/61,988 | 674/16,348,907 | 196.44 | 0.00e+00 | 0.00e+00 |
| Antigens, Differentiation:0 | 44/61,988 | 3,590/16,348,907 | 3.23 | 5.83e-11 | 6.37e-10 |
| EGF gene|EGF:0 | 150/61,988 | 9,344/16,348,907 | 4.24 | 4.32e-46 | 1.82e-44 |
| Skp2 Proteins|SKP2:0 | 38/61,988 | 1,192/16,348,907 | 8.41 | 2.95e-22 | 6.14e-21 |
| Linomide:0 | 15/61,988 | 686/16,348,907 | 5.77 | 1.29e-07 | 1.01e-06 |
| Apomorphine:0 | 2/61,988 | 9,867/16,348,907 | 0.05 | 1.12e-13 | 1.47e-12 |
| Growth Inhibitors:0 | 268/61,988 | 6,962/16,348,907 | 10.19 | 1.56e-165 | 2.21e-163 |
| rituximab:0 | 12/61,988 | 31,592/16,348,907 | 0.10 | 4.85e-36 | 1.58e-34 |
| ^192^Iridium:0 | 7/61,988 | 111/16,348,907 | 16.63 | 4.01e-07 | 2.99e-06 |
| Pulmonary Fibrosis:0 | 5/61,988 | 10,785/16,348,907 | 0.12 | 3.44e-12 | 4.09e-11 |
| Urologic:0 | 13/61,988 | 185/16,348,907 | 18.54 | 1.28e-12 | 1.57e-11 |
| Coronary angiography:0 | 2/61,988 | 14,476/16,348,907 | 0.04 | 4.56e-21 | 9.07e-20 |
| Atypical hyperplasia:0 | 13/61,988 | 489/16,348,907 | 7.01 | 1.02e-07 | 8.10e-07 |
| paracrine:0 | 134/61,988 | 5,903/16,348,907 | 6.00 | 2.29e-57 | 1.18e-55 |
| Tissue, Fresh:0 | 62/61,988 | 2,353/16,348,907 | 6.96 | 7.48e-31 | 2.09e-29 |
| sevoflurane:0 | 3/61,988 | 11,791/16,348,907 | 0.07 | 1.20e-15 | 1.79e-14 |
| Propofol:0 | 10/61,988 | 29,500/16,348,907 | 0.09 | 5.09e-35 | 1.60e-33 |
| Gonadorelin|GHRH:0 | 129/61,988 | 1,835/16,348,907 | 18.58 | 4.61e-111 | 4.25e-109 |
| Saccharomyces cerevisiae:0 | 86/61,988 | 119,916/16,348,907 | 0.19 | 7.11e-100 | 5.75e-98 |
| Regional Disease:0 | 12/61,988 | 514/16,348,907 | 6.16 | 1.17e-06 | 8.21e-06 |
| Pituitary-dependent Cushing's disease:0 | 3/61,988 | 5,746/16,348,907 | 0.14 | 1.43e-06 | 9.93e-06 |
| menthyl 3-(2-pyridylsulfinyl)acrylate:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| Secondary malignant neoplasm of lymph node:0 | 782/61,988 | 27,056/16,348,907 | 7.71 | 0.00e+00 | 0.00e+00 |
| Lupus Erythematosus, Systemic:0 | 23/61,988 | 84,201/16,348,907 | 0.07 | 7.20e-104 | 6.08e-102 |
| Azacitidine:0 | 54/61,988 | 6,628/16,348,907 | 2.15 | 6.26e-07 | 4.57e-06 |
| Alcohols:0 | 6/61,988 | 8,101/16,348,907 | 0.20 | 1.55e-07 | 1.21e-06 |
| Advance:0 | 43/61,988 | 2,581/16,348,907 | 4.40 | 5.82e-15 | 8.31e-14 |
| METHYLATE:0 | 41/61,988 | 1,957/16,348,907 | 5.53 | 1.41e-17 | 2.32e-16 |
| Electromagnetic Energy:0 | 173/61,988 | 12,737/16,348,907 | 3.59 | 1.33e-43 | 5.26e-42 |
| Prostatism:0 | 41/61,988 | 337/16,348,907 | 32.11 | 1.97e-45 | 8.14e-44 |
| Prostatic specific antigen decreased:0 | 23/61,988 | 32/16,348,907 | 189.64 | 3.12e-41 | 1.18e-39 |
| Osteoblasts:0 | 390/61,988 | 25,527/16,348,907 | 4.05 | 1.42e-110 | 1.29e-108 |
| Pulmonary Surfactants:0 | 4/61,988 | 21,691/16,348,907 | 0.05 | 8.86e-30 | 2.42e-28 |
| Gastrointestinal Hemorrhage:0 | 9/61,988 | 9,079/16,348,907 | 0.26 | 5.31e-07 | 3.91e-06 |
| Echocardiography, Transesophageal:0 | 1/61,988 | 8,043/16,348,907 | 0.03 | 4.19e-12 | 4.95e-11 |
| tumor growth:0 | 2,313/61,988 | 48,672/16,348,907 | 12.98 | 0.00e+00 | 0.00e+00 |
| Prostate examination:0 | 33/61,988 | 50/16,348,907 | 174.16 | 1.37e-57 | 7.11e-56 |
| Prostate implantation:0 | 25/61,988 | 41/16,348,907 | 160.88 | 2.42e-43 | 9.47e-42 |
| Granulomatous Disease, Chronic:0 | 1/61,988 | 4,955/16,348,907 | 0.05 | 3.14e-07 | 2.37e-06 |
| Androgen therapy:0 | 2,129/61,988 | 5,391/16,348,907 | 107.83 | 0.00e+00 | 0.00e+00 |
| neutrophil:0 | 36/61,988 | 104,336/16,348,907 | 0.09 | 2.26e-120 | 2.33e-118 |
| PIAS1:0 | 10/61,988 | 257/16,348,907 | 10.26 | 1.05e-07 | 8.34e-07 |
| Hormones:0 | 431/61,988 | 31,814/16,348,907 | 3.59 | 1.51e-105 | 1.31e-103 |
| Heart tissue:0 | 4/61,988 | 7,124/16,348,907 | 0.15 | 1.08e-07 | 8.55e-07 |
| host:0 | 158/61,988 | 74,147/16,348,907 | 0.56 | 1.60e-15 | 2.38e-14 |
| Soluble ErbB-1|EGFR:0 | 85/61,988 | 5,981/16,348,907 | 3.75 | 1.54e-23 | 3.38e-22 |
| Fibrous capsule of kidney:0 | 25/61,988 | 1,429/16,348,907 | 4.62 | 9.19e-10 | 9.04e-09 |
| Citrate:0 | 101/61,988 | 7,857/16,348,907 | 3.39 | 1.75e-24 | 3.98e-23 |
| Local Therapy:0 | 175/61,988 | 3,804/16,348,907 | 12.16 | 8.40e-121 | 8.70e-119 |
| Benign prostatic hypertrophy:0 | 3,638/61,988 | 23,882/16,348,907 | 42.62 | 0.00e+00 | 0.00e+00 |
| Deep Brain Stimulation:0 | 1/61,988 | 11,458/16,348,907 | 0.02 | 1.14e-17 | 1.89e-16 |
| CYP1B1:0 | 23/61,988 | 1,655/16,348,907 | 3.67 | 2.37e-07 | 1.82e-06 |
| Disability NOS:0 | 29/61,988 | 67,403/16,348,907 | 0.11 | 2.02e-72 | 1.27e-70 |
| Population at Risk:0 | 40/61,988 | 2,570/16,348,907 | 4.11 | 3.98e-13 | 5.03e-12 |
| Diltiazem:0 | 5/61,988 | 12,124/16,348,907 | 0.11 | 4.07e-14 | 5.52e-13 |
| Heart Valves:0 | 6/61,988 | 29,405/16,348,907 | 0.05 | 2.93e-39 | 1.05e-37 |
| Markers, Bone:0 | 51/61,988 | 2,040/16,348,907 | 6.60 | 1.06e-24 | 2.44e-23 |
| Ampicillin:0 | 8/61,988 | 9,506/16,348,907 | 0.22 | 3.74e-08 | 3.13e-07 |
| Estrogens, Synthetic:0 | 35/61,988 | 952/16,348,907 | 9.70 | 1.59e-22 | 3.34e-21 |
| Central incisor:0 | 1/61,988 | 4,837/16,348,907 | 0.05 | 4.40e-07 | 3.27e-06 |
| Histone Deacetylase:0 | 115/61,988 | 6,467/16,348,907 | 4.70 | 1.07e-39 | 3.89e-38 |
| Glucagon|GCG:0 | 3/61,988 | 11,322/16,348,907 | 0.07 | 7.27e-15 | 1.03e-13 |
| Patient Selection:0 | 101/61,988 | 3,966/16,348,907 | 6.73 | 6.90e-48 | 3.03e-46 |
| Molecular Chaperones:0 | 125/61,988 | 16,354/16,348,907 | 2.02 | 2.22e-12 | 2.67e-11 |
| Malignant Epithelial Cell:0 | 237/61,988 | 5,936/16,348,907 | 10.57 | 6.28e-150 | 8.04e-148 |
| Females:0 | 19/61,988 | 13,672/16,348,907 | 0.37 | 2.95e-07 | 2.24e-06 |
| Metastatic Lesion:0 | 178/61,988 | 4,588/16,348,907 | 10.26 | 4.11e-111 | 3.80e-109 |
| Cell Transformation, Neoplastic:0 | 93/61,988 | 4,022/16,348,907 | 6.11 | 5.51e-41 | 2.06e-39 |
| Atypical antipsychotic:0 | 1/61,988 | 7,328/16,348,907 | 0.04 | 5.19e-11 | 5.69e-10 |
| TNF-related apoptosis-inducing ligand|TNFSF10:0 | 180/61,988 | 9,521/16,348,907 | 5.00 | 7.35e-65 | 4.22e-63 |
| Microsomes:0 | 49/61,988 | 36,336/16,348,907 | 0.36 | 6.10e-18 | 1.03e-16 |
| Glutamate Decarboxylase:0 | 1/61,988 | 5,135/16,348,907 | 0.05 | 1.49e-07 | 1.16e-06 |
| Able:0 | 106/61,988 | 13,217/16,348,907 | 2.12 | 5.73e-12 | 6.73e-11 |
| Biological Markers:0 | 37/61,988 | 468/16,348,907 | 20.86 | 7.92e-35 | 2.48e-33 |
| alanylalanine:0 | 10/61,988 | 331/16,348,907 | 7.97 | 9.76e-07 | 6.94e-06 |
| Celiac Disease:0 | 6/61,988 | 32,918/16,348,907 | 0.05 | 6.80e-45 | 2.77e-43 |
| Heroin:0 | 2/61,988 | 5,596/16,348,907 | 0.09 | 3.03e-07 | 2.29e-06 |
| Tomography, Emission-Computed:0 | 118/61,988 | 4,214/16,348,907 | 7.40 | 9.28e-60 | 4.97e-58 |
| methylselenic acid:0 | 43/61,988 | 293/16,348,907 | 38.73 | 9.41e-51 | 4.33e-49 |
| cancer care:0 | 52/61,988 | 970/16,348,907 | 14.15 | 2.84e-40 | 1.04e-38 |
| Somatotropin:0 | 312/61,988 | 40,499/16,348,907 | 2.04 | 3.50e-29 | 9.44e-28 |
| Negative Finding:0 | 53/61,988 | 1,293/16,348,907 | 10.82 | 1.80e-35 | 5.78e-34 |
| Flomax:0 | 5/61,988 | 36/16,348,907 | 36.63 | 5.14e-07 | 3.79e-06 |
| Strontium-89:0 | 79/61,988 | 217/16,348,907 | 96.14 | 3.32e-119 | 3.39e-117 |
| Optic Disk:0 | 3/61,988 | 7,570/16,348,907 | 0.10 | 3.01e-09 | 2.82e-08 |
| AMACR:0 | 31/61,988 | 113/16,348,907 | 72.39 | 1.55e-44 | 6.25e-43 |
| ZD1839:0 | 31/61,988 | 1,097/16,348,907 | 7.46 | 4.71e-17 | 7.59e-16 |
| Needle biopsy procedure:0 | 943/61,988 | 5,778/16,348,907 | 43.69 | 0.00e+00 | 0.00e+00 |
| Filament:0 | 9/61,988 | 11,916/16,348,907 | 0.20 | 1.22e-10 | 1.29e-09 |
| SIAH2:0 | 8/61,988 | 193/16,348,907 | 10.93 | 1.25e-06 | 8.75e-06 |
| HIF1A gene|HIF1A:0 | 36/61,988 | 965/16,348,907 | 9.84 | 2.53e-23 | 5.51e-22 |
| ARNT protein, human|ARNT:0 | 11/61,988 | 225/16,348,907 | 12.90 | 2.56e-09 | 2.42e-08 |
| Diphosphonates:0 | 736/61,988 | 22,913/16,348,907 | 8.56 | 0.00e+00 | 0.00e+00 |
| Menstrual cycle:0 | 8/61,988 | 10,568/16,348,907 | 0.20 | 1.60e-09 | 1.54e-08 |
| Macular retinal edema:0 | 1/61,988 | 5,330/16,348,907 | 0.05 | 7.21e-08 | 5.83e-07 |
| cyclin-dependent kinase inhibitor 1B:0 | 8/61,988 | 165/16,348,907 | 12.79 | 4.02e-07 | 3.00e-06 |
| flavopiridol:0 | 30/61,988 | 1,625/16,348,907 | 4.87 | 5.80e-12 | 6.81e-11 |
| EP300 protein, human|EP300:0 | 57/61,988 | 5,267/16,348,907 | 2.86 | 1.19e-11 | 1.36e-10 |
| Falls:0 | 55/61,988 | 31,118/16,348,907 | 0.47 | 1.46e-10 | 1.55e-09 |
| Paget's Disease:0 | 48/61,988 | 3,871/16,348,907 | 3.27 | 5.55e-12 | 6.53e-11 |
| Kidney Diseases:0 | 31/61,988 | 51,721/16,348,907 | 0.16 | 2.34e-48 | 1.03e-46 |
| prostatitis:0 | 240/61,988 | 2,194/16,348,907 | 28.96 | 3.62e-247 | 7.13e-245 |
| Cystoprostatectomy:0 | 129/61,988 | 354/16,348,907 | 96.31 | 1.47e-193 | 2.38e-191 |
| lamotrigine:0 | 2/61,988 | 7,022/16,348,907 | 0.08 | 2.24e-09 | 2.12e-08 |
| Invasive Carcinoma:0 | 114/61,988 | 6,954/16,348,907 | 4.33 | 2.96e-36 | 9.82e-35 |
| Argipressin:0 | 11/61,988 | 31,837/16,348,907 | 0.09 | 2.16e-37 | 7.36e-36 |
| Vascular Endothelial Growth Factor Receptor:0 | 36/61,988 | 2,714/16,348,907 | 3.50 | 3.99e-10 | 4.07e-09 |
| Airway device:0 | 1/61,988 | 7,166/16,348,907 | 0.04 | 1.13e-10 | 1.21e-09 |
| Dominant-Negative Mutation:0 | 37/61,988 | 3,919/16,348,907 | 2.49 | 1.34e-06 | 9.33e-06 |
| Clinical Trials, Phase I:0 | 15/61,988 | 402/16,348,907 | 9.84 | 1.30e-10 | 1.38e-09 |
| GRP gene|GRP:0 | 22/61,988 | 356/16,348,907 | 16.30 | 3.32e-19 | 6.00e-18 |
| Aortic valve replacement NOS:0 | 2/61,988 | 13,121/16,348,907 | 0.04 | 7.47e-19 | 1.32e-17 |
| Calcium:0 | 274/61,988 | 140,538/16,348,907 | 0.51 | 4.41e-35 | 1.39e-33 |
| Decidua:0 | 2/61,988 | 5,482/16,348,907 | 0.10 | 4.27e-07 | 3.18e-06 |
| PTPN6 protein, human|PTPN6:0 | 8/61,988 | 132/16,348,907 | 15.99 | 7.94e-08 | 6.39e-07 |
| Botulinum Toxins:0 | 9/61,988 | 14,127/16,348,907 | 0.17 | 1.41e-13 | 1.85e-12 |
| Jaw:0 | 159/61,988 | 16,387/16,348,907 | 2.56 | 1.02e-24 | 2.33e-23 |
| Health care facility:0 | 587/61,988 | 25,395/16,348,907 | 6.15 | 5.92e-249 | 1.18e-246 |
| Zebrafish:0 | 20/61,988 | 23,008/16,348,907 | 0.23 | 1.15e-17 | 1.91e-16 |
| degarelix:0 | 68/61,988 | 202/16,348,907 | 88.88 | 6.74e-101 | 5.53e-99 |
| beta-Endorphin:0 | 4/61,988 | 14,065/16,348,907 | 0.07 | 4.75e-18 | 8.06e-17 |
| Prostatic Adenoma:0 | 91/61,988 | 697/16,348,907 | 34.48 | 2.93e-101 | 2.42e-99 |
| Ambulatory Care Facilities:0 | 300/61,988 | 30,271/16,348,907 | 2.62 | 1.26e-46 | 5.34e-45 |
| Venoms:0 | 9/61,988 | 10,523/16,348,907 | 0.23 | 1.04e-08 | 9.24e-08 |
| cyclopamine:0 | 31/61,988 | 656/16,348,907 | 12.47 | 3.79e-23 | 8.20e-22 |
| E2F1 Transcription Factor:0 | 15/61,988 | 430/16,348,907 | 9.20 | 3.18e-10 | 3.27e-09 |
| Prostatic duct:0 | 82/61,988 | 164/16,348,907 | 132.04 | 5.94e-133 | 6.78e-131 |
| Seminoma:0 | 66/61,988 | 5,152/16,348,907 | 3.38 | 1.61e-16 | 2.52e-15 |
| Cancer Relapse:0 | 70/61,988 | 538/16,348,907 | 34.35 | 3.27e-78 | 2.18e-76 |
| cell body (neuron):0 | 43/61,988 | 22,299/16,348,907 | 0.51 | 1.06e-06 | 7.48e-06 |
| Bladder Neoplasm:0 | 240/61,988 | 6,440/16,348,907 | 9.86 | 1.87e-145 | 2.32e-143 |
| Caveolae:0 | 35/61,988 | 3,502/16,348,907 | 2.64 | 5.68e-07 | 4.17e-06 |
| Arthritis:0 | 28/61,988 | 43,348/16,348,907 | 0.17 | 4.48e-39 | 1.60e-37 |
| Stomach Diseases:0 | 147/61,988 | 18,714/16,348,907 | 2.07 | 2.96e-15 | 4.31e-14 |
| Nycturia:0 | 46/61,988 | 2,529/16,348,907 | 4.80 | 2.93e-17 | 4.78e-16 |
| Transcranial Magnetic Stimulation, Repetitive:0 | 1/61,988 | 5,543/16,348,907 | 0.05 | 3.55e-08 | 2.98e-07 |
| Urogenital diaphragm:0 | 7/61,988 | 34/16,348,907 | 54.31 | 2.20e-10 | 2.30e-09 |
| Tumor Suppressor Genes:0 | 1,209/61,988 | 33,756/16,348,907 | 9.61 | 0.00e+00 | 0.00e+00 |
| Estrogens, Catechol:0 | 15/61,988 | 817/16,348,907 | 4.84 | 1.09e-06 | 7.68e-06 |
| Microorganism:0 | 13/61,988 | 27,143/16,348,907 | 0.13 | 1.12e-28 | 2.97e-27 |
| Dexamethasone:0 | 164/61,988 | 85,229/16,348,907 | 0.51 | 1.89e-22 | 3.96e-21 |
| Vasospasm:0 | 4/61,988 | 13,074/16,348,907 | 0.08 | 1.60e-16 | 2.50e-15 |
| Movement Disorders:0 | 2/61,988 | 8,207/16,348,907 | 0.06 | 3.12e-11 | 3.47e-10 |
| Green Fluorescent Proteins|HSPA9:0 | 3/61,988 | 1/16,348,907 | 791.27 | 2.15e-07 | 1.65e-06 |
| ATPase, Aminophospholipid Transporter-Like, Class I, Type 8A, Member 2|ATP8A2:0 | 125/61,988 | 83,193/16,348,907 | 0.40 | 4.15e-34 | 1.28e-32 |
| Optic Nerve:0 | 4/61,988 | 14,125/16,348,907 | 0.07 | 5.02e-18 | 8.53e-17 |
| Biomedical tape:0 | 3/61,988 | 6,276/16,348,907 | 0.13 | 2.67e-07 | 2.03e-06 |
| VITAMIN D AND METABOLITES:0 | 16/61,988 | 728/16,348,907 | 5.80 | 4.65e-08 | 3.85e-07 |
| Behavior:0 | 193/61,988 | 73,977/16,348,907 | 0.69 | 3.84e-08 | 3.20e-07 |
| TRPM8:0 | 28/61,988 | 905/16,348,907 | 8.16 | 1.66e-16 | 2.59e-15 |
| Brucella:0 | 1/61,988 | 5,882/16,348,907 | 0.04 | 1.28e-08 | 1.12e-07 |
| Chronic pain:0 | 16/61,988 | 29,017/16,348,907 | 0.15 | 9.69e-29 | 2.57e-27 |
| Multiple tumors:0 | 79/61,988 | 4,324/16,348,907 | 4.82 | 1.50e-28 | 3.93e-27 |
| Erythropoietin:0 | 12/61,988 | 14,560/16,348,907 | 0.22 | 4.57e-12 | 5.41e-11 |
| cancer complication:0 | 5/61,988 | 30/16,348,907 | 43.96 | 2.27e-07 | 1.74e-06 |
| [M]Neoplasm morphology NOS:0 | 13/61,988 | 395/16,348,907 | 8.68 | 9.18e-09 | 8.19e-08 |
| androsterone glucuronide:0 | 8/61,988 | 63/16,348,907 | 33.50 | 3.57e-10 | 3.65e-09 |
| Dopamine Agonists:0 | 7/61,988 | 11,840/16,348,907 | 0.16 | 6.55e-12 | 7.66e-11 |
| Urokinase Plasminogen Activator Receptor:0 | 33/61,988 | 2,312/16,348,907 | 3.77 | 3.55e-10 | 3.64e-09 |
| Meat:0 | 35/61,988 | 2,863/16,348,907 | 3.23 | 5.21e-09 | 4.77e-08 |
| Nulliparous:0 | 3/61,988 | 6,300/16,348,907 | 0.13 | 2.75e-07 | 2.09e-06 |
| Strontium 89 therapy:0 | 13/61,988 | 35/16,348,907 | 97.98 | 5.43e-21 | 1.07e-19 |
| AGR2 gene|AGR2:0 | 9/61,988 | 149/16,348,907 | 15.93 | 1.26e-08 | 1.11e-07 |
| Glycolipids:0 | 6/61,988 | 7,470/16,348,907 | 0.21 | 1.04e-06 | 7.39e-06 |
| Cell Wall:0 | 5/61,988 | 26,558/16,348,907 | 0.05 | 3.58e-36 | 1.18e-34 |
| Luciferases, Firefly:0 | 20/61,988 | 1,175/16,348,907 | 4.49 | 6.39e-08 | 5.21e-07 |
| Bladder outlet obstruction:0 | 117/61,988 | 3,058/16,348,907 | 10.11 | 4.74e-73 | 3.01e-71 |
| Renal pelvis:0 | 63/61,988 | 5,357/16,348,907 | 3.10 | 3.19e-14 | 4.34e-13 |
| Primary Neoplasm:0 | 850/61,988 | 35,552/16,348,907 | 6.38 | 0.00e+00 | 0.00e+00 |
| Workers:0 | 109/61,988 | 59,811/16,348,907 | 0.48 | 5.14e-18 | 8.72e-17 |
| Localized Malignant Neoplasm:0 | 297/61,988 | 2,195/16,348,907 | 35.85 | 0.00e+00 | 0.00e+00 |
| Pathogenicity:0 | 44/61,988 | 40,066/16,348,907 | 0.29 | 1.11e-24 | 2.55e-23 |
| S-Adenosylmethionine:0 | 6/61,988 | 7,321/16,348,907 | 0.22 | 1.39e-06 | 9.64e-06 |
| Therapeutic radiology procedure:0 | 57/61,988 | 116/16,348,907 | 129.72 | 1.35e-92 | 1.04e-90 |
| in vivo Model:0 | 22/61,988 | 1,335/16,348,907 | 4.35 | 2.52e-08 | 2.14e-07 |
| Epiphysial cartilage:0 | 2/61,988 | 10,354/16,348,907 | 0.05 | 1.83e-14 | 2.53e-13 |
| Renal Blood Flow:0 | 1/61,988 | 6,470/16,348,907 | 0.04 | 1.43e-09 | 1.38e-08 |
| ZD4054:0 | 7/61,988 | 54/16,348,907 | 34.19 | 4.00e-09 | 3.70e-08 |
| Reserpine:0 | 1/61,988 | 6,617/16,348,907 | 0.04 | 6.49e-10 | 6.46e-09 |
| Active monitoring:0 | 22/61,988 | 336/16,348,907 | 17.27 | 1.04e-19 | 1.93e-18 |
| Malignant neoplasm of ureter:0 | 12/61,988 | 221/16,348,907 | 14.32 | 1.56e-10 | 1.65e-09 |
| Chlamydia:0 | 2/61,988 | 5,957/16,348,907 | 0.09 | 1.14e-07 | 9.03e-07 |
| AUSTRALIAN:0 | 98/61,988 | 12,653/16,348,907 | 2.04 | 2.96e-10 | 3.06e-09 |
| specific immunity:0 | 89/61,988 | 6,902/16,348,907 | 3.40 | 7.27e-22 | 1.49e-20 |
| Zoladex:0 | 117/61,988 | 673/16,348,907 | 45.94 | 7.63e-143 | 9.19e-141 |
| Two:0 | 388/61,988 | 65,986/16,348,907 | 1.55 | 8.04e-16 | 1.21e-14 |
| Offspring:0 | 67/61,988 | 44,530/16,348,907 | 0.40 | 7.13e-19 | 1.27e-17 |
| Hypertension, Portal:0 | 4/61,988 | 16,007/16,348,907 | 0.07 | 5.95e-21 | 1.17e-19 |
| Resected prostate sample:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| FOXO3A gene|FOXO3:0 | 32/61,988 | 2,286/16,348,907 | 3.69 | 1.03e-09 | 1.00e-08 |
| IGHE:0 | 2/61,988 | 35,388/16,348,907 | 0.01 | 1.08e-54 | 5.35e-53 |
| Drug abuse:0 | 1/61,988 | 10,984/16,348,907 | 0.02 | 7.19e-17 | 1.15e-15 |
| Bupropion:0 | 1/61,988 | 4,495/16,348,907 | 0.06 | 1.26e-06 | 8.85e-06 |
| Silicon Dioxide:0 | 3/61,988 | 9,475/16,348,907 | 0.08 | 3.99e-12 | 4.72e-11 |
| Screw:0 | 4/61,988 | 14,678/16,348,907 | 0.07 | 5.76e-19 | 1.03e-17 |
| Transurethral Resection of Prostate:0 | 472/61,988 | 3,795/16,348,907 | 33.05 | 0.00e+00 | 0.00e+00 |
| Vaccine Therapy:0 | 27/61,988 | 463/16,348,907 | 15.39 | 1.35e-22 | 2.85e-21 |
| CD44 gene|CD44:0 | 163/61,988 | 13,111/16,348,907 | 3.28 | 9.04e-37 | 3.05e-35 |
| Senility:0 | 48/61,988 | 3,577/16,348,907 | 3.54 | 3.78e-13 | 4.79e-12 |
| Electroresection:0 | 11/61,988 | 118/16,348,907 | 24.59 | 3.94e-12 | 4.68e-11 |
| Histidine:0 | 8/61,988 | 9,429/16,348,907 | 0.22 | 5.17e-08 | 4.26e-07 |
| Baclofen:0 | 1/61,988 | 8,810/16,348,907 | 0.03 | 2.20e-13 | 2.85e-12 |
| Mice, Transgenic:0 | 234/61,988 | 39,357/16,348,907 | 1.57 | 1.33e-10 | 1.41e-09 |
| Laser Capture Microdissection:0 | 13/61,988 | 383/16,348,907 | 8.95 | 6.45e-09 | 5.85e-08 |
| CHRFAM7A:0 | 14/61,988 | 403/16,348,907 | 9.16 | 1.29e-09 | 1.25e-08 |
| Human Chorionic Gonadotropin|CTSG:0 | 5/61,988 | 5/16,348,907 | 263.76 | 1.91e-10 | 2.00e-09 |
| Echocardiography:0 | 5/61,988 | 27,963/16,348,907 | 0.05 | 2.40e-38 | 8.39e-37 |
| Demography:0 | 27/61,988 | 2,054/16,348,907 | 3.47 | 6.74e-08 | 5.48e-07 |
| Hepatitis C:0 | 9/61,988 | 16,014/16,348,907 | 0.15 | 3.92e-16 | 5.98e-15 |
| Angiotensinogen:0 | 1/61,988 | 7,436/16,348,907 | 0.04 | 3.65e-11 | 4.04e-10 |
| Neurodegenerative Disorders:0 | 21/61,988 | 37,203/16,348,907 | 0.15 | 4.50e-36 | 1.48e-34 |
| cyclin-dependent kinase inhibitor 1B|CDKN1B|CIB1:0 | 13/61,988 | 139/16,348,907 | 24.67 | 4.28e-14 | 5.79e-13 |
| Malignant neoplasm of testis:0 | 164/61,988 | 5,830/16,348,907 | 7.44 | 1.31e-82 | 9.16e-81 |
| Milk intake:0 | 9/61,988 | 246/16,348,907 | 9.65 | 7.40e-07 | 5.36e-06 |
| Atypical adenomatous hyperplasia:0 | 44/61,988 | 521/16,348,907 | 22.29 | 2.96e-42 | 1.14e-40 |
| Dental caries:0 | 18/61,988 | 17,659/16,348,907 | 0.27 | 2.43e-12 | 2.91e-11 |
| Aplastic Anemia:0 | 4/61,988 | 9,396/16,348,907 | 0.11 | 6.46e-11 | 7.03e-10 |
| Hyperbilirubinemia:0 | 2/61,988 | 5,452/16,348,907 | 0.10 | 4.24e-07 | 3.16e-06 |
| Lack of sensation:0 | 16/61,988 | 27,759/16,348,907 | 0.15 | 5.06e-27 | 1.27e-25 |
| Cyclin B:0 | 25/61,988 | 1,563/16,348,907 | 4.22 | 5.23e-09 | 4.78e-08 |
| Quantitative Reverse Transcriptase PCR:0 | 65/61,988 | 2,358/16,348,907 | 7.28 | 2.42e-33 | 7.35e-32 |
| Surgical margins:0 | 430/61,988 | 7,620/16,348,907 | 14.98 | 0.00e+00 | 0.00e+00 |
| psychological distress:0 | 62/61,988 | 7,946/16,348,907 | 2.06 | 3.53e-07 | 2.65e-06 |
| ZNF135:0 | 61/61,988 | 370/16,348,907 | 43.52 | 4.55e-74 | 2.92e-72 |
| Triton X-100:0 | 4/61,988 | 7,424/16,348,907 | 0.14 | 3.91e-08 | 3.26e-07 |
| established cell line:0 | 89/61,988 | 2,688/16,348,907 | 8.74 | 4.20e-51 | 1.94e-49 |
| Nitrous Oxide:0 | 3/61,988 | 8,101/16,348,907 | 0.10 | 5.44e-10 | 5.46e-09 |
| Congenital heart disease:0 | 4/61,988 | 25,865/16,348,907 | 0.04 | 2.46e-36 | 8.16e-35 |
| Biopsy sample:0 | 494/61,988 | 27,682/16,348,907 | 4.74 | 4.46e-165 | 6.30e-163 |
| Entire common bile duct:0 | 3/61,988 | 6,365/16,348,907 | 0.12 | 1.87e-07 | 1.45e-06 |
| Receptor, EphA2|EPHA2:0 | 7/61,988 | 60/16,348,907 | 30.77 | 7.82e-09 | 7.04e-08 |
| cell invasion:0 | 265/61,988 | 6,448/16,348,907 | 10.88 | 2.24e-170 | 3.23e-168 |
| Salicylic Acid:0 | 5/61,988 | 9,292/16,348,907 | 0.14 | 5.54e-10 | 5.56e-09 |
| Female Breast Carcinoma:0 | 46/61,988 | 1,318/16,348,907 | 9.21 | 3.58e-28 | 9.26e-27 |
| Schizophrenia:0 | 20/61,988 | 118,708/16,348,907 | 0.04 | 2.00e-161 | 2.76e-159 |
| 1-Phosphatidylinositol 4-Kinase:0 | 50/61,988 | 6,156/16,348,907 | 2.14 | 1.33e-06 | 9.29e-06 |
| Ki-67 Antigen|MKI67|PIEZO1|MIB1:0 | 34/61,988 | 700/16,348,907 | 12.82 | 1.35e-25 | 3.22e-24 |
| Chinese Hamster Ovary Cell:0 | 28/61,988 | 18,602/16,348,907 | 0.40 | 1.53e-08 | 1.33e-07 |
| Bilateral Malignant Neoplasm:0 | 12/61,988 | 156/16,348,907 | 20.29 | 3.45e-12 | 4.11e-11 |
| Periodontal Diseases:0 | 9/61,988 | 12,116/16,348,907 | 0.20 | 6.42e-11 | 6.98e-10 |
| Microdissection:0 | 38/61,988 | 1,969/16,348,907 | 5.09 | 2.57e-15 | 3.76e-14 |
| resistin|RETN:0 | 2/61,988 | 6,791/16,348,907 | 0.08 | 4.43e-09 | 4.07e-08 |
| Opportunistic Infections:0 | 2/61,988 | 9,686/16,348,907 | 0.05 | 1.46e-13 | 1.91e-12 |
| Psoriasis:0 | 18/61,988 | 46,513/16,348,907 | 0.10 | 3.04e-52 | 1.44e-50 |
| Sexual problem:0 | 19/61,988 | 1,180/16,348,907 | 4.25 | 3.05e-07 | 2.31e-06 |
| ERCC8|CSH1|HSPA9:0 | 1/61,988 | 6,119/16,348,907 | 0.04 | 3.97e-09 | 3.67e-08 |
| Anesthetics:0 | 36/61,988 | 32,847/16,348,907 | 0.29 | 1.72e-20 | 3.34e-19 |
| PRSS8 protein, human|PRSS8:0 | 16/61,988 | 598/16,348,907 | 7.06 | 3.29e-09 | 3.07e-08 |
| Fruit:0 | 66/61,988 | 5,782/16,348,907 | 3.01 | 3.03e-14 | 4.13e-13 |
| melanoma:0 | 789/61,988 | 96,656/16,348,907 | 2.17 | 1.20e-81 | 8.32e-80 |
| Algae, Green:0 | 1/61,988 | 4,596/16,348,907 | 0.06 | 8.80e-07 | 6.32e-06 |
| KLK13:0 | 6/61,988 | 37/16,348,907 | 42.77 | 1.57e-08 | 1.36e-07 |
| Phenobarbital:0 | 5/61,988 | 16,024/16,348,907 | 0.08 | 8.27e-20 | 1.54e-18 |
| Gland structure:0 | 568/61,988 | 17,877/16,348,907 | 8.45 | 1.80e-307 | 4.40e-305 |
| Human herpesvirus 3:0 | 3/61,988 | 8,097/16,348,907 | 0.10 | 5.41e-10 | 5.44e-09 |
| Surrogate Endpoints:0 | 33/61,988 | 300/16,348,907 | 29.03 | 1.43e-35 | 4.58e-34 |
| tumor suppressor activity:0 | 7/61,988 | 117/16,348,907 | 15.78 | 5.61e-07 | 4.12e-06 |
| Neural Network Simulation:0 | 22/61,988 | 996/16,348,907 | 5.83 | 1.44e-10 | 1.52e-09 |
| mast cell:0 | 14/61,988 | 34,610/16,348,907 | 0.11 | 1.27e-38 | 4.50e-37 |
| Radiation therapist:0 | 15/61,988 | 177/16,348,907 | 22.36 | 1.88e-15 | 2.77e-14 |
| Androstenedione:0 | 124/61,988 | 6,243/16,348,907 | 5.25 | 2.25e-47 | 9.70e-46 |
| Fibrinogen:0 | 21/61,988 | 21,648/16,348,907 | 0.26 | 1.74e-15 | 2.56e-14 |
| JV 1-38:0 | 7/61,988 | 39/16,348,907 | 47.34 | 5.16e-10 | 5.20e-09 |
| Bone structure of calcaneum:0 | 2/61,988 | 7,674/16,348,907 | 0.07 | 1.82e-10 | 1.91e-09 |
| Teleradiotherapy procedure:0 | 989/61,988 | 4,838/16,348,907 | 54.77 | 0.00e+00 | 0.00e+00 |
| N-Methyl-D-Aspartate Receptors:0 | 3/61,988 | 17,486/16,348,907 | 0.05 | 1.74e-24 | 3.96e-23 |
| SLC43A1 gene|SLC43A1:0 | 5/61,988 | 9/16,348,907 | 146.54 | 1.50e-09 | 1.44e-08 |
| Vesicorectal fistula:0 | 8/61,988 | 89/16,348,907 | 23.71 | 4.44e-09 | 4.08e-08 |
| Urinary Incontinence, Stress:0 | 131/61,988 | 16,166/16,348,907 | 2.14 | 1.08e-14 | 1.52e-13 |
| Structure of parenchyma of lung:0 | 36/61,988 | 23,974/16,348,907 | 0.40 | 9.89e-11 | 1.06e-09 |
| Isoproterenol:0 | 7/61,988 | 33,933/16,348,907 | 0.05 | 3.31e-45 | 1.36e-43 |
| Immune Sera:0 | 120/61,988 | 56,235/16,348,907 | 0.56 | 5.10e-12 | 6.01e-11 |
| Proto-Oncogenes:0 | 93/61,988 | 8,723/16,348,907 | 2.81 | 1.42e-17 | 2.33e-16 |
| Viral hepatitis:0 | 1/61,988 | 5,554/16,348,907 | 0.05 | 3.60e-08 | 3.02e-07 |
| Tract:0 | 304/61,988 | 40,586/16,348,907 | 1.98 | 1.57e-26 | 3.87e-25 |
| Erotic interest:0 | 23/61,988 | 1,391/16,348,907 | 4.36 | 1.16e-08 | 1.02e-07 |
| satraplatin:0 | 31/61,988 | 192/16,348,907 | 42.60 | 3.28e-38 | 1.14e-36 |
| Microcirculation:0 | 14/61,988 | 15,386/16,348,907 | 0.24 | 7.20e-12 | 8.40e-11 |
| KLF6 gene|KLF6:0 | 22/61,988 | 243/16,348,907 | 23.89 | 1.54e-22 | 3.23e-21 |
| Amyloid:0 | 11/61,988 | 19,620/16,348,907 | 0.15 | 1.18e-19 | 2.18e-18 |
| Prostate-Specific Antigen:0 | 5,760/61,988 | 14,799/16,348,907 | 113.07 | 0.00e+00 | 0.00e+00 |
| Chromosomes, Human, Pair 10:0 | 79/61,988 | 3,182/16,348,907 | 6.56 | 4.09e-37 | 1.39e-35 |
| inhibitors:0 | 143/61,988 | 13,592/16,348,907 | 2.78 | 1.45e-25 | 3.45e-24 |
| Hepatitis B, Chronic:0 | 1/61,988 | 20,245/16,348,907 | 0.01 | 7.77e-32 | 2.26e-30 |
| insulin sensitivity:0 | 35/61,988 | 21,054/16,348,907 | 0.44 | 3.03e-08 | 2.57e-07 |
| Electrolytes:0 | 9/61,988 | 12,629/16,348,907 | 0.19 | 1.29e-11 | 1.48e-10 |
| Wrist:0 | 10/61,988 | 13,192/16,348,907 | 0.20 | 1.29e-11 | 1.47e-10 |
| DISEASES/DIAGNOSES:0 | 17/61,988 | 979/16,348,907 | 4.58 | 4.58e-07 | 3.39e-06 |
| Mucous Membrane:0 | 98/61,988 | 82,184/16,348,907 | 0.31 | 2.74e-45 | 1.13e-43 |
| Total excision of bladder NOS:0 | 22/61,988 | 650/16,348,907 | 8.93 | 4.76e-14 | 6.42e-13 |
| Corticosterone:0 | 17/61,988 | 27,362/16,348,907 | 0.16 | 1.07e-25 | 2.56e-24 |
| Epithelial Cells:0 | 2,268/61,988 | 126,298/16,348,907 | 4.88 | 0.00e+00 | 0.00e+00 |
| Body Weight decreased:0 | 46/61,988 | 24,712/16,348,907 | 0.49 | 7.99e-08 | 6.42e-07 |
| Fibroblast Growth Factor 8b:0 | 6/61,988 | 58/16,348,907 | 27.29 | 1.80e-07 | 1.40e-06 |
| Glucose concentration, test strip measurement:0 | 1/61,988 | 5,689/16,348,907 | 0.05 | 1.67e-08 | 1.44e-07 |
| Streptococcus Group B:0 | 2/61,988 | 5,518/16,348,907 | 0.10 | 4.40e-07 | 3.27e-06 |
| BECN1:0 | 15/61,988 | 810/16,348,907 | 4.89 | 9.81e-07 | 6.98e-06 |
| Immunoglobulins|WDR20:0 | 6/61,988 | 19/16,348,907 | 83.30 | 4.84e-10 | 4.88e-09 |
| Nursing Homes:0 | 1/61,988 | 4,932/16,348,907 | 0.05 | 3.05e-07 | 2.31e-06 |
| Neoplasms, Second Primary:0 | 93/61,988 | 1,846/16,348,907 | 13.31 | 2.29e-68 | 1.37e-66 |
| Edema:0 | 157/61,988 | 60,264/16,348,907 | 0.69 | 7.09e-07 | 5.14e-06 |
| hearing impairment:0 | 6/61,988 | 29,245/16,348,907 | 0.05 | 3.87e-39 | 1.39e-37 |
| Urethrorectal fistula:0 | 22/61,988 | 90/16,348,907 | 64.49 | 4.24e-31 | 1.20e-29 |
| Entire obturator nerve:0 | 11/61,988 | 370/16,348,907 | 7.84 | 3.31e-07 | 2.49e-06 |
| Amyloid beta-Protein Precursor:0 | 4/61,988 | 13,048/16,348,907 | 0.08 | 1.59e-16 | 2.48e-15 |
| Urethral Stricture:0 | 59/61,988 | 2,335/16,348,907 | 6.67 | 1.55e-28 | 4.07e-27 |
| Male pelvis:0 | 6/61,988 | 37/16,348,907 | 42.77 | 1.57e-08 | 1.36e-07 |
| Open prostatectomy:0 | 86/61,988 | 440/16,348,907 | 51.62 | 2.10e-109 | 1.88e-107 |
| Malignant neoplasm of lung:0 | 1,111/61,988 | 85,433/16,348,907 | 3.47 | 5.64e-256 | 1.16e-253 |
| Decompressive incision:0 | 19/61,988 | 14,752/16,348,907 | 0.34 | 1.96e-08 | 1.68e-07 |
| Tumor focality:0 | 49/61,988 | 228/16,348,907 | 56.73 | 6.95e-65 | 3.99e-63 |
| Dihydroxycholecalciferols:0 | 52/61,988 | 2,980/16,348,907 | 4.61 | 1.46e-18 | 2.55e-17 |
| HIV Seropositivity:0 | 35/61,988 | 51,207/16,348,907 | 0.18 | 1.46e-44 | 5.92e-43 |
| Prostate Leiomyoma:0 | 5/61,988 | 10/16,348,907 | 131.88 | 2.24e-09 | 2.12e-08 |
| Blood supply aspects:0 | 223/61,988 | 30,854/16,348,907 | 1.91 | 3.34e-18 | 5.70e-17 |
| Cecum:0 | 7/61,988 | 10,600/16,348,907 | 0.17 | 3.34e-10 | 3.43e-09 |
| Techniques:0 | 837/61,988 | 133,240/16,348,907 | 1.67 | 1.08e-41 | 4.11e-40 |
| benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone:0 | 32/61,988 | 1,880/16,348,907 | 4.49 | 9.05e-12 | 1.05e-10 |
| Female:0 | 371/61,988 | 148,039/16,348,907 | 0.66 | 1.13e-17 | 1.87e-16 |
| Oral form dexamethasone:0 | 12/61,988 | 507/16,348,907 | 6.24 | 1.02e-06 | 7.22e-06 |
| Etidronate:0 | 43/61,988 | 3,579/16,348,907 | 3.17 | 1.72e-10 | 1.81e-09 |
| Prostaglandins:0 | 113/61,988 | 47,445/16,348,907 | 0.63 | 1.22e-07 | 9.58e-07 |
| Entire tendon:0 | 1/61,988 | 19,900/16,348,907 | 0.01 | 3.67e-31 | 1.04e-29 |
| Cell surface:0 | 372/61,988 | 61,326/16,348,907 | 1.60 | 3.68e-17 | 5.97e-16 |
| Acute prostatitis:0 | 22/61,988 | 168/16,348,907 | 34.55 | 9.23e-26 | 2.22e-24 |
| Bone plates:0 | 22/61,988 | 28,749/16,348,907 | 0.20 | 8.25e-24 | 1.82e-22 |
| Wall of rectum:0 | 68/61,988 | 614/16,348,907 | 29.24 | 1.10e-71 | 6.83e-70 |
| radiologist:0 | 69/61,988 | 5,528/16,348,907 | 3.29 | 1.20e-16 | 1.89e-15 |
| kallikrein 4:0 | 16/61,988 | 125/16,348,907 | 33.77 | 5.29e-19 | 9.48e-18 |
| Intercellular adhesion molecule 1:0 | 28/61,988 | 21,551/16,348,907 | 0.34 | 1.21e-11 | 1.39e-10 |
| Ulcer:0 | 30/61,988 | 32,858/16,348,907 | 0.24 | 7.06e-24 | 1.56e-22 |
| Human cells:0 | 213/61,988 | 27,570/16,348,907 | 2.04 | 1.73e-20 | 3.35e-19 |
| Liver Failure:0 | 7/61,988 | 8,149/16,348,907 | 0.23 | 4.96e-07 | 3.66e-06 |
| Mouse epithelium:0 | 18/61,988 | 997/16,348,907 | 4.76 | 1.23e-07 | 9.68e-07 |
| Gonadotropins|HSD3B1:0 | 4/61,988 | 3/16,348,907 | 351.68 | 7.06e-09 | 6.38e-08 |
| Autophagy:0 | 236/61,988 | 31,557/16,348,907 | 1.98 | 5.78e-21 | 1.14e-19 |
| Egtazic Acid:0 | 2/61,988 | 6,473/16,348,907 | 0.08 | 1.27e-08 | 1.12e-07 |
| Aptamer:0 | 37/61,988 | 3,058/16,348,907 | 3.19 | 2.54e-09 | 2.40e-08 |
| AKR1C3|AKR1A1|PCA3:0 | 25/61,988 | 87/16,348,907 | 75.82 | 1.18e-36 | 3.95e-35 |
| Cholelithiasis:0 | 5/61,988 | 7,141/16,348,907 | 0.18 | 5.71e-07 | 4.19e-06 |
| Papio:0 | 13/61,988 | 10,793/16,348,907 | 0.32 | 8.82e-07 | 6.33e-06 |
| Lymphatic vessel:0 | 67/61,988 | 7,327/16,348,907 | 2.41 | 2.55e-10 | 2.65e-09 |
| Prostatic epithelium:0 | 515/61,988 | 924/16,348,907 | 148.22 | 0.00e+00 | 0.00e+00 |
| Entire sciatic nerve:0 | 4/61,988 | 12,769/16,348,907 | 0.08 | 4.58e-16 | 6.97e-15 |
| TRANCE protein:0 | 54/61,988 | 2,523/16,348,907 | 5.65 | 4.91e-23 | 1.05e-21 |
| Bladder Tissue:0 | 26/61,988 | 1,196/16,348,907 | 5.74 | 4.58e-12 | 5.41e-11 |
| Primary Care Physicians:0 | 38/61,988 | 3,613/16,348,907 | 2.78 | 5.58e-08 | 4.57e-07 |
| TNF protein, human|TNF:0 | 177/61,988 | 71,207/16,348,907 | 0.65 | 1.93e-09 | 1.84e-08 |
| high-LET neutron therapy:0 | 12/61,988 | 150/16,348,907 | 21.10 | 2.24e-12 | 2.70e-11 |
| Diastolic blood pressure:0 | 3/61,988 | 6,761/16,348,907 | 0.12 | 4.73e-08 | 3.92e-07 |
| Inverse:0 | 202/61,988 | 15,399/16,348,907 | 3.47 | 1.99e-48 | 8.82e-47 |
| Radiopharmaceuticals:0 | 163/61,988 | 3,274/16,348,907 | 13.16 | 1.13e-117 | 1.13e-115 |
| Tumor Antigens:0 | 230/61,988 | 8,591/16,348,907 | 7.08 | 6.80e-111 | 6.25e-109 |
| Ammonia:0 | 5/61,988 | 14,241/16,348,907 | 0.09 | 2.87e-17 | 4.68e-16 |
| craniofacial:0 | 2/61,988 | 6,752/16,348,907 | 0.08 | 6.73e-09 | 6.09e-08 |
| NCOA2:0 | 4/61,988 | 15/16,348,907 | 70.34 | 7.54e-07 | 5.45e-06 |
| S100A9 gene|S100A9:0 | 25/61,988 | 1,244/16,348,907 | 5.30 | 5.78e-11 | 6.32e-10 |
| Malignant neoplasm of penis:0 | 36/61,988 | 1,128/16,348,907 | 8.42 | 3.47e-21 | 6.92e-20 |
| Senile Plaques:0 | 13/61,988 | 37,771/16,348,907 | 0.09 | 2.54e-44 | 1.02e-42 |
| Solutions:0 | 15/61,988 | 13,844/16,348,907 | 0.29 | 2.57e-09 | 2.43e-08 |
| Gonadorelin|ZBTB7A|CREBRF:0 | 107/61,988 | 214/16,348,907 | 132.10 | 6.02e-173 | 8.78e-171 |
| Latex:0 | 1/61,988 | 4,783/16,348,907 | 0.06 | 6.75e-07 | 4.90e-06 |
| Cyclin E:0 | 68/61,988 | 4,214/16,348,907 | 4.26 | 5.65e-22 | 1.16e-20 |
| Neprilysin|DDR1|MME:0 | 22/61,988 | 1,319/16,348,907 | 4.40 | 2.05e-08 | 1.76e-07 |
| Left ventricular assist device:0 | 1/61,988 | 6,866/16,348,907 | 0.04 | 3.35e-10 | 3.44e-09 |
| Endocrine therapy:0 | 1,910/61,988 | 16,687/16,348,907 | 31.12 | 0.00e+00 | 0.00e+00 |
| Sexual function:0 | 303/61,988 | 6,404/16,348,907 | 12.54 | 4.25e-211 | 7.31e-209 |
| Pyotraumatic dermatitis:0 | 40/61,988 | 4,192/16,348,907 | 2.52 | 4.09e-07 | 3.05e-06 |
| Tissue specimen from prostate:0 | 170/61,988 | 282/16,348,907 | 159.43 | 1.33e-284 | 3.09e-282 |
| Wing:0 | 10/61,988 | 9,698/16,348,907 | 0.27 | 3.39e-07 | 2.55e-06 |
| Valproate:0 | 3/61,988 | 9,256/16,348,907 | 0.09 | 8.00e-12 | 9.29e-11 |
| FAVOR:0 | 339/61,988 | 33,561/16,348,907 | 2.67 | 2.39e-54 | 1.18e-52 |
| Immunoglobulins, Intravenous:0 | 4/61,988 | 25,544/16,348,907 | 0.04 | 7.05e-36 | 2.28e-34 |
| Choline Kinase:0 | 24/61,988 | 1,352/16,348,907 | 4.68 | 1.49e-09 | 1.44e-08 |
| Duct (organ) structure:0 | 100/61,988 | 6,329/16,348,907 | 4.17 | 8.34e-31 | 2.33e-29 |
| Extracellular Matrix:0 | 215/61,988 | 33,602/16,348,907 | 1.69 | 1.72e-12 | 2.08e-11 |
| Ovaro-:0 | 383/61,988 | 39,578/16,348,907 | 2.56 | 9.99e-57 | 5.08e-55 |
| Human Development:0 | 24/61,988 | 1,976/16,348,907 | 3.20 | 1.34e-06 | 9.34e-06 |
| Durapatite:0 | 9/61,988 | 11,392/16,348,907 | 0.21 | 5.92e-10 | 5.93e-09 |
| Heart failure:0 | 46/61,988 | 124,773/16,348,907 | 0.10 | 7.29e-141 | 8.71e-139 |
| IGFBP3 gene|IGFBP3:0 | 14/61,988 | 335/16,348,907 | 11.02 | 1.29e-10 | 1.37e-09 |
| snail transcription factors:0 | 7/61,988 | 46/16,348,907 | 40.14 | 1.45e-09 | 1.40e-08 |
| ANXA3 gene|ANXA3:0 | 8/61,988 | 42/16,348,907 | 50.24 | 1.93e-11 | 2.17e-10 |
| Numbers:0 | 124/61,988 | 10,848/16,348,907 | 3.02 | 2.53e-25 | 5.97e-24 |
| [D]Extravasation of urine:0 | 40/61,988 | 802/16,348,907 | 13.16 | 3.09e-30 | 8.54e-29 |
| Galactose:0 | 6/61,988 | 9,269/16,348,907 | 0.17 | 3.05e-09 | 2.86e-08 |
| Genitourinary Neoplasms:0 | 15/61,988 | 49/16,348,907 | 80.76 | 6.09e-23 | 1.30e-21 |
| Cancer, Benign:0 | 4/61,988 | 15/16,348,907 | 70.34 | 7.54e-07 | 5.45e-06 |
| rosuvastatin:0 | 1/61,988 | 7,141/16,348,907 | 0.04 | 1.09e-10 | 1.16e-09 |
| Liposomal Doxorubicin:0 | 24/61,988 | 1,520/16,348,907 | 4.17 | 1.32e-08 | 1.16e-07 |
| External Beam Radiation Therapy:0 | 952/61,988 | 4,794/16,348,907 | 53.18 | 0.00e+00 | 0.00e+00 |
| Increased Cellular Death:0 | 19/61,988 | 777/16,348,907 | 6.45 | 4.96e-10 | 5.00e-09 |
| Factor VIIa:0 | 6/61,988 | 10,779/16,348,907 | 0.15 | 3.12e-11 | 3.47e-10 |
| Vinblastine:0 | 87/61,988 | 8,453/16,348,907 | 2.72 | 1.07e-15 | 1.59e-14 |
| Hospitals, Cancer:0 | 17/61,988 | 292/16,348,907 | 15.36 | 8.76e-15 | 1.24e-13 |
| Breast adenocarcinoma:0 | 51/61,988 | 2,999/16,348,907 | 4.49 | 8.59e-18 | 1.43e-16 |
| PLAUR gene|PLAUR:0 | 12/61,988 | 457/16,348,907 | 6.93 | 3.53e-07 | 2.65e-06 |
| Scanning Systems:0 | 73/61,988 | 8,099/16,348,907 | 2.38 | 9.07e-11 | 9.77e-10 |
| Cell Adhesion:0 | 228/61,988 | 15,305/16,348,907 | 3.94 | 1.51e-63 | 8.52e-62 |
| BIRC4 gene|XIAP:0 | 61/61,988 | 3,802/16,348,907 | 4.23 | 9.03e-20 | 1.68e-18 |
| HOXD3:0 | 7/61,988 | 70/16,348,907 | 26.38 | 2.09e-08 | 1.79e-07 |
| Phosphorothioate Oligonucleotide:0 | 12/61,988 | 480/16,348,907 | 6.59 | 5.84e-07 | 4.28e-06 |
| Cytomegalovirus:0 | 33/61,988 | 25,497/16,348,907 | 0.34 | 1.20e-13 | 1.59e-12 |
| Tachycardia:0 | 3/61,988 | 12,243/16,348,907 | 0.06 | 3.09e-16 | 4.74e-15 |
| Electroporation:0 | 36/61,988 | 2,732/16,348,907 | 3.48 | 4.73e-10 | 4.79e-09 |
| Glucokinase:0 | 1/61,988 | 4,685/16,348,907 | 0.06 | 6.14e-07 | 4.48e-06 |
| CLU:0 | 19/61,988 | 720/16,348,907 | 6.96 | 1.46e-10 | 1.54e-09 |
| Prostate feature:0 | 9/61,988 | 10/16,348,907 | 237.40 | 1.40e-17 | 2.30e-16 |
| Oat cell carcinoma:0 | 69/61,988 | 2,518/16,348,907 | 7.23 | 3.89e-35 | 1.23e-33 |
| RNA, Messenger:0 | 628/61,988 | 80,755/16,348,907 | 2.06 | 2.17e-58 | 1.14e-56 |
| parathyroid hormone-related protein:0 | 92/61,988 | 8,021/16,348,907 | 3.03 | 2.51e-19 | 4.57e-18 |
| independency:0 | 4/61,988 | 16/16,348,907 | 65.94 | 9.40e-07 | 6.70e-06 |
| Respiratory Burst:0 | 1/61,988 | 8,933/16,348,907 | 0.03 | 1.58e-13 | 2.06e-12 |
| Cardiac Output:0 | 2/61,988 | 10,003/16,348,907 | 0.05 | 5.03e-14 | 6.77e-13 |
| Demented:0 | 2/61,988 | 6,153/16,348,907 | 0.09 | 5.60e-08 | 4.59e-07 |
| Contraceptives, Oral:0 | 10/61,988 | 12,461/16,348,907 | 0.21 | 1.17e-10 | 1.25e-09 |
| Large Intestine:0 | 50/61,988 | 3,747/16,348,907 | 3.52 | 1.53e-13 | 2.00e-12 |
| Bone structure of pubis:0 | 20/61,988 | 1,024/16,348,907 | 5.15 | 7.17e-09 | 6.47e-08 |
| Immune Sera|EREG|ESR1:0 | 9/61,988 | 34/16,348,907 | 69.82 | 7.86e-14 | 1.04e-12 |
| Mental disorders:0 | 24/61,988 | 65,111/16,348,907 | 0.10 | 4.98e-74 | 3.19e-72 |
| Enoxaparin:0 | 4/61,988 | 7,071/16,348,907 | 0.15 | 1.04e-07 | 8.30e-07 |
| Signaling Molecule:0 | 107/61,988 | 11,831/16,348,907 | 2.39 | 3.32e-15 | 4.82e-14 |
| Anogenital region:0 | 81/61,988 | 5,300/16,348,907 | 4.03 | 2.10e-24 | 4.76e-23 |
| monooxyethylene trimethylolpropane tristearate:0 | 50/61,988 | 2,185/16,348,907 | 6.04 | 1.20e-22 | 2.54e-21 |
| Extensor:0 | 2/61,988 | 9,340/16,348,907 | 0.06 | 6.38e-13 | 7.94e-12 |
| Radium:0 | 19/61,988 | 1,102/16,348,907 | 4.55 | 1.11e-07 | 8.80e-07 |
| Gray matter:0 | 1/61,988 | 6,656/16,348,907 | 0.04 | 6.79e-10 | 6.74e-09 |
| SB 75:0 | 11/61,988 | 68/16,348,907 | 42.67 | 1.59e-14 | 2.21e-13 |
| Adenocarcinoma of prostate:0 | 1,309/61,988 | 2,164/16,348,907 | 162.96 | 0.00e+00 | 0.00e+00 |
| abnormal glucose tolerance test:0 | 3/61,988 | 8,714/16,348,907 | 0.09 | 6.80e-11 | 7.38e-10 |
| Eukaryota:0 | 38/61,988 | 42,726/16,348,907 | 0.23 | 2.53e-31 | 7.24e-30 |
| Aldosterone:0 | 9/61,988 | 24,374/16,348,907 | 0.10 | 2.09e-28 | 5.47e-27 |
| Instillation, Bladder:0 | 38/61,988 | 1,716/16,348,907 | 5.84 | 3.69e-17 | 5.98e-16 |
| Refractory Carcinoma:0 | 253/61,988 | 2,419/16,348,907 | 27.69 | 6.05e-256 | 1.24e-253 |
| Blood Flow Velocity:0 | 1/61,988 | 9,052/16,348,907 | 0.03 | 1.13e-13 | 1.49e-12 |
| Radiation proctitis:0 | 51/61,988 | 357/16,348,907 | 37.71 | 2.45e-59 | 1.30e-57 |
| Brain region:0 | 1/61,988 | 10,064/16,348,907 | 0.03 | 1.89e-15 | 2.78e-14 |
| Vancomycin:0 | 1/61,988 | 16,806/16,348,907 | 0.02 | 2.98e-26 | 7.32e-25 |
| Tooth structure:0 | 11/61,988 | 33,921/16,348,907 | 0.09 | 1.39e-40 | 5.15e-39 |
| TMEM37:0 | 24/61,988 | 389/16,348,907 | 16.28 | 8.54e-21 | 1.68e-19 |
| Scopolamine:0 | 2/61,988 | 6,672/16,348,907 | 0.08 | 6.28e-09 | 5.69e-08 |
| Ureteral obstruction:0 | 73/61,988 | 4,651/16,348,907 | 4.14 | 8.48e-23 | 1.80e-21 |
| Lyase:0 | 40/61,988 | 2,033/16,348,907 | 5.19 | 2.63e-16 | 4.05e-15 |
| Hepatocyte:0 | 91/61,988 | 119,633/16,348,907 | 0.20 | 5.44e-96 | 4.31e-94 |
| Intellectual functioning disability:0 | 3/61,988 | 16,724/16,348,907 | 0.05 | 3.21e-23 | 6.97e-22 |
| Receptors, Nuclear:0 | 178/61,988 | 10,571/16,348,907 | 4.45 | 3.60e-57 | 1.84e-55 |
| Secondary malignant neoplasm of vertebral column:0 | 62/61,988 | 2,051/16,348,907 | 7.98 | 5.18e-34 | 1.60e-32 |
| The science and art of healing:0 | 127/61,988 | 8,531/16,348,907 | 3.93 | 3.51e-36 | 1.16e-34 |
| Polymorphism, Genetic:0 | 500/61,988 | 50,498/16,348,907 | 2.62 | 1.91e-76 | 1.25e-74 |
| URINARY OBSTRUCTIVE SYMPTOMS:0 | 16/61,988 | 25/16,348,907 | 168.84 | 1.62e-28 | 4.24e-27 |
| Residual urine:0 | 16/61,988 | 401/16,348,907 | 10.53 | 1.23e-11 | 1.41e-10 |
| Undifferentiated carcinoma:0 | 36/61,988 | 2,628/16,348,907 | 3.61 | 1.73e-10 | 1.81e-09 |
| Molecular Fingerprint of Tumor:0 | 18/61,988 | 629/16,348,907 | 7.55 | 1.26e-10 | 1.33e-09 |
| Vitamin D3 Receptor:0 | 193/61,988 | 9,185/16,348,907 | 5.56 | 1.64e-76 | 1.08e-74 |
| Gram-Negative Bacteria:0 | 5/61,988 | 15,174/16,348,907 | 0.09 | 1.27e-18 | 2.23e-17 |
| Carcinoma of Nasopharynx:0 | 38/61,988 | 20,311/16,348,907 | 0.49 | 1.39e-06 | 9.63e-06 |
| Chronic lung disease:0 | 1/61,988 | 6,629/16,348,907 | 0.04 | 6.56e-10 | 6.52e-09 |
| PROM1:0 | 59/61,988 | 4,420/16,348,907 | 3.52 | 1.08e-15 | 1.62e-14 |
| CLDN3 gene|CLDN3:0 | 7/61,988 | 103/16,348,907 | 17.93 | 2.48e-07 | 1.90e-06 |
| Leukemia, Lymphocytic, Acute, L1:0 | 1/61,988 | 4,535/16,348,907 | 0.06 | 1.29e-06 | 9.04e-06 |
| CA-15-3 Antigen:0 | 25/61,988 | 2,088/16,348,907 | 3.16 | 1.05e-06 | 7.45e-06 |
| hip bone:0 | 22/61,988 | 749/16,348,907 | 7.75 | 7.17e-13 | 8.87e-12 |
| Neoplasms, Multiple Primary:0 | 17/61,988 | 518/16,348,907 | 8.66 | 5.36e-11 | 5.87e-10 |
| Yohimbe Preparation:0 | 3/61,988 | 6,691/16,348,907 | 0.12 | 6.87e-08 | 5.58e-07 |
| Cancer of Intestines:0 | 20/61,988 | 1,033/16,348,907 | 5.11 | 8.26e-09 | 7.42e-08 |
| Enterobacteriaceae:0 | 1/61,988 | 7,164/16,348,907 | 0.04 | 1.13e-10 | 1.20e-09 |
| Salmonella typhimurium:0 | 5/61,988 | 8,695/16,348,907 | 0.15 | 4.17e-09 | 3.84e-08 |
| Desipramine:0 | 8/61,988 | 9,141/16,348,907 | 0.23 | 1.34e-07 | 1.05e-06 |
| KLK11 gene|KLK11:0 | 15/61,988 | 86/16,348,907 | 46.01 | 9.95e-20 | 1.84e-18 |
| Femur:0 | 140/61,988 | 63,970/16,348,907 | 0.58 | 1.11e-12 | 1.35e-11 |
| Urinary catheter:0 | 21/61,988 | 847/16,348,907 | 6.54 | 4.90e-11 | 5.38e-10 |
| LARP6:0 | 14/61,988 | 225/16,348,907 | 16.41 | 8.40e-13 | 1.04e-11 |
| CCNB1:0 | 7/61,988 | 100/16,348,907 | 18.46 | 2.06e-07 | 1.59e-06 |
| Glycosaminoglycans:0 | 27/61,988 | 18,198/16,348,907 | 0.39 | 1.51e-08 | 1.32e-07 |
| Astrocytes:0 | 20/61,988 | 48,573/16,348,907 | 0.11 | 1.71e-53 | 8.29e-52 |
| PMEPA1:0 | 21/61,988 | 117/16,348,907 | 47.35 | 2.94e-27 | 7.42e-26 |
| Intermittent Positive-Pressure Ventilation:0 | 1/61,988 | 4,512/16,348,907 | 0.06 | 1.27e-06 | 8.90e-06 |
| glycogen synthase kinase 3 beta:0 | 32/61,988 | 2,940/16,348,907 | 2.87 | 2.86e-07 | 2.17e-06 |
| Autoantibodies:0 | 72/61,988 | 44,201/16,348,907 | 0.43 | 1.30e-16 | 2.04e-15 |
| Atropine:0 | 4/61,988 | 18,127/16,348,907 | 0.06 | 3.54e-24 | 7.93e-23 |
| Tachyarrhythmia:0 | 1/61,988 | 6,172/16,348,907 | 0.04 | 4.25e-09 | 3.91e-08 |
| Solvents:0 | 6/61,988 | 10,156/16,348,907 | 0.16 | 2.27e-10 | 2.36e-09 |
| Entire trunk:0 | 20/61,988 | 23,197/16,348,907 | 0.23 | 6.08e-18 | 1.03e-16 |
| Budesonide:0 | 2/61,988 | 8,707/16,348,907 | 0.06 | 5.25e-12 | 6.19e-11 |
| Evolution:0 | 66/61,988 | 34,278/16,348,907 | 0.51 | 1.03e-09 | 1.00e-08 |
| Lambda:0 | 1/61,988 | 4,902/16,348,907 | 0.05 | 3.00e-07 | 2.27e-06 |
| Carcinogen effect:0 | 16/61,988 | 784/16,348,907 | 5.38 | 1.23e-07 | 9.72e-07 |
| Onset of illness:0 | 16/61,988 | 16,607/16,348,907 | 0.25 | 4.49e-12 | 5.31e-11 |
| Lipids:0 | 213/61,988 | 113,403/16,348,907 | 0.49 | 5.16e-31 | 1.45e-29 |
| Phytochemical:0 | 63/61,988 | 2,601/16,348,907 | 6.39 | 2.19e-29 | 5.93e-28 |
| Receptor Gene:0 | 250/61,988 | 9,534/16,348,907 | 6.94 | 1.81e-118 | 1.84e-116 |
| Androgenic precursors:0 | 13/61,988 | 157/16,348,907 | 21.84 | 1.82e-13 | 2.37e-12 |
| Grade:0 | 140/61,988 | 10,108/16,348,907 | 3.66 | 1.73e-36 | 5.78e-35 |
| steroid hormone metabolism:0 | 7/61,988 | 73/16,348,907 | 25.29 | 2.74e-08 | 2.32e-07 |
| Magnetic Resonance Spectroscopy:0 | 195/61,988 | 13,704/16,348,907 | 3.76 | 9.18e-52 | 4.31e-50 |
| Mice, Nude:0 | 1,332/61,988 | 29,179/16,348,907 | 12.28 | 0.00e+00 | 0.00e+00 |
| Retro-pubic prostatectomy:0 | 5/61,988 | 8/16,348,907 | 164.85 | 9.65e-10 | 9.43e-09 |
| Urethra:0 | 258/61,988 | 7,201/16,348,907 | 9.48 | 2.41e-152 | 3.18e-150 |
| Ostium:0 | 6/61,988 | 9,850/16,348,907 | 0.16 | 6.12e-10 | 6.11e-09 |
| Telomerase:0 | 120/61,988 | 9,443/16,348,907 | 3.36 | 2.45e-28 | 6.38e-27 |
| Diagnosis:0 | 1,205/61,988 | 141,324/16,348,907 | 2.27 | 9.94e-137 | 1.16e-134 |
| Concanavalin A:0 | 16/61,988 | 15,325/16,348,907 | 0.28 | 1.58e-10 | 1.67e-09 |
| Mucous body substance:0 | 1/61,988 | 6,907/16,348,907 | 0.04 | 2.17e-10 | 2.27e-09 |
| phenylbutyrate:0 | 17/61,988 | 812/16,348,907 | 5.52 | 3.55e-08 | 2.98e-07 |
| ELAC2:0 | 26/61,988 | 60/16,348,907 | 114.34 | 5.86e-42 | 2.24e-40 |
| Vomiting:0 | 29/61,988 | 21,150/16,348,907 | 0.36 | 8.32e-11 | 8.99e-10 |
| Anatomic Sites:0 | 23/61,988 | 1,128/16,348,907 | 5.38 | 2.51e-10 | 2.61e-09 |
| Instability:0 | 32/61,988 | 19,923/16,348,907 | 0.42 | 2.47e-08 | 2.10e-07 |
| p65|RELA|SYT1|GORASP1|WNK1:0 | 66/61,988 | 6,903/16,348,907 | 2.52 | 5.78e-11 | 6.32e-10 |
| Adenosine:0 | 17/61,988 | 43,565/16,348,907 | 0.10 | 5.73e-49 | 2.55e-47 |
| Suspected malignancy:0 | 32/61,988 | 1,415/16,348,907 | 5.97 | 6.07e-15 | 8.64e-14 |
| STEAP2:0 | 5/61,988 | 25/16,348,907 | 52.75 | 1.01e-07 | 8.08e-07 |
| [M]Papillary neoplasms:0 | 43/61,988 | 2,725/16,348,907 | 4.16 | 3.48e-14 | 4.73e-13 |
| Malignant transformation:0 | 242/61,988 | 10,470/16,348,907 | 6.12 | 1.16e-103 | 9.78e-102 |
| Hemorrhagic cystitis:0 | 27/61,988 | 1,842/16,348,907 | 3.87 | 7.81e-09 | 7.03e-08 |
| prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human|COX8A|COX5A:0 | 68/61,988 | 8,031/16,348,907 | 2.23 | 5.60e-09 | 5.11e-08 |
| prognostic:0 | 40/61,988 | 1,294/16,348,907 | 8.16 | 7.07e-23 | 1.51e-21 |
| FK506 binding protein 5|FKBP4|FKBP5:0 | 15/61,988 | 437/16,348,907 | 9.05 | 3.93e-10 | 4.02e-09 |
| Transplantation, Autologous:0 | 1/61,988 | 11,546/16,348,907 | 0.02 | 7.87e-18 | 1.32e-16 |
| hydroxyflutamide:0 | 88/61,988 | 458/16,348,907 | 50.75 | 2.54e-111 | 2.35e-109 |
| GOLM1:0 | 8/61,988 | 86/16,348,907 | 24.54 | 3.45e-09 | 3.22e-08 |
| Radiation prostatitis:0 | 3/61,988 | 3/16,348,907 | 263.76 | 1.07e-06 | 7.55e-06 |
| Proliferating Cell Nuclear Antigen|PCNA:0 | 30/61,988 | 1,774/16,348,907 | 4.46 | 4.58e-11 | 5.05e-10 |
| pulmonary function:0 | 1/61,988 | 9,053/16,348,907 | 0.03 | 1.14e-13 | 1.50e-12 |
| Punch:0 | 55/61,988 | 3,977/16,348,907 | 3.65 | 2.38e-15 | 3.49e-14 |
| CDK6:0 | 28/61,988 | 1,101/16,348,907 | 6.71 | 1.82e-14 | 2.53e-13 |
| KLF5:0 | 12/61,988 | 508/16,348,907 | 6.23 | 1.04e-06 | 7.35e-06 |
| Minocycline:0 | 4/61,988 | 6,560/16,348,907 | 0.16 | 5.50e-07 | 4.04e-06 |
| Percent Free Prostate-Specific Antigen:0 | 70/61,988 | 125/16,348,907 | 147.86 | 1.75e-116 | 1.73e-114 |
| zoledronate:0 | 45/61,988 | 1,436/16,348,907 | 8.27 | 9.24e-26 | 2.22e-24 |
| Foreign Bodies:0 | 7/61,988 | 12,681/16,348,907 | 0.15 | 4.74e-13 | 5.95e-12 |
| Peripheral Vascular Diseases:0 | 11/61,988 | 23,565/16,348,907 | 0.12 | 2.43e-25 | 5.72e-24 |
| Aneuploidy:0 | 69/61,988 | 6,926/16,348,907 | 2.63 | 3.54e-12 | 4.20e-11 |
| Androgen Antagonists:0 | 1,287/61,988 | 5,655/16,348,907 | 61.28 | 0.00e+00 | 0.00e+00 |
| Untranslated Regions:0 | 53/61,988 | 5,167/16,348,907 | 2.71 | 3.79e-10 | 3.87e-09 |
| Oncologist:0 | 55/61,988 | 1,533/16,348,907 | 9.47 | 6.26e-34 | 1.93e-32 |
| monoclonal antibody J591:0 | 10/61,988 | 17/16,348,907 | 155.17 | 4.70e-18 | 7.99e-17 |
| Entire scalp:0 | 23/61,988 | 16,302/16,348,907 | 0.37 | 3.10e-08 | 2.62e-07 |
| Estramustinphosphate:0 | 4/61,988 | 4/16,348,907 | 263.76 | 1.41e-08 | 1.23e-07 |
| HPC1 gene|STX1A:0 | 4/61,988 | 4/16,348,907 | 263.76 | 1.41e-08 | 1.23e-07 |
| neuropeptide Y|NPY:0 | 13/61,988 | 23,568/16,348,907 | 0.15 | 1.39e-23 | 3.05e-22 |
| Gonadorelin|RHCE|RHD:0 | 31/61,988 | 12/16,348,907 | 681.68 | 1.14e-65 | 6.58e-64 |
| caspase activation:0 | 51/61,988 | 3,835/16,348,907 | 3.51 | 1.00e-13 | 1.32e-12 |
| 5alphaR:0 | 5/61,988 | 30/16,348,907 | 43.96 | 2.27e-07 | 1.74e-06 |
| Single Nucleotide Polymorphism:0 | 725/61,988 | 57,483/16,348,907 | 3.35 | 1.46e-160 | 2.01e-158 |
| Prior Therapy:0 | 29/61,988 | 871/16,348,907 | 8.78 | 7.64e-18 | 1.28e-16 |
| Isoenzymes:0 | 61/61,988 | 5,812/16,348,907 | 2.77 | 7.91e-12 | 9.19e-11 |
| Chronic radiation proctitis:0 | 16/61,988 | 123/16,348,907 | 34.32 | 4.19e-19 | 7.53e-18 |
| Rare Diseases:0 | 24/61,988 | 18,702/16,348,907 | 0.34 | 1.90e-10 | 1.99e-09 |
| Thiobarbituric Acid Reactive Substances:0 | 4/61,988 | 6,996/16,348,907 | 0.15 | 1.47e-07 | 1.15e-06 |
| anakinra:0 | 5/61,988 | 8,545/16,348,907 | 0.15 | 5.63e-09 | 5.14e-08 |
| Vaccines, Peptide:0 | 28/61,988 | 953/16,348,907 | 7.75 | 5.80e-16 | 8.78e-15 |
| Vasoconstrictor Agents:0 | 2/61,988 | 5,151/16,348,907 | 0.10 | 1.20e-06 | 8.47e-06 |
| Green Fluorescent Proteins|PDC:0 | 3/61,988 | 1/16,348,907 | 791.27 | 2.15e-07 | 1.65e-06 |
| Western Blot:0 | 345/61,988 | 21,808/16,348,907 | 4.19 | 6.06e-102 | 5.05e-100 |
| Herceptin|EREG|ESR1:0 | 6/61,988 | 56/16,348,907 | 28.26 | 1.49e-07 | 1.16e-06 |
| Fibrosis:0 | 122/61,988 | 92,404/16,348,907 | 0.35 | 5.80e-45 | 2.37e-43 |
| Hepatitis C, Chronic:0 | 5/61,988 | 38,514/16,348,907 | 0.03 | 3.91e-55 | 1.96e-53 |
| Sinus:0 | 18/61,988 | 15,746/16,348,907 | 0.30 | 4.66e-10 | 4.72e-09 |
| Vascular Endothelial Growth Factor Receptor-2:0 | 40/61,988 | 2,848/16,348,907 | 3.71 | 8.50e-12 | 9.84e-11 |
| Focused Ultrasound Therapy:0 | 32/61,988 | 152/16,348,907 | 55.55 | 1.08e-42 | 4.21e-41 |
| APP gene|APP:0 | 8/61,988 | 20,752/16,348,907 | 0.10 | 7.16e-24 | 1.58e-22 |
| Research Personnel:0 | 163/61,988 | 17,588/16,348,907 | 2.45 | 2.90e-23 | 6.30e-22 |
| cancer recurrence:0 | 88/61,988 | 1,480/16,348,907 | 15.70 | 1.60e-70 | 9.81e-69 |
| epothilone B lactam:0 | 6/61,988 | 80/16,348,907 | 19.78 | 1.05e-06 | 7.47e-06 |
| Population-Based Registry:0 | 9/61,988 | 45/16,348,907 | 52.76 | 7.14e-13 | 8.84e-12 |
| Epidermal Growth Factor Receptor|EGFR:0 | 324/61,988 | 33,803/16,348,907 | 2.54 | 1.91e-47 | 8.28e-46 |
| Esophageal Varices:0 | 2/61,988 | 5,481/16,348,907 | 0.10 | 4.26e-07 | 3.18e-06 |
| Malaise:0 | 16/61,988 | 19,587/16,348,907 | 0.22 | 5.84e-16 | 8.83e-15 |
| Allergic rhinitis NOS:0 | 1/61,988 | 20,679/16,348,907 | 0.01 | 1.91e-32 | 5.67e-31 |
| Inferior hypogastric plexus structure:0 | 9/61,988 | 213/16,348,907 | 11.15 | 2.33e-07 | 1.78e-06 |
| Gonadotropin-Releasing Hormone Analog:0 | 792/61,988 | 7,747/16,348,907 | 27.30 | 0.00e+00 | 0.00e+00 |
| Lymphoma:0 | 359/61,988 | 62,370/16,348,907 | 1.52 | 1.40e-13 | 1.84e-12 |
| Girls:0 | 12/61,988 | 84,654/16,348,907 | 0.04 | 1.96e-118 | 1.97e-116 |
| Sudden infant death syndrome:0 | 1/61,988 | 4,985/16,348,907 | 0.05 | 2.08e-07 | 1.61e-06 |
| Cimetidine:0 | 7/61,988 | 15,694/16,348,907 | 0.12 | 1.83e-17 | 3.00e-16 |
| Multicenter Trials:0 | 29/61,988 | 1,846/16,348,907 | 4.14 | 4.93e-10 | 4.97e-09 |
| HDAC9:0 | 38/61,988 | 2,349/16,348,907 | 4.27 | 4.92e-13 | 6.17e-12 |
| Vacuum Pump:0 | 30/61,988 | 1,017/16,348,907 | 7.78 | 4.91e-17 | 7.90e-16 |
| Residual urine volume:0 | 11/61,988 | 334/16,348,907 | 8.69 | 1.24e-07 | 9.75e-07 |
| Cancer Center:0 | 49/61,988 | 1,238/16,348,907 | 10.45 | 2.93e-32 | 8.64e-31 |
| Prostate Sarcoma:0 | 35/61,988 | 88/16,348,907 | 104.96 | 7.22e-55 | 3.60e-53 |
| Metastatic bone pain:0 | 45/61,988 | 220/16,348,907 | 53.99 | 7.23e-59 | 3.82e-57 |
| Milk Thistle:0 | 19/61,988 | 359/16,348,907 | 13.96 | 1.24e-15 | 1.84e-14 |
| Oryza sativa:0 | 2/61,988 | 15,727/16,348,907 | 0.03 | 6.46e-23 | 1.38e-21 |
| Lymphoma, Non-Hodgkin's:0 | 228/61,988 | 25,472/16,348,907 | 2.37 | 7.14e-30 | 1.95e-28 |
| Smooth muscle (tissue):0 | 137/61,988 | 56,345/16,348,907 | 0.64 | 2.94e-08 | 2.49e-07 |
| Azathioprine:0 | 8/61,988 | 15,738/16,348,907 | 0.13 | 1.21e-16 | 1.90e-15 |
| Muscarinic Acetylcholine Receptor:0 | 8/61,988 | 16,514/16,348,907 | 0.13 | 7.99e-18 | 1.34e-16 |
| Fenofibrate:0 | 4/61,988 | 7,901/16,348,907 | 0.13 | 7.11e-09 | 6.42e-08 |
| Acid phosphatase level:0 | 10/61,988 | 37/16,348,907 | 71.29 | 2.69e-15 | 3.93e-14 |
| Plasma Exchange:0 | 4/61,988 | 7,622/16,348,907 | 0.14 | 1.99e-08 | 1.70e-07 |
| Androgenic steroid:0 | 18/61,988 | 315/16,348,907 | 15.08 | 1.96e-15 | 2.89e-14 |
| probasin:0 | 74/61,988 | 189/16,348,907 | 103.39 | 9.94e-114 | 9.37e-112 |
| Aldehydes:0 | 8/61,988 | 9,184/16,348,907 | 0.23 | 9.52e-08 | 7.61e-07 |
| Clinicians:0 | 206/61,988 | 20,142/16,348,907 | 2.70 | 1.95e-34 | 6.04e-33 |
| Raised prostate specific antigen:0 | 579/61,988 | 829/16,348,907 | 185.93 | 0.00e+00 | 0.00e+00 |
| PLAU gene|PLAU:0 | 57/61,988 | 1,158/16,348,907 | 12.99 | 4.51e-42 | 1.72e-40 |
| docetaxel/estramustine:0 | 26/61,988 | 56/16,348,907 | 122.50 | 1.37e-42 | 5.28e-41 |
| Baresthesia:0 | 66/61,988 | 73,279/16,348,907 | 0.24 | 1.67e-52 | 7.96e-51 |
| Serum testosterone measurement:0 | 30/61,988 | 287/16,348,907 | 27.58 | 7.06e-32 | 2.06e-30 |
| Acid Phosphatase:0 | 776/61,988 | 9,888/16,348,907 | 20.95 | 0.00e+00 | 0.00e+00 |
| Fibrosing adenosis:0 | 9/61,988 | 239/16,348,907 | 9.93 | 5.87e-07 | 4.30e-06 |
| Ruminants:0 | 2/61,988 | 7,566/16,348,907 | 0.07 | 4.05e-10 | 4.13e-09 |
| FGFR2 gene|FGFR2:0 | 26/61,988 | 1,185/16,348,907 | 5.79 | 3.75e-12 | 4.46e-11 |
| Ouabain:0 | 16/61,988 | 15,353/16,348,907 | 0.27 | 1.13e-10 | 1.20e-09 |
| Acute graft-versus-host disease:0 | 1/61,988 | 5,063/16,348,907 | 0.05 | 2.21e-07 | 1.70e-06 |
| Clinic:0 | 98/61,988 | 10,848/16,348,907 | 2.38 | 5.63e-14 | 7.57e-13 |
| Acetylcysteine|ELANE:0 | 9/61,988 | 4/16,348,907 | 593.51 | 1.10e-19 | 2.04e-18 |
| Corneal Diseases:0 | 8/61,988 | 14,102/16,348,907 | 0.15 | 2.52e-14 | 3.46e-13 |
| Amiodarone:0 | 4/61,988 | 13,985/16,348,907 | 0.08 | 6.83e-18 | 1.15e-16 |
| RELB:0 | 20/61,988 | 934/16,348,907 | 5.65 | 1.60e-09 | 1.54e-08 |
| hypoglycemia:0 | 7/61,988 | 22,467/16,348,907 | 0.08 | 1.62e-27 | 4.11e-26 |
| Fatty Streak, Arterial:0 | 3/61,988 | 14,037/16,348,907 | 0.06 | 5.07e-19 | 9.09e-18 |
| Tumor Initiation:0 | 80/61,988 | 1,693/16,348,907 | 12.48 | 4.62e-57 | 2.36e-55 |
| no positive axillary nodes:0 | 38/61,988 | 2,406/16,348,907 | 4.17 | 9.86e-13 | 1.21e-11 |
| Albumins|ALB:0 | 11/61,988 | 17,266/16,348,907 | 0.17 | 2.31e-16 | 3.57e-15 |
| Myocardial Infarction:0 | 74/61,988 | 101,061/16,348,907 | 0.19 | 3.15e-83 | 2.22e-81 |
| PRKD1 gene|PRKD1:0 | 11/61,988 | 355/16,348,907 | 8.17 | 2.23e-07 | 1.71e-06 |
| Bladder cancer recurrent:0 | 20/61,988 | 354/16,348,907 | 14.91 | 6.85e-17 | 1.09e-15 |
| Gangrene:0 | 1/61,988 | 4,859/16,348,907 | 0.05 | 4.52e-07 | 3.35e-06 |
| HL60:0 | 29/61,988 | 2,655/16,348,907 | 2.88 | 9.33e-07 | 6.66e-06 |
| Thermoluminescent Dosimetry:0 | 6/61,988 | 46/16,348,907 | 34.40 | 5.09e-08 | 4.20e-07 |
| Cerebral cortex:0 | 9/61,988 | 44,230/16,348,907 | 0.05 | 9.92e-59 | 5.23e-57 |
| Serum Prostate Specific Antigen Test:0 | 7/61,988 | 8/16,348,907 | 230.80 | 6.87e-14 | 9.16e-13 |
| Salvage Therapy:0 | 248/61,988 | 3,540/16,348,907 | 18.55 | 1.97e-211 | 3.40e-209 |
| Auxins:0 | 1/61,988 | 7,285/16,348,907 | 0.04 | 5.05e-11 | 5.54e-10 |
| KLK10:0 | 11/61,988 | 136/16,348,907 | 21.34 | 1.65e-11 | 1.87e-10 |
| Tissue Extracts:0 | 34/61,988 | 3,298/16,348,907 | 2.72 | 4.16e-07 | 3.10e-06 |
| Psychotherapy:0 | 5/61,988 | 9,265/16,348,907 | 0.14 | 5.46e-10 | 5.48e-09 |
| arginine methyl ester:0 | 1/61,988 | 7,092/16,348,907 | 0.04 | 1.05e-10 | 1.12e-09 |
| Urine:0 | 281/61,988 | 29,355/16,348,907 | 2.53 | 2.56e-41 | 9.70e-40 |
| Urologist:0 | 390/61,988 | 2,124/16,348,907 | 48.73 | 0.00e+00 | 0.00e+00 |
| maspin:0 | 12/61,988 | 204/16,348,907 | 15.52 | 6.53e-11 | 7.10e-10 |
| FRA16D:0 | 8/61,988 | 94/16,348,907 | 22.45 | 6.63e-09 | 6.00e-08 |
| Neck Neoplasms:0 | 18/61,988 | 838/16,348,907 | 5.67 | 9.77e-09 | 8.69e-08 |
| Mammary Carcinoma, Human:0 | 35/61,988 | 2,672/16,348,907 | 3.46 | 9.47e-10 | 9.28e-09 |
| Kininogenase|KLK4:0 | 117/61,988 | 3,819/16,348,907 | 8.09 | 3.46e-63 | 1.94e-61 |
| Acute coronary syndrome:0 | 3/61,988 | 34,413/16,348,907 | 0.02 | 1.98e-51 | 9.22e-50 |
| Neuromuscular Diseases:0 | 2/61,988 | 6,978/16,348,907 | 0.08 | 2.18e-09 | 2.07e-08 |
| establishment and maintenance of substrate location:0 | 252/61,988 | 29,151/16,348,907 | 2.29 | 1.20e-30 | 3.34e-29 |
| Ejaculation:0 | 24/61,988 | 1,871/16,348,907 | 3.38 | 5.31e-07 | 3.91e-06 |
| Chromosome 10 Short Arm:0 | 9/61,988 | 144/16,348,907 | 16.49 | 9.56e-09 | 8.51e-08 |
| Obstetric Patient:0 | 1/61,988 | 4,625/16,348,907 | 0.06 | 8.94e-07 | 6.40e-06 |
| Calcium Channel Blockers:0 | 20/61,988 | 27,809/16,348,907 | 0.19 | 6.22e-24 | 1.38e-22 |
| Decreased Cellular Migration:0 | 6/61,988 | 80/16,348,907 | 19.78 | 1.05e-06 | 7.47e-06 |
| Gram-Positive Bacteria:0 | 3/61,988 | 7,920/16,348,907 | 0.10 | 1.12e-09 | 1.09e-08 |
| MMP2 gene|MMP2:0 | 15/61,988 | 439/16,348,907 | 9.01 | 4.18e-10 | 4.25e-09 |
| Urethral Obstruction:0 | 18/61,988 | 775/16,348,907 | 6.13 | 3.04e-09 | 2.85e-08 |
| Metastasis Suppressor Proteins:0 | 6/61,988 | 31/16,348,907 | 51.05 | 6.11e-09 | 5.55e-08 |
| Depressive Symptoms:0 | 34/61,988 | 26,906/16,348,907 | 0.33 | 1.11e-14 | 1.56e-13 |
| MUC7|MCOLN1:0 | 2/61,988 | 15,060/16,348,907 | 0.03 | 5.16e-22 | 1.07e-20 |
| PCAT4:0 | 6/61,988 | 36/16,348,907 | 43.96 | 1.36e-08 | 1.19e-07 |
| DNA-Directed RNA Polymerase|ERVK-9|ERVK-19|ERVK-11:0 | 7/61,988 | 11,649/16,348,907 | 0.16 | 1.29e-11 | 1.47e-10 |
| N-Methylaspartate:0 | 2/61,988 | 22,056/16,348,907 | 0.02 | 3.12e-33 | 9.45e-32 |
| Neck:0 | 708/61,988 | 74,015/16,348,907 | 2.54 | 3.33e-101 | 2.74e-99 |
| Body Regions:0 | 38/61,988 | 2,951/16,348,907 | 3.40 | 2.98e-10 | 3.08e-09 |
| Neuropathic pain:0 | 9/61,988 | 12,654/16,348,907 | 0.19 | 1.30e-11 | 1.48e-10 |
| Dyskinetic syndrome:0 | 1/61,988 | 8,220/16,348,907 | 0.03 | 1.97e-12 | 2.37e-11 |
| prostein:0 | 8/61,988 | 21/16,348,907 | 100.49 | 1.66e-13 | 2.16e-12 |
| Tissue Model:0 | 27/61,988 | 1,167/16,348,907 | 6.10 | 4.48e-13 | 5.64e-12 |
| activated p21cdc42Hs kinase|TNK2:0 | 11/61,988 | 239/16,348,907 | 12.14 | 4.67e-09 | 4.28e-08 |
| Guanylate Cyclase:0 | 2/61,988 | 6,970/16,348,907 | 0.08 | 2.17e-09 | 2.07e-08 |
| Tumor Promoters:0 | 38/61,988 | 3,840/16,348,907 | 2.61 | 2.45e-07 | 1.87e-06 |
| Wegener's Granulomatosis:0 | 1/61,988 | 5,513/16,348,907 | 0.05 | 3.46e-08 | 2.91e-07 |
| PROSTATE NODULAR:0 | 5/61,988 | 9/16,348,907 | 146.54 | 1.50e-09 | 1.44e-08 |
| bosentan:0 | 2/61,988 | 5,498/16,348,907 | 0.10 | 4.31e-07 | 3.21e-06 |
| Omeprazole:0 | 3/61,988 | 11,901/16,348,907 | 0.07 | 8.50e-16 | 1.28e-14 |
| isoniazid:0 | 6/61,988 | 9,725/16,348,907 | 0.16 | 8.35e-10 | 8.25e-09 |
| CAV1 gene|CAV1:0 | 11/61,988 | 275/16,348,907 | 10.55 | 1.86e-08 | 1.60e-07 |
| Secondary carcinoma NOS:0 | 14/61,988 | 371/16,348,907 | 9.95 | 4.62e-10 | 4.69e-09 |
| imatinib:0 | 45/61,988 | 23,558/16,348,907 | 0.50 | 3.11e-07 | 2.35e-06 |
| Castration, Male:0 | 160/61,988 | 367/16,348,907 | 115.28 | 5.51e-250 | 1.11e-247 |
| Drug resistance:0 | 100/61,988 | 13,041/16,348,907 | 2.02 | 2.33e-10 | 2.43e-09 |
| Estradurin:0 | 15/61,988 | 48/16,348,907 | 82.44 | 4.68e-23 | 1.00e-21 |
| neurodevelopment:0 | 1/61,988 | 5,158/16,348,907 | 0.05 | 1.53e-07 | 1.19e-06 |
| disease stage:0 | 26/61,988 | 717/16,348,907 | 9.57 | 5.25e-17 | 8.42e-16 |
| Serine Proteinase Inhibitors:0 | 53/61,988 | 3,945/16,348,907 | 3.55 | 2.28e-14 | 3.13e-13 |
| Metastatic Carcinoma:0 | 316/61,988 | 9,353/16,348,907 | 8.95 | 3.98e-179 | 5.99e-177 |
| Pulmonary Edema:0 | 2/61,988 | 11,072/16,348,907 | 0.05 | 9.59e-16 | 1.44e-14 |
| [M]Adenocarcinoma, metastatic, NOS:0 | 166/61,988 | 3,099/16,348,907 | 14.16 | 1.46e-124 | 1.57e-122 |
| dopamine transporter:0 | 2/61,988 | 7,798/16,348,907 | 0.07 | 1.29e-10 | 1.37e-09 |
| Prostatic Diseases:0 | 632/61,988 | 1,332/16,348,907 | 126.42 | 0.00e+00 | 0.00e+00 |
| Tumor Angiogenesis:0 | 213/61,988 | 6,207/16,348,907 | 9.08 | 1.32e-122 | 1.39e-120 |
| Urethral anastomosis:0 | 19/61,988 | 70/16,348,907 | 71.61 | 8.13e-28 | 2.09e-26 |
| Prostate cancer stage IV:0 | 71/61,988 | 114/16,348,907 | 164.45 | 1.14e-120 | 1.18e-118 |
| Renal Cell Carcinoma:0 | 520/61,988 | 39,892/16,348,907 | 3.46 | 8.38e-121 | 8.70e-119 |
| Promoter (Genetics):0 | 84/61,988 | 9,176/16,348,907 | 2.42 | 1.74e-12 | 2.11e-11 |
| Protozoa:0 | 3/61,988 | 6,555/16,348,907 | 0.12 | 9.37e-08 | 7.50e-07 |
| clusterin antisense oligonucleotide:0 | 6/61,988 | 28/16,348,907 | 56.52 | 3.57e-09 | 3.32e-08 |
| Globus Pallidus:0 | 2/61,988 | 7,844/16,348,907 | 0.07 | 1.35e-10 | 1.43e-09 |
| Prostate Cancer Prevention Trial:0 | 16/61,988 | 16/16,348,907 | 263.81 | 9.73e-31 | 2.72e-29 |
| Ephrins:0 | 24/61,988 | 1,294/16,348,907 | 4.89 | 6.49e-10 | 6.46e-09 |
| Cations:0 | 7/61,988 | 10,161/16,348,907 | 0.18 | 1.19e-09 | 1.16e-08 |
| Diffusion Magnetic Resonance Imaging:0 | 121/61,988 | 3,123/16,348,907 | 10.24 | 4.54e-76 | 2.95e-74 |
| Learning Disabilities:0 | 2/61,988 | 7,426/16,348,907 | 0.07 | 5.44e-10 | 5.47e-09 |
| New Agents:0 | 13/61,988 | 324/16,348,907 | 10.58 | 9.40e-10 | 9.22e-09 |
| Rats, Zucker:0 | 2/61,988 | 9,247/16,348,907 | 0.06 | 9.22e-13 | 1.13e-11 |
| nerve supply:0 | 16/61,988 | 14,663/16,348,907 | 0.29 | 8.98e-10 | 8.84e-09 |
| purification:0 | 35/61,988 | 22,046/16,348,907 | 0.42 | 3.36e-09 | 3.13e-08 |
| Allopurinol:0 | 7/61,988 | 9,554/16,348,907 | 0.19 | 8.34e-09 | 7.48e-08 |
| Follicle Stimulating Hormone:0 | 114/61,988 | 11,840/16,348,907 | 2.54 | 6.42e-18 | 1.08e-16 |
| Urological examination:0 | 6/61,988 | 40/16,348,907 | 39.57 | 2.39e-08 | 2.04e-07 |
| Ethinyl Estradiol:0 | 51/61,988 | 5,834/16,348,907 | 2.31 | 1.71e-07 | 1.33e-06 |
| Silicones:0 | 7/61,988 | 8,576/16,348,907 | 0.22 | 1.42e-07 | 1.11e-06 |
| transglutaminase 4|TGM4:0 | 5/61,988 | 24/16,348,907 | 54.95 | 8.47e-08 | 6.79e-07 |
| CA1|S100A10:0 | 1/61,988 | 7,227/16,348,907 | 0.04 | 7.45e-11 | 8.07e-10 |
| cardiac arrhythmia:0 | 7/61,988 | 24,895/16,348,907 | 0.07 | 3.66e-31 | 1.04e-29 |
| PAWR protein:0 | 21/61,988 | 884/16,348,907 | 6.27 | 1.04e-10 | 1.12e-09 |
| HPC3:0 | 4/61,988 | 17/16,348,907 | 62.06 | 1.16e-06 | 8.14e-06 |
| Quinazolines:0 | 16/61,988 | 515/16,348,907 | 8.20 | 4.19e-10 | 4.27e-09 |
| LY 294002:0 | 116/61,988 | 6,913/16,348,907 | 4.43 | 9.27e-38 | 3.20e-36 |
| outer membrane:0 | 7/61,988 | 15,714/16,348,907 | 0.12 | 1.87e-17 | 3.06e-16 |
| Photosynthesis:0 | 5/61,988 | 10,523/16,348,907 | 0.13 | 9.75e-12 | 1.12e-10 |
| Bronchitis, Chronic:0 | 2/61,988 | 7,519/16,348,907 | 0.07 | 3.79e-10 | 3.88e-09 |
| Bombesin:0 | 196/61,988 | 6,130/16,348,907 | 8.46 | 9.82e-108 | 8.68e-106 |
| Coronary heart disease:0 | 49/61,988 | 55,695/16,348,907 | 0.23 | 6.95e-41 | 2.60e-39 |
| Relative (related person):0 | 84/61,988 | 9,992/16,348,907 | 2.22 | 1.03e-10 | 1.10e-09 |
| Receptors, Nuclear|AR:0 | 30/61,988 | 115/16,348,907 | 68.84 | 1.40e-42 | 5.40e-41 |
| Repeat Surgery:0 | 23/61,988 | 15,947/16,348,907 | 0.38 | 6.74e-08 | 5.48e-07 |
| Cancer Control:0 | 98/61,988 | 394/16,348,907 | 65.70 | 1.68e-133 | 1.93e-131 |
| Hemagglutinin:0 | 5/61,988 | 10,516/16,348,907 | 0.13 | 9.69e-12 | 1.12e-10 |
| tumor protein D52|TPD52:0 | 9/61,988 | 83/16,348,907 | 28.60 | 1.02e-10 | 1.10e-09 |
| TOOKAD:0 | 12/61,988 | 37/16,348,907 | 85.55 | 6.83e-19 | 1.21e-17 |
| Robotic Systems:0 | 34/61,988 | 1,098/16,348,907 | 8.17 | 1.03e-19 | 1.91e-18 |
| Ovarian Follicle:0 | 9/61,988 | 25,782/16,348,907 | 0.09 | 1.64e-30 | 4.55e-29 |
| osteoblast cadherin:0 | 15/61,988 | 552/16,348,907 | 7.17 | 8.25e-09 | 7.41e-08 |
| Reticulocytes:0 | 2/61,988 | 6,400/16,348,907 | 0.08 | 1.83e-08 | 1.58e-07 |
| Serum specimen:0 | 141/61,988 | 8,689/16,348,907 | 4.29 | 6.15e-44 | 2.44e-42 |
| Alcoholic Intoxication:0 | 356/61,988 | 1,286/16,348,907 | 73.43 | 0.00e+00 | 0.00e+00 |
| ILK gene|ILK:0 | 13/61,988 | 320/16,348,907 | 10.72 | 8.14e-10 | 8.04e-09 |
| Antidepressive Agents:0 | 30/61,988 | 52,115/16,348,907 | 0.15 | 1.09e-49 | 4.92e-48 |
| Knee bone:0 | 1/61,988 | 11,498/16,348,907 | 0.02 | 1.18e-17 | 1.96e-16 |
| Leptin|LEP:0 | 62/61,988 | 61,776/16,348,907 | 0.26 | 1.57e-40 | 5.82e-39 |
| Sleep Apnea, Obstructive:0 | 8/61,988 | 46,337/16,348,907 | 0.05 | 3.13e-63 | 1.76e-61 |
| Recurrent disease:0 | 190/61,988 | 10,145/16,348,907 | 4.95 | 9.58e-68 | 5.65e-66 |
| Phenylephrine:0 | 6/61,988 | 15,635/16,348,907 | 0.10 | 2.52e-18 | 4.34e-17 |
| RBL2 gene|RBL2:0 | 14/61,988 | 665/16,348,907 | 5.55 | 5.17e-07 | 3.81e-06 |
| Physical function:0 | 55/61,988 | 5,205/16,348,907 | 2.79 | 6.31e-11 | 6.87e-10 |
| Pes:0 | 32/61,988 | 29,601/16,348,907 | 0.28 | 7.79e-19 | 1.38e-17 |
| Chromium:0 | 5/61,988 | 8,221/16,348,907 | 0.16 | 1.51e-08 | 1.32e-07 |
| Diuretics:0 | 11/61,988 | 15,653/16,348,907 | 0.19 | 4.28e-14 | 5.79e-13 |
| Urinary organ:0 | 18/61,988 | 178/16,348,907 | 26.68 | 1.64e-19 | 3.01e-18 |
| Entire aortic valve:0 | 1/61,988 | 6,517/16,348,907 | 0.04 | 9.32e-10 | 9.14e-09 |
| Muscle Cells:0 | 11/61,988 | 35,238/16,348,907 | 0.08 | 1.50e-42 | 5.79e-41 |
| Cold Therapy:0 | 193/61,988 | 5,442/16,348,907 | 9.38 | 1.09e-113 | 1.03e-111 |
| microbial:0 | 19/61,988 | 33,087/16,348,907 | 0.15 | 4.90e-32 | 1.44e-30 |
| Endometrioid carcinoma of prostate:0 | 29/61,988 | 46/16,348,907 | 166.35 | 2.34e-50 | 1.07e-48 |
| Neural Stem Cell:0 | 5/61,988 | 7,668/16,348,907 | 0.17 | 1.13e-07 | 8.96e-07 |
| particle:0 | 24/61,988 | 19,212/16,348,907 | 0.33 | 6.49e-11 | 7.05e-10 |
| Observation parameter:0 | 634/61,988 | 97,956/16,348,907 | 1.71 | 2.84e-35 | 9.03e-34 |
| Neoplastic Epithelial Cell:0 | 39/61,988 | 492/16,348,907 | 20.92 | 1.16e-36 | 3.90e-35 |
| Capromab Pendetide:0 | 72/61,988 | 160/16,348,907 | 118.82 | 2.74e-114 | 2.60e-112 |
| Dosimeter:0 | 43/61,988 | 2,755/16,348,907 | 4.12 | 4.97e-14 | 6.70e-13 |
| MET gene|MET|RNMT|SLTM:0 | 36/61,988 | 1,343/16,348,907 | 7.07 | 7.68e-19 | 1.36e-17 |
| Cystitis:0 | 38/61,988 | 3,505/16,348,907 | 2.86 | 2.63e-08 | 2.23e-07 |
| Globo-H:0 | 8/61,988 | 62/16,348,907 | 34.04 | 3.18e-10 | 3.27e-09 |
| SAMARIUM Sm153:0 | 14/61,988 | 39/16,348,907 | 94.70 | 2.52e-22 | 5.25e-21 |
| Manipulation procedure:0 | 105/61,988 | 12,521/16,348,907 | 2.21 | 7.11e-13 | 8.81e-12 |
| Viral Proteins:0 | 11/61,988 | 9,749/16,348,907 | 0.30 | 1.28e-06 | 9.00e-06 |
| Carcinoma, Endometrioid:0 | 32/61,988 | 1,628/16,348,907 | 5.19 | 2.36e-13 | 3.04e-12 |
| PARP1:0 | 41/61,988 | 3,619/16,348,907 | 2.99 | 2.31e-09 | 2.19e-08 |
| Endothelial dysfunction:0 | 6/61,988 | 24,571/16,348,907 | 0.06 | 7.20e-32 | 2.10e-30 |
| Receptors, Cytoplasmic:0 | 11/61,988 | 401/16,348,907 | 7.24 | 7.11e-07 | 5.16e-06 |
| Kininogenase:0 | 83/61,988 | 3,416/16,348,907 | 6.42 | 2.97e-38 | 1.04e-36 |
| MICE:0 | 116/61,988 | 2,602/16,348,907 | 11.78 | 2.73e-79 | 1.85e-77 |
| Fundus:0 | 4/61,988 | 12,581/16,348,907 | 0.08 | 9.31e-16 | 1.40e-14 |
| KLK15 protein, human|KLK15:0 | 4/61,988 | 16/16,348,907 | 65.94 | 9.40e-07 | 6.70e-06 |
| PD 98059:0 | 65/61,988 | 8,118/16,348,907 | 2.11 | 6.63e-08 | 5.40e-07 |
| Embryo:0 | 63/61,988 | 92,742/16,348,907 | 0.18 | 5.82e-80 | 3.97e-78 |
| CLDN4 gene|CLDN4:0 | 10/61,988 | 225/16,348,907 | 11.72 | 3.18e-08 | 2.69e-07 |
| Myenteric Plexus:0 | 1/61,988 | 4,963/16,348,907 | 0.05 | 3.17e-07 | 2.39e-06 |
| Breast Feeding:0 | 33/61,988 | 31,935/16,348,907 | 0.27 | 4.68e-21 | 9.30e-20 |
| Brachytherapy implant:0 | 50/61,988 | 349/16,348,907 | 37.82 | 2.90e-58 | 1.52e-56 |
| Superantigens:0 | 1/61,988 | 5,475/16,348,907 | 0.05 | 5.34e-08 | 4.39e-07 |
| Aspartate:0 | 9/61,988 | 9,520/16,348,907 | 0.25 | 1.59e-07 | 1.24e-06 |
| Acids:0 | 67/61,988 | 36,663/16,348,907 | 0.48 | 1.83e-11 | 2.06e-10 |
| Hypertrophy, Left Ventricular:0 | 2/61,988 | 19,124/16,348,907 | 0.03 | 1.77e-28 | 4.64e-27 |
| SV40 T Proteins:0 | 15/61,988 | 564/16,348,907 | 7.02 | 1.09e-08 | 9.64e-08 |
| Insulin-Like Growth Factor II:0 | 120/61,988 | 12,901/16,348,907 | 2.46 | 9.54e-18 | 1.59e-16 |
| perifosine:0 | 15/61,988 | 753/16,348,907 | 5.25 | 4.05e-07 | 3.03e-06 |
| APC:0 | 55/61,988 | 6,115/16,348,907 | 2.37 | 1.68e-08 | 1.45e-07 |
| Streptococcus:0 | 3/61,988 | 14,108/16,348,907 | 0.06 | 3.42e-19 | 6.17e-18 |
| Androgen-Insensitivity Syndrome:0 | 24/61,988 | 611/16,348,907 | 10.36 | 1.48e-16 | 2.33e-15 |
| Three dimensional treatment planning:0 | 10/61,988 | 87/16,348,907 | 30.32 | 5.51e-12 | 6.48e-11 |
| Lymphocyte Function-Associated Antigen-1:0 | 1/61,988 | 4,758/16,348,907 | 0.06 | 6.47e-07 | 4.71e-06 |
| Growth retardation:0 | 105/61,988 | 8,305/16,348,907 | 3.34 | 7.48e-25 | 1.73e-23 |
| Ascites:0 | 13/61,988 | 11,299/16,348,907 | 0.30 | 2.07e-07 | 1.60e-06 |
| Lysine:0 | 36/61,988 | 20,740/16,348,907 | 0.46 | 1.22e-07 | 9.58e-07 |
| Hydrochlorothiazide:0 | 1/61,988 | 7,383/16,348,907 | 0.04 | 3.51e-11 | 3.90e-10 |
| Medical oncologist:0 | 13/61,988 | 292/16,348,907 | 11.74 | 2.80e-10 | 2.90e-09 |
| Malignant neoplasm of thyroid:0 | 148/61,988 | 23,047/16,348,907 | 1.70 | 3.14e-09 | 2.94e-08 |
| survivin:0 | 154/61,988 | 6,503/16,348,907 | 6.26 | 5.43e-68 | 3.21e-66 |
| Cerebrospinal Fluid:0 | 15/61,988 | 30,415/16,348,907 | 0.13 | 1.44e-31 | 4.16e-30 |
| ras Oncogene:0 | 27/61,988 | 1,795/16,348,907 | 3.97 | 4.63e-09 | 4.25e-08 |
| brain function:0 | 3/61,988 | 6,062/16,348,907 | 0.13 | 5.22e-07 | 3.84e-06 |
| Intestines:0 | 388/61,988 | 144,853/16,348,907 | 0.70 | 4.16e-13 | 5.25e-12 |
| Dietary Fats:0 | 64/61,988 | 5,493/16,348,907 | 3.08 | 3.02e-14 | 4.12e-13 |
| Allergic Reaction:0 | 4/61,988 | 7,061/16,348,907 | 0.15 | 1.04e-07 | 8.30e-07 |
| Death, Sudden:0 | 4/61,988 | 15,478/16,348,907 | 0.07 | 3.41e-20 | 6.51e-19 |
| Esophagectomy:0 | 1/61,988 | 8,944/16,348,907 | 0.03 | 1.61e-13 | 2.10e-12 |
| Clinical Treatment:0 | 26/61,988 | 2,149/16,348,907 | 3.19 | 5.37e-07 | 3.95e-06 |
| Peplomycin:0 | 31/61,988 | 849/16,348,907 | 9.63 | 4.70e-20 | 8.88e-19 |
| Acupuncture procedure:0 | 19/61,988 | 21,766/16,348,907 | 0.23 | 7.45e-17 | 1.19e-15 |
| Death, Sudden, Cardiac:0 | 5/61,988 | 8,811/16,348,907 | 0.15 | 3.04e-09 | 2.85e-08 |
| Peroxynitrite:0 | 2/61,988 | 7,056/16,348,907 | 0.07 | 2.34e-09 | 2.22e-08 |
| Streptococcus pneumoniae:0 | 2/61,988 | 24,454/16,348,907 | 0.02 | 4.94e-37 | 1.67e-35 |
| omega-N-Methylarginine:0 | 1/61,988 | 5,204/16,348,907 | 0.05 | 1.02e-07 | 8.10e-07 |
| Virulence Factors:0 | 4/61,988 | 12,825/16,348,907 | 0.08 | 4.86e-16 | 7.38e-15 |
| Buffaloes:0 | 2/61,988 | 5,558/16,348,907 | 0.09 | 2.99e-07 | 2.27e-06 |
| Anterior Cruciate Ligament:0 | 1/61,988 | 5,302/16,348,907 | 0.05 | 7.08e-08 | 5.74e-07 |
| Hypotensive:0 | 2/61,988 | 6,073/16,348,907 | 0.09 | 5.19e-08 | 4.27e-07 |
| Caspase Inhibitor:0 | 52/61,988 | 2,751/16,348,907 | 4.99 | 5.54e-20 | 1.04e-18 |
| Flexion:0 | 1/61,988 | 4,678/16,348,907 | 0.06 | 9.58e-07 | 6.82e-06 |
| Lamella:0 | 1/61,988 | 5,860/16,348,907 | 0.04 | 1.23e-08 | 1.08e-07 |
| In complete remission:0 | 120/61,988 | 11,670/16,348,907 | 2.72 | 5.62e-21 | 1.11e-19 |
| Obturator fossa:0 | 9/61,988 | 40/16,348,907 | 59.35 | 2.80e-13 | 3.59e-12 |
| Calculators:0 | 12/61,988 | 340/16,348,907 | 9.31 | 1.61e-08 | 1.40e-07 |
| Lower Extremity:0 | 71/61,988 | 51,015/16,348,907 | 0.37 | 9.12e-24 | 2.01e-22 |
| Anions:0 | 27/61,988 | 29,624/16,348,907 | 0.24 | 8.50e-22 | 1.73e-20 |
| Hysterectomy:0 | 11/61,988 | 10,537/16,348,907 | 0.28 | 1.19e-07 | 9.43e-07 |
| Maxilla:0 | 14/61,988 | 27,002/16,348,907 | 0.14 | 1.44e-27 | 3.67e-26 |
| Ileal conduit procedure:0 | 48/61,988 | 1,183/16,348,907 | 10.71 | 4.27e-32 | 1.26e-30 |
| Velcade:0 | 17/61,988 | 773/16,348,907 | 5.80 | 1.78e-08 | 1.53e-07 |
| Hematopoietic Neoplasms:0 | 34/61,988 | 2,677/16,348,907 | 3.35 | 3.43e-09 | 3.19e-08 |
| Contracture:0 | 4/61,988 | 11,852/16,348,907 | 0.09 | 1.06e-14 | 1.49e-13 |
| adenoma:0 | 203/61,988 | 30,081/16,348,907 | 1.78 | 5.84e-14 | 7.84e-13 |
| Binding (Molecular Function):0 | 27/61,988 | 2,248/16,348,907 | 3.17 | 3.78e-07 | 2.83e-06 |
| alpha Catenin:0 | 25/61,988 | 1,261/16,348,907 | 5.23 | 7.61e-11 | 8.24e-10 |
| Parenteral Nutrition:0 | 1/61,988 | 6,156/16,348,907 | 0.04 | 4.14e-09 | 3.81e-08 |
| Prospective Studies:0 | 172/61,988 | 22,170/16,348,907 | 2.05 | 4.21e-17 | 6.80e-16 |
| CD40LG:0 | 13/61,988 | 23,367/16,348,907 | 0.15 | 2.70e-23 | 5.90e-22 |
| Interleukin-13:0 | 7/61,988 | 8,963/16,348,907 | 0.21 | 5.85e-08 | 4.78e-07 |
| Anatomical zone:0 | 9/61,988 | 59/16,348,907 | 40.24 | 6.31e-12 | 7.38e-11 |
| Endothelial Cells:0 | 312/61,988 | 114,443/16,348,907 | 0.72 | 8.20e-10 | 8.11e-09 |
| CAP - NOS:0 | 526/61,988 | 2,768/16,348,907 | 50.54 | 0.00e+00 | 0.00e+00 |
| Radiotherapy, Intensity-Modulated:0 | 406/61,988 | 5,010/16,348,907 | 21.51 | 0.00e+00 | 0.00e+00 |
| Conventional (Clear Cell) Renal Cell Carcinoma:0 | 48/61,988 | 5,444/16,348,907 | 2.33 | 2.25e-07 | 1.73e-06 |
| Bone marrow scintigraphy:0 | 10/61,988 | 128/16,348,907 | 20.61 | 1.88e-10 | 1.97e-09 |
| Androgen Receptor Antagonists:0 | 9/61,988 | 26/16,348,907 | 91.31 | 1.01e-14 | 1.42e-13 |
| Cancer Patient:0 | 1,253/61,988 | 46,816/16,348,907 | 7.18 | 0.00e+00 | 0.00e+00 |
| Familial Mediterranean Fever:0 | 1/61,988 | 6,438/16,348,907 | 0.04 | 1.37e-09 | 1.32e-08 |
| trastuzumab|ERBB2:0 | 24/61,988 | 195/16,348,907 | 32.47 | 2.25e-27 | 5.71e-26 |
| Cytokeratin 18:0 | 16/61,988 | 356/16,348,907 | 11.86 | 2.24e-12 | 2.70e-11 |
| PLAB Protein:0 | 36/61,988 | 822/16,348,907 | 11.56 | 1.49e-25 | 3.54e-24 |
| Calcidiol 1-Monooxygenase|CYP27B1:0 | 24/61,988 | 757/16,348,907 | 8.36 | 1.36e-14 | 1.91e-13 |
| Testosterone 5-alpha-Reductase|SRD5A2:0 | 21/61,988 | 92/16,348,907 | 60.22 | 3.31e-29 | 8.94e-28 |
| Multimodal Treatment Approach:0 | 6/61,988 | 75/16,348,907 | 21.10 | 7.39e-07 | 5.35e-06 |
| Estrus:0 | 3/61,988 | 6,722/16,348,907 | 0.12 | 4.66e-08 | 3.86e-07 |
| O-desmethylangolensin:0 | 8/61,988 | 74/16,348,907 | 28.52 | 1.15e-09 | 1.12e-08 |
| Platelet function:0 | 1/61,988 | 5,787/16,348,907 | 0.05 | 1.16e-08 | 1.03e-07 |
| CD28 gene|CD28:0 | 3/61,988 | 6,438/16,348,907 | 0.12 | 1.31e-07 | 1.03e-06 |
| Ability:0 | 281/61,988 | 42,140/16,348,907 | 1.76 | 4.63e-18 | 7.88e-17 |
| Franzen needle:0 | 7/61,988 | 8/16,348,907 | 230.80 | 6.87e-14 | 9.16e-13 |
| Entire condyle:0 | 2/61,988 | 19,650/16,348,907 | 0.03 | 2.97e-29 | 8.03e-28 |
| MCM7 gene|MCM7:0 | 11/61,988 | 266/16,348,907 | 10.91 | 1.34e-08 | 1.18e-07 |
| Bone necrosis:0 | 156/61,988 | 15,665/16,348,907 | 2.63 | 2.29e-25 | 5.40e-24 |
| isoflavonoids:0 | 19/61,988 | 861/16,348,907 | 5.82 | 2.52e-09 | 2.39e-08 |
| Antibiotics, Aminoglycoside:0 | 3/61,988 | 6,756/16,348,907 | 0.12 | 4.72e-08 | 3.90e-07 |
| Apnea:0 | 1/61,988 | 8,456/16,348,907 | 0.03 | 1.00e-12 | 1.23e-11 |
| Polyarthritis:0 | 1/61,988 | 4,572/16,348,907 | 0.06 | 1.36e-06 | 9.46e-06 |
| MRSA - Methicillin resistant Staphylococcus aureus infection:0 | 2/61,988 | 17,112/16,348,907 | 0.03 | 4.02e-25 | 9.43e-24 |
| G0 Phase:0 | 9/61,988 | 252/16,348,907 | 9.42 | 8.97e-07 | 6.42e-06 |
| tumor-associated antigen 72:0 | 20/61,988 | 358/16,348,907 | 14.74 | 8.40e-17 | 1.34e-15 |
| Proliferating Cell Nuclear Antigen:0 | 137/61,988 | 12,130/16,348,907 | 2.98 | 2.57e-27 | 6.49e-26 |
| statistical power:0 | 14/61,988 | 654/16,348,907 | 5.65 | 4.26e-07 | 3.17e-06 |
| Progesterone:0 | 141/61,988 | 56,234/16,348,907 | 0.66 | 1.95e-07 | 1.51e-06 |
| One:0 | 151/61,988 | 23,160/16,348,907 | 1.72 | 8.73e-10 | 8.61e-09 |
| Prostatic stent:0 | 11/61,988 | 130/16,348,907 | 22.32 | 1.05e-11 | 1.20e-10 |
| Andropause:0 | 15/61,988 | 140/16,348,907 | 28.26 | 7.52e-17 | 1.20e-15 |
| SMAD5-AS1:0 | 2/61,988 | 6,061/16,348,907 | 0.09 | 5.18e-08 | 4.27e-07 |
| % uptake:0 | 12/61,988 | 309/16,348,907 | 10.24 | 5.83e-09 | 5.31e-08 |
| 5-Trimethoxyamphetamine:0 | 13/61,988 | 440/16,348,907 | 7.79 | 3.12e-08 | 2.63e-07 |
| Cytokeratin:0 | 107/61,988 | 7,716/16,348,907 | 3.66 | 2.39e-28 | 6.23e-27 |
| Replacement therapy:0 | 164/61,988 | 11,084/16,348,907 | 3.91 | 7.18e-46 | 2.99e-44 |
| Recombinant Transforming Growth Factor-Beta 1|TGFB1:0 | 12/61,988 | 492/16,348,907 | 6.43 | 7.50e-07 | 5.43e-06 |
| VEGF protein, human|VEGFA:0 | 464/61,988 | 71,574/16,348,907 | 1.72 | 2.21e-26 | 5.45e-25 |
| Methylphenidate:0 | 4/61,988 | 9,770/16,348,907 | 0.11 | 1.57e-11 | 1.78e-10 |
| Nuclease Sensitive Element Binding Protein 1:0 | 11/61,988 | 232/16,348,907 | 12.51 | 3.47e-09 | 3.23e-08 |
| Response Elements:0 | 87/61,988 | 8,833/16,348,907 | 2.60 | 1.39e-14 | 1.93e-13 |
| Malignant neoplasm of cervix uteri:0 | 257/61,988 | 32,720/16,348,907 | 2.08 | 1.80e-25 | 4.27e-24 |
| Female genitalia:0 | 57/61,988 | 6,075/16,348,907 | 2.48 | 2.08e-09 | 1.98e-08 |
| maspin|SERPINB5:0 | 81/61,988 | 2,364/16,348,907 | 9.05 | 1.01e-47 | 4.39e-46 |
| Radical therapy:0 | 84/61,988 | 500/16,348,907 | 44.37 | 6.03e-102 | 5.04e-100 |
| Benzodiazepines:0 | 7/61,988 | 18,899/16,348,907 | 0.10 | 3.05e-22 | 6.33e-21 |
| Survivors:0 | 528/61,988 | 59,275/16,348,907 | 2.36 | 2.41e-66 | 1.41e-64 |
| Ectopic ACTH|POMC:0 | 8/61,988 | 195/16,348,907 | 10.82 | 1.34e-06 | 9.34e-06 |
| Pretreatment:0 | 129/61,988 | 16,232/16,348,907 | 2.10 | 6.10e-14 | 8.16e-13 |
| Pelvis:0 | 1,027/61,988 | 29,285/16,348,907 | 9.39 | 0.00e+00 | 0.00e+00 |
| Testicular Tissue:0 | 44/61,988 | 3,211/16,348,907 | 3.62 | 1.78e-12 | 2.16e-11 |
| Negative Staining:0 | 17/61,988 | 524/16,348,907 | 8.56 | 6.36e-11 | 6.93e-10 |
| arginylarginine|ABL2|RERE:0 | 15/61,988 | 635/16,348,907 | 6.23 | 4.90e-08 | 4.05e-07 |
| hyperthermia treatment:0 | 16/61,988 | 481/16,348,907 | 8.78 | 1.61e-10 | 1.70e-09 |
| Japanese Population:0 | 89/61,988 | 6,281/16,348,907 | 3.74 | 1.76e-24 | 4.00e-23 |
| Endotoxins:0 | 5/61,988 | 29,183/16,348,907 | 0.05 | 3.35e-40 | 1.23e-38 |
| Eating:0 | 25/61,988 | 28,099/16,348,907 | 0.23 | 4.71e-21 | 9.35e-20 |
| Common Neoplasm:0 | 107/61,988 | 4,325/16,348,907 | 6.53 | 1.70e-49 | 7.65e-48 |
| SYP gene|SYP:0 | 11/61,988 | 254/16,348,907 | 11.42 | 8.52e-09 | 7.63e-08 |
| Verumontanum:0 | 19/61,988 | 112/16,348,907 | 44.76 | 2.18e-24 | 4.92e-23 |
| Filters:0 | 43/61,988 | 23,597/16,348,907 | 0.48 | 7.28e-08 | 5.88e-07 |
| IGF1 gene|IGF1:0 | 24/61,988 | 669/16,348,907 | 9.46 | 1.02e-15 | 1.52e-14 |
| Obesity, Morbid:0 | 7/61,988 | 9,292/16,348,907 | 0.20 | 1.54e-08 | 1.34e-07 |
| CXCR6 gene|CXCR6:0 | 12/61,988 | 496/16,348,907 | 6.38 | 8.14e-07 | 5.87e-06 |
| Colon:0 | 1,337/61,988 | 104,980/16,348,907 | 3.41 | 1.39e-299 | 3.32e-297 |
| Relapse:0 | 38/61,988 | 2,188/16,348,907 | 4.58 | 6.11e-14 | 8.18e-13 |
| high-risk group:0 | 105/61,988 | 5,712/16,348,907 | 4.85 | 1.38e-37 | 4.73e-36 |
| GNRH1 gene|GNRH1:0 | 78/61,988 | 2,701/16,348,907 | 7.62 | 5.25e-41 | 1.98e-39 |
| Sex Hormone-Binding Globulin:0 | 108/61,988 | 5,209/16,348,907 | 5.48 | 4.06e-43 | 1.58e-41 |
| brca gene:0 | 9/61,988 | 161/16,348,907 | 14.75 | 2.39e-08 | 2.04e-07 |
| Histological finding:0 | 34/61,988 | 3,101/16,348,907 | 2.89 | 1.06e-07 | 8.42e-07 |
| caspase activity:0 | 17/61,988 | 607/16,348,907 | 7.39 | 5.55e-10 | 5.56e-09 |
| Hemangioma, Cavernous:0 | 1/61,988 | 6,912/16,348,907 | 0.04 | 2.18e-10 | 2.27e-09 |
| Diagnostic Imaging:0 | 31/61,988 | 2,207/16,348,907 | 3.71 | 1.71e-09 | 1.64e-08 |
| anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody:0 | 9/61,988 | 155/16,348,907 | 15.32 | 1.75e-08 | 1.51e-07 |
| comatose:0 | 2/61,988 | 9,338/16,348,907 | 0.06 | 6.37e-13 | 7.93e-12 |
| Arthroplasty:0 | 5/61,988 | 11,697/16,348,907 | 0.11 | 1.59e-13 | 2.08e-12 |
| pertuzumab|EREG|ESR1:0 | 3/61,988 | 1/16,348,907 | 791.27 | 2.15e-07 | 1.65e-06 |
| Multiple Organ Failure:0 | 4/61,988 | 8,746/16,348,907 | 0.12 | 4.79e-10 | 4.84e-09 |
| Bacteria, Anaerobic:0 | 1/61,988 | 4,876/16,348,907 | 0.05 | 4.65e-07 | 3.44e-06 |
| Peroxidase:0 | 25/61,988 | 17,800/16,348,907 | 0.37 | 5.06e-09 | 4.63e-08 |
| Braces-Orthopedic appliances:0 | 1/61,988 | 4,917/16,348,907 | 0.05 | 3.02e-07 | 2.29e-06 |
| Toxic effect:0 | 1,503/61,988 | 110,241/16,348,907 | 3.66 | 0.00e+00 | 0.00e+00 |
| Face:0 | 37/61,988 | 21,665/16,348,907 | 0.45 | 3.61e-08 | 3.02e-07 |
| Sexually active:0 | 41/61,988 | 3,809/16,348,907 | 2.84 | 9.30e-09 | 8.29e-08 |
| Endocrine Gland Neoplasms:0 | 33/61,988 | 2,727/16,348,907 | 3.19 | 1.76e-08 | 1.52e-07 |
| Catechol Oxidase|TYR:0 | 3/61,988 | 6,689/16,348,907 | 0.12 | 6.86e-08 | 5.57e-07 |
| Bladder volume:0 | 14/61,988 | 334/16,348,907 | 11.06 | 1.25e-10 | 1.33e-09 |
| Periodicals:0 | 299/61,988 | 26,251/16,348,907 | 3.01 | 3.32e-58 | 1.74e-56 |
| cancer prevention:0 | 118/61,988 | 1,566/16,348,907 | 19.91 | 5.32e-105 | 4.58e-103 |
| Vitellogenins:0 | 2/61,988 | 5,245/16,348,907 | 0.10 | 1.30e-06 | 9.12e-06 |
| MDM2 gene|MDM2:0 | 89/61,988 | 7,650/16,348,907 | 3.07 | 4.03e-19 | 7.26e-18 |
| Induction:0 | 691/61,988 | 86,627/16,348,907 | 2.12 | 4.78e-68 | 2.84e-66 |
| Platelet Activating Factor:0 | 4/61,988 | 18,317/16,348,907 | 0.06 | 1.71e-24 | 3.90e-23 |
| PS 341:0 | 15/61,988 | 451/16,348,907 | 8.77 | 5.96e-10 | 5.96e-09 |
| EDN1 gene|EDN1:0 | 15/61,988 | 317/16,348,907 | 12.48 | 5.38e-12 | 6.34e-11 |
| TGFB1I1:0 | 18/61,988 | 112/16,348,907 | 42.40 | 8.37e-23 | 1.78e-21 |
| Prostate size:0 | 103/61,988 | 347/16,348,907 | 78.42 | 4.25e-147 | 5.29e-145 |
| Phosphotransferases:0 | 628/61,988 | 85,057/16,348,907 | 1.96 | 2.61e-51 | 1.22e-49 |
| cyclin-dependent kinase inhibitor 1B|CDKN1B:0 | 49/61,988 | 2,591/16,348,907 | 4.99 | 6.20e-19 | 1.10e-17 |
| Fossa:0 | 63/61,988 | 3,429/16,348,907 | 4.85 | 3.08e-23 | 6.68e-22 |
| Glomerulonephritis:0 | 3/61,988 | 15,803/16,348,907 | 0.05 | 7.83e-22 | 1.59e-20 |
| Salmonella:0 | 8/61,988 | 11,714/16,348,907 | 0.18 | 4.70e-11 | 5.18e-10 |
| Retroperitoneal lymph node dissection:0 | 27/61,988 | 1,528/16,348,907 | 4.66 | 1.63e-10 | 1.71e-09 |
| Vacuole:0 | 17/61,988 | 13,667/16,348,907 | 0.33 | 4.00e-08 | 3.33e-07 |
| Histopathologic Grade:0 | 7/61,988 | 121/16,348,907 | 15.26 | 6.95e-07 | 5.05e-06 |
| Depot Preparations:0 | 15/61,988 | 213/16,348,907 | 18.58 | 2.38e-14 | 3.27e-13 |
| prostatic binding protein|PEBP1:0 | 17/61,988 | 426/16,348,907 | 10.53 | 2.85e-12 | 3.40e-11 |
| Metribolone:0 | 41/61,988 | 344/16,348,907 | 31.45 | 4.24e-45 | 1.74e-43 |
| Leuprolide:0 | 244/61,988 | 1,928/16,348,907 | 33.51 | 2.31e-265 | 4.88e-263 |
| Tomatoes:0 | 35/61,988 | 504/16,348,907 | 18.33 | 3.12e-31 | 8.89e-30 |
| Erythropoietin|EPO:0 | 12/61,988 | 14,627/16,348,907 | 0.22 | 3.32e-12 | 3.95e-11 |
| Oxygen:0 | 81/61,988 | 69,439/16,348,907 | 0.31 | 2.73e-39 | 9.86e-38 |
| Rectal symptoms:0 | 10/61,988 | 54/16,348,907 | 48.85 | 7.43e-14 | 9.89e-13 |
| Cystoscopy:0 | 76/61,988 | 2,310/16,348,907 | 8.69 | 1.02e-43 | 4.03e-42 |
| Entire lower urinary tract:0 | 48/61,988 | 2,889/16,348,907 | 4.38 | 1.81e-16 | 2.82e-15 |
| Prefrontal Cortex:0 | 2/61,988 | 27,943/16,348,907 | 0.02 | 1.44e-42 | 5.56e-41 |
| Testicular Neoplasms:0 | 71/61,988 | 3,064/16,348,907 | 6.12 | 9.21e-32 | 2.67e-30 |
| Positive Lymph Node:0 | 219/61,988 | 4,862/16,348,907 | 11.92 | 6.68e-149 | 8.43e-147 |
| Eflornithine:0 | 24/61,988 | 1,759/16,348,907 | 3.60 | 1.82e-07 | 1.41e-06 |
| Weight measurement scales:0 | 213/61,988 | 29,290/16,348,907 | 1.92 | 8.64e-18 | 1.44e-16 |
| Adenocarcinoma, Clear Cell:0 | 47/61,988 | 5,099/16,348,907 | 2.43 | 8.28e-08 | 6.64e-07 |
| Methanol:0 | 15/61,988 | 14,312/16,348,907 | 0.28 | 5.73e-10 | 5.74e-09 |
| Cancer Detection:0 | 360/61,988 | 776/16,348,907 | 123.06 | 0.00e+00 | 0.00e+00 |
| insulin-like growth factor binding protein-related protein 1:0 | 10/61,988 | 189/16,348,907 | 13.96 | 6.59e-09 | 5.97e-08 |
| Membrane receptor:0 | 46/61,988 | 4,889/16,348,907 | 2.48 | 6.88e-08 | 5.58e-07 |
| Limb structure:0 | 46/61,988 | 42,287/16,348,907 | 0.29 | 3.41e-26 | 8.32e-25 |
| Antichymotrypsin:0 | 10/61,988 | 308/16,348,907 | 8.56 | 5.20e-07 | 3.83e-06 |
| Severe Acute Respiratory Syndrome:0 | 2/61,988 | 6,894/16,348,907 | 0.08 | 3.12e-09 | 2.92e-08 |
| Carcinogenesis:0 | 2,030/61,988 | 60,832/16,348,907 | 9.07 | 0.00e+00 | 0.00e+00 |
| Differentiation Inducer:0 | 11/61,988 | 342/16,348,907 | 8.48 | 1.56e-07 | 1.21e-06 |
| Urokinase|UCN2:0 | 9/61,988 | 9/16,348,907 | 263.78 | 7.38e-18 | 1.24e-16 |
| Zometa:0 | 27/61,988 | 133/16,348,907 | 53.56 | 6.84e-36 | 2.22e-34 |
| Myoblasts:0 | 1/61,988 | 7,710/16,348,907 | 0.03 | 1.20e-11 | 1.37e-10 |
| Polyclonal antibody:0 | 90/61,988 | 10,778/16,348,907 | 2.20 | 3.59e-11 | 3.98e-10 |
| Respiratory Tract Infections:0 | 5/61,988 | 16,251/16,348,907 | 0.08 | 2.67e-20 | 5.13e-19 |
| Intraepithelial Neoplasia:0 | 64/61,988 | 2,261/16,348,907 | 7.47 | 1.74e-33 | 5.33e-32 |
| Total proctectomy:0 | 27/61,988 | 2,272/16,348,907 | 3.14 | 4.61e-07 | 3.41e-06 |
| day:0 | 138/61,988 | 15,966/16,348,907 | 2.28 | 1.48e-17 | 2.44e-16 |
| TPD52:0 | 9/61,988 | 35/16,348,907 | 67.83 | 9.84e-14 | 1.30e-12 |
| Algae:0 | 4/61,988 | 10,824/16,348,907 | 0.10 | 5.28e-13 | 6.61e-12 |
| DERIVED:0 | 46/61,988 | 4,206/16,348,907 | 2.89 | 7.60e-10 | 7.52e-09 |
| Eosine Yellowish:0 | 35/61,988 | 3,024/16,348,907 | 3.05 | 1.95e-08 | 1.67e-07 |
| Transforming Growth Factor beta|TGFB1:0 | 33/61,988 | 3,148/16,348,907 | 2.77 | 4.26e-07 | 3.17e-06 |
| Retinoids:0 | 119/61,988 | 16,262/16,348,907 | 1.93 | 8.10e-11 | 8.75e-10 |
| Proliferative diabetic retinopathy:0 | 3/61,988 | 5,719/16,348,907 | 0.14 | 1.41e-06 | 9.78e-06 |
| Breast Carcinoma:0 | 248/61,988 | 21,325/16,348,907 | 3.08 | 4.36e-50 | 1.98e-48 |
| Surgical Flaps:0 | 15/61,988 | 18,703/16,348,907 | 0.21 | 2.25e-15 | 3.29e-14 |
| Leukotriene C4:0 | 1/61,988 | 4,964/16,348,907 | 0.05 | 3.18e-07 | 2.40e-06 |
| Prednisone:0 | 339/61,988 | 23,824/16,348,907 | 3.77 | 1.27e-88 | 9.29e-87 |
| Bacterial Prostatitis:0 | 18/61,988 | 383/16,348,907 | 12.40 | 4.73e-14 | 6.39e-13 |
| Prostatic hypertrophy:0 | 244/61,988 | 1,369/16,348,907 | 47.19 | 3.08e-298 | 7.32e-296 |
| LAMC2:0 | 6/61,988 | 13,670/16,348,907 | 0.12 | 1.68e-15 | 2.49e-14 |
| BMI1 gene|BMI1:0 | 19/61,988 | 1,229/16,348,907 | 4.08 | 5.52e-07 | 4.06e-06 |
| Lymphohistiocytosis, Hemophagocytic:0 | 1/61,988 | 4,999/16,348,907 | 0.05 | 2.09e-07 | 1.61e-06 |
| Cytogen 356:0 | 6/61,988 | 8/16,348,907 | 197.83 | 8.50e-12 | 9.84e-11 |
| Genes, cdc:0 | 61/61,988 | 1,853/16,348,907 | 8.69 | 1.89e-35 | 6.06e-34 |
| Digoxin:0 | 17/61,988 | 14,507/16,348,907 | 0.31 | 4.16e-09 | 3.84e-08 |
| Vasodilation disorder:0 | 3/61,988 | 8,078/16,348,907 | 0.10 | 5.32e-10 | 5.36e-09 |
| PCNA gene|PCNA:0 | 36/61,988 | 2,664/16,348,907 | 3.57 | 2.46e-10 | 2.56e-09 |
| Transcriptional Repression:0 | 38/61,988 | 2,379/16,348,907 | 4.21 | 7.11e-13 | 8.81e-12 |
| Colorectal Cancer:0 | 87/61,988 | 5,059/16,348,907 | 4.54 | 1.76e-29 | 4.79e-28 |
| Insecticides:0 | 3/61,988 | 9,378/16,348,907 | 0.08 | 5.67e-12 | 6.66e-11 |
| caspase-9:0 | 119/61,988 | 4,671/16,348,907 | 6.73 | 4.10e-56 | 2.08e-54 |
| Structure of arteriole:0 | 10/61,988 | 12,160/16,348,907 | 0.22 | 3.03e-10 | 3.13e-09 |
| Lignans:0 | 52/61,988 | 3,259/16,348,907 | 4.21 | 5.28e-17 | 8.46e-16 |
| Flexible fiberoptic sigmoidoscopy:0 | 23/61,988 | 687/16,348,907 | 8.83 | 1.60e-14 | 2.22e-13 |
| Fine needle aspiration biopsy:0 | 186/61,988 | 15,091/16,348,907 | 3.26 | 3.22e-41 | 1.22e-39 |
| Radiotherapy, Targeted:0 | 14/61,988 | 280/16,348,907 | 13.19 | 1.35e-11 | 1.54e-10 |
| Agent:0 | 82/61,988 | 8,846/16,348,907 | 2.45 | 1.41e-12 | 1.72e-11 |
| Carcinoma, Cribriform:0 | 6/61,988 | 60/16,348,907 | 26.38 | 2.17e-07 | 1.67e-06 |
| Chemopreventive Agent:0 | 229/61,988 | 3,458/16,348,907 | 17.53 | 2.84e-190 | 4.52e-188 |
| Matrix Metalloproteinases:0 | 217/61,988 | 26,797/16,348,907 | 2.14 | 2.94e-23 | 6.38e-22 |
| phenylacetate:0 | 13/61,988 | 480/16,348,907 | 7.14 | 8.27e-08 | 6.64e-07 |
| Iron Overload:0 | 2/61,988 | 10,078/16,348,907 | 0.05 | 3.48e-14 | 4.73e-13 |
| Bilateral subcapsular orchidectomy:0 | 5/61,988 | 7/16,348,907 | 188.40 | 5.96e-10 | 5.96e-09 |
| Methylprednisolone:0 | 9/61,988 | 17,939/16,348,907 | 0.13 | 6.72e-19 | 1.19e-17 |
| Mounts:0 | 124/61,988 | 4,609/16,348,907 | 7.11 | 7.14e-61 | 3.86e-59 |
| proteomic profiling:0 | 16/61,988 | 593/16,348,907 | 7.12 | 2.93e-09 | 2.76e-08 |
| Epithelial-Stromal Communication:0 | 13/61,988 | 125/16,348,907 | 27.43 | 1.21e-14 | 1.69e-13 |
| Stromal Invasion:0 | 26/61,988 | 246/16,348,907 | 27.89 | 5.92e-28 | 1.52e-26 |
| Carcinoma, Transitional Cell:0 | 725/61,988 | 28,571/16,348,907 | 6.76 | 0.00e+00 | 0.00e+00 |
| Entire thoracic aorta:0 | 1/61,988 | 10,284/16,348,907 | 0.03 | 9.20e-16 | 1.38e-14 |
| Genasense:0 | 6/61,988 | 47/16,348,907 | 33.67 | 5.73e-08 | 4.69e-07 |
| insulin-like growth factor binding protein-related protein 1|RP1:0 | 6/61,988 | 79/16,348,907 | 20.03 | 9.84e-07 | 7.00e-06 |
| Pathological fracture:0 | 76/61,988 | 4,498/16,348,907 | 4.46 | 1.60e-25 | 3.79e-24 |
| Schizosaccharomyces pombe:0 | 4/61,988 | 9,113/16,348,907 | 0.12 | 1.20e-10 | 1.28e-09 |
| Isothiocyanate:0 | 23/61,988 | 1,788/16,348,907 | 3.39 | 8.63e-07 | 6.20e-06 |
| Lymphocyte:0 | 205/61,988 | 112,902/16,348,907 | 0.48 | 4.62e-33 | 1.39e-31 |
| Osteoclasia:0 | 10/61,988 | 178/16,348,907 | 14.82 | 3.82e-09 | 3.54e-08 |
| Asian diet:0 | 7/61,988 | 27/16,348,907 | 68.39 | 5.40e-11 | 5.91e-10 |
| Diabetes Mellitus, Insulin-Dependent:0 | 16/61,988 | 84,579/16,348,907 | 0.05 | 6.49e-113 | 6.07e-111 |
| Anemia, Hemolytic:0 | 2/61,988 | 6,149/16,348,907 | 0.09 | 5.57e-08 | 4.56e-07 |
| Stilphostrol:0 | 10/61,988 | 19/16,348,907 | 138.83 | 1.11e-17 | 1.84e-16 |
| Nerve graft:0 | 18/61,988 | 892/16,348,907 | 5.32 | 2.45e-08 | 2.09e-07 |
| NR2C2:0 | 10/61,988 | 283/16,348,907 | 9.32 | 2.47e-07 | 1.88e-06 |
| Tumor Promotion:0 | 33/61,988 | 2,364/16,348,907 | 3.68 | 6.10e-10 | 6.09e-09 |
| Entire oral cavity:0 | 97/61,988 | 13,274/16,348,907 | 1.93 | 4.95e-09 | 4.54e-08 |
| PTK2 gene|PTK2:0 | 11/61,988 | 409/16,348,907 | 7.09 | 8.57e-07 | 6.16e-06 |
| Membrane:0 | 296/61,988 | 144,672/16,348,907 | 0.54 | 3.55e-32 | 1.05e-30 |
| Angiogenesis Inhibitors:0 | 305/61,988 | 23,319/16,348,907 | 3.46 | 6.62e-72 | 4.13e-70 |
| Curative treatment:0 | 78/61,988 | 984/16,348,907 | 20.93 | 1.35e-71 | 8.31e-70 |
| Cytosine deaminase:0 | 29/61,988 | 1,029/16,348,907 | 7.44 | 5.02e-16 | 7.60e-15 |
| Glutamate:0 | 29/61,988 | 51,339/16,348,907 | 0.15 | 1.83e-49 | 8.22e-48 |
| Somatomedins|BP1:0 | 9/61,988 | 8/16,348,907 | 296.75 | 3.70e-18 | 6.31e-17 |
| Physicians:0 | 439/61,988 | 68,454/16,348,907 | 1.70 | 3.53e-24 | 7.92e-23 |
| Wound Healing:0 | 132/61,988 | 65,923/16,348,907 | 0.53 | 3.19e-16 | 4.89e-15 |
| Glutamate Carboxypeptidase II:0 | 509/61,988 | 1,550/16,348,907 | 87.32 | 0.00e+00 | 0.00e+00 |
| Knee:0 | 5/61,988 | 37,005/16,348,907 | 0.04 | 1.37e-52 | 6.58e-51 |
| Vegetables:0 | 65/61,988 | 2,897/16,348,907 | 5.92 | 1.79e-28 | 4.69e-27 |
| Regional Blood Flow:0 | 1/61,988 | 24,635/16,348,907 | 0.01 | 4.90e-39 | 1.75e-37 |
| Gonadorelin:0 | 435/61,988 | 23,798/16,348,907 | 4.85 | 4.13e-149 | 5.22e-147 |
| Glomerular Filtration Rate:0 | 13/61,988 | 30,346/16,348,907 | 0.11 | 3.19e-33 | 9.68e-32 |
| Breast Cancer Model:0 | 20/61,988 | 1,001/16,348,907 | 5.27 | 4.97e-09 | 4.55e-08 |
| Additional values:0 | 34/61,988 | 1,004/16,348,907 | 8.94 | 7.31e-21 | 1.44e-19 |
| Radiation Tolerance:0 | 35/61,988 | 1,270/16,348,907 | 7.27 | 1.01e-18 | 1.78e-17 |
| Gynecomastia:0 | 108/61,988 | 2,475/16,348,907 | 11.53 | 4.73e-73 | 3.01e-71 |
| Glycerol:0 | 9/61,988 | 19,608/16,348,907 | 0.12 | 2.07e-21 | 4.16e-20 |
| Ovulation:0 | 10/61,988 | 15,694/16,348,907 | 0.17 | 5.69e-15 | 8.12e-14 |
| Molecular Chaperones|AR:0 | 9/61,988 | 11/16,348,907 | 215.82 | 2.53e-17 | 4.13e-16 |
| Vitamin D Analog:0 | 22/61,988 | 817/16,348,907 | 7.10 | 3.70e-12 | 4.39e-11 |
| Levetiracetam:0 | 2/61,988 | 6,237/16,348,907 | 0.08 | 3.84e-08 | 3.21e-07 |
| CYTOKERATIN ANTIBODY:0 | 9/61,988 | 191/16,348,907 | 12.43 | 9.62e-08 | 7.69e-07 |
| Entire temporomandibular joint:0 | 1/61,988 | 8,680/16,348,907 | 0.03 | 3.11e-13 | 3.97e-12 |
| Chymosin|REN:0 | 1/61,988 | 10,271/16,348,907 | 0.03 | 9.12e-16 | 1.37e-14 |
| Shock, Cardiogenic:0 | 1/61,988 | 8,397/16,348,907 | 0.03 | 9.33e-13 | 1.15e-11 |
| Gene Expression:0 | 538/61,988 | 59,582/16,348,907 | 2.39 | 2.67e-69 | 1.61e-67 |
| Recombinant Interferon-gamma:0 | 94/61,988 | 64,386/16,348,907 | 0.38 | 9.04e-28 | 2.32e-26 |
| RHOA gene|RHOA:0 | 74/61,988 | 9,326/16,348,907 | 2.09 | 1.67e-08 | 1.45e-07 |
| DKK3:0 | 14/61,988 | 262/16,348,907 | 14.10 | 5.83e-12 | 6.84e-11 |
| Pomegranate:0 | 15/61,988 | 211/16,348,907 | 18.75 | 2.10e-14 | 2.89e-13 |
| Insulin-Like-Growth Factor I Receptor:0 | 129/61,988 | 8,147/16,348,907 | 4.18 | 2.61e-39 | 9.42e-38 |
| Varicosity:0 | 2/61,988 | 17,655/16,348,907 | 0.03 | 4.19e-26 | 1.02e-24 |
| Theophylline:0 | 8/61,988 | 17,739/16,348,907 | 0.12 | 1.37e-19 | 2.52e-18 |
| GSTM1 gene|GSTM1:0 | 50/61,988 | 2,544/16,348,907 | 5.19 | 5.91e-20 | 1.11e-18 |
| RC 160:0 | 19/61,988 | 309/16,348,907 | 16.22 | 9.32e-17 | 1.48e-15 |
| Antrum:0 | 1/61,988 | 6,417/16,348,907 | 0.04 | 1.34e-09 | 1.29e-08 |
| GLUCOSE TOLERANCE:0 | 5/61,988 | 9,810/16,348,907 | 0.13 | 1.04e-10 | 1.11e-09 |
| Vitiligo:0 | 3/61,988 | 8,763/16,348,907 | 0.09 | 4.60e-11 | 5.07e-10 |
| TSPY1 gene|TSPY1:0 | 10/61,988 | 294/16,348,907 | 8.97 | 3.45e-07 | 2.60e-06 |
| School (environment):0 | 1/61,988 | 7,432/16,348,907 | 0.04 | 3.63e-11 | 4.02e-10 |
| Percutaneous coronary intervention:0 | 1/61,988 | 27,860/16,348,907 | 0.01 | 2.57e-44 | 1.03e-42 |
| Epidermis:0 | 19/61,988 | 27,452/16,348,907 | 0.18 | 3.11e-24 | 7.01e-23 |
| Clomiphene Citrate:0 | 1/61,988 | 4,981/16,348,907 | 0.05 | 3.27e-07 | 2.46e-06 |
| Nerve Growth Factors:0 | 60/61,988 | 34,072/16,348,907 | 0.46 | 1.98e-11 | 2.23e-10 |
| Mitochondria, Liver:0 | 4/61,988 | 10,594/16,348,907 | 0.10 | 1.01e-12 | 1.24e-11 |
| Entire tooth:0 | 3/61,988 | 7,931/16,348,907 | 0.10 | 1.14e-09 | 1.11e-08 |
| Neurofibromatosis 1:0 | 4/61,988 | 8,374/16,348,907 | 0.13 | 1.94e-09 | 1.86e-08 |
| Metastron:0 | 8/61,988 | 25/16,348,907 | 84.41 | 5.29e-13 | 6.62e-12 |
| HTATIP protein, human|KAT5:0 | 16/61,988 | 577/16,348,907 | 7.32 | 2.02e-09 | 1.92e-08 |
| Fibroblast Growth Factor Receptor 1:0 | 15/61,988 | 710/16,348,907 | 5.57 | 1.97e-07 | 1.52e-06 |
| gamma-Aminobutyric Acid:0 | 9/61,988 | 56,041/16,348,907 | 0.04 | 2.62e-77 | 1.74e-75 |
| Quantitative Trait Loci:0 | 3/61,988 | 12,329/16,348,907 | 0.06 | 2.12e-16 | 3.28e-15 |
| Electroacupuncture:0 | 3/61,988 | 6,130/16,348,907 | 0.13 | 3.63e-07 | 2.72e-06 |
| Xenograft procedure:0 | 564/61,988 | 11,018/16,348,907 | 13.62 | 0.00e+00 | 0.00e+00 |
| sulindac sulfone:0 | 22/61,988 | 381/16,348,907 | 15.23 | 1.29e-18 | 2.25e-17 |
| Augmentation procedure:0 | 22/61,988 | 17,616/16,348,907 | 0.33 | 3.83e-10 | 3.92e-09 |
| resveratrol:0 | 134/61,988 | 22,315/16,348,907 | 1.59 | 6.53e-07 | 4.76e-06 |
| Receptors, Opioid, kappa:0 | 1/61,988 | 4,701/16,348,907 | 0.06 | 6.15e-07 | 4.49e-06 |
| KLK5 gene|KLK5:0 | 8/61,988 | 65/16,348,907 | 32.46 | 4.48e-10 | 4.55e-09 |
| Mixed Function Oxygenases:0 | 98/61,988 | 13,637/16,348,907 | 1.90 | 8.50e-09 | 7.61e-08 |
| Plasmapheresis:0 | 3/61,988 | 6,391/16,348,907 | 0.12 | 1.93e-07 | 1.49e-06 |
| HIF1A:0 | 18/61,988 | 641/16,348,907 | 7.41 | 1.68e-10 | 1.77e-09 |
| Acid phosphatase isoenzyme:0 | 8/61,988 | 69/16,348,907 | 30.58 | 6.91e-10 | 6.86e-09 |
| Thrombocythemia, Hemorrhagic:0 | 2/61,988 | 6,159/16,348,907 | 0.09 | 5.66e-08 | 4.64e-07 |
| device aspects:0 | 17/61,988 | 14,898/16,348,907 | 0.30 | 1.31e-09 | 1.27e-08 |
| Spectrum Analysis:0 | 115/61,988 | 13,731/16,348,907 | 2.21 | 4.70e-14 | 6.35e-13 |
| androgen receptor signaling pathway:0 | 10/61,988 | 17/16,348,907 | 155.17 | 4.70e-18 | 7.99e-17 |
| CARBONATE DEHYDRATASE:0 | 7/61,988 | 8,008/16,348,907 | 0.23 | 9.67e-07 | 6.89e-06 |
| Procedures:0 | 668/61,988 | 93,942/16,348,907 | 1.88 | 4.17e-49 | 1.86e-47 |
| mibolerone:0 | 35/61,988 | 259/16,348,907 | 35.66 | 1.76e-40 | 6.51e-39 |
| Induction of Apoptosis:0 | 27/61,988 | 1,412/16,348,907 | 5.05 | 3.00e-11 | 3.34e-10 |
| Precancerous lesions:0 | 111/61,988 | 5,462/16,348,907 | 5.37 | 1.74e-43 | 6.84e-42 |
| Carbohydrate antigen:0 | 19/61,988 | 779/16,348,907 | 6.43 | 5.17e-10 | 5.20e-09 |
| histological diagnosis:0 | 44/61,988 | 2,134/16,348,907 | 5.44 | 1.70e-18 | 2.94e-17 |
| Proteinuria:0 | 10/61,988 | 24,463/16,348,907 | 0.11 | 1.63e-27 | 4.13e-26 |
| frontal lobe:0 | 6/61,988 | 24,052/16,348,907 | 0.07 | 4.18e-31 | 1.18e-29 |
| Lectin:0 | 60/61,988 | 29,427/16,348,907 | 0.54 | 1.21e-07 | 9.58e-07 |